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Background 
The goal of effective prescribing with the  aim of improving the quality of prescribing in 
primary  care  is  both  a  clinical  and  economic  challenge.  There  are  wide  variations  in 
prescribing in primary care that cannot be fully  accounted for by demographic patterns. 
Over  the  years,  numerous  educational  and policy  initiatives  on improving primary  care 
prescribing in the  NHS  have  been developed  and  implemented.  However,  in  order  to 
achieve both clinical and cost effectiveness, a wider perspective must be adopted.  Focusing 
solely on the reduction of purchasing costs of drugs is not only ineffective, but may result in 
increased  expenditure  in  the  longer  term  due  to  the  cost  of treating  hidden  adverse 
complications. 
Aims 
This  study  aimed  to  investigate  the  effect  of incorporating  adverse  drug  reactions  m 
economic  analyses  of drug  therapies.  Subsequently,  the  impact of this  information  on 
prescribing in primary care is explored. 
Literature Review 
The literature related to  the  clinical and economic burden of adverse drug reactions was 
reviewed.  Adverse  drug  reactions  have  been  shown  to  incur  substantial  clinical  and 
economic burdens to health care systems.  Although different drugs have different adverse 
events profile, no drugs are free of adverse drug reactions and all result in additional costs. 
The  economic  consequences  associated  with  adverse  drug  reactions  have  often  been 
neglected. 
Evidence about the  impact of economic information on primary care decision making is 
sparse.  Several surveys  have attempted to  investigate the  use  and the  role of economic 
evidence  in  primary  care  practice,  but these  studies  are  limited by  their  methodology. 
2 However, the findings of these studies are in general agreement that there is an awareness 
and interest in economic information among general practitioners, but there is no indication 
of  successful  implementation  in  changing  day-to-day  practice.  Several  barriers  to 
implementation of economic evidence have been identified. 
Methods 
In order to  achieve the aims of the study, three main studies were conducted.  In the first 
study, an economic analysis was conducted to estimate the comparative costs of a large UK 
population (N =  98 887) given nonsteroidal anti-inflammatory drug (NSAID) therapy alone 
and  in  combination  of  gastrointestinal  (GI)  protective  agents  including  concomitant 
prescriptions  of H2 blockers,  omeprazole  and  misoprostol.  The  study  population  was 
divided into four groups: NSAID only sub-cohort (N =  49 212), NSAID and co-prescribed 
H2  blockers/omeprazole  sub-cohort  (N =  2 113),  NSAID  and  co-prescribed  misoprostol 
sub-cohort (N = 212) and the general population comparator cohort (N = 47 350).  Direct 
healthcare costs associated with each individual were calculated at days, six months and 12 
months.  In addition to the total costs, the sex and age-specific costs, and the relative cost of 
high and low risk groups associated with NSAID therapy alone and in combination with GI 
protective agents were also calculated. 
The second study  was  a pharmacoeconomic  analysis,  using data from  the  literature  and 
local  expert  opinion,  of three  commonly  prescribed classes  of drugs  in  primary  care  -
NSAIDs,  selective  serotonin  reuptake  inhibitors  (SSRis)  and  angiotensin  converting 
enzyme  (ACE)  inhibitors  for  the  treatment  of  rheumatoid  arthritis,  depression  and 
hypertension respectively.  The total cost of drug therapy, taking into account the cost of the 
drugs  and  the  cost of treating  possible  associated  drug-induced  adverse  drug  reactions 
(ADRs)- termed the 'shadow cost' were calculated. 
Finally,  the results from the pharmacoeconomic  analysis  were  disseminated to  GPs  in a 
local Health Board to  explore the  impact on influencing primary care prescribing.  The 
prescribing trend over a six-month period was analysed using routine data from Prescription 
Cost Analysis for Scotland.  A postal and email survey and qualitative interviews were also 
undertaken to help better understanding of these findings. 
3 Results 
The  results  from  both  economic  analyses  showed  clearly  that  drug  associated  adverse 
clinical events may add substantially to the cost of drug therapy. 
In  the first  study using the population database,  almost all  event rates and costs showed 
significant  differences  between  any  two  groups.  Over  a  period  of  12  months,  the 
incremental cost of the NSAID-only group was £253 compared to  the general population; 
similarly,  the  incremental  cost of the  NSAID  and  misoprostol  group,  and  NSAID  and 
H2/omeprazole,  over the  NSAID  group  was  £417  and £543  respectively.  The costs  of 
prescriptions and cardiovascular (CV) admissions constituted the bulk of the total costs in 
all groups.  Surprisingly, GI endoscopies only accounted for 8%  of the incremental costs. 
Sensitivity analysis showed that the conclusions were robust and that differences in costs 
was not due to differences in sex, age, or previous history of hospital admissions. 
In the second study eight NSAIDs, four SSRis and seven ACE inhibitors were evaluated. 
The economic impact of drug-induced ADRs  was  particularly apparent among NSAIDs, 
when the shadow cost (cost of managing adverse events) accounted for 12% (ketoprofen) to 
59%  (diclofenac sodium) of the  total  cost of therapy.  In some cases,  drugs  that may be 
more costly to  purchase in the first place, resulted in savings in the long term.  This was 
observed  among  NSAIDs  such  as  naproxen,  ketoprofen  and  indomethacin,  and  ACE 
inhibitors such as trandolapril. 
The findings  of the pharmacoeconomic analyses were presented to  12 GPs within a local 
healthcare  co-operative  (LHCC).  Prescribing  volume  of  NSAIDs,  SSRis  and  ACE 
inhibitors were monitored and comparisons were made between the three months pre- and 
post-dissemination.  General practitioners in the same LHCC but who did not participate in 
the study acted as controls and did not receive any interventions.  No change in prescribing 
trends of the three classes of drugs was observed.  The subsequent postal and email survey 
confirmed the  general lack of use  of economic information.  Qualitative interviews have 
revealed that GPs do  not believe that such information should be considered at a practice 
level. 
4 Conclusions 
Economic analyses based on various data sources have shown that the total cost of drug 
therapies are  often much higher than the purchasing cost alone.  There is much value in 
taking  into  account  the  clinical  and  economic  impact  of  drug-induced  ADRs  when 
conducting  pharmacoeconomic  evaluations.  However,  this  is  often  restricted  by  the 
availability of some of the  data that are required to  complete the  economic model.  The 
necessary data do  exist, but linked clinical  data for  this  type  of analysis  are not readily 
available for research purposes. 
General  practitioners  were  generally  supportive  of  econormc  evaluations  and  the 
exploratory  study  on  disseminating  pharmacoeconomic  information.  However,  the 
dissemination exercise had failed to demonstrate a positive relationship.  In addition to the 
barriers highlighted in the literature, it was found that GPs do not feel that there is a role for 
the implementation of economic information in primary care. 
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20 1  INTRODUCTION INTRODUCTION 
1.1  BACKGROUND TO miS STUDY 
National Health Service (NHS) expenditure is rising constantly, and today, the concept of 
scarce healthcare resources is widely accepted by all.  Although administrative inefficiency, 
managerial paralysis, more experimental technical advances and the ageing population have 
frequently been blamed for this,  there  are  many other interacting factors  contributing to 
escalating healthcare costs. 
The expenditure on drug treatment has increased by approximately five-fold over the past 
30 years and currently forms about 12% of all NHS  expenditure 
1
.  In the last decade, the 
rate of increase averaged almost 9% annually 
2
,  well above inflation, faster than any other 
sector in the NHS  (Figure 1).  The reason for this trend may be explained, in part, by the 
rise  in  unit  cost  per  prescription  and  volumes  per  capita.  The  introduction  of new 
therapeutic interventions by the pharmaceutical industry has led to  significant increases in 
drug expenditure within the NHS.  More and more effective drugs are becoming available 
to provide better treatment or deal with conditions which until recently could not be treated 
at all.  It has been estimated that 55% of the increased expenditure is due to new products 
replacing existing agents and 30% due to an increase in number of medicines consumed by 
.  3  patients  . 
The government has committed itself to  'a primary care based NHS'.  Over the years, the 
government has introduced strategies (reviewed in Appendix I)  in attempts to  contain the 
costs in prescribing.  Various approaches  to  cost containment have been introduced and 
adopted throughout the years, ranging from the "stick" approach (e.g. restricted list) to the 
"carrot approach" (e.g. incentives with a prescribing message on them).  However, there is 
often a lack of rigorous  evidence  because  interventions  were  implemented as  part of a 
strategic  decision rather than  on  a formally  evaluated basis.  In addition,  most of these 
methods appear only to  have short-term benefits.  Cost containment strategies could only 
generate a finite amount of savings, which would reach a plateau in the long term.  In order 
to achieve cost effectiveness in healthcare, a wider perspective needs to be adopted. 
21 At the time of the work for this thesis, general practice is the core of primary care, and the 
majority of primary care is delivered by general practice-based teams.  The prominent role 
of general practice in primary care has been strengthened since the  1991  reforms,  which 
have  given purchasing responsibilities  to  general practitioners  (GPs).  It has  given  GPs 
budgets to purchase hospital care as well as  contracting them to provide both clinical and 
preventive primary care for their registered patients.  It has allowed them to keep savings 
made from economies in prescribing for use in providing other services.  It has shifted NHS 
resources  from  secondary  to  primary  care,  and it has  achieved  a  subtle  but undeniable 
increase in the influence of GPs over their colleagues in hospital practice. 
General practitioners occupy a prominent role in the rationing process within the NHS, but 
decision making has become increasingly complex.  The constant rise in cost and demand 
for  healthcare  has  led to  the  need for  optimum use  of limited resources  in  the  face  of 
continuous  and increasing  demand.  More  recently,  economic  considerations,  especially 
cost effectiveness, have become an integral part of clinical decision making, and may be 
essential to the survival of the NHS. 
1.2  PRIMARY CARE 
General practitioners are often described as  "gate-keepers" as  general practice is the first 
port of call for all  patients.  The most frequent contact with the health service, for most 
people,  is  through  their  GPs  in  primary care,  where  drug  therapy  is  the  most common 
therapeutic  approach  adopted  for  treatment.  In  Scotland,  3066  consultations  per  1000 
practice population were recorded in the year 1999 (based on data from 51 practices) 
4
.  It is 
believed that up  to  70%  of GP consultations result in a prescription,  either as  a one-off 
treatment or as part of long-term management of  chronic illness 
5
. 
In  spite of a fairly  steady population growth,  the total quantity of drugs issued and their 
costs rise year after year.  A total of 60.9 million NHS  prescriptions - equivalent to  11.3 
prescriptions per head - were dispensed in 1999/2000 in Scotland 
4
,  representing a 3.6% 
increase from the previous year,  at a cost of £713  million.  A combination of factors  is 
responsible for the rise in prescribing expenditure every year.  This includes the 3% to 4% 
annual increase in the number of prescriptions issued, the changes in the price of drugs, the 
22 introduction of new and often more expensive drugs,  and changes in prescribing practice. 
The average  net ingredient cost per prescription dispensed in Scotland over  the  past 15 
years has risen from £3.94 in 1985 to £10.11 in 2000 (compared with an increase to £6.46 if 
price inflation alone was taken into account).  The substantial increases in the volume and 
cost of prescriptions over the past seven years are shown in Figure 2. 
The quality of prescribing has a direct impact on the quality of patient care and total NHS 
expenditure.  Although  many  GPs  are  generally  efficient  in  their  role,  inappropriate 
prescribing does occur in general practice 
6
.  The Accounts Commission Report published 
in  September  1999 
2  highlighted  current  attempts  at  improving  the  quality  and  cost 
effectiveness of prescribing, which it claimed would lead to annual savings in the region of 
£26 million in Scotland if half of these improvements were achieved.  These include: 
•  Generic prescribing 
The prescribing of generic drugs has continued to rise from around 40% in 1992/1993 
to  almost 67%  in 1998/1999.  Although this  increase  was  already  3.5%  higher than 
previous year, there was still significant variation among Health Boards, ranging from 
50% in Shetland to 74% in the Lothian area 7.  Substantial savings have been generated 
through  increased  generic  substitution,  especially  in  the  mid  1990s.  However,  the 
House of Commons Select Committee on Health recently reported on the increase in the 
price  of generic  drugs,  and  as  much as  500%  increase  has  been observed,  possibly 
related to the shortage of some generic drugs 
8
. 
•  Substitution of therapeutically similar drugs 
Where  efficacy  and  safety  are  not  compromised,  cheaper  alternatives  should  be 
considered.  However,  well-conducted  pharmacoeconomic  evidence,  assessing  all 
aspects of cost implications, is essential to assist such prescribing decisions. 
•  A  void premium priced preparations 
Preparations  such  as  slow  release  or  effervescent  preparations  which  are  more 
expensive  than  the  basic  formulations  should  be  avoided.  They  do  not  offer 
pharmacological  advantages  to  the  majority  of  the  patients  for  whom  they  are 
23 prescribed and should be reserved for a more highly selected patient group who would 
benefit the most. 
•  Reduce prescribing of drugs of limited clinical value 
Since  1999,  a category of drugs considered by the Joint Formulary Committee to  be 
"less  suitable  for  prescribing"  has  been  included in the  British  National  Formulary 
(BNF)
9
•  These  are  drugs  that  are  not  normally  considered  as  a  first  choice  for 
treatment, although their use may be justifiable in certain patient groups and specific 
combinations of disease states (co-morbidity). The main drugs in this group included 
combination analgesics, peripheral vasodilators and compound bronchodilators.  Social 
audit has estimated that over £100 million is spent on preparations that the BNF deems 
less suitable 
9
•  This has provided an indication of the level of potentially inappropriate 
prescribing. 
•  Reduce the use of over-prescribed drugs 
Antibacterials, hypnotics and anxiolytics are all classes of drugs recognised as having 
been over-prescribed.  In addition to cost implications, over-prescribing has an adverse 
clinical impact.  For instance, the  over-prescribing of antibacterial agents may hasten 
development of resistance by micro-organisms.  This has become a growing concern 
nationally  and  internationally.  In  the  case  of  antibacterials  indicated  for  lower 
respiratory tract disorder,  a recent Scottish Intercollegiate Guideline Network (SIGN) 
guideline 
10  has  suggested  that  a  40%  reduction  in  prescribing  would generate  over 
£1 million savings for  the  NHS  in  Scotland.  The estimated figure  did not take  into 
account  of savings  that  may  be  made  from  reduced  GP  consultations  and  reduced 
management of adverse drug reactions. 
•  Improved management of  repeat prescribing systems 
Repeat  prescribing  has  long  been  target  for  improvement.  Unnecessary  treatment 
should be avoided and reduce  the risk of side  effects  and adverse effects from  drug 
interactions. 
24 General practitioners generally agree with the principles of rational prescribing, however, 
they also recognise that there are circumstances when rational prescribing is impractical. 
Instead  of being  an  outcome  of the  consultation,  a  prescription  may  be  viewed  as  a 
problem-solving tool that could be used to manage a variety of patient situations.  There 
may be instances when prescriptions may be used as a means to cope with a busy workload, 
to manage a distressing patient situation or to maintain a doctor-patient relationship. 
In primary care, the Primary Care Trusts (PCTs) have budgets to manage, and GPs are the 
individuals responsible for prescribing decisions.  The process of drug selection and usage 
is  complex.  In  addition  to  making  choices based on  efficacy  and safety,  GPs  have  to 
account for  related cost issues.  They  are  expected to  work within resource  constraints, 
make optimum use of available resources and recognise the effect their decisions may have 
on the resources and choices available to others. 
There  is  a  general  acceptance  among  GPs  that  costs  should  be  accounted  for  when 
prescribing, and prescribing costs could be reduced without affecting care.  However, there 
is a lack of awareness and a poor perception of the cost of drug therapies among some GPs 
- the cost of cheap drugs is often over-estimated, while expensive ones, underestimated 
11
. 
Therefore, it is important that GPs understand both the evidence for new interventions and 
the potential for cost containment.  A report from the King's Fund 
12 has called for more 
responsibility from  health professionals for  deciding how money should be spent.  It is 
believed that promoting cost awareness may influence GPs' prescribing decisions 
13
. 
1.3  THE ROLE OF ECONOMIC EVALUATIONS IN HEALTHCARE 
1.3.1  Economic Evaluations 
Traditionally, when considering cost issues in the NHS, the purchasing cost of new drugs 
was  simply  compared to  existing  alternatives.  The present healthcare  culture  demands 
proper consideration of the economic aspects of drug therapies.  Health economics is now a 
common  term  in public  policy  documents,  scientific  literature  and  even  the  lay  press. 
'Value for money'  is becoming a major concern for health policy makers, and economic 
25 evaluations have become an important tool in assisting clinical decision-making.  Economic 
evaluation is also an accepted tool for the appraisal of healthcare programmes, and there is a 
growing volume of economic analyses of healthcare worldwide. 
An  economic  evaluation  in healthcare  has  been  defined  as  "a comparative  analysis  of 
alternative courses of action in terms of both their costs and consequences" 
14
.  Economic 
analyses are  comparative analyses  and are  applied to  explicit alternatives.  Whatever the 
alternatives, all the direct (associated with resource use) and indirect (associated with loss 
of production to  society)  costs related to  all  aspects  of managing the  disease  should be 
considered.  These should then be weighed against the benefits, in terms of improvement on 
the length or quality of life. 
Depending  on  the  perspective  of the  study  and  the  question  posed,  different  types  of 
economic evaluations can be adopted: 
•  Cost-consequence analyses - when effectiveness is measured in different disease-
specific  measures,  generally  used to  describe costs  and outcomes.  For instance, 
cost-consequence  analysis  may  be  used  to  determine  whether  a  primary  care 
dermatology liaison nurse should be introduced into a health authority 
15
. 
•  Cost-minimisation analyses- generally used to compare treatments within the same 
disease when the effectiveness of comparators are equal.  For instance, the treatment 
of deep vein thrombosis by in-hospital treatment with unfractionated heparin may 
be compared to  at-home therapy with low molecular weight heparin.  Data from a 
clinical  trial  has  demonstrated  that  the  group  sent  home  to  self-inject  with  low 
molecular weight heparin would experience similar rates of bleeding or deep vein 
thrombosis recurrence as  those kept in hospital.  Since the clinical outcomes have 
been  proven  to  be  equivalent  in  the  two  groups,  analysis  may  be  limited  to 
analysing only the costs 
16
. 
•  Cost-effectiveness  analyses  - when  the  outcomes  or  consequences  of different 
interventions vary but can be measured in identical natural units,  then inputs are 
costed.  Interventions  are  compared  in  terms  of cost  per  unit  of consequence. 
Therefore, the intervention associated with the minimum cost per unit outcome, or 
the maximum outcome per unit cost would be the most cost effective option.  For 
26 instance, the prescribing of antibiotic prophylaxis may be compared with no routine 
prophylaxis  in  women  undergoing  caesarean  section 17.  The  cost  per  adverse 
outcome averted was calculated and compared between the two groups. 
•  Cost-utility analyses - when effectiveness is  measured as  combined survival  and 
quality of life (quality-adjusted-life years); generally used to compare treatments for 
different  diseases.  For instance,  cost-utility  analysis  may be  used  to  determine 
whether resources should be allocated to the treatment of established osteoporosis to 
prevent fractures, considering other uses for the equivalent resources 
18
. 
•  Cost-benefit analyses - when both the inputs and outcomes or consequences of the 
comparative interventions are expressed as  monetary benefit (such as  willingness-
to-pay);  generally  used  to  compare  investments  in  the  health  care  sector  with 
investments  in  other  sectors.  For  instance,  this  may  be  used  to  determine  the 
willingness  to  pay for  carrier screening for  a congenital  deafness  gene  from  the 
perspective of pregnant women 
19
• 
All methods of economic evaluation value both inputs and outcomes or consequences and 
follow  the  same three  steps relating to  both inputs  and outcomes:  (1)  identification,  (2) 
measurement and  (3)  valuation.  There  are  potential  difficulties  in conducting  all  three 
phases of the evaluation.  Identification may be difficult as some health care interventions 
have  hidden  or unknown  costs  and  consequences.  For instance,  when  evaluating  drug 
therapies,  in  addition  to  the  acquisition  cost,  cost  associated  with  administration  and 
management  of  associated  side  effects  (termed  'iatrogenic  costs'  or  'shadow 
costs') 
20
•
21  should be taken  into  account.  This  may  include costs incurred by extra GP 
consultations,  drug  changes,  additional  prescriptions,  investigations,  laboratory 
investigations, outpatient referrals and possibly hospital admissions.  The costs of managing 
adverse drug reactions (ADRs) are substantial, and will be discussed in a later section. 
Measurement  of  outcomes  is  not  always  straight  forward  as  there  are  costs  and 
consequences  that  cannot  be  measured  in  appropriate  physical  units  due  to  intangible 
outcomes  such  as  the  reduction  of pain.  Valuing  inputs  and consequences  is  the  most 
difficult aspect of conducting an economic evaluation and the most difficult for health care 
professionals to interpret, as in reality the only readily available measures of value, prices, 
27 exist only where there are true markets, and these cover only a minority of health inputs and 
consequences. 
This thesis focuses on the economic analyses of the 'iatrogenic costs' or the 'shadow costs' 
associated  with  drug  treatments  - non-steroidal  anti-inflammatory  drugs  (NSAIDs), 
selective reuptake serotonin inhibitors (SSRis) and angiotensin converting enzyme (ACE) 
inhibitors for the management of rheumatoid arthritis (RA),  depression and hypertension, 
respectively.  These drugs, each within their own pharmacological family  share the  same 
mechanism of action and have been demonstrated in clinical trials to have equal efficacy. 
1.3.2  Perspective Worldwide 
In response to recognising the role of economic evidence in clinical decision making, many 
countries  have  made  it mandatory  by law  to  include  proof of cost effectiveness  when 
applying  for  licensing  of new  drugs.  Some,  such  as  the  UK,  have  chosen  to  set  up 
specialised groups to  assess current and new therapies, with economic analysis an integral 
part of such assessment. 
Australia was the first country to make submission of proof of cost effectiveness an official 
requirement before pharmaceuticals can be reimbursed for the Australian Pharmaceutical 
Benefits Scheme in 1993 22.  This policy was enacted at the time when drug prices and the 
annual increase in the Australian drugs bill were below the developed world average.  In 
November 1994, Canada was the next to follow suit.  The Canadian Co-ordinating Office 
for  Health  Technology  Assessment  (CCOHTA)  issued  a  set  of national  guidelines  for 
economic  evaluations  of  drugs 
23
.  Since  September  1995  applications  to  Ontario's 
provincial drugs reimbursement formulary  would be considered incomplete if they do  not 
include economic analysis of the drug in question.  In 1997, the World Health Organisation 
(WHO) produced a draft working party document arguing that "sharper questions must be 
asked about final impact of new products before any decision is taken on investing public 
funds in their use" 
24
.  To date, countries including New Zealand, Finland, Norway and the 
Netherlands  have  made  the  submission  of  proof  of  cost  effectiveness  a  mandatory 
requirement for all new drugs, introducing a 'fourth hurdle' to the three existing assessment 
criteria for new therapies-efficacy, safety and effectiveness. 
28 The National Institute for Clinical Excellence (NICE) 
Although  the  Department of Health  has  been promoting cost-effective  initiatives  in  the 
pharmaceutical field, this has not yet extended to licensing.  Over 95% of the drugs on the 
UK market are authorised by the licensing authority, acting through the Medicines Control 
Agency (MCA).  A  small number are now licensed throughout the EC via a centralised 
procedure,  regulated by the  European Agency for  the  Evaluation of Medicinal Products 
(EMEA).  Prior to authorisation, the EMEA or MCA assess the safety, efficacy and quality 
of a drug.  New drugs must be shown to be at least as safe as existing therapies, and also 
show comparable efficacy.  If no suitable comparator exists, then efficacy must be shown to 
be superior to placebo.  While the regulators consider the overall clinical benefit, they do 
not consider the cost effectiveness of the drug. 
In April 1999, the National Institute for Clinical Excellence (NICE) was set up in the UK to 
evaluate  clinical  and cost effectiveness  of new  and existing pharmaceuticals  and  health 
technologies,  and to  prepare guidance on how  they  should be used appropriately by the 
English and Welsh NHS.  The role of the institute is to  promote the use of cost-effective 
treatments,  while  ensuring  that  the  availability  of these  treatments  does  not  vary  by 
geographical  distribution  or  postcode.  Existing  and  new  evidence  contained  in  the 
manufacturers'  submissions  for  drugs  and  technologies  are  reviewed  before 
recommendations are disseminated to health professionals. 
The first NICE recommendation to the NHS was issued in 1999, against the prescription of 
zanamivir  for  the  treatment  of influenza  virus  infection 
25
.  Although  zanamivir  was 
approved by the MCA for its indication, NICE cited evidence which showed only modest 
benefit in otherwise healthy individuals with influenza and at a significant cost.  In addition, 
NICE decided that insufficient evidence was available for recommendations on the use of 
zanamivir in high-risk patient groups. 
Although NICE has not formed a complete barrier to the reimbursement of new drugs, since 
the beginning of 2002 
26
,  health authorities are obliged to  fund treatments based on their 
recommendations.  Some  of the  recommendations  have  been  controversial  and  health 
authorities  have  shown  reluctance  in  allocating  additional  resources  to  implement  the 
guidance 
27
. 
29 Health Technology Board for Scotland CHTBS) 
The Health Technology Board for Scotland (HTBS) was set up  in November 1999.  The 
objective of the board was  to  act as  a national resource  of information and independent 
advice  on  clinical  and  cost  effectiveness  on  new  and  existing  health  technologies  to 
decision makers in local Drugs and Therapeutics Committees (DTC), Health Boards, NHS 
Trusts, and the Scottish Executive Health Department.  The Health Technology Board for 
Scotland was designed to undertake assessment on health technologies that have not been 
reviewed by NICE and provide advice and guidance on NICE technology appraisal in the 
Scottish context. 
To date,  the  HTBS  has completed  14  health technology  assessments  and made over 20 
comments on NICE guidance.  However, its approach to health technology assessment and 
its  efficiency  in  producing  comments  and  guidance  have  been  heavily  criticised.  The 
Health Technology Board for  Scotland has  adopted an  open and consultative process to 
assessing  new  health  technologies  in  attempt  to  reflect  voices  of individual  healthcare 
sectors within the NHS  in Scotland.  Specialised experts in appropriate areas of expertise 
have been invited to review HTBS  assessment reports.  However, these experts are  often 
not representative  of general  clinical  practice.  There  have  also  been doubts  about  the 
practical applications of the HTBS comments that are issued generally six to ten weeks after 
the NICE guidance documents are published. 
In October 2002, the HTBS merged with the Clinical Standards Board for Scotland and the 
Scottish Health Advisory Service to  create the Quality and Standards Board for Health in 
Scotland.  It is believed that the objectives and functions of the HTBS would remain similar 
to those when it was founded in 1999. 
SUMMARY 
The  expenditure  on  drugs  in primary  care  will  continue  to  nse.  In  response  to  this, 
literature  on prescribing management is  growing  and budgetary reforms  are  introduced. 
30 The  establishment  of NICE  and HTBS  in  the  UK have  highlighted the  importance  of 
economic evaluations at national policy level.  However, their impact on clinical practice 
and health costs has been difficult to  measure.  In addition, the optimum strategy for the 
design and effective dissemination of these economic materials is still unclear. 
1.4  STRUCTURE OF THE THESIS 
This  thesis  reports  on  two  closely  related  areas  of research.  Firstly,  it  describes  the 
economic  burden  of ADRs;  then  it  describes  the  impact  of economic  information  on 
decision  making  in  primary  care.  These  distinct  themes  are  reported  in  such  order 
throughout the thesis. 
In order to explore the clinical and economic burden of ADRs in different classes of drugs, 
this thesis used three different classes of drugs as  examples - NSAIDs, SSRis and ACE 
inhibitors in the management of RA, depression and hypertension, respectively.  Due to the 
limited financial scope of the PhD, two different types of ADR data had to be used.  Firstly, 
this thesis reports on a large-scale population study, which estimated the substantial costs 
resulting from drug-associated adverse events while on NSAIDs.  This is followed by three 
meta-analysis-based economic analyses of NSAIDs, SSRis and ACE inhibitors.  It is worth 
noting that the cyclo-oxygenase II inhibitors that selectively target specific inflammatory 
receptors are not included in these analyses due to the different mechanism of action from 
the "traditional" NSAIDs. 
The impact of economic information on decision making in primary care was explored in a 
dissemination exercise and a postal survey, and are reported in subsequent chapters of this 
thesis.  On reviewing the results, an additional qualitative study was introduced to explore 
in-depth,  the  implications  of the  findings  of the  dissemination  exercise  and  the  postal 
survey. 
To avoid excessive fragmentation of the text in the chapters, all the tables and figures have 
been located at the end of the thesis. 
31 2  AIMS AND OBJECTIVES AIMS AND OBJECTIVES 
2.1  STUDY AIMS 
An  initial  literature  review  showed  that  despite  the  growing  literature  on  econonnc 
evaluations on healthcare, there is limited evidence on the role of economic information on 
medical  decision-making,  in  particular,  relating  to  prescribing  issues.  This  study  was 
planned to examine the role of pharmacoeconomic information in primary care prescribing. 
In doing this, two broad aims were developed: 
•  the first aim was to investigate the effect of incorporating adverse drug reactions in 
economic evaluations of drug therapies; 
•  the second aim was to  investigate the impact of this information on prescribing in 
pnmary care. 
2.2  STUDY OBJECTIVES 
This study had seven objectives, which were developed from the study aims.  The first five 
objectives relate to the first aim while the remaining two objectives address the second aim 
of the study.  The study objectives were: 
1.  to evaluate the cost associated with the use of NSAID therapy in a Scottish population 
based on epidemiological data from a population database; 
2.  to  evaluate the  cost associated with NSAID  therapies in the treatment of rheumatoid 
arthritis, based on data reported in clinical trials and expert opinion; 
3.  to evaluate the cost associated with SSRI therapies in the treatment of depression, based 
on data reported in clinical trials and expert opinion; 
32 4.  to  evaluate  the  cost  associated  with  ACE  inhibitor  therapies  in  the  treatment  of 
hypertension, based on data reported in clinical trials and expert opinion; 
5.  to  examine  the  use  of data  from  a  population  database  compared  to  randomised 
controlled trials; 
6.  to  investigate  the  effect  of disseminating  economic  information  on  pnmary  care 
prescribing; 
7.  to  examine  the  role  of economic  information  on  primary  care  prescribing from  the 
perspective of GPs. 
2.3  STUDY HYPOTHESES 
A limited set of hypotheses was  developed from  the above objectives.  These have been 
expressed as experimental hypotheses.  The first three hypotheses address the first aim of 
the study while the remaining two objectives focus  on the second aim of the  study.  The 
study hypotheses were: 
1.  some  drugs  of the  same  pharmacological  family  have  been  shown  to  have  equal 
efficacy, however, these drugs may have different adverse drug reaction profiles; 
2.  the cost associated with treating adverse drug reactions is substantial; 
3.  drugs that are the cheapest to purchase are not necessarily the most cost effective to use; 
4.  targeted dissemination of pharmacoeconomic information can be used to help influence 
primary care prescribing; 
5.  general practitioners believe that economic information has a role in medical decision 
making. 
33 3  ECONOMIC EVALUATION AND 
MEDICAL DECISION MAKING: A 
CRITICAL LITERATURE REVIEW ECONOMIC  EVALUATION  AND  MEDICAL  DECISION 
MAKING: A CRITICAL LITERATURE REVIEW 
3.1  INTRODUCTION 
This literature review is split into two main sections according to the aims - the inclusion of 
ADRs in economic evaluation of drug therapies (Section 3.2), and the impact of economic 
information on decision making in primary care (Section 3.3). 
The review in Section 3.2 has been designed to address the following questions: 
•  What is the incidence of ADRs? 
•  What are the clinical and economic consequences associated with ADRs? 
The first section first looks at the broad issue,  and then specific sections are  given to  the 
three classes of drugs focused by this thesis - NSAIDs, SSRis and ACE inhibitors. 
The  published  evidence  on  the  incidence  of ADR-related  morbidity  and  mortality  is 
reviewed.  Section 3.2.1 discusses and evaluates the various sources of ADR data.  Section 
3.2.2 assesses the ADR incidence reported by studies of spontaneous reporting systems, the 
ADR incidence in hospital patients, including ADR-related hospitalisations, inpatient ADR 
incidents  and  ADR-related  death  found  in  studies  of hospital  patients  and  the  ADR 
incidence in primary care.  The clinical and economic consequences associated with ADRs 
are discussed in Section 3.2.3. 
The next section (Section 3.3) discusses  the findings  of the  studies that investigated the 
impact of economic information on medical decision making in primary care.  The extent of 
knowledge  (Section  3.3.1)  and use  (Section  3.3.2)  of health economics in  primary  care 
decision makers,  in particular among GPs  are  reviewed.  In  addition,  the  source of such 
information is  examined (Section 3.3.3).  Finally,  the barriers to implementing economic 
information in primary care are discussed (Section 3.3.4). 
The extensive literature review conducted on ADRs associated with NSAIDs, SSRis and 
ACE inhibitors is described in the methods section (Section 4.3.1) and the results section 
(Section 5.3). 
34 3.2  THE INCLUSION OF ADVERSE DRUG REACTIONS IN ECONOMIC 
EVALUATIONS 
All drugs undergo a lengthy process of evaluation on efficacy, safety, effectiveness and cost 
effectiveness  prior  to  licensing.  Even  when  used  according  to  its  indication  and  at 
recommended daily doses, no drugs are entirely safe and without a toxicity profile.  Optimal 
drug use is dependent upon the risk-benefit balance.  Adverse drug reactions (ADRs) refer 
to  adverse effects resulting from  appropriate use of medicine, rather than due  to  medical 
error.  The World Health Organisation has defined ADR as:  "a  response to a drug that is 
noxious and unintended and occurs at doses  normally used in  man for the prophylaxis, 
diagnosis or therapy of disease,  or for modification of  physiological function" 
28
•  In the 
UK,  the  Committee  of Safety  of Medicine  (CSM)/Medicines  Control  Agency  (MCA) 
defines  an  ADR  as:  an  unwanted  or  harmful  reaction  experienced  following  the 
administration of a  drug  or combination of drugs  under normal  conditions of use  and 
suspected  to  be  related  to  the  drug" 
29
.  This  thesis  refers  to  ADRs  based  on  these 
definitions and does not include events that resulted from inappropriate use of drugs, non-
compliance and medical negligence. 
Adverse  drug  reactions  are  generally  mild  (e.g.  mild  sedation  from  antihistamines); 
although rare, serious ADRs (e.g. haemorrhage from anticoagulation therapy) may lead to 
hospitalisation  and  occasionally  death.  Therefore,  ADRs  are  a  serious  issue  and 
management of these  events  may  be  associated with  a  substantial  health  and economic 
impact to  the  health  service  and  to  society.  This  is  discussed in later  sections  of this 
chapter. 
3.2.1  Source of Adverse Drug Reaction Data 
Drug safety takes an equally important role alongside drug efficacy in pre-marketing drug 
development.  Similarly, ADRs are monitored post-marketing alongside the effectiveness of 
drug therapies.  All developed countries have some form of spontaneous reporting scheme 
to monitor adverse drug reactions continuously since the thalidomide disaster in 1961.  In 
the  UK,  the  Yell  ow  Card Scheme has been set up  to  encourage reporting  of suspected 
ADRs by healthcare professionals such as  doctors, dentists, coroners, pharmacists and the 
pharmaceutical industry.  This scheme was later extended to  include reporting by nurses, 
35 midwives and health visitors in 2002, and a pilot patient reporting scheme was introduced 
in 2003. 
An  alternative  to  the  Yell  ow  Card  Scheme  is  prescription  event  monitoring  (PEM) 
undertaken by  the  Drug Safety Research  Unit (DSRU)  at Southampton 
30
.  The DSRU 
focuses on a limited number of drugs (10 to  12) at any one time.  The Prescription Pricing 
Authority (PP  A) in England receives records of all dispensed prescriptions in England and 
forwards all the records of prescriptions for the drugs of interest to  the DSRU.  A  'green 
form' is then sent to the prescribing GP enquiring details of any ADRs in the patients who 
were prescribed the drugs of interest.  Unlike the Yell ow Card Scheme, both the numerator 
(returned 'green forms') and denominator in the ADR incidence rate calculation (number of 
dispensed drugs  of interest)  are  known and overall,  the  PEM scheme is  less  limited by 
under-reporting. 
Despite  not  being  designed  with  the  objective  of monitoring  ADR,  there  are  several 
epidemiological databases that contain data that may be potentially used for researching in 
ADRs. 
One of the most extensive database of this kind is the General Practice Research Database 
(GPRD)  which  contains both prescribing  and diagnostic  data 
31
.  The  GPRD  currently 
receives data from approximately 525 practices (3.4 million patients, over 30 million years 
of prescribing histories), recording every prescription and all significant morbidity.  This 
database  can  be  analysed  to  provide  information  on  patients  with  selected  diseases 
prescribed specific drugs.  Although diagnoses are based solely on clinical judgement, the 
data have  been found to  be  reliable  and accurate  when compared to  other sources  (e.g. 
consultants' letters, hospital discharge letters, or questionnaire surveys with GPs). 
Mediplus  is  a  second  dynamic  pnmary  care  database,  most  commonly  used  by  the 
pharmaceutical industry 
32
.  It contains extensive data on patient demographics, morbidity, 
prescribing and mortality.  Over 148 practices serving approximately 1.8 million patients 
participate in this data collection system.  Although under-represented in Scotland, the data 
are believed to be representative of the UK as a whole.  The data has been captured- during 
primary  care  consultation  and  from  other  information  received  in  the  practice  -
systematically, encoded and stored electronically in formatted records and updated monthly. 
The  main  data  set  contains  details  of  patients,  prescriptions,  diagnoses,  symptoms, 
36 observations and tests in primary care, secondary referrals and main outcome of referral. 
Linkage between diagnosis  and prescriptions  is  possible,  but inappropriate linkage may 
cause problems with interpretation of data.  The major limitation to Mediplus however, is 
the cost of accessing the database.  Mediplus is a privately owned database and subscription 
to  the database may cost as much as £25 000 per year.  Therefore, Mediplus is primarily 
used by the pharmaceutical companies for marketing purposes. 
In Scotland, the development of the General Practice Administration System for Scotland 
(GPASS) 
33  and  Continuous  Morbidity  Recording  (CMR) 
34  in  recent years  has  shown 
positive signals in producing a comprehensive database for primary care research.  Over 
80%  of all  practices  in Scotland participate in  a  national  Scottish computer system for 
general practice - GPASS,  which was set up primarily to collect data for  administrative 
functions.  Data from individual practices such as patient registration, repeat prescriptions, 
call  and recall,  health  promotion  and  immunisation  have  been  captured via  Electronic 
Questionnaires (EQ).  Reports on the practice data can be generated, in particular, on areas 
of health promotion, chronic disease management and patient summaries, which has been 
extremely useful to GPs.  Based on the original EQ, the GPASS Data Evaluation Project 
(GDEP) has redeveloped the data capture system to collect anonymous data at patient level 
from over 400 practices (approximately 2.8 million patients).  The GPASS Data Evaluation 
Project has created an extensive primary care database, where relevant patient data can be 
extracted,  interpreted  and compared regionally  and nationally,  with  the  aid of software 
utilities  such  as  Prescribing  Analysis  Tools 
35
,  Practice  Report Utility 
36
,  among  others. 
Feedback  on  individual  practice,  regional  and  national  data  has  been  distributed  bi-
annually. 
Continuous Morbidity Recording is a three-way collaboration between the Information and 
Statistics Division (lSD), Department of General Practice at the University of Aberdeen and 
the Scottish Centre for Infection and Environmental Health (SCIEH), which began as a pilot 
project in 1992.  The project has now evolved into an invaluable national source of primary 
care  morbidity  data  from  over  60  practices  throughout  Scotland 
34
,  and  participating 
practices cover all but two health board areas - Orkney and the Western Isles. 
Continuous  Morbidity  Recording  is  generating  a  database  of active  morbidity  and  GP 
workload.  Morbidity information is collected on a continuing basis from all face-to-face 
consultations between patients and GPs.  Based on the development of the EQ, the CMR 
37 project has been developed to collect and analyse  additional data from the daily work of 
general practice: the patients, symptoms, disease, consulting and prescribing behaviour and 
geographical and socio-economic patterns, including deprivation.  Details of each doctor-
patient contact - at surgeries, home visits or clinics - has been recorded.  However, no data 
are collected about prescribing, direct data entry (health promotion and administration) or 
nurse-led clinic activities.  CMR data provide insight into demand for GP services and can 
be extrapolated to  provide estimates of workload at national level.  However,  due  to  the 
small  number of participating practices  at present,  the  patient population covered is  not 
representative of Scotland as a whole in terms of age, geography and deprivation. 
3.2.2 The Incidence of Adverse Drug Reactions 
Spontaneous Reporting 
Since  1964,  when  the  scheme  was  set  up,  over  400  000  suspected  ADRs  have  been 
reported.  In the year 2000 alone, over 33  000 reports were submitted to the Yellow Card 
Scheme, most were associated with the Meningitis C vaccine 
37
.  Despite some success in 
identifying ADRs such as remoxipride and aplastic anaemia, the main limitation of under-
reporting remain.  A large retrospective review of case notes has revealed that only 2%  to 
4%  of all  ADRs 
38  are  reported  through  spontaneous  reporting.  Similarly,  it has  been 
reported that only 10% of serious ADRs are reported through spontaneous reporting 
39
. 
In 2002,  1369 suspected ADRs were reported to  the  CSM in Scotland 
40
.  Assuming that 
due to under-reporting only 2% to 4% of all ADRs are reported 
38
, the expected number of 
ADRs is  approximately 34 225  to  68  450.  In the  same year,  approximately 66.2 million 
prescription items were dispensed in Scotland (equivalent to  12.4 prescriptions per patient 
on  GPs'  list) 
41
,  giving  an ADR incidence rate  of approximately 0.05%  to  0.10%  of all 
prescriptions.  However, the severity of the ADRs and the proportion of patients who seek 
or require medical treatment are unclear. 
38 Incidence of ADR in Hospital Patients 
Although data from spontaneous reporting schemes gives an indication of the incidence of 
ADRs, the risk, management and cost of ADRs associated cannot be determined.  In order 
to  examine  these  issues,  specifically  designed studies need to  be undertaken.  The risk, 
management and cost of ADRs are not widely investigated.  Studies that have attempted to 
investigate  the  incidence  of ADRs  in  the  medical  literature,  have  focused  primarily on 
serious  events  that  led  to  hospitalisation  or  ADRs  that  occurred  in  patients  whilst  in 
hospital. 
An  early  systematic  review  (1993) 
42  of drug-related  hospital  admissions  (defined  as 
admissions resulting from a patient's non-compliant or unintentionally inappropriate drug 
use),  examined  the  findings  of 36  studies  published  between  1966  and  1989.  The 
prevalence  of the  pooled admissions  resulting from  ADRs  was  5.1%  (95%  CI 4.4%  to 
5.8%).  Of these ADR admissions, 71.5% were classed as "side effects", 16.5% "excessive 
effects", 11.3% hypersensitivity reactions and 0.4% idiosyncratic; 5% of admissions due to 
ADR resulted in mortality. 
In  a  meta-analysis  of 39  prospective  studies  published  from  1966  to  1996  from  US 
hospitals 
43
,  serious  ADRs  were  defined  as  those  requiring  hospitalisation,  were 
permanently disabling  or resulted in  death.  The incidence of serious ADRs that led to 
hospitalisation (4.7%;  95%  CI 3.1% to  6.2%) was combined with the incidence of ADR 
whilst in  hospital  (2.1 %;  95%  CI  1.9%  to  2.3%)  to  determine  the  overall  incidence  of 
serious  ADRs  in  hospital  patients  (6.7%;  95%  CI  5.2%  to  8.2%).  Fatal  ADRs  were 
estimated in 0.32% of all hospitalisations.  A similar overall ADR incidence (6.7%; 95% CI 
6.6% to 6.8%) was estimated in a more recent systematic review and meta-analysis of data 
from 69  studies conducted worldwide published between 1966 and 1999 
44  (US  studies = 
21,  European  studies excluding UK and Ireland = 21  and studies based in the  UK and 
Ireland = 7).  However,  when the  analysis  was  stratified by  geographical setting,  it was 
found that ADR incidence based on data from the UK (7.5%; 95% CI 7.2% to 7.8%) and 
Europe (14.1 %;  95%  CI  13.8%  to  14.3%)  were  significantly higher those reported from 
North American studies (4.6%; 95% CI 4.5% to 4.7%). 
Beijer and de  Blaey (2002) 
45  conducted a systematic review on the rate of ADR-related 
hospitalisation.  Sixty-eight studies from the US  (n =  25), Europe (n =  19) and Australia (n 
39 = 15) were included in the review.  Adverse drug reactions were defined according to the 
WHO definition.  The studies reviewed varied considerably in sample size (ranging from 41 
to  24 000)  and  observed  ADR-related  hospitalisation  (ranging  from  0.2%  to  41.3%). 
Aggregated ADR incidence rates calculated from two different methods were presented: (1) 
a  proportion  calculated  by  the  number  of total  ADR-related  hospitalisations  across  all 
studies  divided by  the  total  number of hospitalisations  across  all  studies  (4.9%;  95%CI 
4.8%  to  5.0%);  (2)  an  average  of the  proportions  of ADR-related  hospitalisation  as 
published in individual studies (12.5%; 95%CI 9.9% to 15.1 %). 
Although no  formal  analysis  of heterogeneity  was  undertaken,  it is  apparent that much 
inconsistency exists between the individual studies included in the reviews.  However, the 
estimated overall incidence of ADR in hospital patients was relatively consistent among the 
systematic reviews,  with overlapping confidence intervals.  Therefore, it is reasonable to 
suggest that the incidence of ADRs in hospital patients fall  within the  range  of 4.4%  to 
15.1%. 
Incidence of ADR in Primary Care 
To date,  no  systematic review has been conducted to evaluate the incidence of ADRs in 
general practice and little is known.  However, the lack of data reflects on the difficulty in 
conducting  research  in  this  area.  The  largest  survey  of ADRs  (based  on  the  WHO 
definition) in general practice in the UK was conducted by Lumley CE et al (1986) 
46
, when 
data  were  collected  from  24  training  practices  in  a  health  region  (former  South  West 
Thames)  in England,  over  a period of four  weeks  (n  =  100).  Of 36 470  consultations 
evaluated,  1.7%  reported ADRs  (n = 638  consultations).  In approximately half of these 
cases  (0.8%),  the  ADR was  the  cause  of the  GP consultation.  However,  only  1.6%  of 
ADRs  reported  (arising  in  0.027%  of  consultations)  were  judged  to  be  senous. 
Cardiovascular drugs and diuretics were the most frequently involved drugs (23%), while 
gastrointestinal (GI) disturbance was the most frequently observed ADR (13%). 
The  most  recent  study  was  conducted  by  Lacoste-Roussillon  C  et  al  (2001) 
47
.  A 
prospective study of the incidence of serious ADRs (based on the WHO definition) in 254 
GPs was conducted in France.  During a five-day period,  13  validated serious ADRs (two 
were fatal) were observed, representing an "incidence density" of 10.2 (95% CI 5.4 to 17.5) 
40 per 1000 days of practice.  If this was extrapolated to  the 60 000 active GPs in France, it 
could be estimated that 123 000 (95% CI 65 400 to  210 000) serious ADRs are seen each 
year by GPs in France.  In this study, antineoplastic and anticoagulant agents were the most 
frequently involved drugs (seven cases), while blood dyscrasia and bleeding were the most 
frequently observed ADRs. 
This thesis focuses  on three different classes - NSAIDs,  SSRis and ACE inhibitors - of 
drugs  with  different mechanisms  of action  for  their  intended  effects.  These  drugs  are 
associated with different ADR profiles, which are discussed below. 
Non-steroidal Anti-inflammatory Drugs 
Non-steroidal  anti-inflammatory  drug  therapy  is  the  dominant treatment in arthritis  and 
musculoskeletal conditions.  The use of these drugs is extensive.  In the UK alone, over 20 
million prescriptions are made for NSAIDs annually, accounting for approximately 5% of 
all the NHS prescriptions 
48
. 
These drugs are extremely effective in appropriately maintained dosages. Currently, there is 
no established method to predict which NSAID will be the most effective for an individual 
patient, but minor differences in efficacy have been found.  Statistically, all  NSAIDs are 
similar  in  potency  despite  consistent  but  unexplained  inter-patient  variability  in  both 
efficacy  and adverse  drug  reactions  profiles.  However,  attention has  been increasingly 
focused upon inherent safety problems, and the size of the problem associated with NSAID-
induced adverse drug reactions is highly significant.  In 1986, the CSM reported that 25% 
of all  the  'yellow  card'  reports  received  in  the  UK are  NSAIDs-related 
49
.  The  most 
frequent, as well as the most severe adverse drug reactions, are located in the GI tract, other 
adverse events are related to the central nervous system (CNS), the kidneys,  the liver, the 
blood  and  the  mucocutaneous  system 
50
•
51
•  There  is  emerging  evidence  of substantial 
differences in toxicity between in NSAIDs 
52
. 
A number of studies  have  been dedicated to  NSAID-induced GI  toxicity.  Gastropathy 
induced  by  the  treatment  with  these  drugs  is  undoubtedly  the  most  common  adverse 
reaction related to the regular use of NSAIDs 
53
-
56
. 
41 Mild GI complications are common, such as dyspepsia, diarrhoea, constipation and gastric 
mucosal damage (with endoscopic evidence of gastritis).  It has been suggested that 5 to 
50% of the patients on NSAID therapy would experience dyspepsia 
57
•
58
. 
Serious  and  often  life-threatening  events  have  also  been  reported  such  as  peptic  ulcer 
disease and upper GI bleeding 
59
•  The incidence of peptic ulcers  (gastric and duodenal) 
range from 10 to 40% of patients who are on NSAID therapy 
60
.  Clinically important peptic 
ulcer  caused  by  NSAIDs  can  occur  in  mucosa  inflamed  because  of infection  with 
Helicobactor pylori or in  histologically  normal  mucosa.  A  study  carried  out  in  1992, 
evaluated  GI  damage  in  713  post  mortems  conducted  on  a  random  series  of hospital 
patients, of whom 249 had taken NSAIDs.  Peptic ulcer was found in 20%  of the NSAID 
users compared with 12% in non-NSAID users 
61
.  In addition to an association with gastric 
ulceration, NSAIDs are also believed to inhibit epithelial regeneration at the edge of gastric 
ulcers, thereby delaying ulcer healing 
62
. 
In  1983,  Venning  published  a  series  of articles  in  the  British  Medical  Journal  on  the 
"identification of adverse reactions to  new drugs" 
63
.  He suggested that the fatal reports 
related to NSAID-induced GI bleeding indicated that it was the third most important drug-
induced cause of death between 1964 and 1980.  Independent studies have indicated that the 
relative risk of ulcer complications for  NSAID  users is  approximately four times  higher 
than  non-users 
64
•
65
•  Estimates  show  that  0.7%  to  1%  of  regular  NSAID  users  are 
hospitalised as a result of upper GI bleeds 
66
. 
Co-prescribing GI protective drugs such as  antacids, H2 blockers, misoprostol and proton 
pump inhibitors are common procedures in treating mild GI adverse drug reactions due to 
NSAIDs.  However, in cases when the symptoms are severe, further investigations such as 
endoscopy or gastric biopsy and hospitalisation may be required.  These procedures make a 
significant contribution to the cost of NSAID therapy. 
Renal dysfunction is a recognised complication of oral NSAIDs.  These drugs may induce 
fluid  and  electrolyte  disorders  and  both  acute  and  chronic  renal  failure 
67
.  The  most 
common renal  adverse  effect is  haemodynamically  mediated,  resulting  in depression  of 
renal  function,  which  is  usually  completely reversible  within  24  to  72  hours  following 
discontinuation of the  drug.  Interstitial nephritis is  an  extremely rare  and idiosyncratic 
event which has been described with many NSAIDs 
52
•
68
. 
42 It has been estimated that approximately 5 to  18% of outpatients receiving NSAIDs have 
renal impairment and the impact on the kidney is the greatest among these patients (usually 
the elderly) who depend on the  synthesis of vasodilatory prostaglandin to  maintain renal 
homeostasis.  There is increasing awareness of the difference in the extent of renal damage 
induced by individual NSAIDs 
60
•  It is believed that drugs  with high renal clearance of 
active metabolites, such as indomethacin and naproxen, are more toxic to the kidneys 
69
. 
Isolated cases of hepatic damage have been noted with almost all NSAIDs in clinical use. 
The severity of liver disease has varied from mild asymptomatic elevation of one or more 
hepatic  enzymes  to  severe  hepatocellular injury  resulting in death,  but these  events  are 
generally uncommon.  Case reports  suggest that NSAIDs  may be  associated with liver 
disease,  but it appears  that  the  risk is  very  small 
70
.  It is  believed  that  greater  risk  is 
observed in RA patients and in those who were concomitantly exposed to other potentially 
hepatotoxic drugs.  One study estimated the incidence rate of acute liver injury induced by 
regular use of NSAIDs to be one per 100 000 prescriptions (equivalent to four per 100 000 
users) 
71
.  These events  are  generally  mild and  are  usually  reversible  with  reduction  in 
dosage or discontinuation of the drug. 
Second to GI toxicity, skin reactions due to NSAIDs are common.  Although these reactions 
(including pruritis  and non-specific rashes)  are  relatively mild in nature,  fatal  reactions, 
including  erythema  multiforme,  have  been  reported.  Most  cases  of  dermatological 
reactions improve when the NSAID is discontinued.  Generally, no treatment is required but 
antihistamines are  sometimes prescribed to  alleviate itching.  It was suggested that drugs 
with  long  half-lives,  such  as  piroxicam,  are  more  commonly  associated  with  adverse 
cutaneous reactions 
72
. 
All  NSAIDs  have  been implicated in adverse events in  the  CNS,  and up  to  10%  of the 
regular NSAID users suffer a variety of these symptoms.  These include severe headache, 
dizziness, trouble with thinking, tinnitus and blurred vision.  Headache is the most common 
NSAID-induced  CNS  side-effect,  particularly  with  patients  taking  indomethacin 
73
. 
Tinnitus is reported rarely, commonly observed in subjects with high doses of salicylates, 
e.g. Aspirin, who also experience a reversible sensorineural hearing deficit of up to 30 - 40 
decibels  across  all  frequencies.  More  severe  side-effects  such  as  aseptic  meningitis, 
psychosis  and  cognitive  dysfunction  have  been documented.  However,  these  cases  are 
43 extremely rare and have not been reported in the clinical trials or post-marketing studies 
consulted in this study 
74
. 
Haematological disorders include aplastic anaemia, agranulocytosis, thrombocytopenia and 
haemolytic  anaemia 
75
•  Agranulocytosis  tends  to  develop  primarily in  younger patients, 
often  after  a  few  days  or  weeks  of  NSAID  therapy,  but  is  usually  reversible  on 
discontinuation.  Phenylbutazone-induced aplastic anaemia was listed as one of the 18 most 
important  adverse  reactions  by  Venning  (1983) 
63
.  This  adverse  effect  occurs  more 
frequently  in  the  elderly  and is  more  likely  to  prove fatal.  Recent studies  suggest that 
indomethacin  and  diclofenac  may  cause  more  haematological  toxicity  than  other 
NSAIDs 
55
. 
In addition to  the  above mentioned NSAID-induced drug reactions discussed,  other side-
events have also been observed with NSAID therapy.  These include a variety of disorders 
such as  pulmonary toxicity (commonly observed as  bronchospasm), cardiovascular (CV) 
oedema,  enhanced  mean  arterial  blood  pressure  of  hypertensive  patients,  lethargy, 
palpitations,  amongst others.  However,  these  events  are  extremely infrequent and have 
mostly been reported only in individual case reports 
76
.  Therefore, these secondary events 
are  believed  to  make  little  or  no  contribution  towards  the  economic  consequences  of 
NSAID therapy and have not been included in this evaluation. 
Selective Serotonin Reuptake Inhibitors 
The group of SSRis including fluoxetine, fluvoxamine, paroxetine and sertraline is one of 
the most common classes of drugs used in the treatment of depression.  Although similar in 
efficacy to the traditional tricyclic anticholinergics (TCAs), overall, these drugs have been 
shown to have a superior safety profile, free from anticholinergic, CNS  and CV effects 
77
• 
However,  no  drugs  are  free  of ADRs  and  events  such  as  nausea,  diarrhoea,  insomnia, 
nervousness, agitation and anxiety have been observed with SSRis 
78
-
80
• Selective serotonin 
reuptake inhibitors act by inhibition of serotonin reuptake, resulting in increasing amounts 
of plasma neurotransmitter being available to interact with the receptors.  Therefore, most 
of the  adverse  events  associated  with  SSRis  are  dose  related  and  can be  attributed  to 
serotonergic  effects.  The  typical  ADRs  associated  with SSRis include GI effects,  CNS 
effects and sexual dysfunction. 
44 Compared with  the  use  of NSAIDs,  SSRis  are  associated  with  a less  substantial  ADR 
profile.  Gastrointestinal disturbance are the most frequently reported ADR among patients 
on SSRis 
81
.  Clinical trials have reported GI events such as nausea, vomiting, dyspepsia, 
abdominal pain, diarrhoea and constipation ranging from 6% to 37%.  During the first two 
years of marketing, gastrointestinal ADRs have been reported between 21.1% (paroxetine) 
and 38.8%  (fluoxetine) of patients in the UK 
78
•  In a meta-analysis  of SSRis for  major 
depression 
79
,  gastrointestinal ADRs such as nausea and diarrhoea were shown to be more 
commonly reported - 10.3%  (95%  CI  7.3%  to  13.3%)  and  9%  (95%  CI  4%  to  14%), 
respectively more than those on TCAs.  However, when compared with TCAs, a lower rate 
of constipation was reported (11 %; 95% CI 8% to 14%, less than that observed with TCAs). 
Between  11%  and 26%  of patients  have  reported ADRs  to  the  central  nervous  system 
(CNS) including insomnia, somnolence, tremor, dizziness and headache.  Other ADRs such 
as dry mouth and sweating have been observed in 9% to 30%. 
Sexual dysfunction is  a common characteristic of depression itself,  as  well as  an  adverse 
reaction  to  antidepression  therapy.  Therefore,  the  true  incidence  of sexual  dysfunction 
attributable to  SSRI use is difficult to measure.  Studies have reported incidences ranging 
from 13.5% to 22% based on checklists and spontaneous reporting, respectively.  However, 
systematic enquiry has reported much higher rates of 54% to 65% 
82
. 
Weight gain or weight loss have been reported in approximately 4% of patients on SSRis. 
In  particular,  the  weight  loss  observed  with  the  early  short-term  clinical  trials  with 
fluoxetine have prompted further investigations into fluoxetine  as  a potential weight loss 
agent 
83
.  Although some SSRis are  associated with  weight loss at the  onset of therapy, 
weight is  often regained after six  months and can be followed by additional weight gain 
with long-term use.  Therefore, weight gain has subsequently been shown to be a common 
ADR of long-term SSRI therapy.  Mean weight gains of 6.75 Kg  to  as  much as  10.8 Kg 
have been observed with sertraline and paroxetine respectively, over a period of six to  12 
months in uncontrolled studies 
84
•
85
. 
Cardiovascular ADRs  are  uncommon.  Symptoms  such  as  palpitation  and  hypotension, 
including postural hypotension and tachycardia have been reported in a small proportion of 
45 patients on SSRis.  Collectively, CV events have been reported in 2.6% to 4.1% of patients 
on SSRis 
78
• 
Angiotensin Converting Enzyme Inhibitors 
ACE inhibitors are widely prescribed as a first line therapy in the management of essential 
hypertension,  particularly  in  patients  with  concomitant  diabetes,  renal  disease  and 
congestive  heart  failure.  Their  efficacy  in  reducing  both  mortality  and  morbidity 
associated with hypertension has been shown in many randomised controlled trials. 
However, in treatment of hypertension, patients often receive sub-optimal treatment due to 
poor compliance, intermittent or switched prescriptions.  Termination of use  disrupts the 
consistency of treatment.  Hypertension is asymptomatic; therefore, patients who are treated 
with an antihypertensive agent that causes adverse events may perceive a lower quality of 
life,  although blood pressure is controlled.  This contributes substantially to  patient non-
compliance.  Non-compliance,  in  tum  results  in  rebound  hypertension  and  potentially 
serious CV and renal complications. 
Adverse drug reactions (ADRs) may be one reason for changing or stopping drug use, but 
the proportion of hypertensive patients who change or discontinue treatment because of 
ADRs is difficult to estimate.  A recent pharmacoepidemiology study in Italy showed that 
physicians (N =  1255) considered the main reason for discontinuation and switching to be 
inadequate blood pressure control (51.2% of patients) and adverse drug events (34.5%) 
86
• 
However,  completed  questionnaires  from  4612  patients  in  the  same  study  considered 
ADRs as the major reason for switching (53.3%) followed by inadequate blood pressure 
control (34.1 %). 
Angiotensin converting enzyme inhibitors are generally well tolerated.  The most frequently 
reported adverse effects include headache, cough, dizziness, fatigue and diarrhoea.  Adverse 
events vary among individual drugs  within the class.  Common side effects include rash 
(often alleviated with reduced dose), hypotension (first dose, common among elderly) and 
cough (non-productive, nocturnal and hacking- up to 5% to 15%) 
87
.  Cough is believed to 
be a class effect of the ACE inhibitors, occurring in about 25% of patients.  The cough is 
46 characterised  as  dry,  non productive,  and persistent,  and may be disturbing  enough  to 
prompt discontinuation of therapy. 
Angioedema, often presenting as swelling of the face and neck has also been reported, but 
in less than 1% of all patients.  Although rare, it is potentially life threatening.  Leukopenia 
also occurs rarely, mostly in patients with specific risk factors- severe renal dysfunction or 
vascular  disease 
88
•  Renal  failure  is  also  uncommon,  but may  occur  in  patients  with 
bilateral renal  artery  stenosis or disease  associated with high renin activity  such as  pre-
existing congestive heart failure.  Uraemia is often observed in those who lack careful renal 
function monitoring for example in vulnerable patients 
88
. 
3.2.3  Clinical and Economic Consequences of Adverse Drug Reactions 
The impact of ADRs on healthcare is difficult to estimate.  There is a lack of real patient 
data; therefore, only extrapolation is possible.  By extrapolating the study findings, Lazarou 
J et al (1998) 
43  estimated that over 2.2 million hospitalised patients had serious ADRs and 
106 000 had fatal ADRs in the US,  making these reactions between the fourth  and sixth 
leading cause of death in 1994.  However, this study has been criticised for bias resulting 
from  heterogeneity  between  the  aggregated  data  and  it  is  believed  that  the  estimated 
mortality has been much inflated 
89
. 
The direct  and indirect costs  are  difficult  to  estimate,  as  data on  the  consequences,  in 
particular on healthcare resource use of most ADRs are very limited.  The costs of incidents 
where ADRs are probable causes of death or hospital admissions may be identified and 
measured.  Costs may also be estimated based on the description of the nature of ADRs, 
which gives indication about the severity of the event.  However, it is extremely difficult to 
measure, for example, the medical expenditure or number of days lost from work due to all 
kinds of ADRs. 
The lengths of stay, and subsequently the cost of hospitalisation associated with ADRs have 
been shown to be substantial 
90
•
91
.  In a matched case-control study, Classen et al (1997) 
91 
matched 1580 patients with one hospital-acquired ADR with 20 197 controls and reported 
an  ADR incident rate  of 2.4%  during  the  three-year  study  period.  These  events  were 
47 associated with an increased length of stay of 1.91 days and an additional cost of US$2262. 
Similarly, Bates et al (1997) 
90 reported an ADR incidence rate of 4.6% in a cohort of 4108 
admissions over a six-month period.  The additional length of stay and costs associated with 
ADRs  and preventable ADRs  were  2.2 days  and US$3244,  and 4.6 days  and US$5857, 
respectively. 
Hospital admissions associated with ADRs are  only one aspect of drug related morbidity. 
A larger proportion of ADRs may never result in hospitalisations, but these events may still 
lead to  substantial health and economic impact in the form  of regular visits  to  GPs,  co-
prescribing and the use of other social services. 
Non-steroidal Anti-inflammatory Drugs 
Non-steroidal  anti-inflammatory  drug  therapy  is  costly.  The  costs  of treating  adverse 
effects add a considerable expense to  the cost of the therapy.  Adverse drug reactions in 
NSAID-therapy add considerable burden to the NHS. 
Blower et al (1997) 
92 attempted to measure the burden of NSAID-related ADRs in the UK 
in a retrospective analysis of all emergency admissions for upper GI disease, as well as an 
analysis of the records of all community deaths attributed to upper GI diagnoses, compared 
with matched controls.  The results showed that NSAID users were more likely to require a 
blood transfusion, a higher volume of transfused blood and to be hospitalised longer than 
those who are not on NSAIDs.  Similar findings were reported by Hawkey et al (1997) 
93 
when 500 patients, aged over 60 years admitted to hospital with peptic ulcer bleeding over a 
five-year  period were  interviewed.  In  addition,  prescribing  in  103  practices  was  also 
examined.  This study reported an average admission rate for bleeding peptic ulcer of 15 per 
1000 000 per year.  In addition, the authors concluded that the findings were equivalent to 
one episode of ulcer bleeding in the elderly per 2823 (95% CI 2095 to 8116) prescriptions. 
In another cohort study of patients over 50 years, based on population data from Tayside 
94
, 
2%  of NSAID  takers  were  admitted  with  GI events  compared to  1.4%  of non  NSAID 
takers, suggesting that about 0.2% of the over 50s population may be admitted in any one 
year because of NSAID-related GI events. 
48 In an attempt to address the GI problems associated with NSAID use, the co-prescription of 
gastroprotective  agents  such  as  H2-receptor  antagonists,  proton  pump  inhibitors  and 
misoprostol has become common practice.  Among these drugs, misoprostol has been found 
in clinical trials to reduce the incidence of gastric and duodenal ulcers in patients requiring 
continuous  NSAID  therapy.  H2  blockers  seem  to  reduce  complications  of gastric  and 
duodenal  ulcers.  In  Scotland,  Omeprazole  was  the  most  costly  and  the  ninth  most 
commonly  prescribed  drug  in  the  year  2000,  at  £37 699 000  for  over  one  million 
prescriptions, lansoprazole was the third most costly at £14 858 000 and ranitidine was the 
sixth most costly drug at £12 252 000 
95
. 
In  another  study,  Moore  and Phillips  (1999) 
96estimated the  annual  burden  of NSAID-
related GI ADRs from the perspective of the NHS by conducting a simulation study based 
on  three  patterns  of  NSAID  co-prescribing.  When  the  costs  for  NSAIDs  and 
gastroprotective  agents  (omeprazole  and  ranitidine)  were  included,  the  cost per patient 
prescribed an NSAID for an average co-prescription estimate amounted to £40 per year, and 
to £215 million when the results were extrapolated to the whole of the UK.  In addition, the 
total costs per patient with an NSAID-related bleed were estimated to be £2198, equivalent 
to an annual cost of £35.5 million in the UK. 
Several  studies  on  the  real  cost  of NSAID  therapy  have  been  documented.  These 
evaluations not only take into account the cost of the drug but also the cost of treating other 
factors  such  as  associated  GI  complications  (the  'shadow'  cost) 
20
•
21
.  De  Pouvourville 
(1992) 
20 suggested in his study that the cost of NSAID therapy may be increased by 2.1  to 
3.6 fold when the shadow cost of treating GI complications has been taken into account. 
The economic consequences of the  unwanted secondary effects of NSAID therapy can be 
demonstrated by a simple  shadow cost model.  The cheapest drug may not be the  least 
expensive in the end. 
Selective Serotonin Reuptake Inhibitors 
The  high  costs  associated  the  treatment  of  depression  have  increased  interest  in 
pharmacoeconomic evaluations of drug treatment, particularly in the  1990s, as  the  use  of 
SSRis  expanded  substantially.  Many  observational  studies  have  been  carried  out  to 
49 compare differences between SSRis and TCAs 
97
-
99
• These studies attempted to estimate the 
costs  to  the  healthcare  system based on  outcomes  such  as  treatment duration  and drug 
switching.  Although  SSRis  are  generally  associated  with  higher acquisition  costs  than 
TCAs,  the  total  healthcare  costs  are  decreased,  by  the  reduction  in  acquisition  costs 
associated with the use of SSRis. 
Results from short-term studies comparing SSRis and TCAs suggested that SSRis are either 
more  cost effective,  or that there  is  no  difference  in  costs.  A prospective,  randomized 
trial 
97  comparing  clinical  outcomes  and  treatment costs  for  patients  who  were  initially 
prescribed an SSRI or TCA, showed that the higher cost of fluoxetine therapy was balanced 
by fewer outpatient and inpatient costs.  Patients who were prescribed fluoxetine reported 
fewer  ADRs  and  lower  rates  of medication  switching  and  were  more  likely  to  reach 
adequate dosing levels in patients who were prescribed TCAs.  The total costs for care over 
six months were equal in both groups. 
Longer term studies,  mainly lifetime  simulation models,  focused more  on the  impact of 
maintenance  antidepressant  therapy  and  showed  more  mixed results,  but still  favoured 
SSRis over TCAs.  The cost effectiveness of treatments was mainly determined by the costs 
associated  with  reduction  in  relapse  rates,  and  the  assumption  of  lower  treatment 
discontinuation rates 
100
.  However, comparative studies of individual SSRis, focusing on 
the costs associated with adverse drug events, have not been identified.  The cost of treating 
some of these adverse effects has been cited as  a major contributor to the overall costs of 
drug therapy 
101
.  Adverse effects leading to discontinuation of medication may, in fact, be 
associated with discomfort and loss of productivity and other indirect costs attributable to 
treatment failure. 
Angiotensin Converting Enzyme Inhibitors 
In the US, the total cost of hypertension treatment in 1998 was estimated at $23.3 billion, 
$7.5 billion of which was the pharmaceutical cost 
102
.  In Sweden, the total annual cost of 
treating hypertension in 1992 was approximately 1.6 billion Swedish Crowns (£160m) 
103
. 
Unlike the case of NSAIDs , the literature for cost effectiveness studies on ACE inhibitors 
in the treatment for hypertension is sparse.  Some cost of illness studies have reported on 
50 the economic burden of hypertension to the healthcare system and society as a whole, but 
few examined the cost effectiveness of drug therapies for the treatment of hypertension. 
Only  a  few  studies  attempted to  evaluate the  cost of individual  ACE inhibitors  for  the 
treatment of hypertension.  These  studies  compared selected ACE inhibitors  with  drugs 
from different classes of antihypertensive agents 
104
-
106
,  Angiotensin I receptor blockers 
107
• 
Others  examined the  economic  and clinical  consequences  in specific  patient groups,  in 
particular, those with type 2 diabetes 
108
•  The cost implications of drug switching have also 
been evaluated 
109
-111 . 
However, the measure of effectiveness, the cost variables included, and the characteristics 
of the patient population varied considerably across the studies.  This lack of conformity 
has made it difficult, "if not impossible",  to  compare the findings  and make conclusions 
about the relative cost effectiveness of different antihypertensive therapies. 
SUMMARY 
The  importance  of ADRs  is  often  underestimated.  These  events  are  common  and  in 
extreme cases, may lead to mortality; while at the opposite end of the scale, these events 
may incur unnecessary expenses to the NHS.  Although the incidence of ADRs and their 
subsequent impact on costs have been investigated in studies based primarily in hospitals in 
the  US,  the  implications  are  clear  from  the  published  results  that  ADRs  constitute  a 
widespread problem that causes adverse clinical events and substantial increases in costs. 
Therefore, a full economic analysis of drug use must take into account not only the cost of 
the drug but also the cost of any potential ADR induced by the use of this drug.  Despite the 
wealth of literature on the effect of ADR on an increase length of stay, and with additional 
hospital admissions, the costs associated with these events in primary care are unknown. 
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MAKING: A PRIMARY CARE PERSPECTIVE 
A literature review on the impact of pharmacoeconomic information in influencing primary 
care prescribing was  initially  intended.  A literature  search for  studies investigating  the 
influence  of economic  information  in  influencing  prescribing  decisions  was  conducted. 
However, extensive trawling of the literature has revealed no studies fulfilling the search 
criteria.  Therefore, a critical review of the impact of economic information, not specific to 
primary  care  prescribing,  but in  overall  medical  decision  making  in  primary  care,  was 
conducted.  This  review  focused  on  studies  that  aimed  to  examine  decision  makers' 
perspective on the usefulness, the value and their awareness of economic information; their 
perceptions about barriers to implementing such information were also examined. 
The search strategies (Appendix II) included searching all major electronic databases, the 
Internet, hand searching of references from relevant literature, author citation search using 
the  Web  of Science Database and consultation  with  other researchers,  in the  attempt to 
capture both the  mainstream and grey  literature in the  area.  Only  articles  published in 
English were retrieved.  All  the  studies meeting the following criteria were included:  (1) 
study participants included medical decision makers in a primary care setting and (2)  the 
aim focused on economic, not cost information. 
Despite  the  volume  of  research  on  health  economic  issues,  few  published  studies 
concerning the impact of economic information in primary care medical decision making 
were identified.  These studies all focused on primary care decision makers' understanding 
and perspectives in the role of  economic information in medical decision making; therefore, 
consisted solely of qualitative research such as  surveys and focus groups (Table  1).  The 
perspectives of a heterogeneous mix of medical decision makers in different countries were 
explored including clinicians (primary and secondary care), prescribing advisers, managers 
and  purchasers,  both  in  government  and  health  authorities.  Although  data  relating  to 
primary  care  decision  makers  cannot be  extracted  in isolation,  these  studies  were  also 
included in this review. 
The literature has identified and highlighted several influencing factors surrounding the role 
of economic information in primary care medical decision making.  The main findings of 
these  studies  are  generally  in agreement,  that  there  is recognition  of the  importance  of 
52 economic information in decision making, but the current evidence available is not being 
used sufficiently, due to various barriers relating to relevance and bias. 
All the studies identified in the literature search are summarised in Table 1. 
3.3.1  Knowledge in Economic Information 
There have been some attempts in the literature to assess the level of knowledge in health 
economics among decision makers through measuring formal training in health economics 
and use of direct questions regarding self-perception of knowledge.  A postal survey (n = 
446) conducted in 1997 
112 reported that health economics training primarily consisted of a 
short course, was modest (37%  overall), among prescribing advisers (40%), pharmacists 
(17%)  and  directors  of public  health  (86% ).  The  high  proportion  observed  among 
directors  of public  health  may be  explained by  the  fact  that  knowledge  about  health 
economics  was  needed  as  part of their qualifying  examinations.  Similar results  were 
observed  in  the  European  Network  on  Methodology  and  Application  of Economic 
Evaluation Techniques (EUROMET) project when decision makers (n =  1022) over nine 
European  countries  (including  the  UK)  were  surveyed by  postal  questionnaire,  semi-
structured interviews, or through focus groups
113
•  The study reported, "on average, those 
who  had  participated  in  health  economic  courses  amount  to  a  third",  with  Norway 
reported to have the highest training rate of 50%. 
The overall lack of training has been reflected in the lack of understanding about economic 
evaluation  techniques.  Duthie et al  (1999) 
114  presented decision makers  with  different 
health economic outcome statements on randomly ordered shuffle cards in a focus  group 
study to determine what decision makers view as relevant to their decision making.  It was 
found  that  a  high  proportion  of the  statements  relating  to  traditional  health  economic 
outcomes such as incremental ratios, quality adjusted life years and willingness-to pay were 
not understood,  or were viewed as  irrelevant.  Similar conclusions were drawn from the 
EUROMET study
113
,  where  the  majority of the  participants were reported to  have poor 
knowledge  of cost benefit,  cost effectiveness  or cost utility  analysis.  In a recent focus 
group  study,  decision  makers  from  two  health  authorities  (n =  12)  were  presented with 
abstracts  retrieved  from  the  NHS  Economic  Evaluation  Database  (NHS  EED) 
115  for 
53 discussion.  The authors reported that some of the participants experienced difficulties with 
the economic terminology used in the literature. 
3.3.2  The Use of Economic Information 
Secondary  to  evidence  of clinical  effectiveness,  there  is  a  general  agreement  among 
decision makers that economic information is an important factor to be taken into account 
in  medical  decision  making,  in  particular,  when  making  decisions  on  adopting  new 
treatments 
113
•
116
•  However, studies have generally reported modest use (approximately one 
third of surveyed participants) of economic information in decision making 
113
•
117
.  Contrary 
to  these findings,  although no numerical data were presented, it is believed that the focus 
group study conducted by Hoffmann et al (2002) 
115 indicated a higher level of use, stating 
that "most of the participants" had used economic information previously. 
3.3.3  Source of Economic Information 
Peer-reviewed  clinical journals have  been reported  to  be  the  most important  source  of 
economic  information  for  decision  makers 
112
•
113
•  The  EUROMET  study  reported  that 
decision  makers  in  the  UK  viewed  secondary  sources  (e.g.  Bandolier 
118
,  effective 
healthcare bulletins 119,  drug and therapeutic bulletins 
120
)  as the most important source of 
information.  Opinions of colleagues have also been perceived by prescribing advisers and 
pharmacists to be reliable sources of information
112
. 
3.3.4  Barriers to the Use of Economic Evaluation 
All  the  studies  included  in  this  review  investigated  barriers  to  the  use  of economic 
evaluation to  some extent.  Despite the different settings of the studies, with regards to the 
country in which the studies were undertaken and the type of decision makers consulted, 
there was a certain pattern to the barriers identified. 
Organisational barriers such as  the rigidity of the  structure of the healthcare  system and 
difficulty in reallocating resources have been highlighted as the major factor associated with 
54 the limited use of economic information in decision making 
112
-
114
.  This is not unique to the 
UK as similar conclusions were drawn from the EUROMET study 
113
,  where "difficulty in 
moving resources from one sector (budget) to another" has been ranked as the main barrier 
to  the use of economic studies in decision making.  Because of this,  decision makers felt 
that there is  limited scope in using economic studies in their everyday practice, and that 
findings from economic studies are of little relevance to their everyday practice.  This was 
echoed by decision makers in the study conducted by Duthie et al 
114
.  All the participants 
in  the  study  indicated that financial  savings  reported in  economic  studies  were  only  of 
interest if the savings were "realisable" and resources could be "physically reduced". 
Another major barrier discussed was the perceived lack of credibility of economic studies. 
This was described by 26% of participants in the survey by Ross et al (1995) 
117
.  Similarly, 
"studies  open  to  bias  because  of large  number  of assumptions"  was  the  second  most 
common  barrier  reported,  described  by  56%  of  decision  makers  in  the  Drummond 
survey 
112
. 
In  addition,  an  equal  proportion  of participants  (26%)  raised concerns  regarding  health 
economics  'jargon' used in the survey by Ross et al  (1995) 
117
.  It was felt that academic 
researchers  seem  to  put  more  emphasis  on  the  rigour  of  their  methods  than  on 
communicating the principles involved to  decision making.  Similar concerns were raised 
by Duthie et al 
114
,  describing a general mistrust in statements containing health economic 
jargons and later, by Hoffmann et al 
113
,  who reported that "sponsorship of studies (e.g. by 
the industry) biases the results" and "economic studies make too many assumptions" as the 
second and fifth most referred barriers by decision makers. 
Decision makers also felt that economic analysis often adopts a long-term perspective.  The 
time horizon adopted in economic studies has often been viewed as impractical and reduces 
the value of the economic studies 
116
.  For instance, studies that identified benefits over five 
to 10 years in exchange for increase spending now; if this were the case, there is a danger of 
overspending  at present.  It was  felt  that faced  with  pressures  to  operate  within  given 
budgets  would  mean  that  investment  in  a  policy  for  long-term  savings  may  often  be 
impossible. 
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Overall, the findings  of the studies included in this review are in general agreement with 
each other.  Primary care decision makers such as  GPs, medical prescribing advisors and 
pharmaceutical prescribing advisors  generally have  a positive interest towards economic 
information  and  agreed  that  economics  should  be  an  integral  part of medical  decision 
making.  However, the knowledge and understanding of health economic principles among 
decision  makers  is limited and the  extent of actual  use  of such information in  decision 
making remains unclear.  Two key barriers to  implementing results of economic studies 
have been identified:  one  practical barrier - the  difficulty  in reallocating resources,  and 
another barrier associated with methodological issues in conducting economic studies. 
The  impact  of  any  intervention  on  decision  makers'  perspectives  and  behaviour  is 
extremely difficult to measure and the current studies have their own limitations.  Several 
methodologies  have  been  adopted  to  attempt  to  measure  the  level  of knowledge  of 
economic issues among primary care decision makers, ranging from examining the level of 
training in economic issues to presenting and discussing economic studies at face-to-face 
meetings.  In  two  separate  studies,  statements  relating  to  economic  principles 
114  and 
abstracts of economic studies 
113  have been presented to  decision makers.  Although this 
gave some indication of the decision makers' understanding on particular health economic 
issues, their wider understanding of health economics was not explored. 
Due  to  the  nature  of the  research  area,  these  studies  have  been  primarily  surveys  and 
qualitative interviews, where responses cannot be validated.  Often, in studies of this nature, 
participants' responses may be more representative of how they believe they should respond 
instead of what they actually think or practise.  This would have particular influence on the 
measure of use of economic information in practice and is likely to over-estimate the actual 
use of economic information.  In addition, the "use" of economic information has not been 
defined.  It is unknown what exactly was meant when respondents claimed to have "used 
economic information". 
Several barriers to  implementing economic  information have been identified.  However, 
how real these barriers are is not clear, since there has been no evidence of any attempts by 
primary  care  decision makers to  actually  use  an  economic evaluation to  influence  their 
practice.  Methodological issues such as the perspectives adopted, assumptions made in the 
56 economic studies and funding sources have been mentioned in all the studies as one of the 
barriers to  implementing economic information.  Over the years,  several  checklists have 
been developed to  tackle these issues specifically, for the purpose of critical appraisal of 
economic studies , based on the  1  0-point checklist developed by Drummond M et al 
121
• 
However,  this  seems  to  have  had little  effect on  improving  the  credibility  of economic 
studies among these decision makers. 
Finally, in addition to the reasons discussed above, these studies are also highly susceptible 
to selection bias.  In general, survey respondents and those who consent to participating in 
interviews are more likely to have particular interest and knowledge in the area.  Those who 
declined to  participate may  be  likely  to  be representative  of those  for  whom economic 
information has the least impact. 
Therefore, findings of the impact studies are difficult to interpret and should be treated with 
caution and firm conclusions cannot be drawn.  The study population of these studies are 
generally  small,  but  this  probably  reflects  the  difficulty  in  conducting  research  and 
collecting  data  in  this  area.  Despite  the  variations  in  study  methodology  and  study 
population,  it is  clear that  the  themes  generated from  the  individual  studies  do  tend to 
support each other. 
57 4  STUDY DESIGN AND METHODS STUDY DESIGN AND METHODS 
4.1  INTRODUCTION 
This thesis set out to explore the inclusion of ADR data in phannacoeconomic evaluations. 
Through  discussions  with local  medical prescribing  advisors,  three  therapeutic  areas  of 
interest were selected: NSAIDs for the management of rheumatoid arthritis, SSRis for the 
management of depression and ACE inhibitors for the management of hypertension. 
An initial phannacoeconomic study on NSAID therapy (described in Section 4.2),  using 
data from a large record linkage database from Tayside (Scotland) was conducted.  Ideally, 
a similar methodology would be adopted for the other two classes of drugs, however, it was 
beyond the financial scope of this PhD to purchase the additional data required.  Therefore, 
an  alternative  data  source,  based  on  published  randomised  controlled  trials,  was  used 
(Section 4.3). 
The  second aim of this  thesis  was  to  explore  the  impact of economic  information  on 
primary care prescribing.  Since there is an absence of literature in this area, no validated 
tools have been developed.  Therefore, three strategies (Section 4.4), based on lessons learnt 
from  studies  examining  the  impact of economic  information in  other  areas  of medical 
decision making were adopted. 
4.2  POPULATION-BASED PHARMACOECONOMIC ANALYSIS: AN 
EXAMPLE WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
(NSAIDs) 
This evaluation is based on clinical data supplied by the record linkage database of MEMO 
in Tayside (population =  427 786;  1995).  This record linkage system contains extensive 
clinical information from 1 January 1989 on all the people who were registered with a GP 
and  residing  in  the  Tayside  Health  Board  area.  Every  person  is  allocated  a  "CHI 
(Community Health Index) number" for effective clinical data records linkage.  The CHI 
number start date is either 1 January 1989 (the MEMO start date) or the date on which a 
58 person  is  subsequently  registered  with  a  local  GP.  This  unique  patient  identifier  was 
recoded into an anonymised sequential number to maintain patient confidentiality. 
This linked data set includes details  of all  dispensed prescriptions within the  community 
and demographic  data.  Diagnostic  data based on International Classification of Disease 
(lCD 9)  and operations based on  the Office of Population Censuses and Surveys (OPCS) 
codes  on  all  the  patients who  have  been admitted to  Tayside hospitals,  each episode  of 
hospital care generating a form- the Scottish Morbidity Record 1 (SMR 1). 
4.2.1  Study Cohort 
All the appropriate population data available at the point of study were incorporated into the 
economic model which covers the recorded data between 1 January 1989 and 31  December 
1993. 
Individuals  less  than  50  years  old  on  1 January  1989  were  excluded  from  the  study. 
Patients' data for six months prior to (recent history) and 12 months after the index date, i.e. 
the start date of the follow-up period were used.  Therefore, those who had died before 30 
June 1990, those who have an index date after 31  December 1992 and those who  died at 
any time during the 12 months of follow-up were excluded from the study. However deaths 
in the year after the end of the study period were linked to an individual's record (Figure 3). 
The cohort of patients who received an  NSAID prescription during the study period was 
classed as the 'NSAID' cohort (Figure 4).  The indications for NSAID prescriptions are not 
recorded routinely in this database, however, it is believed that this sub-population mimics 
NSAID use in the widest sense.  A further cohort who met the selection criteria but did not 
receive  any  NSAID  prescriptions  during  the  study  period  were  categorised  as  the 
COMPARATOR  cohort.  These  were  unselected,  comprising  the  total  population  of 
relevant individuals in Tayside.  This group provided a comparable population of Tayside 
patients for  whom there  was  no  prescribed use  of NSAIDs  throughout the  study period. 
This group provided background rates of events in a local population not on NSAIDs. 
Demographic details for all patients were recorded including their age  at the  start of the 
study, date of birth, sex, date of death (if after the study period) and postcode.  Index dates 
59 for  all  individuals on  NSAIDs  were  created as  the  date  of the  first  NSAID prescription 
dispensed after 1 July  1989 - to  ensure at least six months of previous dispensing history 
prior to  this  index  date  being available.  Since  the  individuals in the  comparator cohort 
would not have received a NSAID prescription throughout the entire course of the study 
period,  index  dates  from  the  NSAID  cohort were  used to  generate  index  dates  for  the 
comparators.  The index dates, in a sequential file of NSAIDs ordered by CHI numbers, 
were randomised and allocated to the individuals in the comparator file. 
The  'NSAID'  cohort was  further  divided into  three  sub-cohorts based on  the  records  of 
concomitant prescriptions.  These were defined as the prescribing within three days of the 
index date, of H2 blockers or omeprazole which generated the 'NSAID and H2/0meprazole' 
sub-cohort,  or  of misoprostol which generated the  'NSAID  and Misoprostol'  sub-cohort. 
The remaining patients formed the 'NSAID Only' sub-cohort.  Details of these drugs such as 
the dispensed date,  the exact type  and dose of the formulations and the amount of drugs 
dispensed were recorded. 
This evaluation compared the economic consequences of the three NSAID sub-cohorts and 
the comparator cohort at 45  days,  six months and 12 months following the index date,  to 
determine the effects of initial prophylactic concomitant prescribing of misoprostol on later 
events, compared with concomitant prescribing of H2 blockers or omeprazole, and with no 
concomitant prescribing.  Data on six months of previous medical history up to  the index 
date were consulted to  allow any potential confounding factors to be investigated.  Details 
of recorded  clinical  events  included  hospitalisations,  GI  endoscopies,  additional  co-
prescriptions dispensed, and changes in prescriptions at 45 days from the index date, from 
45 days to  six months and from six months to 12 months.  Dispensed prescriptions for the 
drugs  of interest and clinical events  (hospital  admissions)  recorded during these periods 
were available for future investigations of possible cause and effect relationships. 
60 4.2.2  Clinical Events 
These  data  included  records  of  diagnoses  and  hospital  admissions  coded  with  a 
gastrointestinal, cardiovascular, rheumatoid and osteoarthritis-diagnosis (ICD/OPCS codes 
- Appendix  Ill)  during  each  episode  of hospital  care  per patient.  For  the  purpose  of 
effective  modelling,  it was  assumed  that  each  episode  of care  represents  one  hospital 
admission.  Although  this  may  over-estimate  the  admission  rate  and  subsequently  the 
hospitalisation costs for the proportion of patients who received more than one episode of 
care during individual hospital admissions, this assumption will be tested extensively in a 
sensitivity analysis. 
The  lengths  of stay  (LOS)  of these  admissions  were  calculated  (discharge  date  minus 
admission  date  plus  one  day).  However,  it was  believed that  there  would be  a  small 
proportion of patients who may remain in hospital for a long period of time which would 
exceed the follow-up period, such as those admitted to geriatric units.  These patients' LOS 
would be censored to  the length or to  the end of the follow-up period (i.e. the maximum 
LOS in the three time periods would be 45 days, 183 days and 365 days respectively). 
Admissions recorded in the  six months prior to  the  index date  were  defined  as  a  'prior 
history of admission'.  Admissions within 45 days following the index date, from 45 days to 
six months and from six months to 12 months were defined as 'events'. 
Diagnostic and admission details, in the form of ICD-9 and OPCS codes respectively, of the 
longest hospital event during each follow-up period were used to indicate possible adverse 
events  associated  with  the  various  drug  therapies.  It was  believed  that  only  a  small 
proportion of patients would have more than one hospital admission over the 12 months of 
the  study period.  Therefore, the  admission with the longest LOS,  which represented the 
most significant cost contribution,  would provide a fair  indication of the  type  (GI,  CV, 
rheumatoid or osteoarthritis admissions)  and specialty  (such as  medical,  orthopaedics  or 
general surgery) of the other admissions if a patient had more than one admission.  All other 
additional admissions were recorded as counts, i.e. the number of additional admissions and 
the LOS for all other admissions was also calculated as one aggregated total.  The LOS for 
the longest admission was recorded separately from other admissions. 
61 Details of GI endoscopies carried out were recorded for the whole study population.  These 
were recorded as counts, i.e. the number of GI endoscopies performed.  Endoscopies during 
the  six  months prior to  the  index dates  were  defined as  'previous endoscopies'.  Those 
recorded  after  the  index  dates  were  grouped  appropriately  to  the  three  time  periods 
according to the date of endoscopy following the index date. 
The drug prescriptions in this data set were based on records of the prescription items which 
were  dispensed.  One  prescription may cover several  items  consisting of different drug 
classes.  These items were recorded individually in the data set. 
The  inception  drugs  (NSAIDs,  H2  blockers,  omeprazole  and  misoprostol)  which  were 
recorded  as  concomitant prescriptions  comprised the  basic  drug  therapies.  These  were 
identified and recorded in detail, including the type and dose of the formulations  and the 
amount dispensed. 
In an  attempt to  account for  all  the  prescription items dispensed during  the  three  study 
periods,  all  dispensed items  were  identified and recorded as  counts,  i.e.  the  number of 
prescription items dispensed, with the exception of the first and the last items in any period 
which were recorded in full.  This was done to  detect changes in drugs the patients were 
being prescribed.  If the first drug recorded differed from the last in any period, then at least 
one switch was assumed to have taken place (Figure 5).  This would also suggest at least 
one visit to the GP during which the change was made.  Records of dispensed items were 
divided into three categories: NSAIDs, ulcer-healing drugs and all other drugs. 
The above data were linked together by the CID number to provide the raw data for this 
economic evaluation.  Thus,  in  addition  to  the  demographic  details,  the  linked data set 
contains  all  the  dispensed prescription item details,  records of endoscopies and hospital 
admissions, and diagnoses for the longest admission of every patient, where appropriate. 
All  the  recorded  data  from  the  three  follow-up  periods  were  aggregated  to  create 
appropriate linked data for the three time spans: from the index date to 45 days, from index 
date to  six months and from index date to  12 months.  The total costs associated with the 
three treatment therapies and the comparator group were calculated separately for the three 
study periods. 
62 The  analysis  for  all  treatment groups  was  split by sex,  and into  three  age  groups,  for 
effective modelling and to allow determination of sex- and age-specific costs.  Independent 
analyses were carried out for males and females, and for patients aged 50 to 59 years, 60 to 
7  4 years and 7  5 years and over. 
4.2.3  Cost Estimates 
Based on the assumption that all co-prescriptions were prescribed for events associated with 
the initial NSAID prescribed, all the drugs were recorded and costed as a clinical event of 
interest. 
The drug  costs  used in  the  models  were  supplied by the  Prescriptions Pricing Division 
(PPD) in place of the commonly used British National Formulary, due to the large number 
of different formulations covered by the population (approximately 12 000).  However, the 
drug prices listed in the two sources appear to be similar.  The actual amount dispensed to 
the patients was calculated exactly.  In addition, the dispensing and container fee (£0.80) for 
each item  which  is  charged by  pharmacists  to  the  NHS  for  each  dispensed  item  was 
incorporated  in  the  model.  The  reference  sources  for  all  the  unit  costs  used  in  the 
calculations are shown in Appendix IV. 
The inception drugs  were  decoded,  identified and costed to  generate the  basic inception 
drug therapy costs for each patient. 
The costs for the first and last dispensed additional prescription items recorded during each 
of the study periods were also calculated in a similar manner.  For all the other prescriptions 
(if any), only the number of items dispensed was available.  Therefore, an average cost of 
the first and last dispensed items recorded during each of the study periods was calculated 
to  give  an  average  dispensed prescription item cost which is  unique  to  each individual 
patient for each study period.  The sum of the total costs for drug therapy over one year for 
each patient was finally calculated by aggregating the inception drug cost, the cost of the 
first  and last prescriptions  dispensed  and  the  average  cost of all  other  additional  items 
dispensed during each of the study periods. 
63 It had to be assumed that all  the GI endoscopies carried out were day cases since details 
defining  inpatient  or  day  case  endoscopies  were  not  available.  The  cost  of all  the 
endoscopic procedures was calculated by multiplying the number of recorded endoscopies 
per person during the follow-up  period by a weighted cost of day case GI endoscopy in 
Tayside  (£208.33).  This  cost  is  an  average  of the  various  costs  of GI  endoscopic 
examinations  in all  the  hospitals  in  Tayside  listed in the  Scottish Health Service  Costs 
1994/5
122 weighted for the number of examinations undertaken in these individual hospitals. 
The  costs  associated  with  four  different  types  of admission  - GI,  CV,  rheumatoid  and 
osteoarthritis admissions- were not the same and were calculated independently.  The cost 
of hospital admissions is dictated by the specialty group (of the longest admission) and the 
LOS.  A  weighted  average  inpatient  cost  for  each  specialty  per  day  was  calculated 
(weighted for  the  number of admissions recorded in these  Tayside hospitals).  For each 
individual patient the  appropriate weighted cost is then multiplied by the total number of 
days in hospital to give the cost of each type of admission. 
For the purpose of modelling, it was assumed that each hospital admission was attached to 
two GP consultations - one prior to  admission, one after - and one outpatient consultation 
following discharge.  The sum of these individual costs was added to the cost of the longest 
hospital admission.  Patients with more than one admission had similar costs added to give 
the total cost of hospitalised events per patient (Figure 6a and 6b  ). 
The  total  cost of therapy  and  their  95%  confidence  intervals  (CI)  associated  with  the 
comparator cohort and the three sub-cohorts was calculated. 
Sex  and  age-specific  analyses  were  performed  across  the  four  groups  and  univariate 
comparisons (F test) between males  and females  and between the three age  groups were 
carried out.  These costs were aggregated for all individuals in each treatment group.  Since 
some individuals incurred much greater costs than others, an average cost for each member 
of the individual group was also calculated. 
64 4.2.4  Sensitivity Analysis 
Extensive  sensitivity  analysis  was  performed  on  all  obvious  confounding  variables 
including co-morbidities  and mortalities.  Patients in the  study group  who  were  aspirin 
takers,  who  had  any  prior  hospital  admissions,  prior  endoscopies,  or  prior  NSAID 
prescriptions, were removed from the dataset for re-analysis.  These exclusions were dealt 
with  singly  and in combination.  This  is  equivalent to  the  restrictive  cohort  technique 
adopted to address confounding factors 
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.  In addition, the cost data that were used in the 
model, including the cost of GP consultations and GI endoscopies, were also tested in the 
sensitivity analysis. 
4.3  MODEL-BASED PHARMACOECONOMIC ANALYSIS: EXAMPLES 
WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs), 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRis) AND 
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS 
Three pharmacoeconomic analyses were conducted on three of the most widely prescribed 
classes of drugs in primary care - NSAIDs for the treatment of rheumatoid arthritis, SSRis 
for the treatment of depression and ACE inhibitors for the treatment of hypertension.  The 
direct costs associated with the use of all three classes of drug therapies were calculated. 
The economic models were based on the key assumption that drugs within each class of 
drugs  were equally effective and the main difference between these drugs was their side 
effect profile, which dominates patients' preferences and the cost of therapy.  The clinical 
outcomes investigated were all associated ADRs, and the total costs of drug therapy were 
calculated as  'economic outcomes'.  Similar methodologies have previously been adopted 
in the evaluation of NSAIDs 
20
•
21
•
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•  The models adopted the perspective of the NHS. 
65 4.3.1  Data Collection 
Identical methodologies were adopted for all three pharmacoeconomic evaluations.  An 
extensive literature search was  carried out on  each individual drug using :MEDLINE 
(1966 to present), BIDS  embase  (1980  to  present)  and the Cochrane Trials Register. 
Search filters published by the SIGN guidelines for randomised controlled trials were 
combined with keywords on individual drugs and treatment indications (Appendix ll). 
The  main  searches  were  restricted  to  references  to  randomised  controlled  trials 
published in English.  Randomised controlled trials of the following comparisons were 
selected: 
•  Comparing  any  of the  individual  NSAIDs  with  active  or placebo  control  in  the 
treatment of uncomplicated rheumatoid or osteoarthritis in adults. 
•  Comparing  any  of the  individual  SSRis  with  active  or  placebo  control  m  the 
treatment of uncomplicated major depression in adults. 
•  Comparing any of the individual ACE inhibitors with active or placebo control in 
the treatment of uncomplicated hypertension in adults. 
Only  double-blind  randomised-controlled  trials  of individual  drugs  of interest  were 
selected for the meta-analysis.  In addition, the trials had to meet the following inclusion 
criteria: 
•  Sample size greater than 20 patients - on the basis that this excludes most pre-phase 
III trials. 
•  Study duration of at least two weeks -excludes most pre-phase III trials. 
•  Control group included. 
•  Reported numerical data on the number of ADRs recorded. 
The  quality  of the  selected  clinical  trials  were  assessed  using  the  five-point  Jadad 
score 
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•  Points  were  awarded  for  the  description  and  the  appropriateness  of 
randomisation and blinding.  For instance, studies that were described as  'randomised 
and double-blinded' would be awarded two points.  If  the method of randomisation and 
blinding were described and believed to be appropriate, an additional two points may be 
66 awarded.  However, if the method of randomisation and blinding were inappropriate, 
negative points should be awarded to the trial.  In order to gain the maximum score of 
five, data (number of patients and reasons) on withdrawal and drop-outs have also to be 
presented. 
4.3.2  Adverse Drug Reactions Data 
All the adverse drug reactions data reported in the included trials were collected.  Meta-
analyses were performed for each individual drug, pooling together all the available side 
effects data on each individual symptom or event.  Average incidence rates, weighted 
by the sample size of the studies, were calculated for each side effect reported for each 
individual  drug.  The  95%  confidence  interval  was  also  calculated,  based  on  the 
equation  which  is  normally  used  to  calculated  95%  confidence  intervals  for  count 
tables: 
!.. ±  1.96~  r(n- r) 
n  n 
(where r =  sum of ADRs reported; n =  sum of patients in all the trials) 
4.3.3  Management of Adverse Drug Reactions 
A list of possible treatment-induced side effects was constructed from the clinical trials. 
Treatment  strategies  for  each  side  effect  were  derived  from  both  the  literature  and 
expert opinions.  All general practitioners in one of the local healthcare co-operatives 
(LHCCs) in the Dumfries and Galloway area were invited to participate in providing 
expert opinion on the management of drug-induced ADRs.  Consent to contacting and 
inviting GPs in this LHCC was given by the LHCC manager, and the author presented 
the aims, objectives and methodology of the study at a monthly LHCC meeting prior to 
recruiting GPs.  A letter was sent to all the GPs by post (Appendix V), and followed-up 
with a telephone call.  During the period between December 2000 and June 2001, face-
to-face, semi-structured interviews were carried out with those who agreed to take part, 
to determine how these symptoms are generally managed.  General practitioners were 
67 asked a series of questions relating to  how they would treat the ADR reported in the 
clinical trials.  Each ADR was considered independently.  The interviews were based on 
a  clinical  scenario  that  resembles  an  average  patient  on  NSAIDs,  SSRis  or  ACE 
inhibitors.  Initially, GPs were asked if they considered the symptom to be drug-related, 
and if so,  what  investigations  and  treatment  they  would recommend,  and  for  what 
proportion of the patients.  A final consensus on how individual adverse events would 
be managed, on average, was estimated. 
Based on a decision-analytic approach, the treatment strategy was noted and a summary 
probability of patients who would receive a particular investigation or treatment when 
suffering  from  a  drug-induced  side  effect  was  generated.  This  was  based  on  the 
estimated  proportion  of  patients  who  would  receive  a  particular  treatment  or 
investigation despite having the  drug changed or stopped.  For instance,  out of 100 
cases of drug-induced constipation, one GP perceived that 80%  of the patients would 
have their drugs changed while 20% would receive a laxative in addition to unchanged 
treatment.  However,  another GP  would change drugs  in 90%  of the  cases  and co-
prescribe laxative to  10% of the patients.  Therefore, the average estimated probability 
for the two GPs, of a patient having NSAID stopped would be 85% and the probability 
of receiving a laxative would be 15%. 
4.3.4  Cost Estimates 
Direct health service costs for the  drugs  and the treatment associated adverse effects 
were calculated.  The acquisition drug costs, based on the defined daily dose, for a one-
month  period,  was  calculated.  The  costs  associated  with  managing  adverse  effects 
included costs of all GP visits, clinical investigations and additional medical treatment. 
The unit costs  for  the investigations  and treatment procedures  are  multiplied by the 
number of units  'consumed' during the time period of interest.  The number of units 
consumed  is  the  calculated  average  of the  GP  treatment  patterns,  expressed  as  a 
probability.  The cost for treating a particular side effect with respect to one patient is 
calculated  for  each  drug.  This  cost  - the  'shadow  cost'  - was  determined  by  the 
incorporation of the expected cost for treating all the different side effects experienced 
for one particular drug, and is dependent on the estimated frequency of occurrence of 
68 the side effect in question.  Finally, the total cost of drug therapy, which incorporates 
the  cost  of  managing  associated  side  effects  and  the  drug  acquisition  cost,  was 
calculated. 
4.3.5  Sensitivity Analysis 
Extensive  sensitivity  analyses  were  undertaken  to  test  the  main  assumptions  in  all  the 
models.  Input variables for the economic models including the incidence rates of the ADRs 
and the unit costs were varied to examine their influence on the model outcomes. 
The ADR rate is a major parameter that may significantly influence the outcome of the 
model.  In addition to the sensitivity analysis of varying the ADR rate by 20% above and 
below that used by the basecase, a scenario-based analysis, based on the 95%  confidence 
intervals  was  also  performed.  The  95%  confidence  intervals  for  the  ADRs  that  are 
investigated  in  the  models  have  been  calculated.  The  upper  and  lower  limit  of the 
confidence interval represents the "best" (lower limit) and the "worse " (upper limit) case 
scenario associated with the use of individual drugs.  It is expected that the ADR rates for 
some of the events would be extremely low due to  their infrequent occurrence.  In cases 
when  the  values  of the  counts  are  low,  the  quadratic  approximation  to  the  confidence 
intervals tends to  have the lower bound below zero.  Since in practice, it is impossible to 
obtain less  than 0%  for  a particular ADR rate,  all  values in the  interval below zero  are 
rejected.  All predicted rates of less than 0%  (lower limit) for a particular event would be 
rounded to 0% and interpreted as near 0%. 
Scenario-based analysis  was  carried  out by  substituting the  ADR incidence rates  in  the 
basecase with the lower limit and the upper limit of the confidence intervals, representing 
the "best" and the "worst" case scenarios, respectively. 
Unit cost data were also investigated by varying cost data by 20%  above and below that 
used for the basecase. 
69 4.4  THE IMPACT OF PHARMACOECONOIMC INFORMATION ON 
PRIMARY CARE PRESCIRBING 
In an attempt to investigate the potential impact of economic information, three strategies 
have been adopted: 
•  Dissemination of the  results  of the  meta-analysis  based economic  analyses,  and 
examination of prescribing behaviour from routine data sources prior to  and after 
the dissemination exercise. 
•  A cross-sectional postal and email survey was conducted to gain insight into GPs' 
views on the usefulness of a variety of economic information and how it related to 
their everyday practice. 
•  Qualitative interviews to explore, in depth, the views and current use of economic 
information among GPs. 
4.4.1  Dissemination Exercise 
Study Population 
Through earlier contacts with GPs while conducting interviews relating to ADRs,  it was 
becoming  apparent  that  the  most  difficult  step  in  conducting  research  among  GPs  is 
recruitment.  Therefore, the same LHCC in the Dumfries and Galloway Health Board area 
that participated in  interviews regarding  management of ADRs  (as  described in  section 
4.3.3) was also selected for this dissemination exercise.  It was hoped that, since this pool of 
GPs had already demonstrated a previous interest in the area of health economics and were 
familiar  with  the  objectives  of the  research  work  and  the  author,  it  would  encourage 
participation in the dissemination exercise. 
This LHCC serves nine practices, with 38  GPs.  Similar to the previous recruitment, the 
author attended one of the monthly meetings and presented the aims and methodology of 
this part of study.  During October 2001 to March 2002, those who consented to taking part 
were later contacted by telephone to arrange a convenient time for meeting.  The GPs were 
visited individually at their practice. 
70 Prescribing Data 
Prescribing  reports  are  now  regularly  produced  to  enable  both  cost  and  quantities  of 
prescribing  to  be  analysed.  Scottish  Prescribing  Analysis  (SPA)  data  were  originally 
designed and generated to aid community pharmacists with reimbursement of prescriptions, 
but have become an essential tool in prescribing support.  Furthermore general practitioners 
are increasingly using audit to rationalise their prescribing 
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Scottish Prescribing Analysis  (SPA)  Level  1 data contain breakdowns of total costs  and 
numbers of items prescribed for major therapeutic categories.  Expensive items (those over 
£100) and drugs of abuse are also included.  These data are specific to individual GPs, and 
comparisons can be made with the averages for the practice, the Health Board and Scotland. 
Scottish Prescribing Analysis Level 2 data contain a full  catalogue of all dispensed items 
over a period of three months, available on request.  Prescribing details include:  separate 
listing of generic and proprietary preparations, dose and formulation of the drug, number of 
times prescribed, total quantity and cost, average quantity per prescription and cost.  SPA 
Level 2 data was used to measure change in prescribing. 
The  results  of  the  pharmacoeconomic  evaluations  were  compared  against  current 
prescribing  data  - overall  Scottish  data  and  practice-specific  data  - to  assess  the  cost 
effectiveness  of  the  prescribing  trends.  Key  messages  of  the  evaluations  plus 
recommendations for change towards more cost-effective prescribing were devised.  This 
was presented to the GPs during a 20-minute meeting with the author.  Comparisons in their 
prescribing prior to and after visits were made using SPA data.  In comparison, self-selected 
controls consisted of those within the LHCC who declined to participate in the study, and 
therefore received no intervention.  Prescribing data from these practices were used as  a 
baseline and compared to the intervention group. 
4.4.2  Survey - Quantitative and Qualitative 
Two questionnaires were designed and disseminated among GP members of the West of 
Scotland Primary Care Research and Development Network (WestNet) during the period 
of  January  to  March  2001.  The  West  of  Scotland  Primary  Care  Research  and 
71 Development Network is  a consortium of 55  general practices,  set up  to  develop  and 
conduct non-commercial research of  benefit to general practice. 
Questionnaire (I)  consisted of five questions, designed to  examine the type of economic 
information  currently  used  by  GPs  in  medical  decision-making  (Appendix  V). 
Questionnaire (II) consisted of four questions, designed to  explore what GPs identify as 
sources  of economic  information  and  their  perception  on  the  relevance  of the  data 
presented (Appendix V). 
A complete list of members and their contact details were obtained from WestNet.  All the 
non-GP members were excluded from the study.  Those included were randomised into 
two groups - questionnaire (I)  and questionnaire (II),  stratified by their accessibility by 
email.  Each member was  either sent the  appropriate questionnaire with a personalised 
covering letter and a pre paid addressed envelope, or emailed the covering letter, with the 
appropriate questionnaire attached. 
4.4.3  Qualitative Interviews 
Following consultation with experienced qualitative researchers in the Department of Public 
Health, a methodology was developed to explore GPs' personal views and opinions about 
the role and impact of economic information.  Due to the recent changes relating to research 
ethics, ethical approval  was  sought for  carrying out this part of the research.  Purposive 
sampling was used to include ten GPs based on their previous consultation with SIGN and 
through snowball sampling.  It was felt that this group of GPs would have some level of 
interest  and  contact  with  health  economic  information.  Participants  were  recruited by 
email, letter and/or telephone contact.  During the period between March and June 2004, 
face to face qualitative interviews, which lasted approximately 45 minutes, were conducted. 
Although the interviews were semi-structured, an interview guide with a list of main points 
to be covered was used.  Answers to pre-set questions were probed with further discussion 
and subsidiary questions.  All interviews were conducted at the GPs' surgery and were tape-
recorded upon consent of the interviewee.  Written consent was obtained. 
Main points covered included: 
72 •  The currently disseminated economic evidence; 
•  The barriers and facilitators in implementing economic evidence; and 
•  The role of economic issues in healthcare decision making. 
Interviewees  were  invited  to  discuss  their  views  and  opinions  of the  decision  making 
process in relation to their own experience.  In general, the interviewees were free to guide 
the interview according to what was felt to be important about decision making in relation 
to prescribing whilst drawing upon other aspects of healthcare decision making they have 
experienced. 
The method of sequential analysis was adopted 
127
,  where data collected at early stages of 
the  study  helped  shape  ongoing  data  collection,  allowing  questions  to  be  refined  and 
negative  cases  identified.  All  the  collected  data  was  also  preserved  in text  form  and 
indexed to generate or develop analytical categories and theoretical explanations. 
The transcriptions of the meeting were compared to the notes taken during the meeting in 
order to  try to  fill  any  blanks in  the  notes  and to  obtain a  different perspective  on  the 
meeting.  Following word-for-word transcribing of the interviews, the data were coded to 
help identify themes and categories.  All the data relevant to each category were identified 
and examined using the method of constant comparison, whereby each item was compared 
with the rest of the data to  establish analytical categories.  Multiple themes may emerge 
from the same section of data.  Each theme was examined individually for different views, 
the frequency of the views that were expressed and how strongly the different views were 
expressed 
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.  Codes were refined and reduced in number by grouping of the data.  It was 
felt that the amount of data collected in this study did not warrant the need of employing 
traditional  software  packages  designed  specially  to  handle  qualitative  data  (such  as 
ATLAS/Ti) 128•  Therefore,  coding and organising of the  data were  conducted manually. 
The  'find' function in Microsoft Word was used to identify keywords that were related to 
the main themes of the study. 
73 5  RESULTS 5  RESULTS 
5.1  INTRODUCTION 
The results of the thesis are presented chronologically in this chapter.  For ease of reading, 
all the tables and figures relating to the results are placed at the end of the thesis. 
In accordance to the first aim of the thesis, section 5.2 presents the results of the economic 
model based on population data.  The clinical data recorded in the database is described 
(section 5.2.1  and 5.2.2), followed by the  cost (section 5.2.3).  Results of the  sensitivity 
analysis are presented in section 5.3.4.  Tables containing detailed breakdown of the data 
are presented in the Appendix VII. 
Section 5.3  presents the results of the three meta-analysis based economic analyses.  The 
results of the literature review of randomised controlled trials for each of the three classes 
of drugs  are  presented in  section 5.3.1.  Relevant data on  adverse  drug reactions  were 
aggregated  and  are  presented  in  section  5.3.2.  The  clinical  management  pattern  was 
determined (section 5.3.3).  Finally, the calculation of costs and the sensitivity analysis are 
presented in section 5.3.4 and 5.3.5. 
In  accordance  with  the  second  aim  of the  thesis,  the  results  of the  impact  study  are 
presented in section 5.4.  The findings of the dissemination exercise are reported in 5.4.1. 
This is followed by results of the GP survey (section 5.4.2).  The findings of the qualitative 
interviews are presented in 5.4.3. 
74 5.2  POPULATION  BASED  PHARMACOECONOMIC  ANALYSIS:  AN 
EXAMPLE  WITH  NONSTEROIDAL  ANTI-INFLAMMATORY  DRUGS 
(NSAIDs) 
5.2.1  Study Population - Demographics 
The study population comprised 98  887 people (42 648 male and 56 239 female),  divided 
into four subgroups for effective modelling: 
•  Comparator cohort (N =  47 350) 
•  NSAID only sub-cohort (N =  49 212) 
•  NSAID and misoprostol sub-cohort (N =  212) 
•  NSAID and H2 blocker or omeprazole sub-cohort (N = 2113) 
Demographic  details  and  clinical  history  of the  patients  from  the  MEMO  population 
database are shown in Table 2.  The age distributions of the patients in the four treatment 
groups are similar, predominantly between the age of 60 and 74 years.  However, both the 
NSAID only and the misoprostol sub-cohorts have a higher percentage of elderly patients 
over 75 years (approximately 20% and 24% respectively) compared with the H2 sub-cohort 
(19%) and the comparator cohort (17% ).  It is evident from the data that female patients 
have  a higher  probability  of receiving  NSAIDs  compared to  male  patients.  Therefore, 
economic analyses were conducted in sex and age specific groups. 
Overall, 4%  (N =  3994) of the study population had a history of a GI diagnosis in the six 
months prior to  the index date.  These patients were almost as likely to be NSAID users 
(52%) as non-NSAID users (50%).  The proportion of patients who had a previous history 
of GI diagnoses was similar in the NSAID only sub-cohort (3%) to the comparator cohort 
(4%).  However,  patients with a prior GI diagnosis  were four times and six  times  more 
likely to be prescribed concomitant prescriptions of misoprostol (13%) and H2/omeprazole 
(18%) respectively. 
Twice as many GI endoscopies (N = 8052) as GI diagnoses (N = 3994) were recorded in the 
six months prior to the index date.  Approximately 7% and 8% of the patients had previous 
endoscopies  in  the  NSAID  only  sub-cohort  and  the  comparator  cohort  respectively. 
75 Patients with prior endoscopies were over four times more likely to receive concomitant 
H2/omeprazole  (32%)  and  three  times  more  likely  to  receive  concomitant  misoprostol 
(20%) than NSAIDs alone. 
Patients with a previous history of CV diagnosis were 39% more likely to be NSAID users 
than those  without a prior CV diagnosis.  Only a relatively small proportion of patients 
(6%) from the comparator group had a previous history of CV diagnoses, which is unlike 
the other treatment sub-cohorts (ranging from 12% observed in the NSAID only sub-cohort 
to  21%  in the H2/omeprazole sub-cohort).  A similar trend was noted for a prior history 
which included a diagnosis of RA/SLE, and OA. 
Based  on  the  details  of the  inception  NSAIDs,  it is  apparent  that,  irrespective  of the 
different  treatment  groups,  ibuprofen,  diclofenac  sodium  and  naproxen  are  the  more 
commonly prescribed NSAIDs in Tayside (Table 2).  The data also show a preference for 
ranitidine among all H2 blockers prescribed by GPs in Tayside, which was given to 81% of 
the patients in the H2/omeprazole sub-cohort. 
Mortality  within  a  year  after  the  study  period  has  been recorded.  The  highest  crude 
mortality rate has been observed among those who were on H2/omeprazole (16.4%).  Lower 
but similar rates  were  found  among  NSAID  takers  (13.7%)  and  those  who  were  given 
misoprostol  (13.2%).  The differences  were reduced after adjusting for  age  and sex,  as 
might be expected given the mean age of the cohorts, but the trends were unchanged. 
5.2.2  Clinical Events 
When comparing the three age groups, the highest endoscopy rate is observed in the 60 to 
74 years  age  group.  Unsurprisingly,  those  aged above  75  years  were  substantially less 
likely to receive endoscopies than younger patients in both the comparator and the NSAID 
cohort.  This pattern is consistent throughout the three study periods (Figure 7). 
Endoscopies were required more often in NSAID patients than in those who were non-users 
of NSAIDs.  Patients deemed to require GI protection and given concomitant H2 blockers or 
omeprazole  have  a  higher  probability  of  receiving  endoscopic  investigations  (  6%) 
compared to those on NSAIDs alone (2%).  Over the 12-month period, the relative risk was 
76 3.67.  The  relative  risk  among  patients  deemed  to  need  GI  protection  and  prescribed 
misoprostol was only 1.21 relative to those on NSAIDs alone. 
There were no endoscopies recorded in the misoprostol sub-cohort during the first 45 days 
of the study period.  The proportion of patients in the NSAID only sub-cohort who received 
endoscopies within the initial45 days (0.2%) is the same as that observed in the comparator 
cohort (Table 3).  A substantial increase (up to four fold in the NSAID only sub-cohort) in 
endoscopies is  observed in all  groups  at six months following the index date.  The high 
rates observed in the  Hz  sub-cohort remained consistent throughout the follow-up period 
(5.7% compared with 1.9% in the misoprostol sub-cohort, 1.6% in NSAID only sub-cohort 
and  1.2%  in the  comparator cohort).  In addition,  female  patients who  are  on  NSAIDs, 
regardless of the sub-cohort (NSAID only, NSAID with concomitant misoprostol or NSAID 
with  concomitant  Hz  blocker/omeprazole)  have  been  shown  to  be  more  likely  to  have 
undergone endoscopic examinations.  A larger number of endoscopic events were observed 
in females in these three sub-cohorts at all time periods (Table 3).  This was most apparent 
among  the  Hz/omeprazole  sub-cohort  where  an  approximately  four-fold  difference  was 
observed in the first 45 days.  However, this may be by chance as few events were actually 
recorded. 
Records of dispensed prescriptions were high in the NSAID cohort, ranging from 35.3% in 
the NSAID only sub-cohort at 45  days,  to  as  much as  93.4%  in the NSAID and Hz  sub-
cohort in 12 months.  Over the period of 12 months, patients on NSAIDs alone received 3.3 
times  more  prescriptions  than  non-users.  Those  on  Hz/omeprazole  received 25%  more 
prescriptions compared with those  on  NSAIDs  alone,  but those  on misoprostol received 
only 9%  more.  Records of any dispensed prescriptions for only 8.7% (45  days) to 22.8% 
(12  months)  of the  comparator cohort  were  formed.  Similar to  that observed  with  the 
endoscopic examinations, there is a consistent trend among the population that, irrespective 
of drug  therapy,  patients  in  the  60  to  74  years  age  group  and  females  have  a  higher 
probability  of being  prescribed drugs  (Table  4).  There  was  no  age  trend  amongst  the 
patients in the comparator cohort.  However,  a clear increase in prescriptions per patient 
with increasing age among NSAID users was observed.  A similar trend was present, but 
less pronounced among the Hz/omeprazole sub-cohort. 
The highest proportion of patients receiving prescriptions was observed with the Hz  sub-
cohort (ranging from 1.13  times greater than that of misoprostol to 6.7  times greater than 
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prescriptions has  also been noted over time,  the  amount of increase mirroring the  above 
trends - an increment of 39.4% was observed in the NSAID only sub-cohort from 45 days 
to  12 months of follow-up  compared to  34.4% increase in the H2/omepazole sub-cohort, 
29.2% in the misoprostol sub-cohort and 14.1% in the comparator cohort. 
All the patients who were admitted due to any diagnosis over the three observation periods 
are  shown in Table 5.  The H2/omeprazole sub-cohort has  the highest hospital admission 
rate for almost all combinations of admission diagnosis and study periods.  Hospitalisations 
of a CV-cause are the most common cause of admission in this population, followed by GI-
cause, OA-cause and RA-cause respectively. 
Admissions of a GI-cause have been observed in all groups.  Patients on NSAIDs  alone 
(1.1%) were  1.5  times more likely to  be admitted for a GI event than non-users (0.7% ). 
Those on NSAIDs and H2/omeprazole were twice as  likely to  be admitted for  GI events 
compared  with  those  on  NSAIDs  alone.  However,  only  one  GI  admission  has  been 
recorded from the misoprostol sub-cohort throughout the follow-up periods.  This resulted 
in a GI admission rate lower than that of the comparator cohort at one year (0.5% compared 
with 0.7%). 
Cardiovascular events were the most common cause for hospital admissions irrespective of 
study groups and study periods.  Over the 12-month period, there were 3.4 times as many 
patients admitted due to a CV event among all NSAID users (N =  2250) than non-users (N 
= 658).  Cardiovascular admission rates ranged from 0.2% at 45  days to  1.4% at one year 
observed in the comparator cohort, and 1.7% at 45 days to 7.6% at one year observed in the 
H2 sub-cohort. 
Patients admitted due to a RA-cause were rare in non-NSAID users (0.03%).  Rheumatoid 
arthritis  admissions  were  more  common  among  NSAID  takers  - 0.2%  recorded  in  the 
NSAID  only  sub-cohort,  0.5%  recorded in  the  NSAID  and misoprostol  sub-cohort,  and 
0.6% recorded in the NSAID and H2/omeprazole sub-cohort.  Similarly, the OA admission 
rate was low among non-NSAID users (0.2%) when compared with NSAID users (1.3%). 
Admissions for OA ranged from 0.2% observed in the comparator cohort to 2.4% observed 
in the misoprostol sub-cohort at one year. Females dominate both OA and RA admissions 
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Table 2). 
Details  for  the  longest  hospital  admission  were  recorded for  each patient in  the  study 
population.  The mean LOS  for  the longest admission and other admissions vary among 
treatment groups and different diagnoses (Table 6).  For instance, the mean LOS due to the 
longest GI admission in the first 45  days of the study period range from 5.57 days in the 
comparator cohort to  34.00 days  in the misoprostol  sub-cohort.  The number of hospital 
admissions  can be deduced from  table  6 by  adding  the  number of cases of the  longest 
hospital admission and the  sum of counts for additional admissions.  For instance, in the 
case of the misoprostol sub-cohort, only a few cases of hospital admissions were recorded 
over the 12-month period- four GI admissions (one recorded as the longest admission plus 
three additional admission counts), 23 CV admissions (13 recorded as the longest admission 
plus  10  additional  admission counts),  one RA admission  (one  longest admission and no 
additional admission counts) and eight OA admissions (five longest admissions recorded 
plus three additional admission counts).  This may be, in part, due to the small sample size 
of this study group.  Therefore, these results are difficult to interpret and may not reflect the 
true pattern in clinical practice. 
On  average,  patients  with  one  admission  are  likely  to  have  one  to  two  additional 
admissions, irrespective of treatment groups and admission causes.  However, no additional 
admissions of any  causes were recorded among the  misoprostol sub-cohort over the  six-
month period.  Over the first 45  days of the  study, no  additional RA and OA admissions 
were recorded in the comparator and Hz blocker sub-cohort respectively. 
The mean additional admission counts were calculated in a similar manner to  that of the 
mean LOS as described above.  For instance, the mean number of additional GI admissions 
during  a  12-month period for  the  few  patients in the  NSAID  only  sub-cohort with  any 
admission  is  3.24  (total  number  of admissions  divided  by  the  number  of individuals 
concerned; for example 327 admissions for 101  individuals).  Similar GI mean additional 
admission counts were recorded in all the NSAID sub-cohorts. 
Over a period of 12 months, the longest mean LOS among NSAID users (ranged from 13.3 
days  among  the  Hz/omeprazole users  to  34 days  among misoprostol users),  were longer 
than non-NSAID users (12 days).  Gastroprotective agents  (Hz  blockers,  omeprazole and 
79 misoprostol) appeared to have no  effect on GI LOS.  The mean LOS  of the longest CV 
admission was  shorter for  patients  in both the  NSAID  only  (16  days)  and NSAID  and 
H2/omeprazole  sub-cohort  (15  days),  relative  to  the  comparator cohort  (25  days).  The 
misoprostol sub-cohort was associated with the longest mean LOS at 31  days.  The longest 
mean LOS of both the comparator cohort (37 days) and NSAID only sub-cohort (25 days) 
was  observed in  RA  admissions.  Osteoarthritis  admissions  were  also  the  cause  of the 
longest mean LOS in the NSAID only (23 days) and H2/omeprazole sub-cohort (24 days). 
5.2.3  Cost Estimates 
Weighted average costs for inpatient admissions and outpatient visits were calculated by 
individual specialty (Appendix IV, Table 34 and 35).  Separate data on admission costs to 
specialties  such  as  nephrology,  cardiology,  anaesthetics  and  haematology  were  not 
available.  These were costed as  medical cases at £188.48 per case per day  of stay.  The 
average LOS and the cost per case per day vary significantly among the various specialities. 
Geriatric  long  stay has  the  longest average  LOS  at  a cost of £96.25  per case per day. 
Although A&E has  the  shortest average LOS  (0.8  days),  it has incurred the highest cost 
amongst all the specialties at £1480 per case per day.  The recorded hospital admissions in 
the dataset were dominated by medical cases. 
All the  additional drugs  and hospital interventions were costed and incorporated into the 
economic  model  to  calculate  the  shadow  cost  of the  drug  therapies  i.e.  the  cost  of 
interventions for events associated with the drug therapy.  This cost is added subsequently 
to the costs of the initial NSAID prescriptions to provide the total cost of the therapy.  The 
individual costs which were  incorporated in the  three  study-period models  are  shown in 
Appendix IV.  The costs of the  additional drugs  (NSAIDs,  ulcer-healing drugs and other 
drugs) dispensed to the patients, the GP consultation costs, the costs contributed by all the 
hospital events (longest admission and other admissions due to GI, CV, RA or OA-causes) 
and the cost of GI endoscopies, all contribute to the shadow cost. 
The composition of the total costs for the three separate study periods is shown in Figures 8 
to  10.  The trends of individual cost composition are similar across the different groups and 
the different time periods.  Endoscopies and GI admissions were not the most cost dominant 
variables, but admission due to CV related events was consistently the most dominant cost 
80 variable.  The individual total cost compositions for all the time periods and sub-cohorts are 
shown in Figure 11.  Although it is a repetition of the data displayed in Figures 8 to  10, it 
allows comparisons across the time periods and study groups to be made readily. 
The estimated average cost per patient for each treatment group is shown in Table 7.  The 
basic inception drug cost for the H2/omeprazole sub-cohort was  substantially higher than 
the basic NSAID drug cost (3.4 times) and the basic misoprostol drug cost (1.7 times).  At 
45 days, the shadow cost associated with the NSAID only sub-cohort was greater than that 
of the comparator cohort (£44.19 and £13.35 respectively).  The H2/omeprazole sub-cohort 
was associated with the highest shadow cost (£104.06) indicating a relatively high level of 
clinical events subsequent to  the initial prescription.  There was  a smaller increase in the 
misoprostol sub-cohort (£75.56).  When the basic drug costs were incorporated, the ranking 
of the total costs of the treatment groups remained the same.  The difference between the 
shadow and total costs represented the cost of all drugs dispensed per patient of each cohort 
averaged across all. 
However, when the study period was extended to  six months, a substantial increase (four 
times) in associated shadow cost was observed for the NSAID group (£179.01  compared 
with £44.19).  This is roughly in line with the four-fold increase in the time covered (six 
months compared with 45  days).  A  similar escalation in cost was  also  observed in the 
misoprostol  group  (shadow costs:  £356.50  and £99.90 respectively).  However,  an  even 
greater difference was noted when the study period is one year.  H2 therapy remained the 
most expensive throughout the three observation periods (£144.79 at 45 days, £458.93 at six 
months and £937.76 at one year). 
Similar patterns are observed when males and females are analysed independently (Table 
8).  The  average  shadow  cost  for  females  is  greater  than  that  of males  in  both  the 
comparator and the  misoprostol therapy groups.  When misoprostol therapy is  compared 
with NSAID only and H2 therapy, potential savings were observed among males- 3% at 45 
days  to  7.4%  at one year when compared with NSAID  therapy and 55%  at one year to 
77.2%  at  six  months  when  compared  with  H2  blocker therapy.  However,  misoprostol 
therapy does not produce savings among females. 
Age specific total costs are shown in Table 9.  Misoprostol therapy remained cheaper than 
H2/0meprazole therapy, with the exception of all time periods for those above 75 years old. 
81 A  savmg  was  also  observed  at  six  months  when  comparing  misoprostol  therapy  with 
NSAID therapy among those  aged 60  to  74.  More  detailed breakdown of sex  and age-
specific costs are shown in Appendix VII (Tables 36 to 38). 
There  is  a  consistent  trend  of substantial  savings  m  total  costs  being  achieved  when 
comparing misoprostol prophylaxis to H2/omeprazole therapy at all ages and time periods 
(13.4%  to  31 %),  the  only  exception  being  females  above  the  age  of 75  years.  These 
potential savings are shown in Tables 10 to 12.  From a NHS perspective, potential savings 
of £34 400  to  £266  513,  according  to  time  period,  may be  achieved if all  the  Tayside 
patients in the H2/omeprazole sub-cohort had their prescriptions replaced by misoprostol. 
However,  the  results  also  show  that  misoprostol  therapy  failed  to  provide  a  saving  for 
female H2  blocker takers,  especially those above  the age  of 75  years.  For male NSAID 
takers, misoprostol therapy has shown to generate potential savings of 5.3% at 45 days and 
33.8% at six months. 
5.2.4  Sensitivity Analysis 
Extensive  sensitivity  analysis  has  been carried  out to  test  the  assumptions  made  when 
developing the economic model.  The basic model has assumed that each episode of care 
recorded in the database is representative of an individual hospital admission.  Therefore, 
the economic consequence of the alternative assumption was investigated (Appendix VIII, 
Tables 39 to 41) - that multiple episodes of care recorded for each patient, were from one 
single hospital admission.  The resultant costs were marginally lower than those from the 
base case, but there were no effects on the results of the basic model (Table 13). 
The much lower history of CV diagnosis observed in the comparator cohort compared with 
the other treatment groups suggested a selection bias.  It was initially suspected that this 
was due to patients who were prescribed aspirin in the treatment groups.  Aspirin may be 
prescribed for prevention of CV disease,  which would explain the high rates of previous 
history  of CV  diagnosis  in  the  NSAID  treatment  cohorts.  Therefore,  as  part  of the 
sensitivity analysis, patients who were receiving aspirin were removed from the study.  The 
results  showed  an  expected reduction  in  the  average  shadow  cost but no  change  was 
observed in the overall ranking of the treatment groups. 
82 Other factors  which may influence the final  results  were  also examined (Appendix VIII, 
Tables 42 to 44).  Patients who had a prior history of GI and CV diagnoses, patients who 
had prior GI endoscopic examinations, those who had received NSAID prescriptions, and 
those who died in the year after the study period- termed 'survivors' -were excluded from 
the  analyses independently.  Analysis was  also carried out by eliminating the  above risk 
factors simultaneously.  Only patients with  'no risk factors'  were included in the analysis. 
No consistent changes were observed in the overall ranking of the drugs (Table 14) . 
Sensitivity analysis  was  also  carried out by  varying  the  cost data.  Other published GP 
consultation costs were also used to  test the robustness of the results.  The costs of £4.77 
and £8.38 have been selected for a low and high cost scenario respectively (Table 15).  In 
addition, the endoscopy cost has also been investigated by increasing and reducing the cost 
of  endoscopy  by  50%  independently.  The  results  remained  consistent  when  these 
alternative costs were used in the modelling, and the actual overall effect was small.  The 
greatest change in  cost was  found  when  the  cost of GP  consultations  was  estimated at 
£4.77.  This only resulted in a modest change in the total costs in all groups - 2%  in the 
comparator cohort and the NSAID and misoprostol sub-cohort, and 3% in the NSAID only 
and the NSAID and H2/omeprazole sub-cohorts. 
The overall effects of varying individual clinical factors and costs on the shadow costs of 
the different therapies are shown in Figures 12 to 14.  The absolute differences between the 
base case costs and each sensitivity analysis are  shown.  The left hand part of the  graph 
shows costs in groups with various risk factors.  These costs tend to be higher than the base 
case.  The rankings of the four groups changed little, but the absolute differences in costs 
varied markedly - mostly because of small numbers of the affected individuals.  Patients on 
misoprostol with a prior GI admission seemed particularly at risk and were expensive, but 
the numbers were small (N =  27). 
The right hand part of the graph shows similar findings for the groups with high risk factors 
excluded.  The size of the groups are much larger, variation is much less. 
83 5.3  MODEL-BASED  PHARMACOECONOMIC  ANALYSIS:  EXAMPLES 
WITH  NONSTEROIDAL  ANTI-INFLAMMATORY  DRUGS  (NSAIDs), 
SELECTIVE  SEROTONIN  REUPTAKE  INHIBITORS  (SSRis)  AND 
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS 
5.3.1  Data Collection 
Despite  a large  number of clinical  trials  being identified by  the  searches,  only  a  small 
proportion of the resulting references fulfilled the inclusion criteria for the meta-analyses 
(Figure 15).  The is particularly the case with NSAIDs as  most of the clinical trials were 
conducted ten to 30 years ago (clinical trials dated as far back as  1972 were included in the 
analysis),  before  quality  guidance  for  conducting  good  clinical  trials  was  established. 
Although  most well  conducted clinical  trials  recorded  and  described  drug-induced  side 
effects, only a small proportion of the trials contained detailed reports of incidence rates of 
side effects of interest to the study.  As a result, the final number of clinical trials included 
in the analyses was small. 
The search filters used in the literature search focused on sensitivity instead of specificity. 
Therefore, the number of references identified by the search differs significantly from the 
number of studies included in the analysis.  In all, over 9000 trials were identified from the 
databases for  NSAIDs,  SSRis and ACE inhibitors.  These included comparative trials of 
any of these drugs against a placebo or active control.  The majority of the trials were small, 
phase III, double-blind, randomised controlled trials of short duration - four to  six weeks. 
A total of only 69 trials met the selection criteria and contributed usable data to the three 
meta-analyses. 
Non-Steroidal Anti-Inflammatory Drugs 
Over 3000 studies were identified by the search through the databases.  Studies that did not 
fulfil  the inclusion criteria, including those evaluating biological inflammatory indicators 
for arthritis, the use of NSAIDs for indications other than RA or osteoarthritis, and absence 
of recorded  frequencies  of individual  adverse  events,  were  excluded.  These  studies 
84 included clinical trials that did not compare individual NSAIDs, those that failed to provide 
detailed figures of individual adverse drugs reactions, trials that reported serious GI adverse 
events only as opposed to all adverse drug reactions. 
Fifteen studies evaluated RA patients, eight studied OA patients and one study included 
both RA and  OA patients.  In  total,  24 studies  were  included in the  meta-analyses  of 
NSAIDs-induced adverse events 
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-152  (Table 16).  The mean study period was 10 weeks 
(range two to 51  weeks).  Eight studies reported efficacy and tolerability of indomethacin, a 
further six on naproxen, assessment of ibuprofen and ketoprofen were all reported in four 
studies; there were three on piroxicam and tolmetin, two on sulindac, fenoprofen, and one 
on  diclofenac.  Although  it  was  possible  to  extract  numerical  adverse  drugs  reactions 
(ADR) data from these trials, the methods used for recording these events are not always 
known  (52.4%).  Only two  trials  (9.5%)  reported the  use  of checklists,  while  11  trials 
(52.3%)  depended on indirect questioning to  obtain ADR data.  No  trials  gave  detailed 
definitions of each ADR.  The qualities of the studies were generally poor, with a Jadad 
score of less than three.  The median Jadad score for the NSAID trials was two. 
Selective Serotonin Reuptake Inhibitors 
Clinical studies on SSRis have been dominated by comparative studies between SSRis and 
TCAs as a class of drug.  Generally, data were presented in aggregated format for the drug 
class instead of individual drugs, focusing on the differences in efficacy and safety between 
SSRis and TCAs.  The search for  studies on SSRis produced 21  randomised controlled 
trials  with usable data on all SSRis 
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173  (Table 17).  The mean duration of study was nine 
weeks  (range  four  to  76  weeks).  Nine  studies  reported  data  on  fluoxetine,  seven  on 
fluvoxamine,  four  on paroxetine and a further four  on sertraline.  Although five  studies 
were found to  report detailed ADR rates associated with citalopram, they were excluded 
from the analysis due to insufficient sample sizes (N < 20). 
Clinical trials on SSRis were performed more recently (1983 onwards) and were of better 
quality than those on NSAIDs.  Only one study had a Jadad score of less than three and the 
median Jadad score for all the studies was three.  Various methods of ADR recording were 
used.  Thirty-eight percent of the trials did not specify the method used to collect ADR data, 
while checklists were the most frequent method, used by 33.3% of the trials. 
85 Angiotensin Converting Enzyme Inhibitors 
The meta-analysis on ACE inhibitors adverse events was based on data from 24 trials 
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(Table 18).  The mean duration of the studies was 11  weeks (range four to 51  weeks).  Ten 
were trials on enalapril,  six on linsinopril, three each on captopril and ramipril.  Data on 
trandolapril, moexipril and perindapril were only based on one randomised controlled trial. 
Although one trial was identified with ADR rates for fosinopril,  the sample size was  too 
small to be included in the analysis. 
The clinical trials for ACE inhibitors were conducted more recently than those for NSAIDs 
and  SSRis.  The Jadad score for  the  clinical  trials  ranged from  two  to  five  (maximum 
score), with a median score of three.  Methods of ADR recording included open (12.5%), 
direct  and  indirect  questioning  (8.3%),  spontaneous  reporting  (33.3%)  and  the  use  of 
checklists  (4%).  However,  16.7%  of the  trials  did  not  specify  the  method  of ADR 
recording. 
5.3.2  Adverse Drugs Reactions Data 
The ADR profile for NSAIDs, SSRis and ACE inhibitors are presented in Tables 19, 20 and 
21  respectively.  The total number of events reported, the weighted number of events and 
the  weighted percentage of events  (weighted according to  the  sample size  of the  group) 
associated with each individual symptom were calculated for each drug. 
Non-Steroidal Anti-Inflammatory Drugs 
A  meta-analysis  of 1987  patients  on  eight NSAIDs  was  conducted  (Table  19).  Large 
variations  in  event rates  have  been observed  among  individual  NSAIDs.  In particular, 
fenoprofen appeared to be the least well tolerated of all the NSAIDs in the analysis.  It was 
shown  to  have  the  highest  rate  for  abdominal  pain,  constipation,  confusion,  headache, 
tinnitus, visual disturbance, rash/pruritis and oedema. 
86 Gastrointestinal  symptoms  such  as  abdominal  pain,  dyspepsia  and nausea and vomiting 
have  dominated  the  ADR  profile  irrespective  of some  variation  in  ADR rates  among 
individual  drugs.  Most  of the  GI  events  reported  are  minor  symptoms.  The  highest 
incidence of GI events has been observed with fenoprofen.  Many of the GI events such as 
abdominal  pain,  constipation,  diarrhoea,  dyspepsia  and  nausea and vomiting  have  been 
reported consistently by all  NSAIDS.  Although less commonly reported,  serious events 
such as peptic ulcer has been reported by 0.03% of patients in trials of ibuprofen. 
Many non-gastrointestinal ADRs have also been reported in the clinical studies.  Dizziness 
and vertigo, and headache have been reported by patients on all the individual NSAIDs.  In 
particular, headache has been reported by 15.2% of those on fenoprofen,  11.1% of those on 
diclofenac, 6.0% of those on sulindac, 2.8% of those on indomethacin, and less than 2% of 
those on the remaining NSAIDs.  Patients have reported high incidences of rash or pruritis, 
up  to  30.8%  on  fenoprofen.  One  case  of anaemia  has  been  reported  by  patients  on 
indomethacin during the clinical trials.  A serious complication, such as anaemia, was only 
recorded by one patient in the indomethacin group. 
Selective Serotonin Reuptake Inhibitors 
An aggregated total of 779  patients was included in the meta-analysis of SSRis-induced 
adverse  events  (Table 20).  There were  194 patients in the fluoxetine  group,  183  in the 
sertraline group, 132 in the fluvoxamine group, and 270 in the paroxetine group.  The ADR 
profiles between individual SSRis vary considerably.  Sertraline appeared to have the worst 
toxicity  profile  among  all  the  SSRis  evaluated.  This  is  most apparent in  drug-related 
decreased  libido  (14.2%  compared  with  0.1%  among  fluoxetine  patients,  0.9%  among 
fluvoxamine  patients  and  3.5%  among  paroxetine  patients).  The most common  ADRs 
reported by patients on SSRis included nausea and vomiting, ranging from  10.4%  among 
those  on  fluvoxamine  to  25.8%  among  sertraline takers,  dry  mouth,  ranging from  2.2% 
among  those  on  fluoxetine  to  21.6%  of sertraline patients,  and drowsiness,  reported by 
1.5% of fluoxetine patients to 23.5% of paroxetine patients. 
Many side effects referable to the central nervous systems such as  dizziness, constipation, 
fatigue  and headache  are  also  prominent with SSRis.  Both fluoxetine  and  fluvoxamine 
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rates  for  fluoxetine  and  fluvoxamine  are  generally  lower  than  those  of sertraline  and 
paroxetine. 
Angiotensin Converting Enzyme Inhibitors 
Data on 2211 patients on ACE inhibitors were used to calculate weighted average incidence 
rates for reported ADRs  (Table 21).  In  general,  with the exception of perindapril, ADR 
incidence rates for  ACE inhibitors were low,  thus they all  appeared to  be well  tolerated. 
The ADR rates recorded in patients taking perindapril were much higher than all the other 
ACE inhibitors being assessed irrespective  of individual  symptoms.  However,  this  was 
only based on one study. 
The most common ADR reported was headache- 0.7% among those on enalapril to 25.5% 
among those on perindapril.  Cough, which is a well-documented adverse event induced by 
ACE inhibitors, was observed among 3.3% to 31.9% of patients who were on lisinopril and 
perindapril  respectively.  No  serious  adverse  drug  reactions  have  been reported  by  the 
published clinical trials. 
5.3.3  Management of Adverse Drugs Reactions 
The  local  LHCC  that participated  in  our  study  consisted  of 38  GPs  in nine  practices. 
Following recruitment via post and telephone follow-up, only nine GPs agreed to take part 
in the interview.  Semi-structured, face-to-face interviews were conducted to determine the 
possible treatment strategies and outcomes associated with the adverse events reported in 
the clinical trials.  When presented with the list of ADRs associated with NSAIDs, SSRis 
and ACE inhibitors, all  GPs recognised the events as symptoms of possible drug-induced 
adverse events.  However, symptoms such as "eyelid soreness", "malaise", "shoulder ache" 
and "taste impairment"  would be unlikely to result in patients seeking consultations with 
their GPs, and were not included in the analysis. 
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experience in dealing with patients who were on any of the three classes of drugs in general 
practice: 
•  the  proportion  of patients  who  would  have  their  drugs  stopped  or  changed  when 
experiencing side-effects, 
•  those who would receive a particular investigation and/or treatment (dependent on the 
estimated rate of  recovery), 
•  those who would fail to improve and require hospitalisation, and 
•  the total number of GP or outpatient visits involved. 
Analysis of the GP interviews has provided a summary of the average probability of a GP 
performing a particular investigation or allocating any specific treatment to  counteract the 
adverse  drug  reactions induced by  a course  of drug  therapy.  The results  are  shown in 
Figure 16a-din the form of decision trees.  When dealing with drug-induced events, it was 
believed that on average,  two  GP  visits would be involved for the purpose of diagnosis, 
investigations and treatment.  Often, patients would be recommended to  stop  the  drug or 
switch to a therapeutically equivalent drug,  possibly of the same class, in the expectation 
that the  ADR would diminish without further management.  This has been the preferred 
choice with all GPs when confronted with suspected drug-induced side effects.  However, 
there  are  instances  when  further  investigations  and  co-prescribing  of additional  drug 
treatment  would be  necessary,  such  as  endoscopies  and  co-prescribing  of ulcer-healing 
drugs in the case of peptic ulcers.  This is most prominent among GI complications. 
5.3.4  Cost Estimates 
Drug costs vary considerably among drugs of the same class.  The calculations for the cost 
of drugs were based on the assumption that where possible, the formulations of the lowest 
purchasing  costs  would be  prescribed,  and  generic  formulations  would be  preferred  to 
proprietary formulations.  It was also assumed that the defined daily dose (DDD) would be 
prescribed.  Ranges of costs representing the lowest and the highest DDD are presented in 
Table 19.  All the drug costs and defined daily doses were taken from the British National 
Formulary (BNF).  The higher the DDD,  the  higher the  drug  acquisition costs,  with the 
exception of ketoprofen.  The maximum DDD of ketoprofen incurs lower costs than when 
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the  drugs.  The  100  mg  formulation  for  ketoprofen  has  a  lower cost  than  the  50  mg 
formulation. 
For consistency purposes, all three classes of drugs were modelled for the same duration of 
treatment.  The average length of all the clinical trials (in all three classes of drugs) used in 
the  meta-analysis  was  approximately  10  weeks;  therefore,  the  costs  of  drugs  were 
calculated for a duration of 10 weeks. 
Amongst NSAIDs, piroxicam and indomethacin have the lowest acquisition costs- £3.54 to 
£11.44  and  £3.57  to  £5.60  respectively,  over  a  10-week  period,  while  ketoprofen  is 
associated with the highest cost- £22.12 to £22.45 over 10 weeks.  There is at least a six-
fold increase in cost when comparing the costs of piroxicam with ketoprofen. 
This is  also  observed among  SSRis,  where  drug  acquisition costs range from £18.01  to 
£54.04 for fluoxetine,  to  £41.44 to £125.81  for  paroxetine,  a three-fold increase in cost. 
This large  difference in costs may be partially explained by the lack of generic versions 
available for  paroxetine  (Seroxat ®) and  sertraline  (Lustral  ®), the  two  more  expensive 
preparations. 
ACE  inhibitors  are  relatively  new  drugs,  only  captopril  and  enalapril  are  available  in 
generic forms.  The drug acquisition costs in this class of drugs ranged between £5.75  to 
£10.51 for captopril and £24.06 to £69.49 for Perindopril, representing as much as a three-
fold increase in costs. 
Unit costs used to calculate the costs for managing individual adverse events are shown in 
Appendix IV.  The direct medical costs related to  the management of individual adverse 
events were calculated.  The calculation of these costs has taken into account the resource 
utilisation and the costs of input variables such as GP consultations, prescriptions, clinical 
investigations (such as  GI endoscopies for suspected ulcers and blood tests for anaemia), 
any outpatient hospital visits and possible hospitalisation in the more serious cases. 
The  least costly  adverse  events  were  those  associated  with  the  central  nervous  system 
including symptoms such as headache, dizziness and tinnitus (Table 23).  The results of the 
GP interviews suggested that only minor cases of these events have been seen and would 
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adverse  events,  such as  peptic ulcers,  incur much greater costs  (£308.41)  due  to  further 
investigations,  referrals  and co-prescriptions.  These costs  were  applied to  the  weighted 
probabilities (Tables 19 to 21), calculated from the meta-analysis and are shown in Tables 
24 to  26.  The sum of these costs is the estimated cost of managing all associated adverse 
drugs reactions - i.e.  the shadow costs.  The shadow costs for each individual drug per 
patient and per 1000 patients are presented in the tables. 
The results of the  cost analyses  are  shown in Table 27.  The drug  acquisition costs,  the 
shadow costs (costs of managing adverse drug reactions) and the total costs of therapies per 
1000  patients  are  presented.  Irrespective  of individual  drugs,  the  total  costs  of drug 
therapies increased substantially when the shadow costs are taken into account. 
In the case of NSAIDs, the cost of drug therapy increased between 12.3% (ketoprofen) and 
59%  (diclofenac sodium) when the cost of managing ADRs was taken into account.  The 
most significant increase was observed in both fenoprofen  (£19 860  to £43 204 per 1000 
patients) and diclofenac sodium (£5850 to £14 288 per 1000 patients), when the total cost of 
therapy rose by over two fold when the shadow costs were taken into account. 
The cost of SSRis therapy increased by approximately 25% (fluoxetine and fluvoxamine) to 
42%  (sertraline) when shadow costs were included in the total cost of therapy. 
The  cost of ACE inhibitors  therapy  increased by  4%  (enalapril  and  lisinopril)  to  54% 
(perindopril) folds when shadow costs were taken into account.  The costs associated with 
managing enalapril and lisinopril  associated ADRs  were low - £357  and £626 per 1000 
patients  over  10  weeks,  respectively - and  have  little  impact on  the  final  cost of drug 
therapy. 
Table 27 also shows the relative ranking of the drugs according to their costs.  The original 
ranking represented the  ranking of drugs  according to  their acquisition costs alone.  For 
NSAIDs,  piroxicam is  the  cheapest  to  purchase,  followed  by  indomethacin,  ibuprofen, 
diclofenac,  naproxen,  sulindac, fenoprofen  and ketoprofen.  However,  when the  shadow 
costs  for  these  drug  therapies  were  taken  into  account,  the  final  ranking  of the  drugs, 
according to the total costs of therapy, changed.  Indomethacin became the therapy with the 
lowest cost, followed by piroxicam.  Naproxen previously ranked fifth,  became the third 
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ketoprofen. 
If NSAID prescribing decisions were based on the  acquisition costs, piroxicam would be 
the preferred choice.  However, when shadow costs were taken into account, indomethacin 
became  less  costly,  a  potential  saving  of £1131.85  (£6651.58  with  piroxicam  minus 
£5519.73 with indomethacin) in 1000 patients over 10 weeks may be achieved. 
A  similar  finding  was  observed  with  SSRis.  Although  the  ranking  of fluoxetine  and 
fluvoxamine  remained  unchanged  when  the  shadow  costs  were  taken  into  account,  the 
ranking of sertraline and paroxetine switches between placed third and fourth.  If SSRI 
prescribing  decisions  were  based on  the  acquisition  costs,  sertraline  (£40 500  per  1000 
patients)  would  be  a  cheaper  alternative  to  paroxetine  (£41 440  per  1000  patients). 
However,  when  shadow  costs  were  taken  into  account,  paroxetine  became  more  cost 
effective, a potential saving of £7063.14 in 1000 patients over 10 weeks may be achieved. 
In the case of the ACE inhibitors.  Moexipril became more costly than trandolapril when the 
shadow costs were taken into account, and a potential saving of £320.34 (£27 155.43 with 
moexipril  minus  £26 835.09  with  trandolapril)  in  1000  patients  over  10  weeks  may  be 
achieved. 
5.3.5  Sensitivity Analysis 
The input values on costs and probabilities of ADRs used in the model above were 
tested in the sensitivity analysis.  Both the unit costs and the probabilities of developing 
an ADR were inflated and reduced by 20%, singly and combined.  Scenario analysis 
based on  the  extremes  of the  95%  confidence  intervals  was  also  conducted.  The 
resultant effect on the three models are  shown in Figure 17,  18  and 19.  Overall, the 
results are robust and the ranking of the drugs all the three models remained unchanged. 
Increasing and reducing the costs and probabilities resulted in corresponding increase 
and reduction in the total cost of drug therapies. 
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PRESCRIBING IN PRIMARY CARE 
5.4.1  Dissemination Exercise 
Recruitment took place during one of the monthly LHCC meetings when seven GPs from 
five different practices were present.  During the meeting, all seven GPs showed interest in 
the  study and also  agreed to  encourage colleagues from the same practice to  participate. 
However, only five GPs participated in the study.  Two GPs were from the same practice, 
while others were from different practices.  The main reason for non-participation was "lack 
of time". 
Prescribing Data 
The national prescribing trends for NSAIDs,  SSRis and ACE inhibitors evaluated in the 
previous sections are shown in table 28.  There is no indication of any particular pattern, in 
relation to purchasing cost and relative cost effectiveness, in prescribing of any of the three 
classes of drugs. 
Overall, there is a general decrease in NSAID prescribing.  This may reflect the increase in 
the use of cyclo-oxygenase II (COX-II) inhibitors, replacing the traditional NSAIDs.  The 
results  from  the  economic  analysis  favoured  the  use  of piroxicam  and  indomethacin. 
However,  the  national  prescribing  trend  showed that  these  drugs  were  not particularly 
favoured by GPs.  Diclofenac, ibuprofen and naproxen- ranked 3, 4 and 5 in the economic 
analysis -were the top three NSAIDs prescribed in Scotland.  The drugs shown to be less 
cost effective - ketoprofen, sulindac and fenoprofen- were the least prescribed drugs. 
Selective serotonin re-uptake inhibitors prescribing appeared to be generally in agreement 
to  the  results  of the  economic  analysis,  with  the  exception of fluvoxamine.  Although 
fluvoxamine  was  the  second most  costly  drug  to  purchase  and  the  second most cost-
effective drug to  use in comparison to  other three SSRis evaluated, it appeared to be the 
least preferred choice among GPs.  While increase in prescribing was recorded for all other 
SSRis, an 11.71% reduction in fluvoxamine prescribing was observed. 
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economic  analysis,  were  prescribed  in  smaller  volumes  than  those  ranked  2,  3  and  4. 
However, the least costly and the most cost effective ACE inhibitor - captopril, was not the 
most commonly prescribed ACE inhibitor. 
The prescribing trend of the LHCC in the study was in agreement with national prescribing. 
The change in national prescribing over a 12-month period differed from those recorded in 
the LHCC in this  study.  This is not unexpected given the  sample size for  this  study is 
small.  Two drugs that were included in the economic analyses- fenoprofen and moexipril 
- were not used by the LHCC. 
Overall, there was a reduction in NSAID prescribing in both groups.  The only exception 
was observed with diclofenac.  A moderate increase (1.02%)  was observed in the  study 
group compared with a 5.27% reduction recorded in the control group over a six-month 
period (table  29).  However,  this  difference  was  not statistically  significant.  The  only 
difference in the change of prescribing was observed with ketoprofen.  A larger reduction in 
prescribing was  recorded in the control group  (29.01 %)  when compared with  the  study 
group (17.23%). 
Increases in fluoxetine, sertraline and paroxetine prescribing were observed in both groups 
over  the  six-month  period.  However,  none  of the  differences  were  of  sustainable 
significance.  Similar  to  that  observed  with  the  national  prescribing  data,  there  was  a 
reduction in fluvoxamine prescribing, but the differences between the study group were not 
statistically significant. 
The only statistically significant difference in the change in prescribing among the ACE 
inhibitors was observed with trandolapril.  The prescribing of trandolapril was reduced by 
8.79% compared with 0.12% in the control group. 
This dissemination exercise appeared to have no obvious effect on prescribing.  Neither a 
significant increase in the more cost effective drugs, nor a significant reduction in the less 
cost effective drugs was observed in the study group.  The significantly large reduction of 
trandolapril prescribing when compared with the control group may be a positive result, 
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of  prescriptions recorded. 
5.4.2  Survey - Quantitative and Qualitative 
A  total  of 53  members  and  17  affiliated  members  were  identified  by  the  WestNet 
database.  Four non-GP members  (pharmacist,  optometrist,  clinical auditor and dentist) 
were  excluded from  the  survey.  All  the  eligible  GPs  (n = 66)  were  divided into two 
groups- email group, i.e. those with a contact email addresses (n =  33) and postal group, 
i.e. those without contact email addresses (n = 33).  However, email was undeliverable to 
five members - three from questionnaire (I) group and two from questionnaire (II) group. 
Response Rates 
A total of 27 GPs returned the questionnaires, an overall response rate of 44%.  Table 30 
gives  a detailed breakdown of the response rate by each group.  Higher response rates 
were  observed  with  the  postal  group  when  compared  with  the  email  group  and  with 
questionnaire  (I)  when  compared  to  (II).  However,  none  of the  differences  between 
groups were significant. 
Questionnaire (I)- Economic Information Used in Medical Decision-Making 
All  respondents  indicated they believe  that economic  information  comparing cost and 
effectiveness of treatments has influenced their medical decision-making.  The majority of 
the respondents (n =  9;  69%) reported that such a decision was made as recently as  one 
month previously or less,  while  15%  (n = 2)  reported such decisions made  one  to  six 
months ago and another 15% (n =  2), over six months ago. 
Both published and verbal economic information produced by local authorities  (Health 
Boards, PCGs, Prescribing Medical Advisors  [PP  As]  and Medical Prescribing Advisors 
[MPAs]) were the most commonly used by GPs, followed by information generated by the 
pharmaceutical industry (table 31).  However, only  13%  (n = 2)  and 20%  (n =  3) have 
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respectively.  A slight preference to published information was noted. 
All  respondents  (n  = 15)  uniformly  reported  changes  in  prescribing  as  their  recent 
economic-information-influenced medical  decision.  Change  in proton pump  inhibitors 
prescribing was described by 33% (n =  5), statin prescribing in 20% (n =  3), and 13% (n = 
2) described changes in the prescribing of non-steroidal anti-inflammatory drugs. 
Four  respondents  described  circumstances  when  economic  information  had  failed  to 
influence their decision-making.  50% (n = 2) felt it was 'impossible to  implement these 
findings into practice', while one respondent disagreed with the results of the information 
presented.  One  respondent  described  the  reason  to  be  due  to  the  'cost  of time  in 
implementing changes not being reimbursed'. 
Questionnaire (IT) - Sources and Relevance of Economic Information 
All respondents believed that economic information should be incorporated in healthcare 
decision-making.  They were all, with the exception of one (n =  11; 92% ), able to describe 
the various sources of economic information they had used (table 32).  The most common 
source was the Scottish Prescribing Analysis (SPA) data- used by 83% of the respondents 
(n = 10),  80%  (n = 8)  of whom found the  material relevant to  their everyday practice. 
This was followed by the literature produced by the pharmaceutical industry, which was 
used by 75% of the respondents (n =  9), but only 20% (n =  2) found the material relevant 
to  practice.  Fifty-eight  percent  (n  = 7)  recognised  medical  prescribing  advisors  and 
pharmaceutical  prescribing  advisors  as  a  source  of economic  information,  while  62% 
(n =  5) regarded the information as relevant. 
However, 80% (n =  8), 73% (n =  8) and 67% (n =  8) of the respondents did not regard the 
British  Journal  of  General  Practice,  locally  produced  newsletters  and  prescribing 
formularies,  and  the  General  Practice  Administration  System  for  Scotland  (GP  ASS) 
feedback as an economic information source. 
Higher proportions of respondents preferred published material compared with verbally 
presented material (table 33).  In particular, locally specific information and summarised 
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5.4.3  Qualitative Interviews 
Fifty letters of invitation were sent to GPs by post and followed up by telephone, only four 
agreed to be interviewed.  Another four GPs were recruited through snowball sampling. 
All of the eight GPs participated in the interviews were from different practices.  None of 
the GPs interviewed had any previous training.  One of the GPs interviewed was relatively 
non-communicative giving brief and often mono-syllabic answers and was excluded from 
the formal analysis. 
The Use of Current Evidence 
All the GPs interviewed were able to describe the most recent economic information they 
have encountered.  However, at the onset, the majority of the interviewees described the 
reviewing of Scottish Prescribing Analysis data. 
"I had economic information coming from the prescribing centre in Edinburgh.  They 
would send out regular analysis on prescribing costs,  etc.;  and it drew attention to 
your placing in terms of  your individual practice, your locality and nationally." (GP 
2) 
"I look at level 2 reports, detail breakdown of  the prescribing quarter and analysis of 
prescribing; and also look at the information the prescribing bureau send us on drugs 
and cost analysis." (GP 3) 
Subsequently  during  the  interview,  the  term  "economic  information"  was  defined  as 
"information  relating  to  both  costs  and  benefits"  and  the  question  was  repeated. 
Although peer-reviewed medical journals, including the Lancet and the  British Medical 
Journal, were the most commonly cited source of recent economic information, none of 
the interviewees were able to recall details of the information they had read.  Some of the 
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drug representatives, however, they showed much scepticism towards the quality and the 
validity  of the  information  presented  to  them.  One  interviewee  recalled  economic 
information that was discussed in a regular newsletter disseminated by the British Heart 
Foundation.  While all the interviewees described the information as of interest to varying 
degrees, none had made or changed decisions in practice based on this information. 
" ... but she was telling me about the additional benefit adding that into statin therapy. 
And if  you double  the  statin dose,  compare that to  the  cost of adding this  additional 
drug,  you get this  benefit and that.  What  the  cost benefit was,  I  can't remember  ... 
That's probably the  most often source I see  it from.  But that's the  source I tend to 
ignore." (GP 5) 
"I think there was something recently in promotional literature concerning the use of 
statins...  there  were  some  explanation,  rationale  to  statin  in  a  much more  broader 
population  context  and its  effect  on  the  reduction  on  ischaemic  heart disease  and 
stroke." (GP 7) 
Despite defining economic information as information relating to both costs and benefits, 
most GPs interviewed did not differentiate between economic evidence and cost data.  All 
the  GPs interviewed stressed that they bear cost issues in mind when prescribing; five 
interviewees described "paying attention" to the costs of drugs that are displayed with the 
GPASS system that they use.  However, one GP described the use of a GPASS-integrated 
online  formulary  produced  by  the  local  medicines  management  team  that  takes  into 
account the relative cost effectiveness of drugs. 
"If  !felt it did not compromise the treatment in any way,  then I would certainly use the 
generic brand of drug;  if I felt there  was an  issue  in  relation to  the  efficacy of the 
medicine,  and  that's  what  the  patient  needed  and  that  was  important,  then  take 
precedence.  But other than that, I would go for generic or the cheapest. " (  GP I) 
" ... the cost of  the drugs comes on the screen with the GPASS and I do  have a look at 
that" (GP 4) 
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above the national average.  So,  I looked at level 2 data and try to  analysis why this 
was ... " (GP 2) 
"I suppose when you  have  two  drugs  and there  is  nothing to  choose between them, 
previously you  would have looked at the  cost;  now with the formulary,  you get first 
choice and second choice...  The formulary takes into account the cost of  buying the 
drugs and the associated costs. " (  GP 7) 
Two interviewees indicated that they were satisfied with the way economic information is 
presented in the literature.  However,  all the GPs interviewed, including these two,  said 
they were unfamiliar with most of the  economic principals presented to  them.  All  the 
interviewees recognised terms  such as  "direct and indirect costs",  "cost effectiveness", 
"cost benefit"  and  "quality of life  adjusted  years";  however,  only  a  small  proportion 
recognised the terms "marginal cost" and "incremental cost effectiveness". 
In  addition  to  the  commonly used economic jargon,  the  concept of "shadow costs"  -
taking  into  consideration  the  cost of managing  adverse  drug  reactions  was  discussed. 
Overall, the interviewees described this to be "interesting" and "relevant".  However, most 
believed that such information is purely academic and would not have significant impact 
on their prescribing decisions. 
"It would be  (of interest)  if you  put it  in  a form  that  is  clear,  that  will  be  good 
information to know." (GP 4) 
" ... it's probably more of  academic interest than anything  ...  it is not going to influence 
prescribing unless it is a side effect that is very common. .. 
... So if  you treat 100 patients and 2% get a side effect and they will be more expensive, 
forget it.  If  you can show that 90% will get the side effect,  therefore, 90% of the time 
more expensive, so that's worth considering." (GP 5) 
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prescribing. 
"Perhaps subconsciously,  this shows an  influencing factor in your choice ...  although 
you  know  this  other product  is  slightly  more  expensive  than  another,  if  from  your 
experience,  patients  seem  to  tolerate  it better,  come  back less  often,  feel  it's more 
efficacious...  Therefore,  you wouldn't necessarily be selecting based on the ways you 
have  been  suggesting,  the  product  that  was  more  expensive...  But  from  your 
perspective is a better product for that individual patient for a combination of  all the 
reasons that I have mentioned,  so  although,  there was economics involved,  they were 
indirect  economics,  of the  kind you  mentioned,  but I  don't particularly  remember 
analysing it in the way you have presented  ... 
.  . . I do wonder a lot of  GPs with experience possibly do the same thing,  but not think in 
those  terms.  These products  work well,  patients takes  them,  like  them.  I know  it's 
slightly more expensive that product B,  but for these  reasons,  I think,  it's worth the 
expense." (GP I) 
"That process you've described is  exactly what (the formulary) has done to decide the 
first choice for (drug) use...  It's not something that I do personally.  It's been done for 
me." (GP 7) 
The Barriers and Facilitators in Implementing Economic Evidence 
All the interviewees uniformly stated lack of time to be the major barrier to implementing 
economic evidence.  It is also clear that the recent introduction of the new GP contract has 
taken priority in the thoughts of most GPs. 
"We don't really have the time ...  a lot of  people come  in  and give you chapters and 
verse on the studies, where to find them and what they show and you tend to just accept 
that -well ok." (GP 4) 
"Time is the key barrier.  We don't have time to do much more than what we're already 
doing." (GP 5) 
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"Frankly, we have the new contract, where is there time to put it in?  There is so much 
in general practice at the moment. " (  GP 7) 
" ... especially with the new contract coming into place, I don't think GPs will have time 
to think about much else" (GP I) 
Some  GPs  interviewed  regard  health  economics  as  an  academic  discipline  and  lacks 
practical applications. 
"I suppose  GPs  traditionally,  again  in  a  non-critical way,  don't see  themselves  as 
academics.  Therefore,  they're practical people getting on with their day-to-day job of 
"real" medicine." (GP 2) 
"They're (economic studies) often are  involved in  hospital trials  rather than general 
practice trials and hospital trials are a different environment to general practice.  And 
you feel  the  conditions  and the  controlling factors  are  quite  different to  the  people 
coming into  general practice in  the  daily  surgery.  Although it might recommend a 
particular product for hypertension  or whatever,  you  did feel  it  didn't necessarily 
provide  the  information  in  the  setting  that  you  were familiar  with.  So,  it  wasn't 
necessarily, you couldn't extrapolate it directly." (GP 6) 
None  of the  GPs  were  able  suggest  facilitators  that  may  help  implement  economic 
information in their practice.  There were suggestions about improving the presentation of 
the findings in a more precise manner.  However, it was also pointed out that although this 
may increase the likelihood that such information may be read, none of the GPs believe that 
the information will be absorbed and used in clinical practice.  This may, in part be due to 
their perspective on the role of economic issues in health care decision making as a whole, 
which is presented below. 
The Role of Economic Issues in Healthcare Decision Making 
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economic issues, however, they don't believe that such information has a role at a practice 
level.  All the  GPs interviewed believed that the  use  of economic information should be 
carried out either nationally or at the least, by the local trusts. 
"I think these decisions should not be taken at a general practice level  ... 
.  . .  these information should be filtered through either regional or national level  ... you 
can't have decisions made at practice level.  You'll then have undoubted result in one 
practice doing one thing and another practice doing  another,  and then you have an 
inequality." (GP 7) 
"And I think it is reasonable that GPs as gatekeepers to these services that cost money 
have responsibility and awareness  ...  I don't think there's a way round for GPs; I think 
they have to have information like that.  Whether they use it or not it's up to them but I 
think they need to  have the  information of cost,  because otherwise,  you  would loose 
sight within a few years absolutely of  relative costs. " (  GP 1) 
"Well, I think...  trusts or nationally.  We're in the sharp end here-we have 10 minutes 
with the patients,  and patients may come with 10 problems each,  so there's really no 
time to think about economics in the wider sense.  But if  we have some sort of  feedback 
from the trusts or nationally, in a simple form, it might be interesting." (  GP 3) 
" ... it would have to done at a national level, probably medicines committee of  the NHS, 
centrally, that would have to do that.  But some sort of  body like that. " (  GP 5) 
Overall,  all the GPs interviewed have regularly come across health economic information 
and feel  that  they  should be  kept informed.  However,  the  difficulty  they  expressed in 
recalling the information has indicated the lack of impact the information has had.  Time 
and  applicability has  been found  to  be  the  key  barrier to  implementing the  findings  of 
economic  studies.  However,  the  view that the implementation of economic information 
should be at a national or a trust level has represented an indirect barrier to their using of 
such information. 
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6.1  INTRODUCTION 
The  discussion  of this  thesis  follows  the  same  order as  the  work described in previous 
chapters.  The  discussion  on  the  results  of the  thesis  starts  with  the  findings  of the 
population based economic analysis in section 6.2.  This is followed by discussion on the 
findings  from  the  meta-analysis  based economic  analyses  of NSAIDs,  SSRis  and ACE 
inhibitors  (section  6.3).  The findings  of the  dissemination exercise,  the  survey  and the 
qualitative interviews follow in section 6.4. 
6.2  POPULATION BASED ECONOMIC ANALYSIS 
The  cost  of drug  therapy  cannot  be  represented  solely  by  its  purchasing  cost.  The 
population  based  pharmacoeconomic  evaluation  of  NSAID  therapy  (section  5.2),  by 
calculating its complete cost, including that of unintended adverse events, is made from a 
NHS perspective. 
The strength of using population data in cost analyses has been demonstrated by this study. 
Detailed recording of epidemiological data,  such as  those recorded by MEMO, provide a 
clear view of drug use in real clinical practice.  These data are particularly valuable when 
investigating unintended adverse effects and subsequently their costs for individual drugs. 
In contrast, clinical trials would not be able to provide accurate data for this type of costing 
exercise due to  issues surrounding the transferability of appropriate prescribing decisions 
into real practice and the methods adopted to record adverse drug reactions.  In addition, the 
number of subjects in clinical trials are several orders of magnitude smaller than those in 
the population-based study described here.  However, this population dataset has one major 
limitation, in that the absence of indication for prescribing makes these studies particularly 
vulnerable to confounding by indication. 
Sensitivity analysis has shown that the results obtained from this study are robust.  Taking a 
NHS perspective, misoprostol therapy concurrent with NSAID treatment has been shown to 
produce  significant  savings  in  a  Tayside  population  compared  with  H2  blockers  or 
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made on males who are over 75 years old, but not females in any age group. 
From a NHS perspective, a disproportionate increase in costs is observed in those who were 
prescribed any GI protective such as H2 blockers, omeprazole or misoprostol, concurrently 
with NSAIDs.  This is likely to be due to confounding by indication in groups perceived by 
GPs  to  have  higher risks  who  were  co-prescribed ulcer-healing drugs.  Patients with GI 
symptoms,  or more  ill are  more  likely  to  be  given  GI  protective  agents  by  their  GPs. 
Therefore, there is  an inherent bias against both the  sub-cohorts receiving GI protectives. 
This study has  attempted to  remove all possible bias in the  sensitivity analysis, by using 
very strict subject selection.  All the patients that are potential confounders, those who may 
be 'more ill' were removed from the dataset for reanalysis.  All the patients with prior GI 
events and endoscopies were excluded.  These patients are perceived to be at high risk of GI 
events and may be prescribed different patterns of drugs from those who were at low risk. 
All  the  patients  who  were  prescribed  aspirin  were  also  excluded  from  the  sensitivity 
analysis.  These  patients  may  be  receiving  prophylactic  aspirin  in  the  prevention  of 
peripheral  CV  disease.  In  addition,  patients  with prior history of CV events  were  also 
excluded.  These patients may be at high risk of developing CV events, thus perceived to be 
'more ill' may be also prescribed different patterns of drugs.  Finally, those who died within 
the  12  months post-study period were also  excluded as  they may also indicate increased 
severity of illness.  These factors were excluded alone and in combination in the various 
analyses performed in the sensitivity analysis to replicate the principles of the  'restrictive 
cohort design' 
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Despite the attempts at removing all potential biases from the  study,  the findings  of this 
study are most probably due to uncontrollable confounding factors that are unmeasured or 
cannot be measured.  The baseline risk in the two groups given NSAID and GI protectives 
were high demonstrating that these patients were not comparable with regards to GI and CV 
risks.  There  are  other recognised  techniques  to  deal  with  confounding  issues  such  as 
propensity scores 
198
.  However,  these analytical techniques are  only useful for reducing 
confounding that has been measured and would add little value to the findings of this study. 
For each individual, the clinical and cost impact of the non-GI related events - shown in 
particular,  by  the  additional  prescriptions,  GP  consultations  and  CV  admissions  - was 
shown to be significantly elevated.  The costs of these events accounted for the excess over 
104 the  comparator group  of £166  in  the  NSAID  only  group,  and £577  in  the  two  groups 
prescribed NSAID and GI protective combined.  It was found that 78% of the incremental 
cost (total cost of the two NSAID and GI protective groups compared with the comparator 
group) was attributable to CV admissions and prescriptions in the NSAID and GI protective 
(Hz  blockers,  omeprazole or misoprostol) patients.  The unexpected finding  was  that GI 
admissions  and  endoscopies  accounted  for  only  8%  of incremental  costs.  The  high 
incidence of CV events, seen in particular among those on GI protectives, is associated with 
a  high  background  rate  of prior  CV  admissions.  This  is  not  unusual  in  a  Scottish 
population.  An  association between NSAIDs  usage  and increased CV events has  been 
documented in some studies - prior history of CV disease has been shown to be one of the 
risk factors  for  serious  upper GI  complications 
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have contributed to the increased CV events observed.  There is additional evidence in the 
literature about the association between biochemical evidence of chronic inflammation and 
increased CV risks 
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difference  between  the  two  NSAID  groups.  Removing  pure  aspirin  takers  from  the 
analyses (suspected to have been prescribed for prophylaxis of CV events) had little effect 
on the results. 
From a cost perspective, the most striking feature of the study is the exceptionally high cost 
of individuals in the groups taking NSAIDs and any GI protective (such as Hz blockers or 
proton pump inhibitors) or misoprostol- these costs were 135% more than the NSAID only 
group.  Further investigation into this sub-cohort of individuals who receive concomitant 
prescriptions  of GI protective  agents  seems  useful.  Although  the  groups  co-prescribed 
misoprostol and GI protectives have a higher mean age,  a greater proportion of females, a 
higher mortality rate and a  greater proportion of individuals with prior endoscopies and 
admissions,  these  findings  do  not explain  the  differences.  Excluding  all  patients  with 
evidence of prior co-morbidity would be expected to  help to  adjust for 'confounding by 
indication',  i.e.  the  groups  prescribed GI protective  or misoprostol  are  more  expensive 
merely because these patients are  already at risk from co-morbidities (and already more 
expensive  to  the  NHS)  and  were  more  likely  to  be prescribed  GI protective  drugs  or 
misoprostol.  The  incremental  cost  of the  groups  prescribed  GI  protective  drugs  or 
misoprostol were unaffected by this  analysis.  Therefore,  factors  such as  sex,  age,  prior 
admissions, and prior use of ulcer healing drugs, did not appear to be responsible for the 
additional cost observed among the  GI protective  and misoprostol takers.  The residual 
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additional  to  the  restricted list of GI,  CV,  RA  and  OA events  recorded in  this  study  -
explaining their greater utilisation of healthcare resources.  The use of GI protective drugs 
and misoprostol may possibly be related to other clinical factors, not measured here. 
There  are  several  recently  developed  population  databases  which  record  reasons  for 
prescribing  (e.g.  General  Practice  Research  Database 
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,  MediPlus 
32  and  Continuous 
Morbidity Recording 
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).  These databases record activities in GP practices and are able to 
provide  indications  for  prescribing.  However,  it is  uncertain  whether  data  from  these 
databases would be able to provide a clear explanation for the additional costs incurred in 
these patients. 
6.3  MODEL-BASED PHARMACOECONMIC ANALYSIS: EXAMPLES WITH 
NSAIDs, SSRis AND ACE INHIBITORS 
The literature review of the large amount of randomised controlled trials of the various drug 
therapies  has  resulted in only  a few  relevant studies  suitable for  inclusion in the  meta-
analysis (24 on NSAIDs, 21  on SSRis and 24 on ACE inhibitors).  This is not unusual in 
meta-analysis, when strict inclusion criteria have to be applied in order to aggregate data 
from  similar  studies  to  calculate  a  weighted  average  rate.  Unlike  most meta-analyses, 
where efficacy data are evaluated, this study is particularly problematic because of the focus 
on ADR data.  Although the lack of good quality clinical trials (mostly due to time-factor, 
especially in the case of NSAIDs) were in part responsible for the resultant lack of data, the 
method of ADR reporting in many trials may have contributed to the problem.  The initial 
result of the literature search has identified many randomised controlled trials with reports 
on associated ADRs.  However, on reviewing the actual papers, it was apparent that ADRs 
are often secondary or tertiary outcome measures and data presented are  often incomplete 
or unextractable.  Graphical display of data or aggregated ADR data according to  major 
organs  or  biological  systems  is  common.  Although  these  studies  may  have  recorded 
reliable drug-induced ADR data, reviewers are unable to extract data for meta-analysis and 
are forced to exclude many studies from the analysis. 
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demonstrated that local economic analysis using local cost and resource data can be easily 
performed.  The results of the studies have proved the importance of taking drug-induced 
ADRs into account when conducting pharmacoeconomic analyses.  These adverse clinical 
events may add significantly to the total cost of therapy.  In the case of NSAIDs,  a 12% 
(ketoprofen) to  59% (diclofenac sodium) increase in cost was observed (table 31).  In the 
more  severe  cases,  inclusion  of the  shadow  costs  changed  the  ranking  of the  drugs. 
Although  a  change  in  ranking  was  not  observed  among  SSRis,  the  incremental  costs 
attributed by the shadow costs ranged from 24% with fluvoxamine to 42% with sertraline. 
Economic evaluations in drug therapies are generally used to calculate the incremental cost-
effectiveness ratio of two interventions.  This ratio provides a standard comparison for the 
cost effectiveness of drugs, based on the difference in cost and clinical efficacy of the drugs 
being compared.  However, in cases where the drug therapies being compared are of similar 
efficacy, as in the case of many drug treatments for chronic diseases such as RA, depression 
and hypertension, the measure of effectiveness is based on improved tolerability.  This is 
often  seen  in  economic  evaluations  of  NSAIDs,  where  drug-induced  GI  toxicity  is 
frequently  used as  a measure of clinical effectiveness.  Similar methodology is  used in 
comparing SSRis with TCAs,  when reduced suicide rates  have been used for  the  same 
purpose.  In addition, these studies are predominantly based in hospital settings. 
Based on this methodology, pharmacoeconomic analyses were carried out to  compare the 
real  costs of NSAID,  SSRI and ACE inhibitor drug  therapies,  taking into  account their 
complete adverse drug reactions profile.  This study attempted to  widen this approach to 
incorporate  all  the  drug-associated adverse  events reported in the  medical literature.  In 
contrast to  hospital-based publications, this  study attempts to assess the real cost of drug 
therapies in a general practice setting. 
The  study  limitations  associated  with  the  economic  analyses  are  inherent  in  any  cost-
effectiveness analysis when definitive data do not exist on the probability of some or all of 
the outcomes examined.  For instance, randomised controlled trials are designed to test the 
efficacy of drugs and may not provide an appropriate answer to effectiveness and safety. 
The objective of economic evaluation is to generate policy-relevant data to inform decision-
makers  about the  incremental costs  and outcomes of the  drugs  that can be expected in 
routine  clinical  practice.  It is  often  felt  that clinical  experiments,  such  as  randomised 
107 controlled trials, may not serve economic analysis  well as  they do  not reflect practice in 
'real  life'.  In  addition,  there  is  concern regarding  generalising  trial  results  to  clinical 
populations that are not studied in the trial but covered by a decision makers' drug plan (e.g. 
specific age  groups),  and to geographical settings and health care systems different from 
those studied.  However, until such data are readily available, there is little alternative to the 
current methodologies. There is current encouragement and guidance to add economic data 
to trials 
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The  literature  searches  on  randomised  controlled  trials  were  conducted  systematically. 
Although  they  were  not  formal  systematic  reviews,  the  process  was  in  line  with  the 
common guidance for carrying out a systematic review 
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of the literature was developed, clinical trials inclusion and exclusion criteria were defined 
and followed, ADR data were extracted systematically and the quality of the clinical trials 
was  assessed.  In the  case  of a  systematic review,  the  literature  search would be more 
intense and at least two reviewers would be required to review the clinical trials and extract 
the data to eliminate personal bias 
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Some heterogeneity may have existed between the trials selected for meta-analysis.  For 
instance,  the  trials  covered  a  range  of drug  dosages  within  the  three  classes  of drugs. 
Adverse  drug  reactions  are  often  dose-related effects  and may potentially  influence  the 
findings of this study.  However, it is believed that the dosages of the drugs covered in the 
clinical trials included in the meta-analysis were within the BNF recommended therapeutic 
range  for  their  indication,  therefore,  it  is  unlikely  that  this  would  have  significantly 
influenced the results. 
The results of the literature review have highlighted the need to  improve adverse events 
data reporting in clinical trials.  The method of gathering adverse  drugs event data and 
number of adverse events reported are often unclear or not reported.  The introduction of 
validation  tools  to  assess  clinical  trial  quality,  such  as  the  Jadad  score,  has  helped  to 
improve the quality of clinical trials substantially over the years.  However, these quality 
assessments  have  focused  on issues relating  to  randomisation,  blinding and withdrawal. 
Given the importance of the potential toxicity profile, it is worth considering introducing 
the  measure  of adverse  clinical  events  into  the  quality  assessment  of clinical  trials. 
Although the adverse clinical data used to  populate the economic models were based on 
randomised  controlled  trials,  the  pooled  probabilities  of individual  adverse  events  are 
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addition to  improving the  quality of adverse events reporting in clinical  trials,  it is also 
important to  report the complete range of adverse events.  In the case of NSAIDs, many 
clinical trials have focused solely on the associated GI events.  Other adverse events such as 
those related to the central nervous system (such as dizziness, headache, insomnia) may be 
of lower clinical risk,  these  events add substantially to  the  cost of the  drug therapy  and 
should not be ignored in pharmacoeconomic models. 
This study,  unlike the population model described in the previous section, was based on 
data from randomised controlled trials.  Although randomised controlled trials are the gold 
standard for examining the  efficacy of drugs,  they  are not designed to  measure the ADR 
profile of drugs.  In addition, clinical trials are often limited by sample size and time.  In 
order to fully appreciate drugs' toxicity profile, observations of a large sample over longer 
periods  of time  is  required.  The  true  ADR rates  associated  with  these  drugs  may  be 
underestimated by clinical trials.  On the other hand, the proportion of patients who actually 
seek medical help as a result of experiencing these ADRs is unknown.  This study is based 
on the  assumption that all  the patients who  experience these  ADRs would seek medical 
management.  This may over-estimate the true costs associated with these drug therapies. 
However,  this  study is a comparative  analysis and the  drugs  are  ranked relative to  each 
other; there is no evidence to suggest particular bias in any of the drugs studied.  . 
The  most  difficult  measurement  in economic  evaluations  is  the  measuring  of resource 
utilisation.  Record linkage  is  a potential  solution  to  this  problem.  Relevant measures 
include data on prescriptions, the number of GP consultations, referrals,  outpatient visits, 
clinical  procedures  and  diagnostic  tests.  Ideally,  these  data  would  be  collected  from 
patients' case notes.  This is possible in situations in which resources used in a hospital 
setting  are  measured.  Here  one  would expect definitive  diagnoses  and  treatments  to  be 
recorded in a relatively standard manner, but often are not.  This is even more rarely the 
case  in  the  primary  care  setting.  Many  databases  are  beginning  to  record  events  and 
resource utilisation in primary care in a standardised format. However, to  date, there is no 
readily available database to enable formal economic evaluations to be undertaken. 
The  MEMO  database  that  was  used  in  the  population  study  is  a  database  with  such 
potential.  However, without linkage between prescriptions and indications, the value of the 
MEMO data in primary care research is limited.  The great strength of the MEMO data lies 
109 in the estimates it provides of the incidence of hospitalisation giving the ability to calculate 
the costs associated with them.  Its weakness, in common with all observational data, is that 
it provides  no  reliable  internal  estimate  of efficacy  due  to  the  inevitable,  but unknown 
extent of confounding by pre-existing risk factors. 
Having explored the various available databases without success, a more traditional method 
of seeking expert opinions on resource utilisation was used in the economic analyses.  The 
difficulty of recruiting GPs for research has been highlighted in all  areas of primary care 
research.  General practitioners are constantly under pressure from their trust and political 
issues which affect their daily practice, in particular working within their new contract; in 
addition,  the  'researchability'  of  this  group  of  healthcare  professionals  are  reaching 
saturation point due to the large amount of academic and commercial research carried out in 
primary care.  Therefore, it is unsurprising that only a small sample of GPs was successfully 
recruited for the economic study. 
A further problem with  determining resource  utilisation data from  expert opinion is  the 
method  of surveying  itself.  General  practitioners  respond  to  questions  posed  at  these 
interviews based on their own personal perspective and clinical experience.  As a result, a 
subjective perspective of management strategies and resource used is  obtained.  A more 
effective method is to  adopt the Delphi technique, an approach used for establishing and 
developing  consensus 
207
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questionnaire,  analysing the responses, feeding back a summary of the  group's view and 
asking respondents to re-evaluate their own views given the results.  If  a substantial amount 
of disagreement remains a further round of feedback may ensue.  However, due to time and 
financial restraints, it was felt that revisiting andre-interviewing the participated GPs would 
not be feasible in this study. 
This thesis recruited GPs who have no special interest in the drugs being evaluated and the 
conditions they are indicated for.  It is believed that a sample selected in this manner would 
represent average GP behaviour in primary care.  Although the GPs in this study were not 
representative due to the small sample size, this could be the case if a large sample size can 
be achieved and if GPs were selected at random.  An alternative approach is to  create an 
expert panel with healthcare professionals who have special interest and knowledge in the 
area  being  investigated.  This  is  the  current  approach  adopted  by  the  HTBS  when 
conducting  economic  evaluations 
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110 approach.  Creating an expert panel would overcome the problems related to  recruitment 
and  commitment,  but such  panels  are  unlikely  to  be  representative  of average  clinical 
behaviour. 
The meta-analysis based economic analyses have attempted to measure and compare all the 
indirect costs associated with NSAIDs, SSRis and ACE inhibitors.  Based on the measure 
of primary clinical outcomes such as  pain reduction and mobility scores associated with 
arthritis,  the  Hamilton  Rate  Scale  for  Depression  (HRSD)  and  the  Clinical  Global 
Impression (CGI) associated with major depression and the measure of blood pressure in 
hypertension, the literature has shown that there are no statistically significant differences in 
the efficacy of the individual preparations within these three classes of drugs.  This was 
evident from the studies included in the meta-analysis.  All the included studies that made 
comparisons between the  drug being investigated and an  active  comparator reported no 
statistically significant difference in the measured outcomes.  As a result, a therapeutic class 
effect may be speculated.  In particular, the class effect of ACE inhibitors have been widely 
discussed in the literature 
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Therefore,  the  measure of secondary clinical outcomes associated with ADRs  should be 
considered,  but these  are  extremely  difficult  to  measure.  Adverse  drug  reactions  are 
symptoms arising from  drug  therapy,  and all  the  morbidity that may be associated with 
these events is limited and usually reversible on stopping or switching of drugs.  Measures 
of health loss such as  disability adjusted life years  (DALYs) and quality of adjusted life 
years  (QALYs)  have been  designed to  measure  health loss based on  the  assumption  of 
permanent change and would not be applicable for morbidities associated with ADRs. 
One  way  of addressing  non-permanent  health  loss  associated  with  ADRs  may  be  the 
measuring of utilities from the patients' perspective.  Cost benefit analysis may be carried 
out to  determine whether the benefits of preventing certain ADRs during drug treatment 
therapy outweigh costs from a societal perspective.  The contingent valuation method 
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may be  used  to  measure  willingness  to  pay for  a  reduction  of certain ADR symptoms 
associated with individual drugs.  This would potentially provide an estimate of the 'value' 
of preventing  or  reducing  certain  drug-associated  ADRs  from  a  societal  perspective. 
However,  this  would  require  assessment  at  the  level  of individual  patients  which  was 
beyond the scope of this thesis. 
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PRIMARY CARE PRESCIRBING 
The impact study was an exploratory exercise to assess any change in prescribing pattern by 
GPs as a result of disseminating pharmacoeconomic information. 
Implementation of research findings has been recognised as a major hurdle in public health 
research.  The  implementation  of the  various  strategies  on improving  clinical  and cost 
effectiveness of primary care prescribing has been met with similar difficulties.  A recent 
study 
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suggested  that  it was  possible  to  identify  strategies  that  were  more,  or  less  effective. 
Strategies  such  as  postal  distribution  of materials  or didactic  educational  sessions  were 
found to be largely ineffective.  Local consensus conferences, the use of opinion leaders or 
audit  and  feedback  were  of variable  effectiveness,  and  strategies  such  as  interactive 
educational  workshops,  reminder  systems,  educational  outreach  and  multifaceted 
interventions were suggested to be largely effective.  In the case of influencing prescribing, 
the conclusions from implementation studies on different methods of changing prescribing 
behaviour in primary care are generally in agreement with those described in the review. 
The key to  successful implementation of evidence in prescribing, and probably all other 
areas of healthcare is to conduct multifaceted, but tailored interventions. 
None of the strategies described in the literature, such as dissemination of printed material, 
educational outreach and feedback,  are novel approaches to dissemination.  These are  all 
methods that have been adopted by the pharmaceutical industry in promoting the  use  of 
their products.  Dissemination of printed material via simple advertising in journals and 
postal  marketing  literature  and  outreach  visits  by  medical  representatives  are  routine 
activities within the pharmaceutical industry.  This is probably an indication of the potential 
benefit of these strategies. 
The impact study on pharmacoeconomic information on prescribing has failed to promote 
significant changes in prescribing patterns.  There is no strong evidence in the literature to 
support or refute  any  particular interventions for  changing  prescribing in  primary  care. 
There is much diversity in the methodology and the quality of the implementation studies. 
Therefore,  the  transferability  of the  results  from  these  studies  is  questionable,  and  it is 
112 impossible  to  draw  any  firm  conclusions  about  the  effectiveness  of  the  various 
interventions.  The reported success of various interventions at influencing primary care 
prescribing, based on both clinical and economic material, is unclear. 
Generally studies that have shown positive results were those that involved GPs who hoped 
to implement change in their clinical practice irrespective of the type of intervention in the 
first place, thus willingness to participate.  This has contributed to  over-estimation of the 
impact of many interventions.  In addition, confounding factors are extremely difficult to 
measure.  Since it is impossible to create a controlled environment, factors that may play a 
role in influencing prescribing may not be identified or adjusted for.  This is not always 
clear whether the observed effects are genuine effects as a result of the intervention. 
Due to the nature of this type of research, the majority of these studies are often focused on 
a small group and tend to have a limited follow-up period.  Results of these studies are often 
interpreted  as  ineffective,  however,  size  limitations  meant  that  it  is  often  difficult  to 
demonstrate a positive effect, which does not equate to deducing there is no effect.  Even in 
cases where positive effects were observed, there is no evidence to suggest such effects will 
be sustained over time. 
In  a  discussion paper on  implementing  evidence  in  general  practice,  Wensing M  et al 
(1998) 
212 summarised the challenge ahead.  "Not all interventions to induce change achieve 
the  intended results.  Change is a stepwise process,  in which several barriers have to  be 
removed.  For change to be successful it is necessary for the target group of clinicians to 
have the knowledge, skills and motivation needed to adopt a practice.  In addition, it is that 
practical  and  organisational  conditions  make  the  new  behaviour  possible  and  that 
colleagues, patients and others accept it.  Interventions to  induce change should focus on 
the  removal of these  barriers,  support the  process of change,  and consolidate  the  new 
practice."  There is no "magic bullet" to achieve change. 
Salisbury  C et al  (1999) 
213  conducted a  study to  attempt to  understand the barriers and 
facilitators to  implementation, and to  study  the characteristics of those who  successfully 
implement  evidence-based  change,  using  prescribing  as  a  model.  Three  key  areas  of 
change in prescribing were audited,  and amalgamated to  give an "implementation score" 
per practice.  Wide variations were noted between practices' implementation scores.  An 
innovative  approach among GPs  and fundholding  status were the  only factors  shown to 
113 have significant relationship with prescribing changes.  Use of clinical protocols, disease 
registers,  or computers was not associated with high implementation scores, nor was the 
GP' s age.  It was also found that GPs feel that there is an information overload.  It was felt 
that analysis at a practice level may be realistic, as patients' treatment may reflect decisions 
made by several different GPs  as  well as  practice policy, but may mask the influence of 
characteristics such as the GP' s age. 
The most important factor in implementation is to recognise and understand the barriers that 
influence  effectiveness.  For  instance,  educational  outreach  as  a  strategy  for  changing 
prescribing behaviour has been the  most extensively researched area in this field.  Many 
American studies have  suggested these  interventions to  be  effective,  and in  some  cases, 
even  cost  saving,  but  the  UK  studies  have  reported  mixed  findings.  One  uniform 
conclusion  may  be  drawn  from  these  studies  - untargeted  educational  outreach  1s 
ineffective.  However, how these interventions should be targeted, remains unclear. 
Another important factor in influencing behaviour and effectiveness is the acceptability of 
the  intervention  to  the  intended  audience.  The  willingness  to  change  and  improve 
prescribing behaviour in both clinical and economic terms is crucial to the success of these 
studies. 
Finally,  many small but important factors  come into play during decision making.  It is 
important to identify these factors and understand their interplay.  For instance, the style of 
data presentation has significant influence of the acceptability of evidence.  In one study, 
Elting LS  et al  showed that clinical investigators'  decisions could be  affected by  factors 
unrelated  to  the  actual  data 
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•  The  study  showed  that  the  accuracy  of decisions  was 
affected by the type of data display and by positive or negative framing of the data.  Their 
principle conclusions were  that the  mean times  to  make decisions were  similar for  each 
display and professional group.  The formats preferred by doctors were not the ones that led 
to  optimal  decision making.  Pie charts  and bar graphs  were inferior to  tables  and icon 
displays.  Icon displays and negatively framed data in tables led to superior decisions, but 
icons were not liked. 
The measure of effectiveness of interventions influencing prescribing is dependent on the 
available prescribing data.  Prescribing data differ in quality and ease of data extraction. 
114 There  is  growing  pressure  to  make  effective  use  of prescribing data in  order to  inform 
policy and to ensure equitable distribution of resources. 
Prescribing  Analysis  and  Costs  (PACT)  data is  the  main  source  of prescribing  data  in 
England  (from  Prescribing  Prescriptions  Authority).  These  data  are  universal, 
comprehensive and accurate.  Indicators based on PACT data could be used fairly easily for 
financial management of the  drug bill.  However,  these data are not linked to  patients or 
their diagnoses and it is difficult to use them to assess quality or cost-effectiveness.  There 
are many limitations.  The PACT data are based on costs.  The cost included on data was 
the  net ingredient cost (NIC) - i.e.  the  Drug Tariff price,  not including dispensing fees, 
container costs  and VAT.  The  number of items  prescribed (indication of frequency  of 
prescribing) is  described, but not the  item size,  which is particularly important in repeat 
prescribing.  There  is  no  individual  patient data  although  various  prescribing  measures 
weighted to registered populations are included in PP  A reports. 
The advent of electronic PACT data has already had a considerable impact on prescribing 
analysis 
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•  Further developments are taking place centring on electronic data interchange 
(EDI)  which,  unlike  PACT,  will  be  patient-based  and  comprise  complete  medication 
profiles  with  information  on  prescription quantities,  frequencies,  and duration.  Various 
scenarios  are  being considered,  involving transmission of electronic prescription records 
directly from  GPs  to  pharmacies  or indirectly via the  PP  A;  the  PP  A would also  receive 
electronic  dispensing  records  from  pharmacies.  These  records  will  contain  a  patient 
identifier code that will enable, for example, comparison of drugs prescribed and dispensed. 
A further  step  might involve using  EDI to  evaluate expert systems  such as  PRODIGY 
(Prescribing  Rationally  with  Decision  support In  General practice  studY) 
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,  which  are 
currently being developed to provide on screen advice to  GPs on treatment options.  Other 
sources of prescribing data include EPACT, epact.net, community.net and the prescribing 
toolkit  (a  stand  alone  information  system  which  currently  contained  information  on 
potential  savings  from  generic  substitution,  a  specialist  drugs  catalogue  and  various 
prescribing indicators). 
The  situation in  Scotland is  not  that  dissimilar.  Basic  prescribing  statistics  have  been 
available  to  Health  Boards  and  GPs  in  Scotland  since  1954  based  on  prescriptions 
dispensed  in  a  single  month  and  supplied  as  an  analysis  three  times  each  year.  The 
Pharmacy  Practice  Division  (PPD)  was  set  up  originally  as  the  Prescription  Pricing 
115 Division  to  process  GPs'  prescriptions  and pay  community  pharmacists  and  dispensing 
doctors.  Following computerisation at PPD (commenced in 1987) a project was set up to 
develop  a  comprehensive  database  on  GPs'  prescribing  which  would  enable  speedy 
publications of more meaningful prescribing statistics to GPs and enable them to assess and 
develop their prescribing practice.  The result of the project was the paper-based Scottish 
Prescribing Analysis (SPA).  From April 1990 SPA level  1 has been sent quarterly to  all 
GPs  and health boards,  containing basic  information that gives  feedback  on prescribing 
frequency  and cost compared with health board average.  SPA level 2 is  a very detailed 
catalogue of all prescribing over a three-month period supplied by PPD on request. 
It was recognised that paper-based information was of limited value to prescribing advisers 
and that access to  computerised databases would be necessary.  As  a result,  the  Scottish 
Office  funded  PPD  to  develop,  with  input from  prescribing  advisers,  a computer-based 
information system (Prescribing Information System for  Scotland PRISMS), which holds 
detailed  information  on  prescribing  down  to  the  root  drugs  (but  not  individual 
formulations),  at  GP,  practice, health board and national level.  It distinguishes between 
generic and proprietary prescribing on an  'intention to prescribe' basis.  PRISMS has been 
available since 1993 and has proven to be an invaluable tool for analysing and monitoring 
trends  in  prescribing.  A  pilot project - the  Computerised  Prescribing  Information  for 
Practices (CPiP) has been set up to examine the feasibility of providing similar information 
on  computer  to  interested  practices  and  the  preliminary  feedback  from  GPs  has  been 
favourable.  In  addition,  the  PPD  also  provide  regular  reports  on  generic  prescribing, 
monographs  on  new  drugs  and  information  tracking  the  prescribing  of newly  launched 
drugs. 
It has  been argued that prescribing  analysis  should not focus  solely on readily available 
measures  (e.g.  number  of items  prescribed  or  total  costs).  Other  factors  influencing 
prescribing such as volume, patient demographics and morbidity, are susceptible to should 
be  taken  into  account to  avoid misinterpretation  of unadjusted  'raw'  data 
217
•
218
.  More 
sophisticated measurements of prescribing - prescribing indicators have been developed. 
This  study  has  not been able  to  adopt  any  prescribing indicators in the  analysis  of the 
prescribing data. 
The limited dissemination of economic information in this  study has  failed to  show  any 
impact on  prescribing.  However,  this  may  be in part due  to  the  limited design  of the 
116 dissemination  exercise.  Firstly,  research  in  primary  care,  in  particular  among  GPs  are 
extremely difficult to  conduct due  to  lack of time  and research fatigue.  This study had 
attempted to  address this issue by targeting an LHCC that is familiar to the researcher has 
shown interest in the research area.  The majority of the ground work such as meeting the 
group  and  introducing  the  concept  of the  research  was  conducted  during  their  regular 
LHCC meetings in order to limit the taking up of the GPs' free time.  However, recruitment 
remained relatively unsuccessful and ultimately, this study suffered from a lack of adequate 
sample size. 
Secondly, although the drugs evaluated were recommended by local prescribing advisers, 
these drugs may not be an individual GP's priority.  Individual GPs within the same locality 
may have different patient mix,  the drugs evaluated may not be commonly prescribed by 
all. 
Thirdly,  there  are  many  factors  involved  in  prescribing  decisions.  The  dissemination 
exercise  has  failed  to  adjust for  external  influences  such  as  visits  from  pharmaceutical 
industry representatives and other sources  of prescribing information.  These may play a 
significant role in GPs' prescribing behaviour. 
Finally,  the  study  duration  may  have  been  insufficient  to  measure  any  real  change  in 
prescribing.  Promoting changes in any form of behaviour will take time to implement.  The 
dissemination exercise was conducted over a period of six months which is not sufficient to 
examine prescribing trends. 
A GP perspective on economic information has not been explored previously.  It is unclear 
what type of materials are being recognised and interpreted as economic information.  The 
relevance  and  the  extent  of use  of the  wide  variety  of economic  information  being 
presented are also unknown. 
Despite  the  small  sample  size  and  low  response  rate,  this  survey  has  provided  some 
preliminary indication about GPs'  perceptions and their use of economic information in 
medical decision-making. 
Although  questionnaire  (I)  was  designed  to  record  recent  activities  - using  economic 
information  in  decision-making,  while  questionnaire  (II)  examined  perceptions  of 
117 economic information, the results were comparable.  Both questionnaires showed the SPA 
data being recognised and used by most respondents as a source of economic information. 
The SPA data (level  1)  consist of a breakdown of total costs and the number of items 
dispensed for major therapeutic areas.  These are  sent automatically to  GPs,  comparing 
their own average values with those of other practices, the Health Board and Scotland as a 
whole.  However, such data contain solely cost information on prescribing are not strictly 
an  economic  information  source,  they  give  no  indication  of the  real  quality  of the 
prescribing  taken  place.  Therefore,  it  is  beneficial  to  consider  including  reliable 
economic information such as cost-effectiveness data, with the feedback information. 
The  results  have  also  showed  that  published  materials  are  used  in  preference  to 
information  from  verbal  presentations.  In  particular,  locally  specific  evaluations  and 
summary leaflets of studies were favoured by 54%.  However, 73% did not regard locally 
produced newsletters and prescribing formularies as  economic sources.  This may be an 
indication  that  locally  produced  newsletters  and  formularies  lack  adequate  economic 
information that  GPs  find  useful.  The  need for  precise  and  summarised information, 
produced locally, has been highlighted. 
Since the launch of the Scottish Office's primary care communications initiative in April 
1997,  99%  of the practices in Scotland were computer-connected by the  year 2000 
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However, a recent survey of internet connectivity and use in Lothian 
220 reported that 43% 
of their respondents spend no time using email.  Therefore, it is not surprising that our 
survey  has  shown  that  email  communications  from  GPs  are  still  scarce  and  often 
unreliable. 
It is clear that GPs recognise that economic information should be incorporated in medical 
decision-making.  However,  the  task  of  incorporating  economic  into  practice  is  a 
challenging one.  Although all of our respondents in questionnaire (I) have indicated that 
economic  information  has  previously  influenced  their  medical  decision-making,  four 
described situations where such information had failed to influence their decision-making. 
This  suggests  that  some  economic  information  can  only  be  applied  in  certain 
circumstances, and despite the effort and the cost spent on compiling and presenting such 
economic evidence, there is still wide variation in their usefulness and quality. 
The  results  of the  survey  have  confirmed  the  difficulties  of getting  economics  into 
118 practice.  This revelation may not be novel,  but it is  important as  it suggests that the 
message, and the information, is not getting through to GPs.  Despite the time and money 
spent on compiling and synthesising the  evidence, and the prominent position GPs  still 
occupy  in  the  rationing process,  especially  after  the  creation  of LHCCs,  there  is  little 
evidence  on  effective  use  of economic  information.  Although  these  GPs  are  not 
representative  of all  GPs  in  the  UK,  the  results  of this  study  are  likely  to  be  an 
underestimation of the prevalence of poor understanding and implementation of economic 
information in primary care. 
The qualitative research had set out to interview a sample size of ten GPs, however, only 
eight could be interviewed during the given time of the study.  Given the introduction of 
the  new GP contract,  the  political  turbulence  and sense  of "survey fatigue"  known  to 
characterise GPs, this is not surprising.  There is also an inherent selection bias in this type 
of research.  Several GPs added hostile comments to justify their non-participation, which 
may suggest that the non-participants may have been a more negative or hostile group. 
Therefore, the findings of this study may represent the overall GP perspective in economic 
matters in a less negative picture than actually obtains in practice. 
There  is  a  "healthy"  awareness  relating  to  health  economics  among  all  the  GPs 
interviewed.  Often, despite the incomplete understanding about the economic information 
they were exposed to, there is still evidence of interest, which was reflected through their 
reading and partial recalling of  relevant information. 
Similar to the findings in the current literature (reported in Section 3.3), the lack of time 
and  the  lack  of practical  applications  have  been  described  as  the  key  barriers  to 
implementing economic information.  However, the barriers that have been identified are 
not unique to  health economics.  Similar findings  have been reporting in implementing 
changes in other aspects of medical decision making and practice based on other sources 
of information.  There is  much similarity to  the  situation and responses  at the  time  of 
introduction of evidence-based medicine in clinical practice.  Many health professionals 
are  still  getting to  terms  with some  of the  evidence-based medicine principals such  as 
"relative risk reduction" and "numbers needed to  treat".  Promoting changes in practice 
take time, as has been evident with the case of evidence-based medicine over the years. 
Overall, the  GPs  interviewed were  unable to  suggest a facilitating factor that may help 
119 improve  the  use  of economic information in practice.  This may be explained by the 
feeling that economic issues should not be considered at a practice level.  All the  GPs 
interviewed believed that economic information should be considered at a higher level -
nationally through the NHS, or locally through the health board.  This information should 
be "filtered" and incorporated in their guidance through guidelines and formularies.  This 
should be viewed as a positive finding;  although GPs do not feel they should personally 
digest  and  use  economic  information,  they  are  demonstrating  receptiveness  and 
willingness to use guidance produced for them that has incorporated economic thinking. 
Finally,  this  qualitative  study  has  helped  to  explain  the  findings  of the  dissemination 
exercise in Section 5.4.2.  While GPs found such information of interest to their practice, 
they are reluctant to implement change.  Overall, there is a strict adherence to prescribing 
formularies,  although  there  is  prescribing  out  with  the  recommendations  of  the 
formularies, it was felt that this has to be justified.  Despite being purchasers themselves, 
it is becoming evident that GPs are implementers of other's decisions. 
Does health economics work?  Does it not work?  The answer is far from black and white. 
The lack of "use" described by GPs may be disappointing, however, in an indirect manner, 
GPs are taking into account of health economics in their decision making.  In terms of 
prescribing, GPs are aware of the costs of the drugs and would always "choose the generic 
version or the cheaper alternative" if they feel that their patient care is not compromised. 
This reflects decisions based upon both the costs and the benefits; GPs might not use the 
terms that health economists' use, but they appear to be taking economics into account all 
the time. 
6.4  CONCLUSIONS 
Pharmacoeconomic information in healthcare is becoming an important component of the 
process  of medical  decision-making.  This has been highlighted by  the  introduction of 
groups such as  NICE and HTBS in the UK.  Despite the volume of literature produced, 
there is still much confusion regarding the understanding, application and transferability of 
this information to clinical (patient) decision making. 
120 This thesis has investigated the effect of incorporating ADRs in economic analyses of drug 
therapies  including  NSAIDs,  for  the  management of rheumatoid  arthritis,  SSRis in  the 
treatment of depression and ACE inhibitors in the management of hypertension. 
Adverse drug reactions add a considerable clinical and economic burden to the NHS.  The 
economic studies included in this thesis have demonstrated the importance of adopting a 
wider perspective in considering cost effectiveness rather than costs alone.  The population 
based economic analysis has demonstrated that the shadow costs associated with NSAID 
takers are substantial.  Population databases such as  the MEMO database are invaluable in 
reflecting  'real  life'  clinical  practice.  However,  similar  to  all  observational  data,  the 
interpretation of these data is limited by confounding issues.  This study has attempted to 
address this by conducting sensitivity analyses based on the restrictive cohort technique, 
which did not alter the main conclusions.  In the absence of prescribing indications, it is 
difficult to  determine whether the recorded events  and subsequently the  costs are  solely 
attributed to the drug therapy.  Therefore, the MEMO database, at its current format may 
not be an appropriate data source for this type of economic analysis.  Economic studies in 
other disease areas where the primary clinical outcomes of interest are focused primarily on 
the number of deaths prevented, number of hospital admissions prevented or the duration of 
hospital stay reduced may find the MEMO database an appropriate source of data. 
In the meta-analysis based economic analysis, the substantial costs due to management of 
drug-induced ADRs have been revealed.  This was particularly prominent among NSAIDs, 
where as much as a 59% increase in costs associated with treatment of ADRs was observed 
with diclofenac sodium.  In cases where clinical effectiveness is not compromised and costs 
may be one of the influencing factors,  it is important not to be dependent on acquisition 
costs  alone.  A  higher purchasing cost may result in cost savings in the  long term if a 
broader perspective is adopted - as found for NSAIDs including naproxen, ketoprofen and 
trandolapril  in this  study,  SSRis including sertraline and paroxetine  and ACE inhibitors 
including  lisinopril  and  moexipril.  The  meta-analysis  based  economic  analyses  allow 
comparisons to be drawn between the costing of three classes of drugs.  When the shadow 
costs  were  incorporated,  the  impact  on  NSAID  costs  were  more  substantial  than  that 
observed with SSRis and ACE inhibitors.  This may be explained by the more prevalent 
ADR profile associated with NSAID use.  In particular, NSAID use is associated with GI 
events,  some of which are  extremely costly to  manage.  In  contrast to  NSAID  therapy, 
SSRis and ACE inhibitors were associated with ADRs that are less costly to manage. 
121 However, all three classes of drugs have demonstrated a change in ranking when taking into 
account shadow costs.  This reflects the  importance of adopting a wider perspective and 
taking the associated costs of managing ADRs when considering the cost effectiveness of 
drugs. 
This  thesis  demonstrated  that producing  pharmacoeconomic  evaluations  based  on local 
ADR management data is possible.  This study  has pooled together ADR incidence data 
from  the  literature,  disease  management  strategies  and  resource  utilisation  from  expert 
opinions locally,  and local costs and prescribing data.  However, recent developments in 
population databases  such  as  GP ASS  and  CMR could eventually lead to  a much more 
effective means of carrying out such research.  Currently, CMR produces and disseminates 
regular  reports  on  GP  workload,  prescribing  and  disease  prevalence.  It  provides  a 
potentially  ideal  setting  for  inclusion  of not  solely  cost,  but  also  limited  economic 
information. 
The course of researching this thesis has provided many opportunities for communicating 
with GPs.  Within the small sample of GPs  who  were involved in this research,  through 
face-to-face  interviews for  the  purpose  of extracting  ADR management profile  and  the 
discussion of the pharmacoeconomic results during dissemination, a general consensus that 
echoes the research findings on GPs' perspective on economic matters was observed.  Many 
of them were aware of the importance of pharmacoeconomic information and often recall 
studies published by major journals or information presented to them from industry medical 
representatives.  However,  there  was  a general feel  of uncertainty  on  how  these results 
should be understood  or  applied to  their  everyday  practice.  Their perspective  on  this 
research was generally positive and supportive.  This is  supported by the findings  of the 
impact study and the qualitative interviews. 
The interpretation and implementation of economic information, with regards to prescribing 
are  increasingly being conducted at a national or a local level by  the  health boards  and 
PCTs.  As  a  result,  GP  prescribing  decisions  have  become  limited  and  implementing 
economic information at a practice level is not feasible. 
122 RECOMMENDATIONS 
Adverse Drug Reactions and Economic Evaluations 
It is clear that ADRs add considerable clinical and economic burden to the NHS.  Although 
different drugs  are  associated with different ADR profile,  and some  drugs  may  only be 
associated with mild, symptomatic ADRs that may not result in hospitalisation or death, at 
the minimum, they may still cause inconvenience to  the patients and incur an element of 
cost.  Adverse events should be taken into account when conducting economic studies. 
When conducting such studies, clinical events, resource utilisation and cost are taken into 
account.  Electronic  record linkage  has  the  potential  to  produce  efficient  and  powerful 
economic evaluations based on real patient data.  The lack of reliable data, especially about 
resource utilisation, has resulted in the reliance on expert opinions in economic modelling. 
This  has  often been criticised as  one  of the  limitations  of economic  evaluations.  The 
development  of electronic  record linkage  such  as  MEMO  and  CMR may  result in  the 
possibility of conducting more powerful economic models for the NHS, based on local data. 
The scope of this should be explored. 
Incorporating Economic Information in Clinical Guidance Literature 
There is general acceptance among GPs that economic information is a factor when making 
decisions about prescribing.  Despite having purchasing power, GPs  are implementers of 
others'  decision making.  There is  confidence among GPs  that clinical guidance such as 
those produced by NICE and HTBS, clinical guidelines such as SIGN guidelines and local 
prescribing formularies provide the best evidence on clinical management and prescribing 
issues.  Economic information should become and remain an integral part of these sources. 
There  is  much  ongoing  research  in  developing  frameworks  for  incorporating  cost 
effectiveness in evidence-based clinical guidelines 
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.  Recently NICE has called for tender 
to develop methodology in incorporating economic evidence in guidelines.  However, there 
is to date no formal framework for introducing the cost consequences of ADRs in economic 
analyses. 
123 There  is  also  a  general  agreement  among  GPs  that  they  should  not be  sheltered from 
economic  evidence  themselves.  Therefore,  there  is  still  a  need to  improve  the  current 
presentation of economic evidence to a more applicable form. 
Currently,  econormc  studies  have  focused  on  evaluation  of new  drugs  and health  care 
technologies.  However, the bulk of the drugs prescribed on a daily basis are established 
drugs and economic information on these preparations are rare.  Therefore, more research 
into the economic consequences of the more established therapies are needed. 
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Table 1  Studies exploring the role and impact of economic evidence in decision making in primary care. 
AUTHOR  STUDY TYPE  PARTICIPANTS  METHODS 
Structured interviews containing a mixture of 
open and closed questions.  Points covered: 
participants' characteristics, programme/policy 
characteristics, use of economic evaluation, if 
Decision makers - senior  used how cost and benefits are measured, other 
KEY FINDINGS 
Ross J 
(1995) 
117
; 
Australia  Survey  managers in government (n = 34)  factors and barriers. 
High level of awareness of economic evaluation among 
the group and that some (38%) had used it in decision 
making.  However, there is not often time to consider 
economic evaluations when making decisions.  Other 
limiting factors include availability of data and lack of 
expertise.  Participants recommended that researchers 
should be more responsive to the needs of the decision 
makers using them. 
DrummondM 
et al ( 1997) 
112
; 
UK  Survey 
Walley T et al 
(1997) 
116
; UK  Survey 
Duthie T et al 
(1999) 
114
; UK  Survey 
GinsburyME 
et al (2000) 
122
; 
US  Survey 
A questionnaire was developed following a 
Prescribing advisors (n = 178),  focus group meeting, covering four main  The use of economic studies was limited.  The major 
hospital directors (n = 202),  themes: knowledge, importance, barriers and  barriers were inflexibilities in healthcare budgets and 
directors of  public health (n = 66)_  awarenes~-- concerns relating to methodological issues. 
Prescribing advisors in the UK 
(n= 178) 
Heterogeneous mix of decision 
makers (n = 34) 
Randomly selected physicians 
(n = 512) 
A questionnaire was developed following a 
focus group meeting, covering four main 
themes: knowledge, importance, barriers and 
awareness. 
Duo interviews (semi-structured) - participants 
were grouped in pairs to encourage quality 
discussion. 
Questionnaire containing 30 close-ended 
questions. 
Economic issues were rated to be less important than 
clinical issues, but were considered at most meetings 
between prescribing advisors and GPs.  While they 
wish to consider true cost effectiveness, they often feel 
obliged to consider drug acquisition costs and risk of 
budgetary overspends.  The perceived inflexibility of 
the system and the lack of credibility of evaluations 
were major barriers. 
A large proportion of statements relating to traditional 
health economics principals (e.g. incremental ratios, 
QAL  Y s) were not understood or considered irrelevant. 
Most physicians regard cost effectiveness as important 
and appropriate in clinical practice.  However, they 
varied considerably in terms of how such information 
should be implemented. - N 
0\ 
Table 1 (cont)  Studies exploring the role and impact of economic evidence in decision making in primary care. 
Motheral BR et 
al (2000) 
123
; 
US  Survey 
Hoffmann C et 
al (2000) 
113
; 
Europe  Survey 
Hoffmann C et 
al (2002) 
115
; 
UK  Focus group 
Pharmacists and physicians 
(n = 409) 
Three questionnaires: (1) use and importance of  Half the respondents reported to consider economic 
economic information, (2) sources of economic  information for most or every decision, but 62% 
information used and (3) internal research  indicated that only occasionally did this result in action 
activities and barriers to the use of economic  or change.  Peer-reviewed journals were identified as 
information.  the key source of information. 
Survey by postal questionnaires, semi-structured Despite positive attitude, knowledge about formal 
interviews and focus group discussions.  methodology is rather limited.  Economic studies are 
Questions include issues about the extent of  not widely used in decision making.  Institutional 
knowledge on economic evaluations, the actual  problems and credibility of the studies were viewed as 
Decision makers in nine European and potential use of study results as well as  major barriers.  Training and better explanations of the 
countries (n = 1041).  barriers and incentives of the use of studies.  practical relevance of economic studies is needed. 
Decision makers from two UK  Focus group with convenience sampling.  Four 
health authorities who had  meetings (two at each HA) conducted: (1) 
demonstrated interest in health  current knowledge and use of economic 
economics and willing to  information, (2) usefulness of NHS EED 
participate (n = 12).  abstracts. 
The value of economic studies was generally 
recognised, but methodological improvement was 
viewed to be necessary to increase the reliability of the 
studies. 
The study cohort described in  Walley et al (  1997) was a sub-cohort of  those examined by Drummond Metal (  1997).  Walley et al reported detailed findings of  the prescribing advisor sub-
cohort.  QALYs-quality adjusted life years; HA- health authorities; NHS EED-National Health Service Economic Evaluation Database Table 2  Demographics and characteristics of the study population 
COMPARATOR  % 
Total (N) 
Age (years) 
47350  100 
Sex 
50 to 59 
60 to 74 
75+ 
Mean Age (years) 
Male 
Female 
History of GI Diagnosis 
Yes 
No 
History of Endoscopy 
Yes 
No 
History of CV Diagnosis 
Yes 
No 
History of RA/SLE Diagnosis 
Yes 
No 
History of OA Diagnosis 
Yes 
No 
NSAID Prescriptions 
Acemetacin 
Azapropazone 
Diclofenac Sodium 
Diflunisal 
Etodolac 
Fenbufen 
Fenoprofen 
Flurbiprofen 
Ibuprofen 
Indomethacin 
Ketoprofen 
Mefenamic Acid 
Nabumetone 
Naproxen 
Naproxen Combination Pack 
Piroxicam 
Sulindac 
Tenoxicam 
Tiaprofenic Acid 
Tolectin 
Concomitant use of H2 
Cimetidine 
Ranitidine 
Nizatidine 
Famotidine 
18259  38.56 
20959  44.26 
8132  17.17 
64 years 
21918  46.29 
25432  53.71 
2012  4.25 
45338 
3458  7.30 
43892 
2835  5.99 
44515 
44  0.09 
47306 
531  1.12 
46819 
Concomitant use of Omeprazole - Losee 
Concomitant use of Misoprostol - Cytotec 
Concomitant use of Aspirin 
Death After Study Period to 1994 
crude rates (observed) 
adjusted for sex and age+ 
*  Hz blockers/omeprazole 
5269  11.13 
11.13 
NSAID &  NSAID &  NSAID 
ONLY  %  MISOPROSTOL  %  Hz*  % 
49212  100 
16509  33.55 
22913  46.56 
9790  19.89 
65 years 
19801  40.24 
29411  59.76 
1582  3.21 
47630 
3872  7.87 
45340 
6069  12.33 
43143 
187  0.38 
49025 
1483  3.01 
47729 
9  0.02 
1077  2.19 
6321  12.84 
437  0.89 
121  0.25 
876  1.78 
44  0.09 
785  1.60 
12512  25.42 
1814  3.69 
1074  2.18 
4026  8.18 
628  1.28 
7469  15.18 
3079  6.26 
139  0.28 
384  0.78 
252  0.51 
5  0.01 
8160  16.58 
6767  13.75 
12.61 
212  100  2113  100 
57  26.89  594  28.11 
103  48.58  1115  52.77 
52  24.53  404  19.12 
67 years  66 years 
62  29.25 
150  70.75 
27  12.74 
185 
42  19.81 
170 
29  13.68 
183 
3  1.42 
209 
12  5.66 
200 
0  0.00 
9  4.25 
33  15.57 
0  0.00 
2  0.94 
3  1.42 
0  0.00 
4  1.89 
34  16.04 
7  3.30 
8  3.77 
2  0.94 
4  1.89 
79  37.26 
30  14.15 
16  7.55 
0  0.00 
3  1.42 
0  0.00 
0  0.00 
182  85.85 
8  3.77 
28  13.21 
11 .25 
867  41.03 
1246  58.97 
373  17.65 
1740 
680  32.18 
1433 
448  21 .20 
1665 
30  1.42 
2083 
97  4.59 
2016 
0  0.00 
56  2.65 
341  16.14 
14  0.66 
7  0.33 
54  2.56 
3  0.14 
38  1.80 
334  15.81 
59  2.79 
51  2.41 
146  6.91 
47  2.22 
275  13.01 
165  7.81 
11  0.52 
26  1.23 
9  0.43 
2  0.09 
338  16.00 
1703  80.60 
14  0.66 
41  1.94 
17  0.80 
475  22.48 
346  16.37 
14.92 
+  Mortality rates were adjusted by the direct method to the comparator cohort distribution. 
127 Table 3  Gastrointestinal endoscopies recorded in the three follow-up periods 
NSAID & 
Comuarator (n =  47 350}  NSAID Onll: (n =  49 212}  NSAID & Misourostol (n =  212}  H2 blocker/Omeurazole (n =  2113} 
Male  Female  %(Both Sexes)  Male  Female  % (Both Sexes)  Male  Female  %(Both Sexes)  Male  Female  %(Both Sexes) 
45 days 
50 to 59 years  14  19  0.07%  12  21  0.07%  0  0  0.00%  2  5  0.33% 
60 to 74 years  18  23  0.09%  15  21  0.07%  0  0  0.00%  1  7  0.38% 
75+ years  1  7  0.02%  4  7  0.02%  0  0  0.00%  0  2  0.09% 
sub-total  33  49  31  49  0  0  3  14 
%of each sex  0.15%  0.19%  0.16%  0.17%  0.00%  0.00%  0.35%  1.12% 
Total  82  0.17%  80  0.16%  0  0.00%  17  0.80% 
Six months 
50 to 59 years  57  49  0.22%  47  81  0.26%  0  0  0.00%  9  12  0.99% 
60 to 74 years  69  65  0.28%  74  110  0.37%  0  1  0.47%  9  19  1.33% 
75+ years  10  27  0.08%  22  51  0.15%  0  0  0.00%  3  5  0.38% 
sub-total  136  141  143  242  0  1  21  36 
%of each sex  0.62%  0.55%  0.72%  0.82%  0.00%  0.67%  2.42%  2.89% 
Total  277  0.59%  385  0.78%  1  0.47%  57  2.70% 
12 months 
50 to 59 years  110  102  0.45%  105  138  0.49%  1  0  0.47%  15  24  1.85% 
60 to 74 years  129  143  0.57%  153  234  0.79%  0  3  1.42%  27  42  3.27% 
75+ years  25  45  0.15%  40  100  0.28%  0  0  0.00%  6  7  0.62% 
sub-total  264  290  298  472  1  3  48  73 
%of each sex  1.20%  1.14%  1.50%  1.60%  1.61%  2.00%  5.54%  5.86% 
Total  554  1.17%  770  1.56%  4  1.89%  121  5.73%  ,__. 
N 
00 Table 4  Prescription items recorded in the three follow-up periods 
NSAID& 
Coml!arator (n = 47 350}  NSAID Onll: (n = 49 212}  NSAID & Misol!rostol (n = 212}  H2 blocker/Omel!razole (n = 2113} 
Male  Female  %(Both Sexes)  Male  Female  %(Both Sexes)  Male  Female  %(Both Sexes)  Male  Female  %(Both Sexes) 
45 days 
50 to 59 years  594  801  2.95%  1967  2894  9.88%  10  16  12.26%  119  194  14.81% 
60 to 74 years  863  1051  4.04%  3439  4948  17.04%  14  39  25.00%  266  384  30.76% 
75+ years  268  561  1.75%  1188  2910  8.33%  5  27  15.09%  75  208  13.39% 
sub-total  1725  2413  6594  10752  29  82  460  786 
%of each sex  7.87  9.49%  33.30%  36.56%  46.77%  54.67%  53.06%  63.08% 
Total  4138  8.74%  17346  35.25%  111  52.36%  1246  58.97% 
Six months 
50 to 59 years  1200  1722  6.17%  3721  5558  18.86%  17  24  19.34%  210  302  24.23% 
60 to 74 years  1549  1869  7.22%  6264  8783  30.58%  21  54  35.38%  442  559  47.37% 
75+ years  414  950  2.88%  2182  4892  14.37%  6  33  18.40%  110  268  17.89% 
sub-total  3163  4541  12167  19233  44  111  762  1129 
%of each sex  14.43%  17.86%  61.45%  65.39%  70.97%  74.00%  87.89%  90.61% 
Total  7704  16.27%  31400  63.81%  155  73.11%  1891  89.49% 
12 111011ths 
50 to 59 years  1742  2395  8.74%  4652  6768  23.21%  20  25  21.23%  232  310  25.65% 
60 to 74 years  2157  2658  10.17%  7195  10211  35.37%  23  63  40.57%  459  583  49.31% 
75+ years  610  1248  3.92%  2420  5485  16.06%  6  36  19.81%  115  274  18.41% 
sub-total  4509  6301  14267  22464  49  124  806  1167 
%of each sex  20.57%  24.78%  72.05%  76.38%  79.03%  82.67%  92.96%  93.66% 
Total  10810  22.83%  36731  74.64%  173  81.60%  1973  93.37%  ....... 
N 
\0 Table 5  Hospitalised patients recorded 
GI ADMISSIONS  CV ADMISSIONS 
50 to 59 ~ears  60 to 74 ~ears  75+ ~ears  50 to 59  ~ears  60 to 74  ~ears  75+ ~ears 
N  F  M  Total  F  M  Total  F  M  Total  Incidence  F  M  Total  F  M  Total  F  M  Total  Incidence 
45 days 
Comparator  47350  7  7  14  13  13  26  5  2  7  0.10%  I  22  23  9  16  25  35  8  43  0.19% 
NSAID  49212  7  9  16  25  18  43  23  10  33  0.19%  23  52  75  86  119  205  69  28  97  0.77% 
Misoprostol  212  0  0  0  0  0  0  I  0  1  0.47%  0  0  0  I  0  1  I  0  1  0.94% 
H2 blocker/Omeprazole  2113  3  I  4  0  4  4  I  0  1  0.43%  3  8  11  5  13  18  4  3  7  1.70% 
Six months 
Comparator  47350  21  26  47  45  37  82  19  12  31  0.34%  13  58  71  47  64  Ill  97  48  145  0.69% 
NSAID  49212  24  33  57  80  51  131  72  23  95  0.58%  73  171  244  240  334  574  226  105  331  2.33% 
Misoprostol  212  0  0  0  0  0  0  I  0  1  0.47%  0  0  0  I  0  I  3  0  3  1.89% 
H2 blocker/Omeprazole  2113  5  4  9  6  9  15  8  I  9  1.56%  6  16  22  21  32  53  14  5  19  4.45% 
12 months 
Comparator  47350  41  56  97  95  72  167  52  32  84  0.73%  36  114  150  98  135  233  176  99  275  1.39% 
NSAID  49212  58  62  120  153  98  251  142  44  186  1.13%  158  310  468  418  585  1003  401  205  606  4.22% 
Misoprostol  212  0  0  0  0  0  0  I  0  1  0.47%  0  I  I  4  I  5  7  0  7  6.13% 
H2 blocker/Omeprazole  2113  12  6  18  II  15  26  II  2  13  2.70%  II  25  36  36  50  86  28  10  38  7.57% 
RA ADMISSIONS  OA ADMISSIONS 
50 to 59 ~ears  60 to 74 ~ears  75+ ~ears  50 to 59 ~ears  60 to 74  ~ears  75+ ~ears 
N  F  M  Total  F  M  Total  F  M  Total  Incidence  F  M  Total  F  M  Total  F  M  Total  Incidence 
45 days 
Comparator  47350  0  0  0  I  I  2  0  0  0  0.00%  0  I  I  4  2  6  9  I  10  0.04% 
NSAID  49212  2  3  5  7  0  7  2  0  2  0.03%  5  6  II  15  17  32  26  4  30  0.15% 
Misoprostol  212  0  0  0  0  0  0  0  0  0  0.00%  0  0  0  0  0  0  0  0  0  0.00% 
H2 blocker/Omeprazole  2113  I  0  I  0  I  I  0  0  0  0.09%  2  0  2  2  I  3  2  0  2  0.33% 
Six months 
Comparator  47350  0  0  0  2  I  3  5  0  5  0.02%  3  6  9  8  9  17  24  4  28  0.11% 
NSAID  49212  8  7  15  25  2  27  13  I  14  0.11%  21  29  50  72  58  130  99  20  119  0.61% 
Misoprostol  212  0  0  0  0  0  0  0  0  0  0.00%  0  0  0  0  0  0  0  0  0  0.00% 
H2 blocker/Omeprazole  2113  I  0  I  4  2  6  I  0  I  0.38%  4  2  6  5  4  9  8  0  8  1.09% 
12 months 
Comparator  47350  I  0  I  3  2  5  6  0  6  0.03%  4  13  17  16  14  30  38  9  47  0.20% 
NSAID  49212  17  II  28  49  8  57  28  3  31  0.24%  53  52  105  172  124  296  192  47  239  1.30% 
,....  Misoprostol  212  0  0  0  I  0  I  0  0  0  0.47%  0  I  I  2  0  2  2  0  2  2.36% 
v,) 
H2 blocker/Omeprazole  2113  3  0  3  6  2  8  2  0  2  0.62%  6  3  9  13  8  21  12  0  12  1.99%  0 
F =females; M =males - w  -
Table 6  Details of hospital events recorded in  three follow-up periods 
longest admission 
mean los (days) 
GASTROINTESTINAL EVENTS 
comparator 
comparator 
comparator 
nsaid 
nsaid 
nsaid 
misoprostol 
misoprostol 
misoprostol 
h2 blocker/omeprazole 
h2 blocker/omeprazole 
h2 blocker/omeprazo\c 
CARDIOVASCULAR EVENTS 
comparator 
comparator 
comparator 
nsaid 
5.57 
7.20 
11.85 
I 1.05 
10.15 
14.84 
34.00 
34.00 
34.00 
8.33 
12.73 
13.29 
16.48 
22 85 
24.96 
10.58 
nsaid  14.17 
nsaid  15.93 
misoprostol  20.50 
misopros10l  36 50 
misoprostol  30.92 
h2  blocker/omeprazole  9.36 
h2 blockcr/on1eprazole  II 90 
h2 blocker/omeprazole  15.34 
RHEUMATOID ARTHRITIS EVENTS 
comparator 
comparator 
comparator 
nsaid 
nsaid 
nsaid 
misoprostol 
misoprostol 
misoprostol 
h2  blocker/omeprazole 
h2 blocker/omeprazole 
h2 blocker/omeprazole 
OSTEOARTHRITIS EVENTS 
comparator 
comparntor 
comparator 
nsaid 
nsaid 
13.50 
49.25 
37.17 
13.64 
18.84 
24.76 
0.00 
0.00 
5.00 
5.00 
12.50 
14.85 
22.06 
30. JJ 
33.52 
18.71 
23.46 
nsaid  23.02 
misoprostol  0.00 
misoprostol  0.00 
misoprostol  25.20 
h2  blocker/omeprazole  23.57 
h2 blocker/omeprazole  23.00 
h2 blockeriomeprazole  23.55 
EVENTS OBSERVED IN THE FIRST 45 DAYS. 
minimum 
los (days) 
13 
0 
15 
3 
maximum 
los (days) 
45 
77 
365 
45 
183 
365 
34 
34 
34 
26 
183 
183 
45 
183 
365 
45 
183 
365 
34 
88 
163 
45 
183 
365 
14 
183 
183 
27 
18J 
365 
46 
46 
45 
18J 
365 
45 
ISJ 
282 
0 
38 
42 
47 
58 
sum  no. of  cases 
los (days)  N 
262 
11 52 
4704 
1017 
2872 
12257 
34 
34 
34 
75 
420 
1010 
1500 
7472 
16421 
3987 
16280 
33092 
41 
146 
402 
337 
1119 
2454 
27 
394 
446 
191 
1055 
2872 
0 
0 
10 
100 
193 
375 
1627 
3184 
1366 
7016 
14735 
0 
126 
165 
529 
989 
47 
160 
397 
92 
283 
826 
33 
57 
91 
327 
658 
377 
1149 
2077 
2 
4 
13 
36 
94 
160 
12 
14 
56 
11 6 
0 
0 
13 
17 
54 
95 
73 
299 
640 
0 
23 
42 
additional admissions 
mean los (days) 
2.80 
6.11 
8.71 
6.71 
10.37 
8.81 
0.00 
0.00 
15.00 
2.00 
4.75 
9.29 
6.14 
12 56 
19.77 
5.53 
12 56 
14.20 
0.00 
000 
11.67 
4.92 
9.87 
17.52 
0.00 
1600 
68.25 
4.00 
17 80 
51.79 
0.00 
000 
0.00 
0.00 
J 50 
20.25 
16.00 
32 00 
35.00 
8.00 
17.44 
35.58 
0.00 
0.00 
2.00 
0.00 
8.67 
27.00 
EVENTS OBSERVED SIX MONTHS FOLLOWING THE INDEX DATE. 
minimum 
los (days) 
I 
0 
0 
I 
I 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
maximum 
los (days) 
18 
37 
15 
22 
95 
0 
15 
2 
I 
18 
21 
76 
259 
26 
87 
245 
0 
30 
31 
72 
29 
212 
4 
66 
249 
0 
0 
0 
48 
24 
53 
145 
12 
57 
236 
0 
0 
0 
sum 
los (days) 
14 
165 
592 
94 
425 
890 
15 
19 
65 
135 
1093 
3539 
531 
109J 
10322 
0 
35 
64 
375 
946 
0 
32 
273 
178 
725 
0 
0 
81 
32 
128 
21 0 
32 
471 
2206 
0 
additional admissions 
mean counts 
1.00 
2.41 
3.59 
3.33 
2.27 
3.24 
0.00 
0.00 
3.00 
1.00 
2 25 
3.14 
1.32 
2 31 
3.51 
1.39 
10 30 
3.62 
0.00 
000 
3.33 
1.54 
2 53 
4.15 
~00 
200 
325 
1m 
2M 
D l 
~00 
~00 
~00 
~00 
~00 
~00 
1.00 
2 00 
3.00 
1.25 
2.07 
3.13 
0.00 
0 00 
3.00 
0.00 
16  26  900 
II  43  108  3.25 
EVENTS OBSERVED 12  MONTHS FOLLOWING THE INDEX DATE. 
minimum 
counts 
0 
maximum 
counts 
12 
17 
0 
0 
18 
6 
0 
sum 
counts 
65 
244 
20 
93 
327 
0 
9 
22 
29 
201 
628 
133 
896 
2635 
0 
0 
10 
20 
96 
224 
13 
22 
45 
0 
0 
0 
4 
16 
18 
56 
194 
0 
0 
0 
27 
13 
no. of  cases 
N 
27 
68 
14 
41 
101 
22 
87 
179 
96 
87 
727 
0 
13 
J8 
54 
10 
14 
0 
0 
0 
0 
4 
6 
27 
62 
0 
average admissions 
per person 
1.11 
I 41 
1.61 
1.22 
I ~ 
I.W 
1m 
100 
~00 
I. II 
1n 
1 .~ 
1.32 
1.6 1 
1.95 
1.35 
1.78 
2.27 
1.00 
1.00 
1 77 
1.56 
2 02 
2.40 
1.00 
1.50 
2.08 
1.07 
1.39 
1.39 
0.00 
0.00 
1.00 
1.00 
1. 50 
2.2J 
1.12 
1. 15 
1.1 9 
1.07 
1. 19 
1.30 
0.00 
0.00 
I 60 
1.00 
2.17 
1.3 1 Table 7  Calculated shadow and total costs (£) per individual 
Inception  Period 1  Period 2  Period 3 
N  Drug Costs  (0 to 45 days)  (0 to six months)  (0 to12 months) 
Comparator  47350  £0.00 
shadow costs  £13.35  £59.63  £141.51 
total costs  £13.35  £59.63  £141.51 
95%CI  (£11.44 to £15.27)  (£53.82 to £65.45)  (£126.58 to £156.43) 
NSAID Only  49212  £7.51 
shadow costs  £44.19  £179.01  £386.93 
total costs  £51.70  £186.52  £394.44 
95%CI  (£47.38 to £56.03)  (£176.71 to £196.32)  (£374.79 to £414.09) 
NSAID & Misoprostol  212  £24.34 
shadow costs  £75.56  £332.16  £787.29 
total costs  £99.90  £356.50  £811.63 
95%CI  (£22.75 to £177.05)  (£40.26 to £672.73)  (£403.93 to £1219.32) 
NSAID & H2 Blocker/Omeprazole  2113  £40.73 
shadow costs  £104.06  £418.20  £897.03 
total costs  £144.79  £458.93  £937.76 
95%CI  (£119.71 to £169.87)  (£403.64 to £514.22)  (£805.01 to £1070.51) 
*  F test probabilities:  p =  0.00 (45 days)  p =  0.00 (six months)  p =  0.00 (12 months) 
-
(.)) 
N ........ 
(j;) 
(j;) 
Table 8 
FEMALE 
Comparator 
NSAIDOnly 
NSAID & Misoprostol 
NSAID & Hz blocker/Omeprazole 
MALE 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID & Hz blocker/Omeprazole 
*  F test probabilities 
Sex-specific total costs per individual (95% Cl) 
Total Costs (£) 
N  45 Days  Six Months  12Months 
25432  £14.71  £64.71  £148.97 
(£11. 79 to £17.63)  (£55.91 to £73.52)  (£128.78 to £169.16) 
29411  £48.37  £184.20  £393.86 
(  £43.97 to £52. 77)  (£171.88 to £196.52)  (£368.82 to £418.91) 
150  £119.02  £451.89  £971.56 
(£9.83 to £228.20)  (£4.52 to £899.26)  (£406.27 to £1536.86) 
1246  £135.30  £438.94  £934.25 
(£104.25 to £166.35)  (£269.13 to £508.75)  (£733.22 to £1135.29) 
21918  £11.78  £53.74  £132.85 
(£9.41 to £14.15)  (£46.42 to £61.06)  (£110.70 to £154.99) 
19801  £56.66  £189.96  £395.30 
(£48.12 to £65.19)  (£173.87 to £206.05)  (£363.65 to £426.44) 
62  £53.64  £125.70  £424.66 
(£43.70 to £63.58)  (£95.19 to £156.22)  (£150.50 to £698.84) 
867  £158.43  £487.65  £942.81 
(£116.60 to £200.26)  (£397.57 to £577.73)  (  £796. 72 to £1088.89) 
Comparator  p = 0.13 (45 days)  p = 0.06 (6 months)  p = 0.29 (12 months) 
NSAID  p = 0.06 (45 days)  p = 0. 57 (  6 months)  p = 0.94 ( 12 months) 
Misoprostol  p = 0.45 (45 days)  p = 0.36 (6 months)  p = 0.23 (12 months) 
H;/Omeprazole  p = 0.37 (45 days)  p = 0.40 (6 months)  p = 0.95 (12 months) Table 9 
50 to 59 years 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID &Hz 
Blocker/Omeprazole 
60 to 74 years 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID &Hz 
Blocker/Omeprazole 
75+years 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID &Hz 
Blocker/Omeprazole 
*  F test probabilities 
Age-specific total costs per individual (95% Cl) 
N 
18259 
16509 
57 
594 
20959 
22913 
Comparator 
NSAID 
Misoprostol 
103 
1115 
8132 
9790 
52 
404 
H  z/Omeprazole 
45Days 
£7.45 
(£6.02 to £8.88) 
£35.30 
(£27.31 to £43.30) 
£50.32 
(£40.55 to £60.09) 
£133.38 
(£94.84 to £171.92) 
£11.42 
(£8.97 to £13.85) 
£55.10 
(£49.27 to £60.93) 
£67.32 
(£40.56 to £94.08) 
£149.96 
(£113.11 to£186.81) 
£31.60 
(£23.00 to £40.22) 
£71.41 
(£61.17 to £81.64) 
£218.77 
(£0 to £534.46) 
£147.31 
(£86.46 to £208.16) 
p = 0.00 (45 days) 
p = 0.00 (45 days) 
p =  0.22 (45 days) 
p = 0.85 (45 days) 
Total Costs (£) 
Six Months 
£32.08 
(£26.90 to £37.26) 
£108.77 
(£97.66 to £119.88) 
£122.60 
(£88.59 ti £156.61) 
£358.26 
(£293.44 to £423.09) 
£51.10 
(£44.42 to £57.77) 
£189.41 
(£175.48 to £203.33) 
£156.48 
(£118.95 to £194.01) 
£486.93 
(£399.02 to £574.83) 
£143.51 
(£116.83 to £170.19) 
£310.87 
(£279.14 to £342.58) 
£1,009.06 
(£0 to £2312.02) 
£529.67 
(£404.40 to £654.92) 
p = 0.00 (6 months) 
p = 0.00 (6 months) 
p =  0.07 (6 months) 
p =  0.07 (6 months) 
12Months 
£76.79 
(£60.60 to £92.98) 
£226.03 
(£207.98 to £244.07) 
£370.26 
(£97.70 to £642.82) 
£683.18 
(£578.87 to £787.50) 
£120.35 
(£102.59 to £138.10) 
£384.54 
(£361.64 to £407.43) 
£466.97 
(305.58 to £628.37) 
£942.35 
(£812.10 to £1072.59) 
£341.35 
(£277.22 to £405.48) 
£701.61 
(£624.77 to £778.46) 
£1,978.09 
(£375.18 to £3580.99) 
£1,299.41 
(£725.21 to £1873.61) 
p = 0.00 (12 months) 
p = 0.00 (12 months) 
p =  0.00 (12 months) 
p = 0.01 (12 months) 
134 Table 10  Comparisons between the two NSAID and gastroprotectives sub-cohorts (45 Days) 
% Greater than  %Less than  Tayside 
N  NSAID Only  N  H 2 blocker/Omeprazole  Savings(£) 
Base Case  49212  93.23%  2113  31.00%  £34,399.64 
Sex and Age-Specific 
Female 
50 to 59 years  9324  91.08%  339  60.68%  £26,886.09 
60 to 74 years  13319  51.62%  623  42.98%  £33,374.11 
75+ years  6768  218.76%  284  -57.00%  -£26,576.72 
Total  29411  146.06%  1246  12.03%  £20,284.88 
Male 
50 to 59 years  7185  5.67%  255  64.34%  £22,465.50 
60 to 74 years  9594  -13.89%  492  68.54%  £61,381.92 
75+ years  3022  9.53%  120  48.77%  £6,286.80 
Total  19801  -5.33%  867  66.14%  £90,852.93 
Sensitivity Analysis 
Non-aspirin Takers  41554  117.12%  1683  22.13%  £48,285.61 
No Prior GI  Admissions  47630  106.11%  1740  20.23%  £45,830.03 
No Prior CV  Admissions  43143  32.88%  1665  52.27%  £105,439.79 
No Prior RA Admissions  49025  96.43%  2083  30.78%  £92,919.09 
No Prior OA Admissions  47729  106.76%  2016  25.99%  £71,128.71 
No Prior Endoscopies  45340  122.92%  1433  22.30%  £45,224.62 
Survivors  42445  141.38%  1767  24.41%  £60,063.69 
No Risk Factors *  30513  60.20%  764  35.45%  £22,726.25 
* Excluded aspirin takers, those with prior Gf, CV, RA or OA  admissions, prior endoscopies and those died 
during the study. 
% indicates the percentage of  shadow costs greater than the NSAID Only and less than NSAID & H2 
blocker/Omeprazole sub-cohort. 
135 Table 11  Comparisons between the two NSAID and gastroprotectives sub-cohorts (six months) 
% Greater than  %Less than  Tayside 
N  NSAID Only  N  H2 blocker/Omeprazole  Savings(£) 
Base Case  49212  91.13%  2113  22.32%  £216,434.59 
Sex and Age-Specific 
Female 
50 to 59 years  9324  48.68%  339  59.00%  £66,328.74 
60 to 7  4 years  13319  -4.03%  623  61.55%  £158,983.37 
75+ years  6768  251.71%  284  -131.20%  -£170,956.64 
Total  29411  145.33%  1246  -2.95%  £16,135.70 
Male 
50 to 59 years  7185  -20.59%  255  73.53%  £73,809.75 
60 to 7  4 years  9594  -33.00%  492  74.32%  £211,520.64 
75+ years  3022  -52.85%  120  60.09%  £22,713.60 
Total  19801  -33.83%  867  74.22%  £313,810.65 
Sensitivity Analysis 
Non-aspirin Takers  41554  120.38%  1683  9.30%  £62,341 .18 
No Prior GI Admissions  47630  16.36%  1740  49.47%  £352,159.82 
No Prior CV  Admissions  43143  96.54%  1665  18.00%  £109,907.65 
No Prior RA Admissions  49025  94.53%  2083  21.74%  £205,713.96 
No Prior OA Admissions  47729  112.18%  2016  18.12%  £163,524.0 I 
No Prior Endoscopies  45340  129.97%  1433  6.54%  £40,844.37 
Survivors  42445  157.79%  1767  4.68%  £33,177.72 
No Risk Factors *  30513  0.85%  764  59.12%  £112,097.82 
* Excluded aspirin takers. those with prior GI.  CV.  RA or OA admissions. prior endoscopies and those died during the study. 
%indicates the percentage of  shadow costs greater than the NSAID Only and less than NSAID & H2 blocker/Omeprazole sub-cohort. 
136 Table 12  Comparisons between the two NSAID and gastroprotectives sub-cohorts (12 months) 
N 
Base Case  49212 
Sex and Age-Specific 
Female 
50 to 59 years  9324 
60 to 74 years  13319 
75+ years  6768 
Total  29411 
Male 
50 to 59 years  7185 
60 to 7  4 years  9594 
75+ years  3022 
Total  19801 
Sensitivity Analysis 
Non-aspirin Takers  41554 
No Prior GI Admissions  47630 
No Prior CV  Admissions  43143 
No Prior RH  Admissions  49025 
No Prior OS Admissions  47729 
No Prior Endoscopies  45340 
Survivors  42445 
No Risk Factors *  30513 
% Greater than 
NSAIDOnly  N 
105.77%  2113 
44.16%  339 
35.79%  623 
219.25%  284 
146.68%  1246 
85.97%  255 
4.24%  492 
-48.73%  120 
6.96%  867 
135.80%  1683 
65.86%  1740 
87.33%  1665 
110.50%  2083 
126.20%  2016 
148.30%  1433 
139.38%  1767 
37.44%  764 
%Less than 
H2 blocker/omeprazole 
Tayside 
Savings(£) 
13.41%  £266,512.69 
54.14%  £115,632.90 
40.81%  £202,524.84 
-50.12%  -£227,631.68 
-3.99%  -£46,488.26 
36.05%  £69,298.80 
59.64%  £330,673.20 
65.63%  £46,446.00 
54.96%  £449,236.05 
1.31%  £18,312.55 
27.80%  £420,345.55 
20.19%  £255,151.26 
12.71%  £246,639.49 
8.90%  £165,073.51 
-5.29%  -£66,884.42 
6.51%  £86,662.34 
36.26%  £123,475.77 
* Excluded aspirin takers, those with prior Gl,  CV,  RA or OA admissions, prior endoscopies and those died during the study. 
%indicates the percentage of  shadow costs greater than the NSAID Only and less than NSAID & H2  blockerlomeprazole sub-cohort. 
137 Table 13  Sensitivity analysis - base case versus one admission (multiple episodes of care representing one individual admission) 
Cost of  Cost of All  CostofGP  Cost of  Cost of  Cost of  Cost of  Cost of  Shadow  Total 
Inception Drugs  EventRx *  Consultations  Endoscopy  GI admissions  CV admissions  RA admissions  OA admissions  Costs  Costs 
45Days 
Comparator 
base case  £0.00  £3.18  £1.36  £0.40  £1.32  £5.28  £0.11  £1.70  £13.35  £13.35 
one admission  £0.00  £3.18  £1.36  £0.40  £1.31  £5.24  £0.11  £1.69  £13.29  £13.29 
NSAID 
base case  £7.51  £7.34  £5.61  £0.34  £4.39  £19.40  £0.84  £6.37  £44.29  £51.80 
one admission  £7.51  £7.34  £5.51  £0.34  £4.35  £19.24  £0.84  £6.36  £43.98  £51.49 
Misoprostol 
base case  £24.34  £18.74  £11.62  £0.00  £19.36  £25.84  £0.00  £0.00  £75.56  £99.90 
one admission  £24.34  £18.74  £11.62  £0.00  £19.36  £25.84  £0.00  £0.00  £75.56  £99.90 
H2 blocker/omeprazole 
base case  £40.73  £24.92  £12.27  £1.77  £7.26  £36.32  £0.95  £20.58  £104,07  £144.80 
one admission  £40.73  £24.92  £12.27  £1.77  £7.23  £35.70  £0.95  £20.58  £103.42  £144.15 
Six Months 
Comparator 
base case  £0.00  £14.59  £4.25  £1.46  £5.63  £26.63  £1.03  £6.04  £59.63  £59.63 
one admission  £0.00  £14.59  £4.25  £1.46  £5.49  £26.41  £1.02  £6.02  £59.24  £59.24 
NSAID 
base case  £7.51  £37.52  £18.91  £1.82  £11.92  £72.31  £4.11  £32.41  £179.00  £186.51 
one admission  £7.51  £37.52  £18.91  £1.82  £11.71  £71.30  £4.09  £32.34  £177.69  £185.20 
Misoprostol 
base case  £24.34  £78.94  £30.11  £1.97  £27.53  £193.61  £0.00  £0.00  £332.16  £356.50 
one admission  £24.34  £78.94  £30.11  £1.97  £27.06  £192.97  £0.00  £0.00  £331.05  £355.39 
H2 blocker/omeprazole 
base case  £40.73  £144.69  £41.74  £6.70  £31.70  £121.46  £9.05  £62.85  £418.19  £458.92 
one admission  £40.73  £144.69  £41.74  £6.70  £31.26  £118.85  £8.95  £62.62  £414.81  £455.54 
12Months 
Comparator 
base case  £0.00  £33.88  £8.10  £3.00  £17.33  £65.68  £1.35  £12.16  £141.50  £141.50 
one admission  £0.00  £33.88  £8.10  £3.00  £18.89  £64.96  £1.34  £12.10  £142.27  £142.27 
NSAID 
base case  £7.51  £83.47  £33.89  £3.83  £26.68  £156.08  £12.81  £70.17  £386.93  £394.44 
one admission  £7.51  £83.47  £33.89  £3.83  £26.07  £153.31  £12.74  £69.84  £383.15  £390.66 
Misoprostol 
base case  £24.34  £181.79  £49.11  £6.88  £45.01  £361.06  £4.71  £138.72  £787.28  £811.62 
one admission  £24.34  £181.79  £49.11  £6.88  £43.95  £358.12  £4.71  £138.47  £783.03  £807.37 
H2 blocker/omeprazole  -
base case  £40.73  £312.61  £72.25  £14.99  £49.70  £309.49  £18.16  £119.83  £897.03  £937.76 
w  one admission  £40.73  £312.61  £72.25  £14.99  £48.33  £303.40  £17.73  £119.18  £888.49  £929.22 
00  *  Rx =prescription items. Table 14  Sensitivity analysis - excluding various clinical risk factors 
45 Days  Six Months  One Year 
Shadow  Total  Shadow  Total  Shadow  Total 
N  Costs  Costs  Costs  Costs  Costs  Costs 
Base Case 
comparator 47350  £13.35  £13.35  £59.63  £59.63  £141.51  £141.51 
NSAID 49212  £44.19  £51.70  £179.01  £186.52  £386.93  £394.44 
misoprostol  212  £75.56  £99.90  £332.16  £356.50  £787.29  £911.63 
Hz blocker/omeprazole  2113  £104.06  £144.79  £418.20  £458.93  £897.03  £937.76 
Non-aspirin Takers 
comparator 47350  £16.03  £16.03  £59.63  £59.63  £141.51  £141.51 
NSAID 41554  £44.47  £52.95  £155.40  £163.88  £339.62  £348.10 
misoprostol  206  £93.12  £117.62  £336.65  £361.15  £796.31  £820.81 
Hz blocker/omeprazole  1683  £110.54  £152.35  £356.38  £398.20  £789.87  £831.69 
No Prior History of GI Diagnosis 
comparator 45338  £13.46  £13.46  £52.49  £52.49  £127.40  £127.40 
NSAID 47630  £48.99  £56.50  £170.15  £177.66  £370.79  £378.30 
misoprostol  185  £95.39  £119.45  £182.65  £206.71  £603.38  £627.44 
Hz blocker/omeprazole  1740  £112.61  £152.80  £369.29  £409.48  £828.83  £869.02 
No Prior History of CV Diagnosis 
comparator 44515  £12.99  £12.99  £47.81  £47.81  £111.14  £111.14 
NSAID 43143  £41.78  £49.59  £145.20  £153.02  £315.56  £323.38 
misoprostol  183  £49.04  £72.80  £276.97  £300.73  £582.01  £605.78 
Hz blocker/omeprazole  1665  £102.24  £143.34  £325.64  £366.74  £717.92  £759.02 
No Prior History of GI Endoscopy 
comparator 43892  £12.38  £12.38  £49.07  £49.07  £119.97  £119.97 
NSAID 45340  £47.58  £55.08  £169.58  £177.08  £366.35  £373.85 
misoprostol  170  £101.68  £125.92  £382.55  £406.79  £904.04  £928.29 
Hz blocker/omeprazole  1433  £124.44  £162.95  £397.23  £435.75  £843.10  £881.61 
No Prior NSAID Prescriptions 
comparator 47350  £16.03  £16.03  £59.63  £59.63  £141.51  £141.51 
NSAID 37871  £48.15  £55.14  £149.93  £156.92  £321.82  £328.82 
misoprostol  193  £95.47  £119.70  £350.13  £374.36  £811.03  £835.27 
Hz blocker/omeprazole  1452  £114.60  £154.70  £389.70  £429.81  £774.15  £814.26 
No Risk Factors * 
comparator 40612  £7.84  £7.84  £36.01  £36.01  £87.30  £87.30 
NSAID 27635  £29.05  £36.82  £99.72  £107.50  £216.67  £224.44 
misoprostol  116  £32.94  £56.02  £87.87  £110.95  £390.29  £413.37 
Hz blocker/omeprazole  610  £45.17  £83.32  £194.49  £232.64  £396.09  £434.24 
Survivors 
comparator 42081  £12.41  £12.41  £38.85  £38.85  £87.57  £87.57 
NSAID 42445  £42.23  £49.78  £140.70  £148.25  £286.92  £294.47 
misoprostol  184  £96.91  £121.38  £357.70  £382.18  £680.43  £704.90 
Hz blocker/omeprazole  1767  £121.11  £161.91  £360.15  £400.95  £713.14  £753.94 
Survivors with no risk factors 
comparator 36721  £6.33  £6.33  £25.57  £25.57  £59.14  £59.14 
NSAID 25332  £25.61  £33.35  £86.09  £93.83  £172.65  £180.39 
misoprostol  105  £32.41  £55.77  £76.36  £99.72  £219.93  £243.28 
Hz blocker/omeprazole  548  £43.95  £81.86  £160.09  £197.99  £350.75  £388.66 
* Excluded aspirin takers, those with prior Gl,  CV, RA or OA admissios, prior endoscopies and those who died during 
the study. 
139 Table 15  Sensitivity analysis - varying costs 
45 Days  Six Months  12Months 
Shadow  Total  Shadow  Total  Shadow  Total 
N  Costs  Costs  Costs  Costs  Costs  Costs 
Low GP Cost (£4.77) 
Comparator  47350  £12.83  £12.83  £57.98  £57.98  £138.33  £138.33 
NSAID Only  49212  £42.08  £49.59  £171.74  £179.25  £373.84  £381.35 
NSAID & Misoprostol  212  £71.19  £95.53  £320.86  £345.20  £768.37  £792.71 
NSAID & Hz hlocker/omeprazole  2113  £99.34  £140.07  £402.16  £442.89  £869.19  £909.91 
Low Endoscopy Cost (£208.33 x 0.5) 
Comparator  47350  £12.83  £12.83  £58.90  £58.90  £140.01  £140.01 
NSAID Only  49212  £45.24  £52.75  £178.10  £185.61  £385.01  £392.52 
NSAID & Misoprostol  212  £75.56  £99.90  £331.18  £355.51  £783.85  £808.19 
NSAID & Hz blocker/omeprazole  2113  £103.18  £143.91  £414.85  £455.58  £889.54  £930.27 
Base Case 
Comparator  47350  £13.35  £13.35  £59.63  £59.63  £141.51  £141.51 
NSAIDOnly  49212  £44.19  £51.70  £179.01  £186.52  £386.93  £394.44 
NSAID & Misoprostol  212  £75.56  £99.90  £332.16  £356.50  £787.29  £811.63 
NSAID & Hz blocker/omeprazole  2113  £104.06  £144.79  £418.20  £458.93  £897.03  £937.76 
High Endoscopy Cost (£208.33 x 1.5) 
Comparator  47350  £13.24  £13.24  £60.37  £60.37  £143.00  £143.00 
NSAID Only  49212  £45.58  £53.09  £179.92  £187.43  £388.84  £396.35 
NSAID & Misoprostol  212  £75.56  £99.90  £333.14  £357.48  £790.73  £815.07 
NSAID & Hz blocker/omeprazole  2113  £104.95  £145.68  £421.55  £462.28  £904.53  £945.26 
High GP Cost (£8.38) 
Comparator  47350  £13.51  £13.51  £60.12  £60.12  £142.44  £142.44 
NSAIDOnly  49212  £44.81  £52.32  £181.14  £188.65  £390.78  £398.29 
NSAID & Misoprostol  212  £76.85  £101.18  £335.48  £359.82  £792.85  £817.18 
NSAID & Hz blocker/omeprazole  2113  £105.45  £146.18  £422.91  £463.64  £905.22  £945.95 
...... 
..j::;.. 
0 Table 16  NSAID trials included in the meta-analysis 
Year  Author  Indication  Duration  N  Drugs Included in the Studl:  Method of ADR Recording  Jadad Score 
1982  AbeT  RA  6 weeks  164  Piroxicam 10-20 mg; indomethacin 75 mg  Unspecified  2 
1982  Abruzzo JL et al  OA  12 weeks  114  Piroxicam 20 mg; aspirin 2.6-3.9 g  Indirect questions  2 
1977  Aylward Metal  RA  6 weeks  44  Tolmetin 1.6 g, alclofenac 4 g  Spontaneous reporting  3 
1986  Bellamy N et al  OA  6 weeks  57  Piroxicam 10-20 mg, isoxicam 100-200 mg  Unspecified  3 
1983  BerryH et al  OA  2 weeks  24  Naproxen 750 mg, antrafenine 450-900 mg, placebo  Indirect questions  3 
1978  Bijlsma A  RA  6 months  36  Diclofenac 75-125 mg, indomethacin 75-125 mg  Unspecified  2 
1975  Blechman WJ et al  RA  51  weeks  885  Ibuprofen 3-6 g, aspirin 800-1600 mg  Indirect questions  4 
1975  Bowers DE et al  RA  16 weeks  80  Naproxen 250-750 mg, aspirin 0.8-4.8 g  Questionnaire  4 
1977  Brewis IDL  RA  2 weeks  30  Indomethacin 100 mg, flurbiprofen 240 mg, placebo  Indirect questions  2 
1976  BrookeJW  OA  12 weeks  30  Fenoprofen 200-600 mg, aspirin 325-975 mg, placebo  Daily checklist  2 
1986  Brown BL et al  OA  6 weeks  148  Sulindac 300 mg, flurbiprofen 100 mg  Unspecified  3 
1977  Cardoe N et al  RA  4 weeks  24  Tolmetin 1600 mg, phenylbutazone 400 mg  Spontaneous reporting  3 
1978  Castles JJ et al  RA  20 weeks  132  Naproxen 500 mg, indomethacin 100 mg, aspirin 3.6 g, placebo  Indirect questions  2 
1979  Daymond TJ et al  RA  4 weeks  41  Ibuprofen 1200 mg, tiaprofenic acid 600 mg  Unspecified  4 
1973  Fries JF et al  RA  6 weeks  30  Fenoprofen 1.6-2.4 g, aspirin 4.0-6.0 g, placebo  "Queried"  3 
1972  Gyory AN eta  RA/OA  2 weeks  88  Ketoprofen 100 mg, indomethacin  Indirect questions  4 
1976  Kirchheiner B et al  RA  2 weeks  30  Ketoprofen, indomethacin  Unspecified  1 
1977  KrugerHH  RA  2 weeks  30  Indomethacin 150 mg, flurbiprofen 300 mg  'Enquired for' at each visit  2 
1981  Liyanage SP et al  OA  4 weeks  30  Naproxen 750 mg, sulindac 400 mg  Indirect questions  2 
1977  McMillen JI  RA  12 weeks  104  Ibuprofen 1600 mg, tolmetin 1200 mg  Unspecified  3 
1973  Mills SB et al  RA  2 weeks  35  Ketoprofen 150 mg, ibuprofen 1200 mg  Indirect questions  2 
1987  Vasey FB et al  RA  6 months  367  Naproxen 500 mg, nabumetone 1500 mg  Unspecified  4 
1987  Vetter G  OA  4 weeks  36  Indomethacin 150 mg, SAMe 1200 mg  Unspecified  2  - 1978  Woolheim FA et al  OA  4 weeks  30  Ketoprofen 200 mg, naproxen 750 mg  Checklist  2 
~  -Table 17  SSRI trials included in the meta-analysis 
Year  Author  Countr;r  Duration  N  Drugs Included in the Stud;r  Method of  ADR Recording  Jadad Score 
1994  Ansseau M et al  Belgium  6 weeks  190  Milnacipran 100 mg, fluoxetine 20 mg  Checklist and spontaneous reporting  3 
1995  Bennie EH et al  UK  6 weeks  308  Sertraline 50-100 mg, fluoxetine 20-40 mg  Spontaneous reporting  3 
1994  Bersani G et al  Italy  8 weeks  68  Sertraline 50-100 mg, amitriptyline 50-150 mg  Unspecified  3 
1988  Byerley WF et al  us  6 weeks  103  Fluoxetine 20-80 mg, imipramine 75-300 mg  Unspecified  4 
1996  Claghorn JL et al  us  6 weeks  138  Fluvoxamine 50-150 mg, imipramine 80-240 mg, placebo  Indirect questions  3 
1991  Dunbar GC et al  us  6 weeks  717  Paroxetine 20-50 mg, imipramine 80-275 mg, placebo  COST  ART  3 
1991  Fabre LF et al  us  5 weeks  205  Nortriptyline 43 mg, fluoxetine 17.4 mg  Unspecified  3 
1985  Feighner JP  us  5 weeks  44  Fluoxetine 55 mg, amitriptyline 159 mg  Unspecified  3 
1995  Geretsegger C et al  Australia  6 weeks  91  Paroxetine 20-30 mg, amitriptyline 50-150 mg  Checklist  3 
1983  Guelfi JD et al  France  4 weeks  158  Fluvoxamine 300 mg, imipramine 200 mg  Checklist  3 
1983  Itil TM et al  us  4 weeks  69  Fluvoxamine 101 mg, imipramine 127 mg  DOTES/TWIS  2 
1998  Keller MB et al  us  76 weeks  169  Sertraline 200 mg, placebo  Unspecified  3 
1997  Kiev A et al  us  7 weeks  60  Fluvoxamine 50-150 mg, paroxetine 20-50 mg  Spontaneous reporting  4 
1987  Lapierre YD  Canada  6 weeks  63  Fluvoxamine 50-300 mg, imipramine 50-300 mg, placebo  DOTES/TWIS  3 
1988  Muijen M et al  UK  6 weeks  81  Fluoxetine 20-80 mg, mianserin 20-80 mg, placebo  Unspecified  3 
1991  Noguera R et al  Spain  6 weeks  120  Fluoxetine 20-40 mg, chlorimipramine 100 mg  Unspecified  3 
1984  Norton KRW et al  UK  4 weeks  91  Fluvoxamine 132.8 mg, imipramine 153.3 mg, placebo  DOTES/TWIS  3 
1989  Perry PJ et al  us  6 weeks  40  Fluoxetine 21-50 mg, trazodone 241-357 mg  Adverse events form  3 
1989  Rickels K et al  us  6 weeks  111  Paroxetine 10 mg, placebo  Recorded in open-ended fashion  3 
1990  Reimherr FW et al  us  8 weeks  448  Sertraline 104 mg, amitriptyline 145 mg, placebo  Unspecified  3 
1987  Young JPR et al  UK  6 weeks  64  Fluoxegne 40-8Q mg~mitriptyline 50-150 mg  Adverse events form  3 
- .,J::.. 
N Table 18  ACE inhibitor trials included in the meta-analysis 
Year  Author  Countr~  Duration  N  Drugs Included in the Stud~  Method of ADR Recording  Jadad Score 
1991  Beevers DG et al  UK  8 weeks  144  Lisinopril10-40 mg, atenolol50-100 mg, placebo  Open questioning  3 
1987  Bolzano K et al  Austria  12 weeks  490  Lisinopril20-80 mg, atenolol50-200 mg  Unspecified  3 
1994  Chrysant SG et al  us  12 weeks  505  LisinoprillO mg, HCTZ 12.5 mg, lisinoprillO  "Questioned"  2 
mg/HCTZ 12.5 mg, placebo 
1998  Cushman WC et al  us  12 weeks  891  Enalapril5 mg, diltiazem ER 120-180 mg, enalapril5  Indirect questions  3 
mg/diltiazem ER 120-180 mg, placebo 
1984  EHSG  UK  12 weeks  54  Enalapril5-20 mg, propranolol40-120 mg  Open questioning  2 
1990  Ferme I et al  France  4 weeks  96  Enalapril 20 mg, diltiazem SR 300 mg, enalapril 20  Unspecified  3 
mg/diltiazem SR 300 mg 
1994  Fernandez M et al  Mexico  8 weeks  67  Fosinopril 20 mg, HCTZ 12.5 mg, fosinopril 20  Spontaneous reporting  3 
mg/HCTZ 12.5 mg, placebo 
1995  Gradman AH et al  us  8 weeks  576  Enalapril20 mg, losartan 10-150 mg, placebo  Observed and reported  3 
1997  Gradman AH et al  us  8 weeks  707  Enalapril5-20 mg, felodipine 2.5-10 mg, enalapril5-20  Spontaneous reporting  2 
mg/felodipine 2.5-10 mg, placebo 
1990  Grunfeld J-P et al  France  8 weeks  186  Enalapril20 mg, spironolactone 15 mg/altizid 25 mg  Spontaneous reporting  3 
1993  Lacourcciere Y et al  Canada  8 weeks  43  Captopril25-50 mg, amlodipine 5-10 mg  Indirect questions  3 
1988  Mehta Jet al  us  12 weeks  26  Lisinopril 20-80 mg, lisinoprill 20-80 mgHCTZ 12.5- "Interviewed"  3 
50mg 
1998  Meserli F et al  us  6 weeks  631  Trandolapril 4 mg, verapamil SR 20 mg, trandolapril 4  Unspecified  3 
mg/verapamil SR 20 mg, placebo 
1992  Morgan  Australia  12 weeks  190  Perindopril 2 mg, atenolol 25 mg  Direct questioning and  2 
spontaneous reporting 
1987  Morlin C et al  Sweden  12 weeks  136  Lisinopril 20-80 mg, nifedipine 40-80 mg  Unspecified  3 
1991  Mroczek WJ et al  us  4 weeks  159  Enalapril5-20 mg, ramipril2.5-10 mg  "Questioned"  2 
1995  Nicaise J et al  Belgium  8 weeks  100  Captopril12.5-25 mg, diltiazem SR 200-300 mg  Observed and reported  3  - .j:::.. 
(.),) Table 18 (cont)  ACE inhibitor trials included in the meta-analysis 
--
Year  Author  Country  Duration  N  Drugs Included in the Study  _Method of ADR Recording 
1995  Prisant L et al  US  12 weeks  218  Enalapril5-20 mg, amlodipine 2.5-10 mg,  Spontaneous reporting 
bisoprolol2.5-10 mg/HCTZ 6.25 mg 
1996  Stimpel M et al  Germany  12 weeks  159  Captopril25 mg, moexipril 7.5 mg  Open questioning 
1995  Thijs Let al  Belgium  4 weeks  611  Ramipril 5 mg, piretanide 6 mg, ramipril 5  Spontaneous reporting 
mg/piretanied 6 mg 
1991  TOMHS  us  12 months  902  Enalapril 5 mg, acebutolol 400 mg, amlodipine 5  Checklist 
mg, chlorthalidone 15 mg, doxazosin 2 mg, placebo 
1991  Vasmant D et al  France  8 weeks  205  Ramipril 2.5-5 mg, placebo  Spontaneous reporting 
1991  V  erkaaik R et al  The Netherlands  8 weeks  44  Enalapril 20-40 mg, nitredipine 20-40 mg  Open questioning and 
spontaneous reporting 
1987  Zachariah PK et al  US  8 weeks  179  Lisinopril 40-80 mg, metoprolol 100-200 mg  Unspecified 
....... 
t 
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3 Table 19  Adverse drug reactions data extracted from NSAID trials 
Ibuprofen  Naproxen  Piroxicam  Sulindac 
(N= 560)  (N= 548)  (N= 138)  (N= 85) 
Weighted  Weighted  Weighted  Weighted 
N  N  %  N  N  %  N  N  %  N  N  % 
Abdominal Pain  36  24.02  4.29%  32  6.41  1.17%  14  4.90  3.55%  4  3.29  3.88% 
Anorexia  7  4.07  0.73%  3  0.29  0.05%  2  0.81  0.59%  2  1.65  1.94% 
Constipation  6  3.97  0.71%  34  6.37  1.16%  3  1.22  0.88%  8  4.65  5.47% 
Diarrhoea  9  4.94  0.88%  14  3.65  0.67%  5  1.77  1.28%  5  4.12  4.84% 
Peptic Ulcer  2  0.19  0.03% 
Dyspepsia  28  14.98  2.67%  30  4.10  0.75%  2  0.77  0.56%  3  1.18  1.38% 
Flatulence  0.09  0.02%  4  0.66  0.12% 
GI Haemorrhage 
Nausea/Vomiting  44  26.71  4.77%  45  9.64  1.76%  3  1.00  0.72%  6  4.29  5.05% 
Oral Ulcers  9  2.73  0.50%  3  1.00  0.72%  1  0.18  0.21% 
Fatigue  3  0.28  0.05%  2  0.24  0.04%  8  2.96  2.15%  2  1.65  1.94% 
Confusion 
Depression  6  3.25  0.58%  10  2.08  0.38%  0.82  0.97% 
DizzinessN  ertigo  16  11.14  1.99%  14  3.21  0.59%  4  1.21  0.88%  8  5.94  6.99% 
Drowsiness  0.06  O.Ql%  4  0.31  0.06%  2  0.42  0.30% 
Dry Mouth  0.21  0.15% 
Headache  28  10.69  1.91%  39  7.55  1.38%  0.41  0.29%  7  5.12  6.02% 
Nervousness 
!Irritability  5  3.22  0.58%  4  0.83  0.15% 
Sleep/Restlessness  0.06  0.01%  3  0.47  0.09% 
Nightmares 
Tinnitus  13  10.17  1.82%  17  3.01  0.55%  3  1.17  0.85%  2  1.65  1.94% 
Visual Disturbance  -
Flu-Like Symptoms  - 5  0.33  0.06%  2  0.62  0.45% 
Rash/Pruritis  30  19.23  3.43%  50  7.50  1.37%  8  2.99  2.16%  3  2.47  2.91% 
Oedema  2  0.19  0.03%  8  1.66  0.30%  10  3.04  2.20% 
Anaemia 
145 Table 19 (cont)  Adverse drug reactions data extracted from NSAID trials 
Fenoprofen  Ketoprofen  Indomethacin  Diclofenac 
(N= 57)  (N= 186)  (N = 395)  (N = 18) 
Weighted  Weighted  Weighted 
N  N  %  N  N  %  N  N  %  N  % 
Abdominal Pain  22  11.37  19.94%18  3.65  1.96%29  4.16  1.05%  -
Anorexia  - 2  0.31  0.17%  7  1.19  0.30%  -
Constipation  6  3.16  5.54%  4  0.97  0.52%  7  1.25  0.32%  -
Diarrhoea  - 6  2.03  1.09%16  3.64  0.92% 1  5.56% 
Peptic Ulcer 
Dyspepsia  -18  5.28  2.84%18  1.86  0.47%  -
Flatulence 
GI Haemorrhage  - - 1  0.05  0.01%  -
Nausea/Vomiting 11  5.53  9.70%17  4.13  2.22%51  6.79  1.72%3  16.67% 
Oral Ulcers  - 7  2.52  1.35%  5  0.93  0.24%  -
Fatigue  - 4  1.38  0.74%10  1.47  0.37%  -
Confusion  6  3.16  5.54%  -
Depression  - 6  2.04  1.10%  4  0.84  0.21%  -
DizzinessN  ertigo  6  3.16  5.54%  3  0.81  0.43%31  5.18  1.31%2  11.11% 
Drowsiness  6  3.16  0.29%  - - 3  0.17  0.04%  -
Dry Mouth  - 1  0.15  0.08%  1  0.08  0.02%  -
Headache  17  8.68  15.24%  8  1.27  0.68%62  10.93  2.77%2  11.11% 
Nervousness/ 
Irritability  6  3.16  5.54%  - - 1  0.29  0.07%  -
Sleep/Restlessness  - - 1  0.29  0.07%  -
Nightmares  - 1  0.05  0.01%  -
Tinnitus  26  13.26  23.27%  2  0.30  0.16%  8  1.67  0.42%  -
Visual 
Disturbance  12  6.32  11.08%  1  0.15  0.08%  -
Flu-Like 
Symptoms  - 3  0.35  0.09%  -
Rash!Pruritis  35  17.53  30.75%15  3.70  1.99%18  3.81  0.96%  -
Oedema  12  6.32  11.08%  - - 3  0.72  0.18%  -
Anaemia  - 1  0.08  0.02%  -
146 Table 20  Adverse drug reactions data extracted from SSRI trials 
Fluoxetine (N =  194)  Sertraline (N =  183) 
N  WeightedN  Weighted%  N  WeightedN  Weighted% 
CNS  Anxiety  27  8.60  4.43%  18  14.66  8.01% 
Blurred Vision  14  3.37  1.74%  16  13.03  7.12% 
Confusion  4  0.52  0.27% 
Depersonalized Syndrome 
Dizziness/Syncope  12  3.33  1.72%  26  18.66  10.19% 
Drowsiness  17  2.80  1.45%  29  23.61  12.90% 
Dry Mouth  16  4.31  2.22%  57  39.50  21.58% 
Dysmenorrhoea 
Fatigue  8  1.21  0.62%  13  10.58  5.78% 
Headache  23  4.98  2.57%  24  19.54  10.68% 
Insomnia  16  4.66  2.40%  26  21.17  11.57% 
Palpitation 
Paraesthesia 
Sweating  0.11  0.06%  11  8.96  4.89% 
Taste Perversion  4  3.26  1.78% 
Tinnitus 
Tremor  18  4.17  2.15%  24  19.54  10.68% 
GI 
Anorexia  6  4.89  2.67% 
Constipation  9  2.64  1.36%  21  14.58  7.97% 
Decreased Appetite  2  0.27  0.14% 
Diarrhoea  7  1.88  0.97%  35  28.50  15.57% 
Flatulence  0.11  0.06% 
Dyspepsia  0.11  0.06%  23  12.44  6.80% 
Nausea!V  omiting  52  13.87  7.15%  58  47.22  25.81% 
Weight Gain, Excessive  3  1.44  0.74% 
Weight Loss, Excessive  8  3.47  1.79% 
cv 
Hypotension  3  1.44  0.74% 
Tachycardia-Palpitations  7  3.36  1.73%  7  5.70  3.11% 
Vasodilation 
Skin 
Dermatites/  Allergy  19  4.48  2.31%  18  14.66  8.01% 
Flu Symptoms 
Flu-Like Symptoms  5  0.54  0.28% 
Urinary Problems 
Urinary Problems  4  1.92  0.99%  2  1.63  0.89% 
Sexual Problems 
Abnormal Ejaculation 
Decreased Libido  0.11  0.06%  32  26.05  14.24% 
lml!otence 
147 Table 20 (cont)  Adverse drug reactions data extracted from SSRI trials 
Fluvoxamine {N = 132)  Paroxetine (N- 270) 
N  WeightedN  Weighted%  N  WeightedN  Weighted% 
CNS 
Anxiety  31  8.74  6.62%  6  0.67  0.25% 
Blurred Vision  12  10.67  3.95% 
Confusion 
Depersonalized 
Syndrome  2  0.45  0.34%  4  0.44  0.16% 
Drowsiness  39  10.64  8.06%  82  63.56  23.54% 
Dry Mouth  43  10.82  8.20%  64  48.33  17.90% 
Dysmenorrhoea  2  0.71  0.54%  3  0.33  0.12% 
Headache  32  9.20  6.97%  12  1.33  0.49% 
Insomnia  23  5.26  3.98%  9  1.00  0.37% 
Palpitation  0.23  0.17%  4  0.44  0.16% 
Paraesthesia  12  10.67  3.95% 
Sweating  20  5.09  3.86%  29  23.44  8.68% 
Taste Perversion  5  4.44  1.65% 
Tinnitus  2  1.78  0.66% 
Tremor  22  5.52  4.18%  27  21.67  8.02% 
GI 
Anorexia  28  7.32  5.54% 
Constipation  19  5.30  4.01%  40  34.00  12.59% 
Decreased Appetite  19  16.89  6.26% 
Diarrhoea  26  7.25  5.49%  14  1.56  0.58% 
Flatulence  1  0.23  0.17%  4  0.44  0.16% 
Dyspepsia  9  2.69  2.04%  7  0.78  0.29% 
Nausea!V  omiting  54  13.77  10.43%  78  60.78  22.51% 
Weight Gain, Excessive 
Weight Loss, Excessive 
cv 
Hypotension 
Tachycardia-
Palpitations  9  8.00  2.96% 
Vasodilation  5  1.46  1.11%  5  4.44  1.65% 
Skin 
Dermatites/  Allergy  15  3.69  2.79%  2  0.22  0.08% 
Flu Symptoms 
Flu-Like Symptoms  20  7.12  5.39% 
Urinary Problems 
Urinary Problems  17  15.11  5.60% 
Sexual Problems 
Abnormal Ejaculation  5  1.39  1.06%  15  12.56  4.65% 
Decreased Libido  5  1.14  0.86%  14  9.33  3.46% 
lml!otence  3  0.68  0.52%  2  0.22  0.08% 
148 Table 21  Adverse drug reactions data extracted from ACE inhibitor trials 
Lisino~ril (N =  653)  Enala~ril (N =  699)  Trandola~ril (N =  159) 
Weighted  Weighted 
N  N  %  N  N  %  N  % 
CNS 
Asthenia/Fatigue  25  6.37  0.98%  18  2.13  0.30%  5  3.14% 
Ataxia  2  0.27  0.04% 
Depression  0.10  O.Ql% 
Dizziness/ 
Vertigo/Syncope  28  7.85  1.20%  21  2.58  0.37%  4  2.52% 
Dryness Of Mouth 
Headache  39  11.03  1.69%  41  4.81  0.69%  17  10.69% 
Insomnia  2  0.13  0.02% 
Nervousness 
Paresthesia  3  0.34  0.05%  0.13  0.02% 
Somnolence 
/Tiredness  2  0.36  0.06%  3  0.18  0.03% 
Ageusia/Taste Impairment  0.13  0.02% 
Tinnitus 
Visual Disturbance  0.02  0.00% 
GI 
Abdominal Pain  5  3.14% 
Anorexia  0.13  0.02% 
Constipation  0.04  O.Ql%  0.63% 
Diarrhoea  6  0.91  0.14%  6  0.68  0.10%  5  3.14% 
Dyspepsia  2  0.20  0.03% 
Nausea & Vomiting  9  3.43  0.52%  8  0.79  0.11%  5  3.14% 
cv 
Oedema  0.14  0.02%  13  1.96  0.28%  4  2.52% 
Palpitations 
/Breathlessness  12  1.00  0.14% 
Postural Hypotension  8  0.98  0.14% 
Flu Symptom  36  36  4.84  0.69%  25  15.72% 
Skin Rash  9  2.67  0.41%  5  0.31  0.04%  5  3.14% 
Im,eotence  3  0.19  0.03% 
149 Table 21 (cont)  Adverse drug reactions data extracted from ACE inhibitor trials 
Ramipril  Captopril  Moexipril  Perindapril 
(N=397)  (N = 104)  (N= 105)  (N= 94) 
Weighted  Weighted 
N  N  %  N  N  %  N  %  N  % 
CNS 
Asthenia/Fatigue  5  1.15  0.29%  7  3.63  3.49%  11  10.48%  24  25.53% 
Ataxia 
Depression  4  2.11  0.53%  0.48  0.46% 
Dizziness/ 
Vertigo/Syncope  17  7.79  1.96%  8  4.12  3.96%  8  7.62%  25  26.60% 
Dryness Of 
Mouth  16  17.02% 
Headache  20  8.98  2.26%  10  5.12  4.92%  13  12.38%  24  25.53% 
Insomnia  6  3.16  0.80%  0.48  0.46%  27  28.72% 
Nervousness  3  1.56  1.50%  4  3.81% 
Paresthesia 
Somnolence 
/Tiredness  9  4.74  1.19%  3  1.56  1.50%  0.95% 
Ageusia/Taste 
ImpairmEnt  0.48  0.46% 
Tinnitus  1  0.48  0.46%  8  8.51% 
Visual 
Disturbance 
GI 
Abdominal Pain  2  0.54  0.14% 
Anorexia 
Constipation 
Diarrhoea  0.27  0.07%  6  5.71%  14  14.89% 
Dyspepsia 
Nausea & 
Vomiting  4  1.85  0.47%  20  21.28% 
cv 
Oedema  5  2.56  2.46%  12  11.43% 
Palpitations/ 
Breathlessness  4  2.11  0.53%  3  1.56  1.50%  2  1.90% 
Postural 
Hypotension  16  17.02% 
Flu Symptom  11  5.79  1.46%  17  8.75  8.41% 
Skin Rash  0.48  0.46%  14  14.89% 
lm}!otence  7  3.69  0.93%  3  3.19% 
150 Table 22  Drug costs 
Defined Dail~ Dose (DDD)  Cost 
Minimum  Maximum  MinimumDDD  MaximumDDD 
NSAIDs 
Ibuprofen  1200 mg  2400mg  £5.58  £11.17 
Naproxen  500mg  1000 mg  £7.85  £15.10 
Piroxicam  10mg  30mg  £3.54  £11.44 
Sulindac  200mg  400mg  £18.63  £32.50 
Fenoprofen (Fenopron ®)  900mg  2400mg  £19.85  £51.21 
Ketoprofen  lOOmg  200mg  £22.45  £22.12 
Indomethacin  50mg  200mg  £3.57  £5.60 
Diclofenac Sodium  75mg  150mg  £5.85  £9.28 
SSRis 
Fluoxetine  20mg  60mg  £18.01  £54.04 
Sertraline (Lustral®)  50mg  200mg  £40.50  £132.55 
Fluvoxamine  100mg  300mg  £38.71  £116.13 
Paroxetine (Seroxat ®)  20mg  50mg  £41.44  £125.81 
ACE Inhibitors 
Captopril  25mg  100mg  £5.75  £10.51 
Cilazapril (Vascace ®)  1 mg  5mg  £16.15  £35.70 
Enalapril Maleate  5mg  40mg  £9.40  £30.60 
Fosinopril (Staril ®)  10mg  40mg  £30.10  £65.00 
Imidapril Hydrochloride (Tanatril ®)  5mg  20mg  £14.13  £19.18 
Lisinopril (Zestril ®)  2.5 mg  40mg  £15.65  £54.85 
Moexipril (Perdix ®)  7.5mg  30mg  £20.30  £70.20 
Perindopril (Coversyl ®)  2mg  8mg  £24.06  £69.49 
Quinapril (Accupro ®)  lOmg  80mg  £17.93  £48.75 
Ramipril (Tritace ®)  1.25 mg  lOmg  £13.25  £32.50 
Trandolapril ®)  0.5mg  4mg  £20.45  £61.40 
>--' 
VI 
>--' Table 23  Calculated cost of managing clinical adverse events 
Adverse Drug Events  Cost(£) 
Dyspepsia  £  30.89 
Suspected peptic ulcer  £  33.02 
Abdominal pain  £  21.88 
Nausea and vomiting  £  33.55 
Constipation  £  22.22 
Diarrhoea  £  17.24 
Peptic ulcers  £ 308.41 
Rash or Pruritis  £  20.24 
Insomnia  £  18.14 
Other CNS symptoms  £  8.50 
Oedema  £  23.74 
Anaemia  £  91.87 
152 - VI 
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Table 24 
Abdominal Pain 
Anorexia 
Constipation 
Diarrhoea 
Peptic Ulcer 
Dyspepsia 
Flatulence 
NauseaN  omiting 
Oral Ulcers 
Fatigue 
Confusion 
Depression 
Dizziness!V  ertigo 
Drowsiness 
Dry Mouth 
Headache 
Nervousness/ 
Irritability 
lnsonmia 
Tinnitus 
Visual Disturbance 
Flu-Like Symptoms 
Rash!Pruritis 
Oedema 
Anaemia 
Cost 
£21.88 
£8.50 
£22.22 
£17.24 
£308.41 
£30.89 
£8.50 
£33.55 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£18.14 
£8.50 
£8.50 
£8.50 
£20.24 
£23.74 
£91.87 
The cost of managing adverse drug reactions in NSAID therapies 
Fenoprofen !N =  57) 
Weighted 
Diclofenac !N = 18)  Sulindac !N - 85l  Ibuprofen !N - 560)  Ketoprofen !N - 186)  Piroxicam !N = 138)  Naproxen !N =  548)  Indomethacin !N =  395l 
%  Cost  %  Cost  Weighted %  Cost  Weighted %  Cost  Weigllted %  Cost  Weighted %  Cost  Weighted %  Cost  Weighted %  Cost 
19.94% 
5.54% 
9.70% 
5.54% 
5.54% 
0.29% 
15.24% 
5.54% 
23.27% 
11.08% 
30.75% 
11.08% 
£4.36 
£1.23 
£3.25 
£0.47 
£0.47 
£0.02 
£1.30 
£0.47 
£1.98 
£0.94 
£6.22 
£2.63 
5.56%  £0.96 
16.67%  £5.59 
11.11%  £0.94 
11.11%  £0.94 
3.88% 
1.94% 
5.47% 
4.84% 
1.38% 
5.05% 
0.21% 
1.94% 
0.97% 
6.99% 
6.02% 
1.94% 
2.91% 
£0.85 
£0.16 
£1.21 
£0.84 
£0.43 
£1.69 
£0.02 
£0.16 
£0.08 
£0.59 
£0.51 
£0.16 
£0.59 
4.29% 
0.73% 
0.71% 
0.88% 
0.03% 
2.67% 
0.02% 
4.77% 
0.05% 
0.58% 
1.99% 
0.01% 
1.91% 
0.58% 
0.01% 
1.82% 
3.43% 
0.03% 
£0.94 
£0.06 
£0.16 
£0.15 
£0.10 
£0.83 
£0.00 
£1.60 
£0.00 
£0.05 
£0.17 
£0.00 
£0.16 
£0.05 
£0.00 
£0.15 
£0.70 
£0.01 
1.96% 
0.17% 
0.52% 
1.09% 
2.84% 
2.22% 
1.35% 
0.74% 
1.10% 
0.43% 
0.08% 
0.68% 
0.16% 
0.08% 
1.99% 
£0.43 
£0.01 
£0.12 
£0.19 
£0.88 
£0.74 
£0.11 
£0.06 
£0.Q9 
£0.04 
£0.01 
£0.06 
£0.01 
£0.Ql 
£0.40 
3.55% 
0.59% 
0.88% 
1.28% 
0.56% 
0.72% 
0.72% 
2.15% 
0.88% 
0.30% 
0.15% 
0.29% 
0.85% 
0.45% 
2.16% 
2.20% 
£0.78 
£0.05 
£0.20 
£0.22 
£0.17 
£0.24 
£0.06 
£0.18 
£0.07 
£0.03 
£0.01 
£0.02 
£0.07 
£0.04 
£0.44 
£0.52 
1.17% 
0.05% 
1.16% 
0.67% 
0.75% 
0.12% 
1.76% 
0.50% 
O.Q4% 
0.38% 
0.59% 
0.06% 
1.38% 
0.15% 
O.Q9% 
0.55% 
0.06% 
1.37% 
0.30% 
£0.26 
£0.00 
£0.26 
£0.11 
£0.23 
£0.01 
£0.59 
£0.04 
£0.00 
£0.03 
£0.05 
£0.00 
£0.12 
£0.01 
£0.02 
£0.05 
£0.01 
£0.28 
£0.07 
1.05% 
0.30% 
0.32% 
0.92% 
0.47% 
1.72% 
0.24% 
0.37% 
0.21% 
1.31% 
0.04% 
0.02% 
2.77% 
0.07% 
0.08% 
0.42% 
0.09% 
0.96% 
0.18% 
0.02% 
£0.23 
£0.03 
£0.07 
£0.16 
£0.15 
£0.58 
£0.02 
£0.03 
£0.02 
£0.11 
£0.00 
£0.00 
£0.24 
£0.01 
£0.02 
£0.04 
£0.01 
£0.20 
£0.04 
£0.02 >-' 
Ul 
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Table 25 
CNS 
GI 
cv 
Skiu 
Flu Symptoms 
Urinary Problems 
Sexual Problems 
The cost of managing adverse drug reactions in SSRI therapies 
Sertraline {N- 183  Paroxetine {N =  270) 
Unit Costs  Weighted%  Cost  Weighted% 
Anxiety  £8.50  8.01%  £0.68  0.25% 
Blurred Vision  £8.50  7.12%  £0.61  3.95% 
Confusion  £8.50 
Depersonalized Syndrome  £8.50  0.16% 
Dizziness/Syncope  £8.50  10.19%  £0.87  14.40% 
Drowsiness  £8.50  12.90%  £1.10  23.54% 
Dry Mouth  £8.50  21.58%  £1.83  17.90% 
Dysmenorrhoea  £8.50  0.12% 
Fatigue  £8.50  5.78%  £0.49  15.43% 
Headache  £8.50  10.68%  £0.91  0.49% 
Insomnia  £18.14  11.57%  £2.10  0.37% 
Palpitation  £8.50  0.16% 
Paraesthesia  £8.50  3.95% 
Sweating  £8.50  4.89%  £0.42  8.68% 
Taste Perversion  £8.50  1.78%  £0.15  1.65% 
Tinnitus  £8.50  0.66% 
Tremor  £8.50  10.68%  £0.91  8.02% 
Anorexia  £8.50  2.67%  £0.23  6.26% 
Constipation  £22.22  7.97%  £1.77  12.59% 
Diarrltoea  £17.24  15.57%  £2.68  0.58% 
Flatulence  £8.50  0.16% 
Dyspepsia  £30.89  6.80%  £2.10  0.29% 
Nausea/Vomiting  £33.55  25.81%  £8.66  22.51% 
'Veight Gain, Excessive  £17.00 
'Veight Loss, Excessive  £17.00 
Hypotension  £8.50 
Tachycardia-Palpitations  £8.50  3.11%  £0.26  2.96% 
Vasodilation  £8.50  1.65% 
Dennatites/  Allergy  £20.24  8.01%  £1.62  0.08% 
Flu-Like Symptoms  £8.50 
Urinary Problems  £8.50  0.89%  £0.08  5.60% 
Abnonnal Ejaculation  £17.00  4.65% 
Decreased Libido  £17.00  14.24%  £2.42  3.46% 
Impotence  £17.00  0.08% 
Fluvoxamine {N -JJ2l  Fluoxetine {N-124l 
Cost  Weighted%  Cost  Weighted%  Cost 
£0.02  6.62%  £0.56  4.43%  £0.38 
£0.34  1.74%  £0.15 
0.27%  £0.02 
£0.Ql  0.34%  £0.Q3 
£1.22  4.19%  £0.36  1.72%  £0.15 
£2.00  8.06%  £0.69  1.45%  £0.12 
£1.52  8.20%  £0.70  2.22%  £0.19 
£0.01  0.54%  £0.05 
£1.31  1.50%  £0.13  0.62%  £0.05 
£0.04  6.97%  £0.59  2.57%  £0.22 
£0.Q7  3.98%  £0.72  2.40%  £0.44 
£0.Ql  0.17%  £0.01 
£0.34 
£0.74  3.86%  £0.33  0.06%  £0.00 
£0.14 
£0.06 
£0.68  4.18%  £0.36  2.15%  £0.18 
£0.53  5.54%  £0.47  0.14%  £0.Ql 
£2.80  4.01%  £0.89  1.36%  £0.30 
£0.10  5.49%  £0.95  0.97%  £0.17 
£0.01  0.17%  £0.Ql  0.06%  £0.00 
£0.Q9  2.04%  £0.63  0.06%  £0.02 
£7.55  10.43%  £3.50  7.15%  £2.40 
0.74%  £0.13 
1.79%  £0.30 
0.74%  £0.06 
£0.25  1.73%  £0.15 
£0.14  1.11%  £0.09 
£0.02  2.79%  £0.57  2.31%  £0.47 
5.39%  £0.46  0.28%  £0.02 
£0.48  0.99%  £0.08 
£0.79  1.06%  £0.18 
£0.59  0.86%  £0.15  0.06%  £0.01 
£0.Ql  0.52%  £0.09 - VI 
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Table 26 
CNS 
Asthenia/Fatigue 
Ataxia 
Depression 
Dizziness/Vertigo/Syncope 
Dryness Of Mouth 
Headache 
Insomnia 
Nervousness 
Paresthesia 
Somnolence/Tiredness 
Ageusia/Taste Impairmnt 
Tinnitus 
Visual Disturbance 
GI 
Abdominal Pain 
Anorexia 
Constipation 
Diarrhoea 
Dyspepsia 
Nausea & Vomiting 
cv 
Oedema 
Palpitations/Breathlessness 
Postural Hypotension 
Flu Symptom 
Skin Rash 
Impotence 
Cost per Patient 
Cost per 1 000 Patients 
The cost of managing adverse drug reactions in ACE inhibitor therapies 
PerindaJlril (N =  94l  Moexiuril (N - 105l  Trando!auril ili =  159l  Cautouril (N - 104l 
Unit Cost  %  Cost  %  Cost  %  Cost  Weighted%  Cost 
£8.50  25.53%  £2.17  10.48%  £0.89  3.14%  £0.27  3.49%  £0.30 
£8.50 
£8.50  0.46%  £0.04 
£8.50  26.60%  £2.26  7.62%  £0.65  2.52%  £0.21  3.96%  £0.34 
£8.50  17.02%  £1.45 
£8.50  25.53%  £2.17  12.38%  £1.05  10.69%  £0.91  4.92%  £0.42 
£18.14  28.72%  £5.21  0.46%  £0.08 
£8.50  3.81%  £0.32  1.50%  £0.13 
£8.50 
£8.50  0.95%  £0.08  1.50%  £0.13 
£8.50  0.46%  £0.04 
£8.50  8.51%  £0.72  0.46%  £0.04 
£8.50 
£21.88  3.14%  £0.69 
£8.50 
£22.22  0.63%  £0.14 
£17.24  14.89%  £2.57  5.71%  £0.99  3.14%  £0.54 
£30.89 
£33.55  21.28%  £7.14  3.14%  £1.06 
£23.74  11.43%  £2.71  2.52%  £0.60  2.46%  £0.58 
£8.50  1.90%  £0.16  1.50%  £0.13 
£8.50  17.02%  £1.45 
£8.50  15.72%  £1.34  8.41%  £0.72 
£20.24  14.89%  £3.01  3.14%  £0.64  0.46%  £0.09 
£17.00  3.19%  £0.54 
£28.69  £6.86  £6.39  £3.03 
£28,691.49  £6,855.43  £6,385.09  £3,027.72 
Ramiuril ili =  ~97l  Lisinouril (N - 653l  Enalauril (N =  699l 
Weighted%  Cost  Weighted%  Cost  Weighted%  Cost 
0.29%  £0.02  0.98%  £0.08  0.30%  £0.03 
0.04%  £0.00 
0.53%  £0.05  0.01%  £0.00 
1.96%  £0.17  1.20%  £0.10  0.37%  £0.03 
2.26%  £0.19  1.69%  £0.14  0.69%  £0.06 
0.80%  £0.14  0.02%  £0.00 
0.05%  £0.00  0.02%  £0.00 
1.19%  £0.10  0.06%  £0.00  0.03%  £0.00 
0.02%  £0.00 
0.00%  £0.00 
0.14%  £0.03 
0.02%  £0.00 
0.01%  £0.00 
0.07%  £0.01  0.14%  £0.02  0.10%  £0.02 
0.03%  £0,0) 
0.47%  £0.16  0.52%  £0.18  0.11%  £0.04 
0.02%  £0.00  0.28%  £0,07 
0.53%  £0.05  0.14%  £0.01 
0.14%  £0,0) 
1.46%  £0.12  0.69%  £0.06 
0.41%  £0.08  0.04%  £0.01 
0.93%  £0.16  0.03%  £0.00 
£1.20  £0.63  £0.36 
£1,199.17  £625.58  £357.35 Table 27  Total costs of the three drug therapies 
Original  Final 
MinimumDDD  Drug Costs  Shadow Costs  Total Costs  Ranking_  Ranking_ 
NSAIDs 
Ibuprofen  £5.58  £5,580.00  £5,133.63  £10,713.63  3  4 
Naproxen  £7.85  £7,850.00  £2,144.27  £9,994.27  5  3 
Piroxicam  £3.54  £3,540.00  £3,111.58  £6,651.58  1  2 
Sulindac  £18.63  £18,630.00  £7,308.74  £25,938.74  6  7 
Fenoprofen (Fenopron ®)  £19.85  £19,850.00  £23,353.56  £43,203.56  7  8 
Ketoprofen  £22.45  £22,450.00  £3,164.71  £25,614.71  8  6 
Indomethacin  £3.57  £3,570.00  £1,949.73  £5,519.73  2  1 
Diclofenac Sodium  £5.85  £5,850.00  £8,438.23  £14,288.23  4  5 
SSRis 
Fluoxetine  £18.01  £18,010.00  £6,026.56  £24,036.56  1  1 
Sertraline (Lustral®)  £40.50  £40,500.00  £29,878.45  £70,378.45  3  4 
Fluvoxamine  £38.71  £38,710.00  £12,500.68  £51,210.68  2  2 
Paroxetine (Seroxat ®)  £41.44  £41,440.00  £21,875.31  £63,315.31  4  3 
ACE Inhibitors 
Captopril  £5.75  £5,750.00  £3,027.72  £8,777.72  1  1 
Enalapril Maleate  £9.40  £9,400.00  £357.35  £9,757.35  2  2 
Lisinopril (Zestril ®)  £15.65  £15,650.00  £625.58  £16,275.58  4  4 
Moexipril (Perdix ®)  £20.30  £20,300.00  £6,855.43  £27,155.43  5  6 
Perindopril (Coversyl ®)  £24.06  £24,060.00  £28,691.49  £52,751.49  7  7 
Ramipril (Tritace ®)  £13.25  £13,250.00  £1,199.17  £14,449.17  3  3 
......  Trandolapril ®)  £20.45  £20,450.00  £6,385.09  £26,835.09  6  5  Vl 
0'1 Table 28  National prescribing trends (Scotland) 
No of Items Prescribed 
2001  2002  Difference in Prescribing 
NSAIDs 
Ibuprofen  603 438  576 681  -4.43% 
Naproxen  174 258  156 350  -10.28% 
Piroxicam  37 578  37 809  0.61% 
Sulindac  3743  3216  -14.08% 
Fenoprofen  1048  860  -17.94% 
Ketoprofen  18 593  9274  -50.12% 
Indomethacin  58 550  51  389  -12.23% 
Diclofenac  639 938  626 941  -2.03% 
SSRis 
Fluoxetine  463 076  500 390  8.06% 
Sertraline  195 388  210 468  7.72% 
Fluvoxamine  4073  3596  -11.71% 
Paroxetine  456 232  468 847  2.77% 
ACE Inhibitors 
Captopril  105 781  89 992  -15.78% 
Enalapril  387 311  388 295  0.25% 
Lisinopril  543 257  599 070  10.27% 
Moexipril  131  73  -44.27% 
Perindopril  113 748  135 479  19.12% 
Ramipril  219 472  369630  68.42% 
Trandolaeril  18 025  17 381  -3.57% 
157 Table 29  Study prescribing trends over six months 
Study Group Prescribing  Control Group Prescribing 
(n=5 GPs)  (n=33 GPs)  P values 
NSAIDs 
Ibuprofen  -2.48%  -3.96%  0.55 
Naproxen  -3.51%  -9.59%  0.08 
Piroxicam  -2.90%  -2.97%  0.98 
Sulindac  -31.58%  -27.78%  0.56 
Fenoprofen  Not Prescribed  Not Prescribed  N/A 
Ketoprofen  -17.23%  -29.01%  *0.05 
Indomethacin  -2.63%  -8.51%  0.07 
Diclofenac  1.02%  -5.27%  0.08 
SSRis 
Fluoxetine  9.78%  9.62%  0.97 
Sertraline  10.85%  13.61%  0.96 
Fluvoxamine  -20.31%  -28.92%  0.92 
Paroxetine  5.48%  7.34%  0.59 
ACE Inhibitors 
Captopril  -18.17%  -29.4%  0.06 
Enalapril  4.65%  0.44%  0.06 
Lisinopril  8.58%  10.47%  0.65 
Moexipril  Not Prescribed  Not Prescribed  N/A 
Perindopril  10.45%  17.00%  0.12% 
Ramipril  5.3%  2.25%  0.26 
Trandolapril  -8.79%  -0.12%  *0.00 
*statistical significance 
158 Table 30  Survey response rates (number returned/number sent) 
Email 
Postal 
Total 
Questionnaire(!) 
6/13 (46%) 
9/17 (53%) 
15/30 (50%) 
Questionnaire (II) 
4/15 (27%) 
8/16 (50%) 
12/31 (39%) 
Total 
10/28 (36%) 
17/33 (51%) 
Table 31  Economic information influencing decision-making 
Published Information 
Local Health Board/PCG/PP  As/MP  As 
Articles in Journals 
Industry Literature 
Others 
Verbally Presented Information 
Meetings with Representatives from Local Health Board/PCG/PP  As/MP  As 
Conferences and Seminars 
Pharmaceutical Industry Representatives 
Others 
Missing Data n=O 
'Yes'  N (%) 
12 (80%) 
3 (20%) 
5 (33%) 
2 (13%) 
6 (40%) 
2 (13%) 
5 (33%) 
2 (13%) 
159 Table 32  Sources of economic information used (numbers found the material 
relevant) 
Yes  No  (Sometimes)  Don't Know  Missing 
SPA Prescribing Feedback  10 (8)  2 (0)  (2) 
Industry Literature  9 (2)  2 (2)  (4) 
MP  As and PPAs  7 (5)  3 (0)  (2) 
British Medical Journal  6 (4)  5 (0)  (2) 
Industry Representatives  6 (1)  5 (2)  (2) 
GP  ASS Feedback  4 (2)  8 (0)  (2) 
Local Newsletter  *  3 (3)  8 (1)  (1) 
Other Journals  ** 3 (2)  3 (0)  (2) 
British Journal of General Practice  2 (1)  8 (0)  (2) 
Local Prescribing Formulary  2 (1)  8 (0)  (1) 
*Newsletters generated from the Local Healthcare Co-operatives, Glasgow Prescriber 
**Prescriber, Journal of  Health Economics, Bandolier, Durgs & Therapeutics Bulletin 
Table 33  Preferred methods of presenting economic data 
Locally specific evaluations and studies 
Summary of  evaluations and studies published in leaflet format 
Evaluations and studies published in literature 
Simple recommendations presented in leaflet format 
Summary of evaluations and studies presented verbally at a meeting 
Simple recommendations presented verbally at a meeting 
Missing Data n=l 
0 (0) 
1 (2) 
2 (1) 
0 (0) 
1 (2) 
0 (1) 
0 (1) 
0 (0) 
0 (0) 
1 (2) 
N(%) 
6 (54%) 
6 (54%) 
5 (45%) 
5 (45%) 
3 (27%) 
1 ( 9%) 
0 (2) 
0 (2) 
0 (4) 
1 (6) 
0 (5) 
0 (7) 
1 (6) 
6 (8) 
2 (9) 
1 (8) 
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Figure 1  The annual percentage increase in expenditure for NHS as a whole and community prescribing, compared with hospital and community 
health services pay and price inflation 
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Figure 2  The increase of prescribing volume and cost over time (1994 to 2000) 
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Figure 3  Study population from the Medicines Monitoring Unit (MEMO) database 
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Figure 4  The population study - study cohot1 (not drawn to scale) 
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N = 400 000 
Comparator Group 
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N = 49212 
NSAID & Ulcer 
Healing Drugs 
N =  2113 
Study population 
N = 98 887 
• All living individuals residing in the Tayside health board area during the period: 1 January 89 to 31 December 93. 
•Registered with a GP. 
•Individuals less than 50 years old on 1 Jan 89 were excluded  . ....... 
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Figure 5  Cost composition of  the population study 
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Figure 6a  The contribution of drug prescriptions and GP consultation costs (example for 45 days and for six months) 
dayO  45 days 
Rxl EJ  Rx2 Rx3 
GP~v 
GP3 
0 
GP4 
Rx 1 = First prescription recorded at inception 
Rx 2 = Last prescription recorded during the 45-day period 
Rx 3 = First prescription recorded at the onset of the 45 days to 6 months period 
Rx 4 = Last prescription recorded at the 45 days to 6 months period 
COSTS OF DRUG PRESCRIPTIONS 
Cost of all prescriptions at 45 days: 
Rx 1 + Rx 2 + 112(Rx 1 + Rx 2) x N1 
Cost of all prescriptions at 6 months: 
Rx 1 + Rx 2 + 1/2(Rx 1 + Rx 2) x N1 + Rx 3 + Rx 4 + 1/2(Rx 3 + Rx 4) x N2 
COSTS OF GP CONSULTATIONS 
Based on the assumption that prescription switches have taken place: 
At 45 days, total cost of GP consultations = £7.56 x 2 
At 6 months, total cost of GP consultations = £7.56 x 4 
6 months 
Rx4 
N1 =number of additional prescriptions recorded from 0 to 45 days 
N2 =  number of additional prescriptions recorded from 45 days to 6 months 
GP 1-4 =visits to GPs (for change in prescriptions) 
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Figure 6b  The contribution of endoscopy and hospital admission costs and costs to total cost (example for 45 days and for six months) 
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E1 =number of endoscopies recorded at 45 days 
E2 
LOS2 
E2 = number of endoscopies recorded at 45 days to six months 
LOS 1 = length of stay of the longest admission at 45 days 
LOS 2 = length of stay of the longest admission from 45 days to six months 
COSTS OF GASTROINTESTINAL ENDOSCOPIES 
Cost of all endoscopies at 45 days: £208.33 x E1 
Cost of all endoscopies at six months: £208.33 x (E1 + E2) 
COSTS OF HOSPITAL ADMISSIONS 
Cost of hospital admissions at 45 days: 
6months 
N (admit) 1 =number of other admissions at 45 days 
N (admit) 2 =number of other admissions from 45 days to six months 
(LOS 1 x specialty cost+ 2 x GP visits+ 1 x outpatient visit)+ [1: length of stay of additional admissions x specialty cost+ 2 x N (admit) 1 x GP visits+ N (admit) 1 x outpatient visits] 
Cost of hospital admissions at six months: 
(LOS  1 x specialty cost+ 2 x GP visits+ 1 x outpatient visit)+ [1: length of stay of additional admissions x specialty cost+ 2 x N (admit) 1 x GP visits+ N (admit) 1 x outpatient visits] 
+ 
(LOS 2 x specialty cost+ 2 x GP visits+ 1 x outpatient visit)+ [1: length of stay of additional admissions x specialty cost+ 2 x N (admit) 2 x GP visits+ N (admit) 2 x outpatient visits] 
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Figure 7  Trend of  gastrointestinal endoscopies recorded by the three study periods 
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Figure 8  Composition of  total costs for the 45-day follow-up period 
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0 GP Visits (Rx) Figure 9  Composition of  total costs for the six-month follow-up period 
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Figure 10  Composition of  total costs for the 12-month follow-up period 
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....  x:  . Figure 15  Studies selected for meta-analysis 
Potentially relevant randomised 
controlled trials identified and 
screened for retrieval, excluding 
hand searches. 
•  NSAIDs (n =  3132) 
•  SSRis (n = 1660) 
•  ACE inhibitors (n = 4508) 
Trials excluded: reviews, pilot 
studies, co-morbidities, drugs 
indicated for other reasons or 
generally did not fulfil inclusion 
criteria. 
1
----------1~~  •  NSAIDs (n = 2861) 
•  SSRis (n =  1270) 
Trials retrieved for more detailed  •  ACE inhibitors (n =  4273) 
evaluation 
•  NSAIDs (n 271) 
•  SSRis (n =  390)  Trials excluded: either not 
•  ACE inhibitors (n =  235)  randomised clearly or did not fulfil 
inclusion criteria 
..  •  NSAIDs (n =  66) 
r 
1lr  •  SSRis (n =  65) 
Potentially appropriate trials to be  •  ACE inhibitors (n =  115) 
included in meta-analysis 
•  NSAIDs (n =  205) 
•  SSRis (n =  325) 
•  ACE inhibitors (n =  120)  Trials not included in meta-
analysis: clinical heterogeneity, 
insufficient reporting of primary 
..  data  r 
'lr 
Trials included in meta-analysis  •  NSAIDs (n =  181) 
•  SSRis (n =  304) 
•  NSAIDs (n =  24)  •  ACE inhibitors (n =  96) 
•  SSRis (n =  21) 
•  ACE inhibitors (n =  24) 
176 Figure 16a  The Management of Adverse Events 
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177 Figure 16b  The Management of Adverse Events 
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UHDs - ulcer healing drugs; OP- outpatient visits, FOB -fecal occult blood Figure 16c  The Management of Adverse Events 
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179 Figure 16d  The Management of Adverse Events 
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Figure 17  Sensitivity Analysis- NSAID Study 
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Sensitivity Analysis-ACE Inhibitor Study 
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184 Cost Containment Strategies 
The  need  to  control  escalating  NHS  prescribing  expenditure  has  long  been  recognised 
(Figure  20).  Early evidence  dated back to  1911,  when  prescribing  policies  included a 
national formulary,  a list of prescribable products, the use of regional medical officers to 
visit high cost prescribers, and an incentive scheme designed to encourage GPs to  control 
their prescribing costs.  The latter scheme was called the "floating sixpence" which offered 
a financial reward to GPs who spent less than the allocated budget per patient.  This scheme 
was  abolished in  1920 because it was  felt  that patients  were  not getting the  drugs  they 
needed 
222
• 
Prescription charges were  first imposed by  the  government in 1951  when they  used the 
legislation to bring in a one-shilling (five pence) charge per prescription.  The charges have 
remained (except between 1965 and 1968) and risen progressively since 1979, from £0.45 
to the present value of £6.20 per item.  However, approximately five out of six prescriptions 
are exempt from charges under the exemption scheme.  Of all the items prescribed, almost 
half were issued to those over 60 years old (one of the categories eligible for exemption). 
Between the years 1969 and 1992, there was a 3.2% fall in paid-for prescriptions following 
a 10% increase in the charge.  The 1992 increase in the charge from £3.75 to £4.25 brought 
in  £17.3  million of extra revenue  and cut the  55  million prescriptions not exempt from 
charge by 2.3  million.  Although, the increases in prescription charge seemed to  have an 
impact on the consumption of prescribed drugs, there is concern about the adverse effect on 
compliance for  some patients requiring chronic  treatment.  If those  deterred from  using 
prescription  drugs  ended up  being treated for  more  serious  conditions,  the  cost of that 
treatment could erode the savings 
223
•  Other strategies on unit cost reduction such as retail 
networks  and  manufacturer contracting  were  introduced in  the  1970s.  However,  these 
schemes were designed solely to reduce drug acquisition costs. 
Over the years the government introduced several initiatives to improve prescribing.  At a 
national level, strategies included educational publications, improving prescribing data and 
prescribing advice to GPs.  Locally, Health Boards began to introduce measures to control 
the growth of local drug costs, in an attempt to promote rational prescribing.  Prescribing 
advisers were employed to do this, this is discussed later. 
185 Drug Formularies 
Drug formularies  introduced in  the  1980s formed  the  cornerstone of strategies  aimed at 
influencing the range of pharmaceutical preparations available for prescription.  They were 
originally designed to control the introduction of new therapies in hospitals.  Subsequently, 
this  concept has  been developed in primary  care  by  using practice-based formularies  to 
promote rational and quality prescribing, and to limit costs.  These vary from a simple list 
of pharmaceuticals with no prescribing information to a comprehensive prescribing guide 
which is usually agreed through the local Drugs and Therapeutics Committees.  In 1985, the 
government introduced the  'selected list', which barred GPs from prescribing certain drugs 
in their proprietary state.  However, this measure has had little impact on cost and, in some 
instances  was  counter-productive  as  relatively  cheap proprietary products  were  replaced 
with more expensive alternatives 
5
•  However, a recent review 
224 concluded that acquisition 
cost was the prime influencer of formulary decisions, rather than overall benefits and costs 
in  healthcare.  By  1990  the  Department  of Health  recommended  development  and 
ownership, and voluntary implementation of local practice formularies. 
Although it has been possible to demonstrate that formularies have an impact on prescribing 
habits,  it is  very  difficult to  extrapolate  this  into real  savings because of the  number of 
influencing variables, particularly the increase in numbers of patients treated.  There is little 
evidence to show whether formularies reduced cost, improved care or both.  A recent search 
to locate systematic reviews, reviews, or randomised trials looking at the effect of formulary 
restriction on benefits and costs, was rather fruitless 
225
•  One open-label, randomised trial 
of two  formulary  systems  was  found 
226
•  Prescribers  were  randomised  into  either  a 
restricted thyroxine dose  (five  doses)  formulary  or an  unrestricted one  where more  dose 
strengths (ten doses) were available.  Treatment efficacy was assessed by thyroid function 
tests,  prescriptions  were  analysed  and  their  cost calculated.  The  study  concluded  that 
simplifying the doses of thyroxine available to prescribers did not adversely affect patients 
or increase costs.  In another study, Avery AJ et al demonstrated the effect of a formulary to 
produce positive changes  in  prescribing towards  greater compliance  over time 
227
•  Ten 
practices in Lincolnshire developed a formulary for NSAIDs, to help GPs to prescribe from 
a narrower range of drugs.  Prescribing analyses and cost (PACT) data from intervention 
practices and matched controls were analysed to determine whether changes had occurred. 
186 The results  showed significant differences in the  reduction  of mean number of different 
drugs used (focused on three main NSAIDs) and an increase in prescribing NSAIDs in their 
defined daily doses. 
In 1996, Hill-Smith conducted a controlled trial comparing prescribing by 50 GPs (from 11 
practices) who participated in creating a district drug formulary,  with other GPs in south 
Bedfordshire 
228
•  The  proportion  of prescription  items  listed  in  the  formulary  rose 
significantly  in  three  therapeutic  groups:  cardiovascular  (by  7-12%  above  control), 
musculoskeletal  (by  1-11%) and obstetrics and gynaecology (by 6-9% ).  The number of 
items  prescribed  per  prescribing  unit  fell  significantly  in  three  therapeutic  groups: 
musculoskeletal (by 1-7% below control), nervous (by 7-12%) and nutrition and blood (by 
15-21% ).  It was suggested that estimated savings of up to £150 000 (£3 000 per doctor per 
year)  were  achieved,  but  this  was  not  based  on  any  formal  calculations  or  economic 
analysis.  One  American  study  did  provide  empirical  evidence  about  the  influence  of 
hospital formulary restrictions 
229
•  They found  that across-the-board restrictions  did not 
result in cost savings, although savings may be realised for particular drug categories.  The 
observations from these studies could neither prove nor disprove the effect of formularies 
on overall benefit and cost savings to the NHS. 
The concept of outcomes or disease management, which originated in North America in the 
late  1990s,  brought  in  the  introduction  of disease  management  guidelines  and  shared 
protocols between primary and secondary healthcare sectors.  Unlike formularies, clinical 
guidelines contain guidance on how drugs should be used.  Prescribers were given clinical 
scenarios  and  then  taken  through  the  treatment  of the  clinical  situation  step  by  step  -
diagnosis,  treatment,  monitoring and discharge policy.  The focus  is  the  disease  and its 
optimum cost effective management, rather than on the drug acquisition costs alone.  It was 
believed that such programs would ensure higher and more consistent standards of care, and 
that treatment and support were received in the most appropriate setting. 
In Scotland, the Scottish Intercollegiate Guidelines Network (SIGN) was formed in 1993, to 
improve  the  quality  of healthcare  by  reducing  variation  in  practice  and  outcome  by 
developing  and  disseminating  national  clinical  guidelines  based  on  current  evidence. 
Improvements in the quality of care resulted by complying to  SIGN guidelines have been 
187 apparent 
230
,  but there is  still no evidence, to date, about their impact on costs.  In recent 
years,  guidelines  produced  by  SIGN  are  beginning  to  introduce  evidence  on  resource 
utilisation and cost effectiveness. 
Deregulation of Pharmaceuticals 
In the early 1980s, deregulation of pharmaceuticals was introduced in the hope of helping to 
strengthen the role of community pharmacists and to create savings in the NHS prescribing 
budget.  The first radical deregulation occurred in  1983,  when the legal classification of 
loperamide was changed from prescriptions-only-medicine (POM)  to  pharmacy medicine 
(P).  This was followed by a wide range of drugs that were previously POMs, subsequently 
deregulated to  be  available  for  sale  from  community pharmacists.  In  1994,  cimetidine 
became the first H2 blocker to become available over-the-counter (OTC).  By the beginning 
of 1997, the UK and Germany each had 67  switched products, which was the  highest in 
Europe.  This number continued to increase over the following years. 
Newly deregulated pharmaceuticals are widely purchased.  However, it is unclear whether 
this  increase  in  commercial  sales  translates  into  NHS  savings.  A  clear  reduction  in 
prescriptions for aciclovir was observed since its deregulation.  In addition, early economic 
analyses were able to demonstrate significant savings to the NHS through the deregulation 
of loperamide and hydrocortisone 
231
•  These reductions in prescriptions and costs were not 
apparent in all  deregulated drugs,  as  demonstrated by  the  case  with H2  blockers.  Since 
deregulation,  the  number  of prescriptions  for  H2  blockers  and  proton  pump  inhibitors 
continued to  rise.  This  may be  in part  due  to  patients  who  previously  self-medicated 
themselves  for  chronic  dyspepsia  with  antacids,  found  H2  blockers  to  be  effective  but 
expensive, and subsequently seeking long-term supply through prescriptions. 
Prescribing Advisers 
In addition to  organisational reforms,  it was  apparent that prescribing support at  a local 
level is extremely important.  At a local level, Health Boards were becoming increasingly 
188 active in providing prescribing support, promoting high quality and cost-effective drug use, 
and in improving pharmaceutical care of patients.  Practices, especially fundholders,  have 
sought extra prescribing advice or pharmaceutical expertise and have employed staff from a 
variety  of pharmaceutical backgrounds  to  assist.  Initially  Medical Prescribing Advisers 
(MP  As)  were  introduced,  and  later  Pharmaceutical  Prescribing  Advisers  (PP  As)  were 
created to supplement the role of MP  As. 
Subsequent to  the  1990 White Paper  'Improving Prescribing', Prescribing Advisers were 
employed by local Health Boards in attempt to  control prescribing costs in primary care. 
Their  role  included  provision  and  interpretation  of information  on  prescribing  matters 
mainly  to  GPs,  Health  Boards,  regional  office  and  secondary  care.  Their methods  of 
managing GP prescribing involved working with hospitals to ensure appropriate shared care 
and provide  primary  care oriented input into  local Drugs  and Therapeutics committees. 
They  also  introduced  programmes  to  reduce  patients'  demand  for  prescriptions,  and 
promoted  cost-effective  prescribing  among  GPs  via  education,  feedback  and  possible 
manipulation  of financial  incentives.  In  addition,  the  Scottish  Association  of Medical 
Prescribing Advisers (SAMP  A) - their professional group, met regularly to share ideas and 
offer mutual support and training.  The group also meets Scottish Office personnel two to 
three times a year to discuss national prescribing issues. 
Prescribing advisers  have  been visiting  GPs  to  offer prescribing support since  the  early 
1990s.  During their visits, they presented GPs with prescribing data including feedback on 
practices'  prescribing and making comparisons with their peers,  offering suggestions for 
rationalisation.  Prescribing Bulletins, containing therapeutic articles written from a local 
perspective,  were  disseminated  on  a  regular  basis.  Later,  they  became  increasingly 
involved in production  and  implementation  of formularies  and  guidelines.  Prescribing 
advisers  have  been successful  in  promoting  good  quality  evidence  based,  cost-effective 
prescribing, while reducing the expenditure on drugs in general practice without depriving 
patients of essential medications.  In Glasgow alone, the result was the transformation of a 
budget £3.4m overspend in 1992 to £1.3m below budget in 1998.  GPs also recognise them 
as a useful source of independent information and advice about prescribing matters 
232
• 
189 Many  factors  hampered prescribing  advisers  in  their  attempts  to  alter local  prescribing 
patterns  and behaviour.  For instance,  prescribing  advisers  work  to  counter generously 
financed  and  well  organised  marketing  from  pharmaceutical  industry.  However,  the 
number of pharmaceutical  company representatives  still  outnumber prescribing  advisers 
(8000 vs.  200 in 1997), with a promotional expenditure of £250 million a year, while the 
Department of Health now  spent £4 million  a year on  advising  GPs  on prescribing 
233
. 
Industry  representatives  are  extremely  well  trained  in  communication  and  presentation 
skills, but lack credibility among GPs.  Although prescribing advisers have high credibility 
with GPs, they do not have the benefit of the extensive training in interviewing, influencing, 
and the persuasion skills that industry representatives receive.  While fulfilling their other 
duties,  the lack of time to  make repeat visits to  the same practice regularly reduces their 
effectiveness.  Other  factors  include  local  hospitals'  prescribing  policies  and  patient 
demands, which significantly affect attempts made by advisers to change local prescribing 
behaviour. 
The majority of prescribing advisers  now  sit within  Public  Health Directorates  and the 
remainder  within  Primary  Care  Directorates.  Recent  reforms  in  primary  care,  the 
introduction of PCTs,  together with central and local policy directives (such as  National 
Service Frameworks and Clinical Governance) have provided prescribing advisers with the 
opportunity to grow their activities beyond their more traditional boundaries.  The focus of 
the work of prescribing advisers is changing.  They are likely to become more involved in 
providing  strategic  direction,  devising  local  policies  and  acting  as  PCT prescribing  co-
ordinators. 
Until  recently,  medical  and  pharmaceutical  advisers  provided  the  mainstay  of formal 
prescribing advice and support to  GPs at a local level.  However, there is still a need for 
greater local support of the prescribing process beyond that able to be provided by Health 
Boards.  Therefore, many locally led initiatives have begun to look at additional models of 
providing  prescribing  support.  These  initiatives  have  considered  the  role  of various 
healthcare professionals in the prescribing process. 
190 Drugs and Therapeutics Committees (DTCs) 
In 1994, all Health Boards were instructed to establish joint prescribing committees- Area 
Drugs and Therapeutics Committees, Purchasing Prescribing Committees or Therapeutics 
Committees - for the development of local prescribing strategies.  Prescribing advisers and 
other healthcare professionals worked together in attempts to resolve issues surrounding the 
responsibilities  for  prescribing  high  cost therapies  and  the  need  to  plan  for  therapeutic 
development.  They work closely with local Drugs and Therapeutics Committees, especially 
in the management of entry of new drugs, and to improve prescribing across the primary-
secondary care interface. 
Local Research Ethics Committees were instructed to standardise procedures used to review 
research applications, including local evaluations of new pharmaceutical products.  At the 
Health Board level, introduction of new interventions would require review by Drugs and 
Therapeutics  Committees.  Evidence  for  efficacy  and  safety  would  be  reviewed,  often 
without taking into account cost effectiveness and the financial implications of the decision 
for  the  trust or the  Health Board as  a whole.  However,  even if a request was  refused, 
consultants may  ask GPs  to  prescribe the  therapy,  thereby circumventing the  Drugs and 
Therapeutics Committees and shifting the cost to primary care. 
Indicative Prescribing Scheme (IPS) and GP Fundholding 
Prescribing in primary care had been viewed as  too  unpredictable to  impose a cash limit 
system, and until the NHS reforms in 1991  no attempt had been made to impose a ceiling 
on the total primary care drugs bill.  A range of measures has been adopted to encourage 
prescribers to take costs as well as effectiveness of drugs into account.  These have ranged 
from  exhortation  of  GPs  not  to  waste  resources,  through  provision  of  prescribing 
information  (the  PACT  scheme)  and  the  setting  of indicative  prescribing  targets,  to 
provision of financial incentives to achieve savings within GP fundholding. 
Indicative Prescribing Scheme (IPS) and GP fundholding made more subtle alterations to 
prescribing habits.  The emphasis of IPS  was on improving prescribing through enhanced 
191 information,  education and reasoned persuasion.  General practitioners were  given more 
discretion but a financial rigour, which was perceived to be absent previously.  The scheme, 
in particular amongst fundholders, led to some cost containment of expenditure without any 
apparent disadvantage to patients.  However, these effects seemed to be less for later waves 
and early gains made were not sustained over time. 
The Fundholding Scheme stemmed from a blueprint for the  'internal market' drawn up by 
Alain Enthoven, a health management specialist at Stanford University.  In theory, under 
this scheme, health authorities would be able to buy and sell services from each other and 
the private sector instead of providing the full  range of services themselves.  In  1984,  as 
part  of the  government's  review,  two  health  economists  - Alan  Maynard  and  Nick 
Bosanquet - suggested  that  GPs  should be  given  control  of their  own  budgets  to  buy 
hospital services.  They believed that this would help in directing funds towards hospitals 
and specialists who did most to meet patients' needs, as interpreted by their GPs.  However, 
at the time, the idea was dismissed on the grounds that GPs lacked the skills to administer 
such budgets. 
Following  the  publication  of the  White  Paper  "Working  for  Patients"  in  1991,  GP 
prescribing budgets were established as  one of a number of measures to  exert pressure on 
expenditure on drugs within the NHS - indicative prescribing or cash-limited budgets for 
fundholders.  On 1 April 1991, as part of the NHS reform, GP fundholding was introduced. 
Each year,  the Treasury approves the cash resources for the primary care bill in Scotland 
based on the estimated expenditure submitted by the Scottish Office.  The money was held 
centrally by the Management Executive and a notional sum -representing the expected cost 
of prescribed drugs  and appliances - is  allocated to  each Health Board.  In tum,  this  is 
divided  amongst  practices  as  Target  Budgets  (initially  termed  Indicative  Prescribing 
Amounts) set by each Health Board's prescribing advisers.  Larger practices could choose 
to  have  an  overall  practice  budget  with  which  to  buy  treatment  for  their  patients  -
'fundholding practices'.  However, a GP could still overspend his target budget in order to 
prescribe necessary interventions. 
192 The original Target Budgets were based on previous patterns of prescribing expenditure. 
However,  as  prescribing  advisers  became  more  familiar  with  their  practices,  weighted 
capitation - based on the age/sex profile of practice lists, morbidity in the locality, and the 
degree  of socio-economic  deprivation  - was  introduced  to  set  budgets  which  closely 
reflected the predicted health needs of the patients.  Similarly, the Management Executive 
introduced a simple needs based element into their prescribing budget setting methodology 
for Health Boards.  A working group, the Prescribing Allocation Review Group, has been 
commissioned by the Scottish Office to examine the current pattern of prescribing costs at 
Health Board level  with  a  view  to  recommending  a budget setting methodology  which 
would more closely reflect the varying needs of the population in different Health Board 
areas.  These figures  were  intended as  benchmarks.  Practices  and Health Boards were 
expected to  contain prescribing costs  within  their  allocated amounts  unless  they  had to 
exceed their amount for justifiable clinical need.  The prescribing budget became part of the 
allocated  sum  for  fundholding  and  the  fundholder  was  expected  to  live  within  the 
prescribing budget. 
In addition, each GP and Health Board received a monthly budget schedule prepared by the 
Pharmacy Practice Division (PPD) to enable the performance against Target Budgets to be 
monitored.  Similarly,  each  GP  in  England and Wales  received  a  monthly  expenditure 
statement, a monthly 'Merec Bulletin' (provides information on an area of therapeutics) and 
a three-monthly PACT standard report (summary of prescribing data for the practice over 
the past quarter). 
This had been the strongest move yet,  to  shift emphasis from secondary to  primary care. 
Under  the  voluntary  fundholding  scheme,  GPs  were  given  responsibilities  to  buy  non-
urgent treatments for their patients and placed budgetary responsibility firmly on GPs.  Any 
savings achieved by a practice within its total budget could be reinvested at the practice's 
discretion.  As purchasers, however, GPs increasingly recognise that they are responsible 
for the whole care of the patient and the  optimal use of the drug budget.  This has made 
some  fundholders  re-evaluate  their  role  in  accepting  recommendations  of  hospital 
consultants.  They  began  to  question  the  appropriateness  of some  proposed  treatment 
options when the health gain may be small. 
193 Over the years, increasing numbers of practices joined the scheme, and by 1997/98,60% of 
the population was covered by fundholding GPs. 
Early studies showed positive effects of fundholding on prescribing costs.  Baines et al 
233 
found  a clear consensus  that fundholding  practices  achieved one-off reductions  in  their 
prescribing  costs  relative  to  non-fundholders,  releasing  savings  for  use  elsewhere. 
Brandlow  &  Coulter  (1993) 
234  compared prescribing  and  cost information  (prescribing 
costs, number of items prescribed, the proportion of generics) of 15 practices (fundholding 
vs  non-fundholding, dispensing vs non-dispensing, use of formularies and protocols) over 
two  six-month  periods.  They  showed  that  fundholders  seemed  to  curb  increasing 
prescribing costs.  Similar results were seen in a study by Wilson et al (1995) who analysed 
growth in prescribing costs as measured by the percentage increase in annual net ingredient 
cost per prescribing unit of virtually all practices (412 in total) in the former Mersey Region 
between April  1990 to  March 1994. Their results suggested that in comparison growth in 
prescribing costs of fundholders tended to be substantially lower in the early period, but had 
subsequently returning to a growth rate similar to that of non-fundholders 
235
•  Thus the GP 
fundholding scheme appeared to have controlled costs in the short-term only. 
Later studies in England and Wales have concluded that fundholding did not contribute to 
any great extent to  the  observed variation in prescribing behaviour between practices but 
that  fundholders  have  contained  their  prescribing  costs  more  effectively  than  non-
fundholders 
235
•
236
•  This  may be because  GPs  who  become  fundholders  have  different 
attributes to those who do not.  It was suggested that financial incentives can bring about 
changes  and motivate  GPs in both fundholding  and non-fundholding,  but there  is  doubt 
about how long the effects persist.  Initial savings can be from increased generics use and 
other strategies that are relatively easy to implement, but sustained improvement requires a 
more fundamental change in attitudes and a commitment to cost-effective prescribing. 
The  Indicative  Prescribing  Scheme  (IPS)  stressed  cost  containment,  and  made  little 
allowance for the consideration of the quality of appropriateness of prescribing.  Overall, 
the  IPS  has  generally failed to  control the  increasing drug expenditure due  to  unrealistic 
targets and the absence of an incentive or penalty to encourage compliance.  Fundholding 
has been shown to reduce the rates of rising drug costs in participating practices. However, 
194 the  overall  evidence  of their  success  in  restraining  the  rise  in  prescribing  costs  was 
inconclusive.  Often many studies targeted selected practices and only looked at short-term 
outcomes.  Prescribing budgets for fundholders and indicative prescribing amounts for non-
fundholding practices, especially in the early years, were often set arbitrarily.  In some cases 
disproportionately large budgets were  given  to  fundholders,  which inevitably meant that 
they could more easily under-spend than others.  Fundholding was eventually abolished in 
March  1999.  However,  GPs  retained  their  role  in  buying  treatment  through  'locality 
purchasing', whereby groups of practices in an area make decisions about purchasing. 
Primary Care Trusts (PCTs) and Local Healthcare Co-operatives (LHCCs) 
In  April  1999,  cash-limited unified budgets were introduced and called Joint Investment 
Funds.  These  were  expected to  tackle costs at the primary-secondary care interface,  by 
transferring  resources  to  match  changes  in  clinical  practice.  Under  this  new  scheme, 
overspending in  prescribing  would be managed within  the  overall  primary care  budget, 
resulting  in  a  reduction  in  resources  available  for  hospital  and  community  services. 
Conversely,  more  rational  and  effective  prescribing  of high  cost  drugs  should  allow 
resources to be "freed up" and redirected to areas of unmet clinical needs, or to areas seen 
as national or local priorities. 
Primary Care Trusts were introduced to offer new ways for GPs in the same area, regardless 
of whether  previously  fundholding  or  not,  to  work  with  each  other  and  other  health 
professionals to  plan the  way in which care  should be provided.  These trusts receive  a 
budget to manage purchasing of hospital services, prescriptions and employ staff.  The total 
number of trusts was reduced and most Health Boards now have one primary care trust and 
one acute trust.  The responsibility for primary care was moved from being a Health Board 
function to become a PCT function,  which include services for primary care and all other 
community-based healthcare.  PCTs will typically include community hospitals and mental 
health  services,  as  well  as  networks  of local  healthcare  co-operatives  (LHCCs).  Local 
healthcare co-operatives are  voluntary groupings  of GPs  and primary care professionals, 
accountable to PCTs, and members are accountable for their use of resources and quality of 
care. 
195 Currently,  there  are  79  LHCCs  across  Scotland,  covering  952  practices  in  all  mainland 
areas,  except West Lothian 
237
•  The size of the LHCCs vary widely,  patient populations 
range from  4  000  to  172 000 patients,  the  number of practices covered by each LHCC 
ranges from two to 31, and the number of GPs ranges from eight to 115. 
Local  healthcare  co-operatives  are  positioned  to  have  major  impact  on  improving  the 
quality and cost-effectiveness of prescribing, and significant work is being done.  Eighty-
eight percent of the LHCCs in the survey have dedicated pharmacist input, varying from 
one  session  per  week  in  25%  of the  LHCCs  to  30  sessions  per  week  in  one  LHCC. 
Seventy-five percent (n=44) of LHCCs are involved in specific prescribing projects, while 
32%  (n=19)  use  a  formulary.  The  average  prescribing budget,  based on  data from  26 
LHCCs, is 38% (ranging from 23% to 68%) of the total devolved budget. 
Primary Care Trusts (PCTs)  and LHCCs were designed to  encourage the development of 
joint working between GPs  and pharmacists on prescribing,  medicines management and 
direct patient care services.  Often each locality has a small team of GPs with a full-time 
general  manager,  a  core  management  team  and  a  multi-disciplinary  board,  such  as  a 
pharmacist for prescribing advice, which determines policy and direction. 
Summary 
The continuing rise in the  prescribing expenditure is an ongoing challenge for the  NHS. 
Over  the  years,  a  confusion  of policies  including  cost containment and  reallocation  of 
budgets  have  been  introduced.  Various  approaches  to  cost  containment  have  been 
introduced  and  adopted  throughout  the  years,  ranging  from  the  "stick"  approach  (e.g. 
restricted list) to the "carrot" approach (e.g. incentives with a prescribing message on them). 
However,  there  is  often  a  lack  of  rigorous  evidence  because  interventions  were 
implemented as  part of a strategic decision rather than on a formally evaluated basis.  In 
addition, most of these methods appear only to have short-term benefits.  Cost containment 
strategies could only generate a finite amount of savings, which would reach a plateau in 
196 the  long  term.  In  order to  achieve  cost effectiveness in healthcare,  a wider perspective 
needs to be adopted. 
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-··-··-··-··-··-··-··-··-··-··----------------------------· 
1990  Prescribing Advisers  ...._ 
..... 
1991 to 1999  Indicative Prescribing Scheme/Fundholding 
1993  Scottish Intercollegiate Guidelines 
...._ 
..... 
1994  Drugs Therapeutics 
...._  ..... 
Primary Care Trusts 
Local Healthcare Co-operatives  1999 
National Institute for Clinical Excellence  ------!  .... 
Health Technology Board for Scotland 
Figure drawn to scale from 1970 APPENDIX II 
LITERATURE SEARCH STRATEGIES 
199 LITERTURE REVIEW-THE IMPACT OF ECONOMIC INFORMATION OF 
PRIMARY CARE DECISION MAKING 
The  following  search  strategy  was  used  to  search  Medline,  EMBASE  and  Cinahl  for 
relevant studies. 
1.  Economic$ in ti ab 
2.  Cost$ in ti ab 
3.  (Primary adj3 care) inti ab 
4.  (General adj3 practice$) inti ab 
5.  (General adj3 practitioner$) inti ab 
6.  Impact$ in ti ab 
7.  Influen$ inti ab 
8.  Chang$ in ti ab 
9.  Attitude$ inti ab 
10. Deci$ inti ab 
11. Or/1-10 
200 LITERTURE REVIEW- META-ANALYSIS 
The search filters recommended by the SIGN guidelines were used to retrieve randomised 
controlled trials in Medline, EMBASE and Cinahl.  Keywords for the individual drugs were 
combined with the appropriate filters to retrieve relevant studies. 
Medline 
12. Randomized controlled trials/ 
13. Randomized controlled trial. pt. 
14. Random allocation/ 
15. Double blind method/ 
16. Single blind method/ 
17. Clinical trial.  pt. 
18. Exp clinical trials/ 
19. or/1-7 
20. (cline$ adj trial$).tw. 
21. ((sigl$ or doubl$ or treb$ or trip$) adj (blind$3 or mask$3)).tw. 
22. Placebos/ 
23. Placebo$.tw. 
24. Randomly allocated.tw. 
25.  (allocated adj2 random).tw. 
26. or/9-14 
27. 8 or 15 
28. Case report.tw. 
29. Letter.pt. 
30. Historical article.pt. 
31. Review of  reported cases.pt. 
32. Review, multicase.pt. 
33. or/17-21 
34. 16 not 22 
201 EMBASE 
1.  Clinical trial! 
2.  Randomized controlled trial/ 
3.  Randomization/ 
4.  Single blind procedure/ 
5.  Double blind procedure/ 
6.  Crossover procedure/ 
7.  Placeb/ 
8.  Randomi?ed controlled trial$.tw. 
9.  Rct.tw. 
10. Random allocation.tw. 
11. Randomly allocated.tw. 
12. Allocated randomly. 
13. (allocated adj2 random).tw. 
14. Single blind$.tw. 
15. Double blind.tw. 
16. ((treble or triple) adj (blind$)).tw. 
17. Placebo$.tw. 
18. Prospective study/ 
19. Or/1-18 
20. Case study/ 
21.  Case report. tw. 
22. Abstract report/ 
23. Letter/ 
24. Or/20-23 
25. 19 not 24 
202 Cinahl 
1.  Exp clinical trials/ 
2.  Clinical trial.pt. 
3.  (cline$ adj trial$).tw. 
4.  (singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$)).tw. 
5.  Randomi?ed control$ trial$.tw. 
6.  Random assignment/ 
7.  Random$ allocat$.tw. 
8.  Placebo$.tw. 
9.  Placebos/ 
10. Quantitative studies/ 
11. Allocat$ random$.tw. 
12. Or/1-11 
203 APPENDIX III 
DIAGNOSTIC (ICD-9) AND OPERATIONAL 
(OPCS) CODES OF CLINICAL EVENTS OF 
INTEREST 
204 Gastrointestinal Events 
208  leukaemia of unspecified cell type 
530  disease of oesophagus 
531  gastric ulcer 
532  duodenal ulcer 
533  peptic ulcer, site unspecified 
534  gastrojeujunel ulcer 
535  gastritis and duodenitis 
536  disorder of function of stomach 
578  gastrointestinal haemorrhage 
787  symptoms involving digestive systems 
Cardiovascular Events 
401 to 405  Hypertensive Disease 
401  essential hypertension 
402  hypertensive heart disease 
403  hypertensive renal disease 
404  hypertensive heart and renal disease 
405  secondary hypertension 
410  acute myocardial infarction 
411  to 414  Ischaemic Heart Disease 
411  other acute and subacute form of ischaemic heart disease 
412  old myocardial infarction 
413  angina pectoris 
414  other forms of chronic ischaemic heart disease 
415  acute pulmonary heart disease 
416  chronic pulmonary heart disease 
425  cardiomyopathy 
426  conduction disorders 
427  cardiac dysrhythmias 
205 428  heart failure 
429  ill-defined descriptions and complications of heart disease 
440  atherosclerosis 
441  aortic aneurysm 
Rheumatoid Arthritis 
710  diffuse diseases of connective tissue 
714  rheumatoid arthritis and other inflammatory polyarthropathies 
Osteoarthritis 
715  osteoarthrosis and allied disorders 
W37  total prosthetic replacement of hip joint using cement 
W38  total prosthetic replacement of hip joint not using cement 
W39  other total prosthetic replacement of hip joint 
W40  total prosthetic replacement of knee joint using cement 
W41  total prosthetic replacement of knee joint not using cement 
W42  other total prosthetic replacement of knee joint 
W43  total prosthetic replacement of other joint using cement 
W44  total prosthetic replacement of other joint not using cement 
W45  other total prosthetic replacement of other joint 
206 APPENDIX IV 
UNIT COSTS USED IN THE ANALYSIS 
207 The following unit costs were used in the non-population model. 
Resources  1993 Values  1995 Values  2000 Values 
GP Visit  £  6.90  £  8.50 
Investigations 
ESR  £  3.00  £  4.02 
FBC  £  3.00  £  4.02 
WBC  £  5.00  £  6.70 
WBC diff  £  7.00  £  9.38 
Ferritin  £  12.00  £  16.08 
Marrow  £  70.00  £  93.81 
Bloods  £  23.00  £  30.82 
LFT  £  11.00  £  14.74 
U&E  £  7.00  £  9.38 
Glucose  £  3.00  £  4.02 
Amylase  £  3.00  £  4.02 
Renal Biopsy  £  60.00  £  80.41 
Gastric Biopsy  £  58.00  £  77.73 
Creatinine  £  4.00  £  5.36 
Immunoglobin  £  15.00  £  20.10 
XR abdo  £  21.00  £  28.14 
XR chest  £  12.00  £  16.08 
IVP  £  80.00  £  107.21 
Barium meal  £  34.00  £  45.56 
Barium enema  £  41.00  £  54.94 
Upper endoscopy  £  119.00  £  159.47 
Sigmoidoscopy  £  50.00  £  67.01 
ECG  £  6.00  £  8.04 
Faeces OB  £  11.00  £  14.74 
Faeces Culture  £  10.00  £  13.40 
GP consultation cost was taken from the following study and inflated to present value. 
Graham B & McGregor K.  What does a GP consultation cost? BJGP 1997; 47:170-172 
All investigative costs were taken from a previous study and inflated to present value. 
Knill-Janes RP. An economic evaluation of  Arthrotec in the treatment of  arthritis. 
Br J Med Econ 1992;5:51-58 
208 Table 34  Tayside Weighted Average Inpatient Costs by Specialty 
Inpatients 
Acute Specialties 
General Surgery 
Weighted Values 
Orthopaedics 
Weighted Values 
ENT 
Ophthalmology 
Urology 
Weighted Values 
Neurosurgery 
Cardiothoracic Surgery 
Plastic Surgery & Burns 
Weighted Values 
Oral Surgery & Medicine 
Weighted Values 
Medical 
Weighted Values 
Neurology 
Dermatology 
Rehab Medicine 
Respiratory Med 
Communicable Disease 
Radiotherapy 
Spinal Paralysis 
Surgical Paediatrics 
Medical Paediatrics 
Weighted Values 
Gynaeco1ogy 
Weighted Values 
LOS• 
Code  (days) 
2 
4 
5 
6 
7 
12 
16 
19 
23 
26 
28 
31 
34 
38 
39 
40 
42 
5.7 
3.7 
4.6 
4.39 
7.1 
8.1 
8.2 
30.5 
8.19 
29 
2.9 
4.1 
4.1 
4.10 
7.6 
4.8 
2.4 
4.78 
1.8 
1.1 
1.55 
5.2 
6.9 
5.5 
5.4 
5.38 
8.3 
13.2 
8.8 
7.7 
10.8 
1.9 
2.9 
2.8 
2.87 
3.6 
3.1 
1.8 
3.41 
Baby Special/Intensive  46  16 
9.4 
13.60  Weighted Values 
•  LOS = length of  stay in hospital 
Cost/Case  Number of  Cost/Case  Inpatients  LOS •  Cost/Case  Number of  Cost/Case 
Discharges  per Day (£)  (£)  Discharges  per Day(£)  Acute Specialties  Code  (days)  (£) 
1451 
926 
1049 
1080.52 
1794 
2336 
1951 
12038 
2234.63 
907 
892 
1222 
1198 
1218.32 
2787 
1405 
938 
1400.77 
1008 
681 
892.44 
1085 
1219 
813 
955 
1013.14 
2468 
2050 
1136 
2768 
1586 
683 
1024 
822 
966.67 
870 
994 
250 
916.68 
7279 
3677 
5968.57 
1725 
3770 
1793 
7288 
3116 
1843 
1279 
158 
6396 
2803 
1909 
2112 
383 
2495 
842 
1751 
16 
1767 
666 
364 
1030 
12014 
972 
4422 
3067 
20475 
474 
562 
2895 
1361 
1006 
397 
2728 
1081 
3809 
1725 
1076 
4 
2805 
341 
195 
536 
Intensive Therapy Unit 
Weighted Values 
245.86 
A&E 
48 
49 
6.6 
1.5 
2.57 
0.8 
Geriatric Assess  50  15.3 
272.98 
312.76  Weighted Values 
21.5 
28 
44.5 
25.3 
25.41 
307.59 General Practice  73  21.2 
297.15 
366.71 
Weighted Values 
18.9 
10.6 
14.4 
24.1 
17.7 
13.1 
16.3 
17.7 
16.18 
Acute Other  98  14.4 
293.15 
574.79 
188.48 
297.35 
155.30 
129.09 
359.48 
146.85 
359.47 
Weighted Values 
Geriatric Long Stay  51 
Weighted Values 
Young Chronic Sick 
336.63 
52 
269.17 Casted as Medical Cases: 
Nephrology  24 
Cardiology  17 
Anaesthetics  41 
438.90  Haematology  62 
14.4 
14.4 
14.40 
10611 
1221 
3194.00 
1184 
1945 
2331 
3276 
4745 
3438 
3010.97 
2363 
2038 
1223 
1390 
2527 
1927 
1434 
1623 
2674 
1759.12 
2738 
3345 
2633 
2815.07 
270 
1015 
1285 
766 
494 
930 
652 
368 
815 
3259 
281 
104 
422 
326 
148 
289 
175 
265 
86 
2096 
409 
200 
409 
1018 
Cost per iopatient week 
466  21 
589 
736 
820 
579 
19 
389 
110 
203 
666  52 
580 
517 
547 
535 
678 
850 
689 
673.75 
1243 
61 
40 
20 
11 
7 
6 
18 
957 
130 
209 
1242.03 
1480.00 
118.50 
108.74 
195.49 
96.25 
177.57 
188.48 
188.48 
188.48 
188.48 Table 35  Tayside Weighted Average Outpatient Costs by Specialty 
Outpatients  Total  Cost  Outpatients  Total  Cost 
Se,ecialties  Code  Attendance  e,er Attendance (£1  Se,ecialties  Code  Attendance  e,er Attendance (£) 
General Surgery  18400  175  Neurology  19  5031  41 
2308  37  249  36 
736  20  976  49 
673  43  Weighted Cost  6256  42.05 
8446  23  Dermatology  23  28962  33 
386  93  1319  31 
1003  46  632  28 
589  42  4408  32 
580  29  520  50 
170  47  707  44 
183  77  Weighted Cost  36548  33.18 
173  110  Rehab Medicine  26 As Medical Outpatients 
Weighted Values  33647  110.20 
Orthopaedics  2  26200  35  Respiratory Medicine  28  441  39 
2171  31  297  54 
73  27  1230  45 
681  37  645  42 
11019  35  7415  53 
5438  55  Weighted Values  10028  50.73 
1280  42  Communicable Disease  31  1521  93 
378  42 
46  65  Radiotherapy  34  6724  52 
37  27  1333  26 
39  51  Weighted Values  8057  47.70 
43  116  Spinal Paralysis  38 As Medical Outpatients 
Weighted Values  47405  37.48  Surgical Paedicatrics  39  1137  206 
ENT  3  15660  47  Medical Paediatrics  40  6676  78 
1496  40  438  39 
246  37  161  43 
625  42  3247  120 
4116  27  146  55 
1053  45  1742  46 
566  51  Weighted Values  12410  82.40 
268  30  Gynaecology  42  12782  41 
246  28  793  32 
138  36  192  31 
Weighted Values  24414  115.52  417  41 
Ophthalmology  4  24935  34  3346  71 
1790  32  482  60 
1132  42  311  51 
9894  22  93  43 
369  65  109  28 
489  31  38  79 
Weighted Values  38609  31.32  Weighted Values  18563  46.59 
Urology  5  5379  112  Baby Care Intensive  46  896  35 
18  278  A&E  49  4844  57 
274  47  46801  34 
499  80  3041  20 
Weighted Values  6170  107.01  2497  24 
Neurosurgery  6  3472  43  25687  37 
Ill  117  5446  61 
Weighted Values  3583  45.29  4475  21 
Plastic Surgery & Burns  8  11646  20  1372  24 
529  30  1576  34 
Weighted Values  12175  20.43  1441  37 
Oral Surgery & Medicine  12  650  108  696  45 
4435  45  2165  26 
309  178  8  125 
Weighted Values  5394  274.38  Weighted Values  100049  35.91 
Medical  16  53933  35  Geriatric Assessment  50  535  82 
6459  53  687  95 
3111  47  1409  45 
621  19  489  27 
597  65  Weighted Values  3120  59.53 
15029  49 
1391  92  General Practice  73 As Medical Outpatients 
810  60 
378  79  Acute Other  98  974  49 
252  44  1106  45 
253  40  389  98 
128  63  6742  128 
138  36  Weighted Values  9211  108.41 
3  333 
Wei  hted Values  83103  40.97 
210 APPENDIXV 
CORRESPONDANCES AND QUESTIONNAIRES 
211 From:  Olivia Wu 
Direct line: 0141 330 3296 
Dr R P Knill-Jones 
Direct line: 0141 330 5010 
[Date] 
Dear 
UNIVERSITY 
of 
GLASGOW 
Pharmacoeconomic Evaluations of Adverse Drug Reactions 
We are conducting research on the impact of pharmacoeconomic information on GP 
prescribing.  Part of our research involves conducting economic evaluations on three classes 
of drugs - NSAIDs, ACE  inhibitors and SSRis.  This involves modelling the additional costs to 
the NHS of treating most side effects, onto the basic drug dispensing cost.  This calculation of 
the total costs of prescriptions leads to a more accurate comparative evaluation of the 'real' 
costs of prescribing different NSAIDs. 
In order to calculate the costs of treating side effects, we need to establish a general 
treatment model from GPs.  This activity involves a half-hour interview asking about the 
actions GPs would take, and investigations/follow-up initiated, given a series of complications 
which could arise in a patient on one of the three classes of drugs mentioned above.  No 
special interest or expertise in the particular drugs or economic evaluations is needed.  We 
have had experience in doing this successfully on several occasions in the past. 
This study is independent of any pharmaceutical sponsorship for good academic reasons.  We 
would be most grateful if you could help. 
Yours sincerely 
Olivia Wu 
Research Student 
Dr Robin Kniii-Jones 
Senior Lecturer in Epidemiology 
Honorary Consultant in Public Health 
Department of Public Health, University of Glasgow 
1 Lilybank Gardens, Glasgow  G12 SRZ 
Tel: +44 141 330 4039  Fax:  +44 141 330 5018 
212 From:  Olivia Wu and Dr Robin Kniii-Jones 
Direct line: 0141  330 3296/5010 
[Date] 
Dear 
Dr Philip Wilson 
WestNet 
4 Lancaster Cresent 
Glasgow  G12 ORR 
UNIVERSITY 
of 
GLASGOW 
Exploratory Survey among WestNet Members 
We have noted the large increase in economic data about health care.  These range from 
simple recommendations on cost issues to purposefully designed economic evaluations.  Many 
GPs are concerned about the increasing dominance of economic issues in major decisions 
about clinical care, and feel their opinions on economic matters have not been heard.  However, 
it is unclear whether this information has any impact on everyday clinical practice in a primary 
care setting. 
We are conducting a short exploratory survey among WestNet members to look into this.  This 
survey would allow us to gain valuable insight into your views on the usefulness of a variety of 
economic information in relation to your everyday practice.  We believe the results of this survey 
would provide a sense of direction to future research in this area. 
From personal experience, we know that there is very little spare time in a GP's day.  We have 
restricted this survey to a very short questionnaire which is enclosed.  We would be most 
grateful if you could take some time to complete this and return it in the reply-paid envelope 
provided. 
Yours sincerely 
OliviaWu 
Research Student 
pp  Dr Philip Wilson 
Enc 
Dr Robin Kniii-Jones 
Senior Lecturer in Epidemiology 
Honorary Consultant in Public Health 
Section of Public Health and Health Policy 
Division of Community Based Sciences, University of Glasgow 
1 Li1ybank Gardens, Glasgow  G12 8RZ 
Tel: +44 141 330 4039  Fax: +44 141 330 5018 
213 Please mark 'x' or type, where appropriate, within the brackets provided. 
1.  Has economic information comparing cost and effectiveness of treatments ever influenced 
your decision-making? 
Yes  (please proceed to fill in questions 2 to 4) 
No  (please go straight to question 5) 
Don't Know  (thank you for your time, your questionnaire ends here) 
2.  If yes, when was the last time economic information has influenced your decision-making? 
3.  What was the source of this information (pick all relevant options)? 
Published information: 
] from local Health Board/PCG/PPAs/MPAs 
] articles in journals 
] from pharmaceutical industry 
] others, please specify 
Verbally presented information: 
] from individual meetings with representatives from local Health 
Board/PCG/PPAs/M  PAs 
] from conferences and seminars 
] from pharmaceutical industry representatives 
] others, please specify 
4.  What was the decision made? 
5.  Why has economic information failed to influence your decision-making (pick all relevant 
options)? 
I never receive any economic information. 
I do not receive economic information relevant to my decision-making. 
It is not possible to implement the economic information into my everyday practice. 
I do not agree with the results of the information presented. 
Other reasons, please specify. 
Please return the completed questionnaire in the reply-paid envelope provided. 
Thank you very much for your time.  If you have any questions regarding this survey, please contact: 
Olivia Wu or Dr Robin Knill-Janes 
Department of Public Health 
University of Glasgow 
Tel: 0141  330 3296/5010Fax: 0141  330 5018 
Email: 9406070w@clinmed.gla.ac.uk or 
R.P.Knill-Jones@udcf.gla.ac.uk 
Dr Philip Wilson 
WestNet, 4 Lancaster Crescent 
Glasgow  G12 ORR 
Tel: 0141  2111690  Fax: 0141  2111667 
Email: p.wilson@clinmed.gla.ac.uk 
Exploratory Survey among WestNet Members (I)  214 Please mark 'x' or type, where appropriate, within the brackets provided. 
Have you ever used this as a source of 
economic information?  By economic 
information, we mean information  If yes, do you find this information of 
comparing the costs and benefits of  relevance to your everyday practice? 
different kinds of health care.  (Y = yes  N = no  S = sometimes 
(Y =yes  N = no  DK = don't know)  DK = don't know) 
MPAs and/or PPAs  Y[  N[  ]DK[  Y[  N[  S[  OK[ 
Prescribing Feedback (SPA)  Y[  N [  ]OK[  Y[  N [  S[  DK[ 
Prescribing Feedback (GPASS)  Y[  N [  ]OK[  Y[  N [  S[  DK[ 
Locally Produced Newsletters, please 
specify [  ] Y[  N [  ]OK[  Y[  N [  S[  DK[ 
Local Prescribing Formulary  Y[  N [  ]OK[  Y[  N [  S[  DK[ 
Pharmaceutical Industry Literature  Y[  N [  ]OK[  Y[  N[  S[  DK[ 
Pharmaceutical Industry Representatives  Y[  N [  ]DK[  Y[  N [  S[  DK[ 
British Medical Journal  Y[  N [  ]OK[  Y[  N[  S[  DK[ 
British Journal of General Practice  Y[  N [  ]DK[  Y[  N [  S[  DK[ 
Other Journals, please specify 
]  Y[  N [  ]DK[  Y[  l  N [  l  S[  l  DK[ 
2  If there are sources of economic information that you find relevant and are not on the list above, please specify. 
3  How do you think economic information should be presented to you (pick all relevant options)? 
evaluations and studies published in literature 
summary of evaluations and studies presented in a leaflet format 
summary of evaluations and studies presented verbally at a meeting 
simple recommendations presented in a leaflet format 
simple recommendations presented verbally at a meeting 
]  locally specific evaluations and studies 
4  Do you think economic information should be used in health care decision-making? 
Yes 
No 
Please return the completed questionnaire in the reply-paid envelope provided. 
Thank you very much for your time.  If you have any questions regarding this survey, please contact: 
Olivia Wu or Dr Robin Kniii-Jones 
Department of Public Health, University of Glasgow. 
Tel: 0141  330 3296/5010  Fax: 0141  330 5018 
Email: 9406070w@clinmed.gla.ac.uk or 
R.P.Knill-Jones@udcf.gla.ac.uk 
Dr Philip Wilson 
WestNet, 4 Lancaster Crescent 
Tel: 0141  2111690  Fax: 0141  2111667 
Email: p.wilson@clinmed.gla.ac.uk 
Exploratory Survey among WestNet Members (II)  215 From:  Olivia Wu and Dr Robin Kniii-Jones 
Direct line: 0141  330 3296/5010 
[Date] 
Dear 
UNIVERSITY 
of 
GLASGOW 
The Use of Economic Evidence in Primary Care 
We have noted the large increase in economic data about health care.  These range from 
simple recommendations on cost issues to purposefully designed economic evaluations.  Many 
GPs are concerned about the increasing dominance of economic issues in major decisions 
about clinical care, and feel their opinions on economic matters have not been heard. 
We are conducting an exploratory survey to look into this.  This survey would allow us to gain 
valuable insight into your views on the role of economic information in relation to your everyday 
practice.  We believe the results of this survey would provide information that will help the 
design of useful and comprehensible economic evidence for GPs and tackle 'information 
overload'. 
Your participation in this would be voluntary and should you agree to be involved, you may 
withdraw at any point without prejudice.  If you consent to take part, then we will need to 
undertake one semi-structured interview with you.  This will last no longer than 45 minutes and, 
with your permission, will be audio-recorded.  These interviews will be transcribed and your 
replies will be treated as confidential.  We will also ensure that none of your responses can be 
directly attributed to you. 
As a general guide, the interview will cover your views on the use of economic evidence in 
clinical decision making.  However, no special knowledge on economics is required.  If you 
require further information or wish to discuss this in more detail, please do not hesitate to 
contact us. 
Yours sincerely 
Olivia Wu 
Research Assistant 
Dr Robin Kniii-Jones 
Reader in Epidemiology 
Honorary Consultant in Public Health 
Section of Public Health and Health Policy  216 
Division of Co=unity Based Sciences, University of Glasgow 
1 Lilybank Gardens, Glasgow  G12 8RZ 
Tel: +44 141 330 4039  Fax: +44 141 330 5018 APPENDIX VI 
BREAKDOWN OF COSTS-POPULATION 
MODEL 
217 N  ...... 
00 
Table 36 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total Comparator Cohort 
NSAID ONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
N 
8640 
11360 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
50 to 59yrs  7 t 85 
60 to 74yrs  9594 
75+yrs  3022 
sub-total of all male  19601 
Total NSAID Only Sub-Cohort  49212 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
33 
75 
42 
150 
24 
28 
10 
62 
Total NSAID & Misoproslol Sub-Cohort  212 
Female 
Male 
NSAID & H2/0MEPRAZOLE 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
339 
623 
284 
1246 
255 
492 
120 
867 
Total NSAID & H210meprazole Sub-Cohort  2113 
All the Costs(£) Incorporated In the Economic Modelling of the Tayside Population Based on 45 Days Observations (from the Index date) 
Base Cost  Additional  Additional  Addlllonal  Event Cost  GP Visit (Rx)  Cost of  Cost of  Cost of  Cost of  Cost of  Cost or  Hidden  Shadow 
Drug Rx  NSIAD RX  Ulcer Rx  Other Rx  All Rx  Costs  Endoscopies  Gl admissions  CV admissions  RH admissions  OS admissions  all admissions  Costs  Costs 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7.11 
7.51 
23.37 
25.14 
22.17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41 .08 
41.32 
40.28 
40.37 
37.00 
39.88 
40.73 
2.47 
2.92 
3.30 
2.87 
2.04 
2.49 
2.80 
2.37 
2.67 
5.01 
3.07 
8.58 
5.04 
4.05 
2.33 
3.09 
3.12 
4.48 
3.87 
3.64 
5.40 
4.10 
2.68 
3.14 
2.98 
2.98 
3.64 
1.39 
1.88 
2.17 
1.77 
1.48 
2.36 
2.20 
1.96 
1.88 
1.49 
1.85 
1.75 
1.71 
1.42 
1.75 
1.42 
1.58 
1.66 
9.68 
8.79 
11.07 
9.62 
8.30 
11.95 
9.83 
10.20 
9.79 
14.88 
16.30 
18.15 
16.33 
13.22 
13.48 
14.44 
13.54 
15.18 
1.50 
1.26 
2.02 
1.50 
0.85 
1.30 
1.39 
1.12 
1.32 
2.83 
3.16 
3.67 
3.17 
1.97 
3.21 
3.29 
2.77 
3.01 
3.31 
4.82 
5.05 
4.55 
2.13 
5.85 
5.05 
4.28 
4.47 
5.16 
6.76 
6.34 
6.23 
4.17 
6.56 
6.89 
5.90 
6.10 
2.89 
3.14 
4 19 
3 28 
2.33 
3.67 
359 
3.07 
3.18 
6.79 
7 93 
8 72 
775 
5 43 
7 45 
7 51 
6 73 
7 34 
17.98 
1668 
24.70 
1921 
14.48 
20.14 
17 96 
17 60 
\8 74 
2390 
26 70 
29.89 
26 67 
20.05 
23 17 
24.31 
22.41 
24.92 
I 28 
151 
I 86 
1.50 
086 
I 42 
I 56 
I  19 
1 36 
4 46 
6.01 
7 44 
585 
3 76 
551 
6 31 
500 
551 
10 05 
10 92 
15 47 
12 01 
818 
12.09 
12.86 
10.70 
11.62 
11.02 
12 71 
17 38 
13 32 
9 32 
11 .01 
1281 
10.76 
12 27 
0 51 
0 44 
0 27 
0 43 
0.37 
0 48 
008 
0 38 
0 40 
0 49 
0 33 
0 22 
0 35 
0 35 
0 33 
028 
0 33 
0 34 
000 
000 
0.00 
000 
000 
0.00 
000 
000 
000 
3.07 
2 34 
I 47 
2.34 
I 63 
0.85 
000 
0.96 
1.77 
0.70 
1.21 
2.04 
1.21 
0.79 
2.18 
1.13 
1.44 
1.32 
0.94 
4.87 
9.19 
4.62 
2.62 
3.60 
8.96 
4.06 
4.39 
0.00 
0.00 
97.71 
27.36 
0.00 
0.00 
0.00 
0.00 
19.36 
5.68 
0.00 
4.44 
2.56 
4.65 
22.28 
0.00 
14.01 
7.26 
0.64 
1.99 
23.34 
6.07 
3.93 
3.89 
7.59 
4.37 
5.28 
4.07 
13.57 
30.39 
14.43 
23.97 
31 .97 
17.03 
26.78 
19.40 
0.00 
18.34 
97.71 
36.53 
0.00 
0.00 
0.00 
0.00 
25.84 
12.34 
24.74 
24.51 
21 .32 
60.99 
62.27 
33.30 
57.88 
36.32 
0.00 
0.22 
0.00 
0.10 
0.00 
0.28 
0.00 
0.12 
0.11 
0.30 
1.89 
0.96 
1.17 
0.99 
0.00 
0.00 
0.36 
0.84 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
0.00 
0.00 
1.26 
0.00 
0.88 
0.00 
0.50 
0.95 
0.00 
0.96 
7.93 
2.12 
0.46 
1.81 
1.72 
1.21 
1.70 
1.81 
4.57 
16.39 
6.42 
1.64 
10.67 
3.46 
6.29 
6.37 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
27.76 
17.26 
45.41 
26.53 
0.00 
21.19 
0.00 
12.03 
20.58 
I 34 
4 38 
33.31 
9.50 
5.18 
817 
\0 44 
7 14 
8 41 
7 II 
24 90 
56 93 
26 63 
29 21 
46 24 
29 45 
37 50 
3100 
0.00 
18 34 
195 41 
63 89 
000 
000 
0.00 
000 
45.20 
50.39 
42.00 
74  36 
51.66 
6565 
106.62 
33.30 
84 42 
85.10 
6.02 
9.47 
39.62 
14.71 
8.74 
13.73 
15.67 
11.78 
13.35 
18.85 
39.17 
73.30 
40.58 
38.75 
59.53 
43.55 
49.55 
44.19 
28.03 
45.94 
235.58 
95.10 
22.66 
32.22 
30.82 
28.30 
75.56 
88.39 
83.76 
123.09 
93.98 
96.65 
141.65 
70.42 
118.55 
104.06 
6.02 
9.47 
39.62 
14.71 
8.74 
13.73 
15.67 
11.78 
13.35 
26.90 
46.88 
80.86 
48.37 
46.2\ 
86.50 
50.24 
56.66 
51.70 
51.40 
71.08 
257.75 
11 9.02 
48.83 
57.26 
55.03 
53.64 
99.90 
130.71 
124.65 
164.17 
135.30 
136.93 
182.02 
107.42 
158.43 
144.79 N  ,.... 
\0 
Table 37 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to59yrs 
60 to 74yrs 
75+yrs 
sul>-lolal of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of afl male 
Total Comparator Coh0/1 
NSAID ONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
N 
8640 
11360 
5410 
25432 
9617 
9579 
2722 
219t8 
47350 
9324 
13319 
6768 
29411 
50 to 59yrs  7185 
60 to 74yrs  9594 
75+yrs  3022 
sub-total of all male  19801 
Total NSAID Only Sui>-Cohort  492t 2 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
33 
75 
42 
150 
24 
28 
10 
62 
Total NSAID & Misoproslol Sui>-Coh0/1  212 
NSAID & H2/0MEPRAZOLE 
Female 
50 to 59yrs  339 
60 to 74yrs  623 
75+yrs  284 
sul>-lolal of  all female  1246 
Male 
50 to 59yrs  255 
60 to 74yrs  492 
75+yrs  t20 
sub-total of all male  867 
Tolal NSAID & H2/0meprazole Sui>-Coh0/1  2t t3 
All the Costs(£) Incorporated In the Economic Modelling of the Tayside Population Based on Six Months Observations (from the Index date) 
Base Cost  Event Costs  Event Costs  Event Costs  Event Costs  Costs of  Cost of  Cost of all  Cost of all  Cost of all  Cost of all  Cost of all  Hidden  Shadow 
Drug R)(  NSAID Rx  H21Losec Rx  Other Rx  All Rx  GP VIsits (Rx)  Endoscopies  Gl admissions  CV admissions  RH admissions  OS admissions  admissions  Costs  Costs 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7.11 
7.51 
23.37 
25.14 
22.t7 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41 .08 
41 .32 
40.28 
40.37 
37.00 
39.88 
40.73 
11.16 
13.92 
16.32 
13.59 
8.57 
11.88 
14.27 
11.04 
12.57 
12.64 
14.82 
21.17 
16.t2 
15.34 
12.14 
16.62 
14.10 
15.53 
20.09 
18.96 
25.49 
20.75 
13.25 
15.25 
16.11 
14.78 
18.30 
6.49 
8.18 
9.27 
7.83 
6.72 
9.54 
8.14 
8.13 
7.97 
6.t8 
8.44 
8.47 
7.73 
6.31 
8.20 
7.32 
7.38 
7.59 
27.76 
41 .06 
36.73 
36.92 
28.05 
47.78 
34.93 
38.07 
37.26 
90.27 
94.00 
104.11 
95.29 
75.54 
90.20 
87.48 
85.51 
91.28 
7.90 
6.69 
8.77 
7.55 
4.12 
6.67 
6.85 
5.55 
6.62 
16.22 
17.73 
20.59 
17.91 
12.50 
18.28 
20.77 
16.56 
17.36 
43.48 
23.56 
24.30 
28.15 
12.66 
31.44 
13.83 
21.33 
26.15 
28.25 
36.05 
38.46 
34.48 
25.34 
40.85 
39.73 
36.02 
35.11 
14.39 
14.87 
18.04 
15 38 
10.84 
16 21 
14 79 
13 68 
14.59 
33.56 
4008 
45 37 
39 23 
27 37 
3835 
42 36 
34 98 
37.52 
83.88 
79 44 
82 20 
81  19 
56 04 
91 .36 
85.38 
73 50 
78 94 
138 61 
149 01 
168.06 
150 52 
I 14.13 
146.10 
143.33 
136.31 
144.69 
4 40 
4 59 
549 
4.72 
2.85 
4 37 
4.42 
3 71 
4 25 
15 52 
20 38 
24 88 
19 87 
12 76 
19.36 
22 81 
17 49 
18.91 
28 72 
30 96 
34.49 
31 .46 
2200 
32.16 
23.70 
2686 
30 II 
3890 
42.63 
52 01 
43.76 
33.05 
40.43 
44.68 
38.85 
41 .74 
1 30 
I 52 
I  16 
1 37 
1.45 
I 81 
I  15 
1.57 
I 46 
2.08 
I 91 
1 79 
I 93 
I 51 
1 74 
165 
164 
1 82 
0.00 
5.56 
0.00 
2 78 
0.00 
000 
000 
000 
1 97 
7 37 
7 02 
660 
7.02 
7 35 
5.93 
5 21 
6 25 
6.70 
1.78 
8.45 
7.08 
5.89 
3.05 
6.46 
9.42 
5.33 
5.63 
2.73 
11 .92 
30.03 
13.17 
6.53 
9.60 
19.88 
t0.05 
11 .92 
0.00 
0.00 
138.98 
38.92 
0.00 
0.00 
0.00 
0.00 
27.53 
18.62 
11.17 
33.04 
18.18 
13.36 
81 .54 
6.75 
51 .14 
31 .70 
3.27 
16.83 
92.33 
28.28 
t6.20 
t7.94 
78.72 
24.73 
26.63 
15.45 
49.15 
141.98 
59.82 
60.12 
114.45 
89.08 
90.87 
72.3t 
0.00 
18.34 
944.50 
273.63 
0.00 
0.00 
0.00 
0.00 
193.61 
28.25 
97.35 
134.07 
86.92 
151.89 
203.74 
78.01 
171.09 
121.46 
0.00 
0.45 
7.53 
1.80 
0.00 
0.28 
0.00 
0.12 
1.03 
2.78 
9.08 
5.38 
6.23 
1.65 
0.54 
0.61 
0.96 
4.11 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
12.68 
14.80 
10.97 
0.00 
11.11 
0.00 
6.30 
9.05 
1.85 
3.00 
24.94 
7.28 
2.28 
5.67 
9.05 
4.60 
6.04 
11.28 
25.90 
90.56 
36.15 
13.84 
30.71 
45.64 
26.87 
32.41 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
52.94 
53.88 
170.72 
80.26 
33.60 
49.25 
0.00 
37.83 
62.85 
689 
28 73 
131  88 
43 25 
21 53 
3036 
97 20 
34 79 
39 33 
32 25 
9604 
267 96 
I 15 38 
82 15 
155 30 
155 21 
128 74 
120.76 
26.98 
49.71 
156.57 
64.71 
36.67 
52.75 
I 17.55 
53.74 
59.63 
83.40 
158.41 
339.99 
176.42 
123.79 
214.75 
222.D3 
182.86 
179.01 
0.00  I 12.61 
18.34  134.30 
1083 48  1200.17 
312.54  427.97 
0.00 
000 
000 
000 
221  14 
104 43 
175 07 
352.63 
196.32 
198.85 
345.85 
84.76 
266 36 
225.06 
78.05 
123.52 
89.08 
100.36 
332.16 
289.31 
373.74 
579.30 
397.62 
353.39 
538.10 
277.98 
447.77 
418.20 
26.98 
49.71 
156.57 
64.71 
36.67 
52.75 
117.55 
53.74 
59.63 
91.45 
166.13 
347.54 
184  20 
131 .25 
221  72 
228.73 
189.96 
186.52 
135.97 
159.44 
1222.34 
451.89 
104.22 
148.56 
11 3.28 
125.70 
356.50 
331.63 
414.63 
620.38 
438.94 
393.67 
578.48 
314.98 
487.65 
458.93 N 
~ 
Table 38 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 lo 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
Total Comparator Cohort 
NSAIDONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
Total NSAIO Only Sub-Cohort 
NSAID & MISOPROSTOL 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
1otal NSAIO & Misoprostol Sub-Cohort 
NSAID & H210MEPRAZOLE 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
. NSAIO & H2/0meprazole Sub-Cohort 
N 
8640 
11380 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
7185 
9594 
3022 
19801 
49212 
33 
75 
42 
150 
24 
28 
10 
62 
212 
339 
623 
284 
1246 
255 
492 
120 
867 
2113 
All the Costs (E) Incorporated In the Economic Modelling of the Tayside Population Based on 12 Months (from the Index date) 
Base Cost  Event Costs  Event Costs  Event Costs  Event Costs  Costs of  Costs of all  Costs of all  Costs of all  Costs of all  Costs of all  Costs of all 
Drug Rx  NSAID Rx  H21Losec Rx  Other Rx  All Rx  GP Visits (Rx)  Endoscpies  Gl admlsslonsCV admlsslonsRH admisslo"'OS admlsslo"'  admissions 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7.11 
7.51 
23.37 
25.14 
22.17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41.08 
41.32 
40.28 
40.37 
37.00 
39.88 
40.73 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
21 .72 
27.18 
31.91 
26.54 
16.50 
23.45 
28.02 
21.63 
24.56 
24.75 
30.80 
31 .20 
29.58 
28.29 
23.34 
31.27 
26.53 
28.69 
39.29 
37.32 
46.42 
39.93 
29.30 
30.00 
31 .33 
29.98 
35.85 
13.23 
17.48 
18.99 
16.35 
13.89 
19.89 
16.91 
16.89 
16.60 
14.02 
18.90 
18.76 
17.32 
14.16 
18.23 
15.78 
16.38 
16.94 
52.68 
91.23 
84.28 
75.21 
57.45 
96.12 
75.05 
77.75 
75.95 
184.48 
194.05 
211 .11 
195.33 
165.42 
192.37 
188.51 
183.91 
190.65 
19.74 
17.36 
22.75 
19.31 
10.39 
17.72 
21 .11 
14.93 
17.28 
39.35 
42.14 
45.63 
42.06 
31.87 
46.53 
50.53 
41.82 
41 .96 
143.66 
68.93 
49.58 
79.95 
42.38 
107.54 
33.55 
70.38 
77.15 
74.80 
89.85 
84.65 
84.57 
67.39 
100.22 
84.10 
88.33 
86.11 
32.97 
34.83 
41.74 
35.67 
24.29 
37.61 
38.01 
31 .81 
33.88 
75.10 
88.22 
96.29 
85.92 
62.53 
88.20 
94.33 
79.82 
83.47 
221.10 
190.96 
145.07 
184.74 
128.11 
227.00 
139.87 
174.67 
181.79 
298.57 
321 .22 
342.18 
319.83 
262.1  I 
322.60 
303.94 
302.22 
312.61 
8.58 
8.81 
9.95 
8.97 
5.52 
8.29 
8.34 
7.08 
8.10 
28.30 
36.46 
43.33 
35.46 
23.21 
34.91 
40.77 
31 .56 
33.89 
44.52 
52.54 
52.06 
50.64 
39.49 
52.95 
38.59 
45.42 
49.11 
67.80 
73.38 
86.60 
74.88 
59.36 
70.93 
77.80 
68.48 
72.25 
2.75 
3.33 
2.12 
2.88 
2.82 
3.57 
2.76 
3.14 
3.00 
3.66 
4.19 
3.76 
3.92 
3.65 
3.84 
3.24 
3.68 
3.83 
0.00 
16.67 
0.00 
8.33 
8.68 
0.00 
0.00 
3.36 
6.88 
15.36 
17.05 
9.54 
14.88 
15.52 
16.09 
10.42 
15.14 
14.99 
5.98 
17.48 
25.42 
15.26 
19.60 
16.26 
32.38 
19.73 
17.33 
7.04 
21 .55 
82.26 
30.92 
14.44 
16.71 
46.22 
20.39 
26.68 
0.00 
0.00 
227.18 
63.61 
0.00 
0.00 
0.00 
0.00 
45.01 
35.87 
21 .06 
44.63 
30.46 
31 .27 
116.04 
16.59 
77.34 
49.70 
8.75 
46.41 
212.36 
68.92 
31 .22 
45.98 
226.51 
61.92 
65.68 
41.29 
106.38 
313.35 
133.37 
120.43 
224.22 
245.56 
189.82 
156.08 
0.00 
56.57 
1607.34 
478.34 
24.94 
149.82 
0.00 
77.31 
361.06 
52.17 
195.32 
766.53 
286.57 
280.17 
423.11 
143.96 
342.43 
309.49 
0.57 
1.13 
7.66 
2.33 
0.00 
0.52 
0.00 
0.23 
1.35 
10.71 
14.70 
17.19 
14.01 
2.72 
1.44 
61 .25 
11.03 
12.81 
0.00 
13.31 
0.00 
6.66 
0.00 
0.00 
0.00 
0.00 
4.71 
14.01 
23.92 
31.75 
23.01 
0.00 
19.72 
0.00 
11 .19 
18.16 
1.95 
8.28 
49.74 
14.95 
7.04 
8.21 
18.17 
8.94 
12.16 
26.32 
68.03 
188.30 
82.48 
24.75 
59.99 
90.66 
51 .89 
70.17 
0.00 
116.33 
346.98 
155.32 
254.62 
0.00 
0.00 
98.56 
138.72 
103.98 
103.75 
276.98 
143.30 
65.06 
118.03 
0.00 
86.11 
119.83 
17.25 
73.30 
295.18 
101.45 
57.86 
70.97 
277.06 
90.81 
96.53 
85.36 
210.67 
601.09 
260.78 
162.34 
302.36 
443.68 
273.12 
265.75 
0.00 
186.22 
2181 .50 
703.93 
279.56 
149.82 
0.00 
175.87 
549.50 
206.04 
344.06 
I I 19.89 
483.34 
376.49 
676.91 
160.55 
517.08 
497.19 
Hidden 
Costs 
61.55 
120.28 
348.99 
148.97 
90.49 
120.43 
326.17 
132.85 
141.51 
I  92.42 
339.54 
744.47 
386.08 
251.73 
429.32 
582.03 
388.19 
386.93 
265.62 
446.38 
2378.64 
947.64 
455.84 
429.76 
178.46 
399.32 
787.29 
587.77 
755.71 
1558.21 
892.93 
713.49 
1086.53 
552.71 
902.93 
897.03 
Shadow 
Costs 
61 .55 
120.28 
348.99 
148.97 
90.49 
120.43 
326.17 
132.85 
141 .51 
200.47 
347.25 
752.02 
393.86 
259.19 
436.30 
588.72 
395.30 
394.44 
288.99 
471.52 
2400.81 
971.56 
482.01 
454.80 
202.66 
424.66 
811 .63 
630.09 
796.60 
1599.29 
934.25 
753.77 
1126.90 
589.71 
942.81 
937.76 APPENDIX VII 
SENSITIVITY ANALYSIS -POPULATION MODEL 
221 N 
N 
N 
Table 39 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total Comparator Cohort 
NSAID ONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total NSAID Only Su!>-Cohort 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
N 
8640 
11380 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
7185 
9594 
3022 
19801 
49212 
33 
75 
42 
150 
24 
28 
10 
62 
Tofal NSAID & Misoprostol Su!>-Cohort  212 
Female 
Mafe 
NSAID & H2/0MEPRAZOLE 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
339 
623 
264 
1246 
50 to 59yrs  255 
60 to 74yrs  492 
75+yrs  120 
sub-total of all mafe  867 
Total NSAID & H2/0meprazo/e Su!>-Cohort  2113 
Costs (£} Incorporated In the Sensitivity Analysis -when multiple episodes of care represent one single admission - Based on 45 Days Observations 
Base Cost  Additional  Additional  Additional  Event Cost  GP Visit (Rx)  Cost of  Cost of  Cost of  Cost of  Cost of  Cost  of  Hidden  Shadow 
Drug Rx  NSAID RX  Ulcer Rx  Other Rx  All Rx  Costs  Endoscopies  Gl admissions  CV admissions  RH admissions  OS admissions  all admissions  Costs  Costs 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7.11 
7.51 
23.37 
25.14 
22.17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41.08 
41.32 
40.28 
40.37 
37.00 
39.88 
40.73 
2.47 
2.92 
3.30 
2.87 
2.04 
2.49 
2.80 
2.37 
2.67 
5.01 
3.07 
8.58 
5.04 
4.05 
2.33 
3.09 
3.12 
4.48 
3.87 
3.64 
5.40 
4.10 
2.66 
3.14 
2.98 
2.98 
3.64 
1.39 
1.68 
2.17 
1.77 
1.48 
2.36 
2.20 
1.96 
1.86 
1.49 
1.85 
1.75 
1.71 
1.42 
1.75 
1.42 
1.58 
1.68 
9.68 
8.79 
11.07 
9.62 
8.30 
11.95 
9.83 
10.20 
9.79 
14.68 
16.30 
18.15 
16.33 
13.22 
13.48 
14.44 
13.54 
15.18 
1.50 
1.26 
2.02 
1.50 
0.85 
1.30 
1.39 
1.12 
1.32 
2.83 
3.16 
3.67 
3.17 
1.97 
3.21 
3.29 
2.77 
3.01 
3.31 
4.82 
5.05 
4.55 
2.13 
5.85 
5.05 
4.28 
4.47 
5.16 
6.76 
6.34 
6.23 
4.17 
6.56 
6.89 
5.90 
6.10 
2.89 
3.14 
4.19 
328 
2.33 
3.67 
3 59 
3.07 
3.18 
679 
7 93 
8 72 
775 
5 43 
7 45 
7 51 
6 73 
7 34 
17.98 
16.68 
24.70 
19.21 
14.48 
20.14 
17.96 
17.60 
18.74 
23.90 
26.70 
29.89 
26.67 
20.05 
23. 17 
24.31 
22.41 
24.92 
I 28 
1.51 
186 
150 
086 
I 42 
1.56 
1.19 
1 36 
4 46 
6.01 
7 44 
5 85 
3 76 
5 51 
6 31 
500 
5 51 
10 05 
10 92 
15 47 
12.01 
818 
1209 
12.68 
10.70 
11.62 
t1  02 
12 71 
17.38 
13.32 
9.32 
11  01 
12.81 
10.76 
12 27 
051 
0 44 
0.27 
0 43 
0 37 
0.48 
0.08 
0 38 
0 40 
0 49 
0 33 
0 22 
0 35 
0 35 
0 33 
028 
0 33 
0.34 
0.00 
0.00 
0.00 
000 
000 
000 
000 
000 
0.00 
3 07 
2 34 
1.47 
2 34 
1 63 
0.85 
000 
096 
1.77 
0.70 
1.19 
2.03 
1.20 
0.78 
2.18 
1.13 
1.44 
1.31 
0.92 
4.86 
9.06 
4.58 
2.58 
3.56 
8.92 
4.03 
4.35 
0.00 
0.00 
97.71 
27.36 
0.00 
0.00 
0.00 
0.00 
19.36 
5.68 
0.00 
4.44 
2.56 
4.85 
22.16 
0.00 
13.95 
7.23 
0.64 
1.97 
23.25 
6.05 
3.86 
3.85 
7.54 
4.31 
5.24 
4.02 
13.45 
30.19 
14.31 
23.78 
31 .68 
16.93 
26.56 
19.24 
0.00 
18.34 
97.71 
36.53 
0.00 
0.00 
0.00 
0.00 
25.64 
12.01 
24.85 
23.72 
21.00 
59.35 
61.24 
33.30 
56.82 
35.70 
0.00 
0.22 
0.00 
0.10 
0.00 
0.28 
0.00 
0.12 
0.11 
0.30 
1.89 
0.96 
1.17 
0.98 
0.00 
0.00 
0.35 
0.64 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
0.00 
0.00 
1.26 
0.00 
0.68 
0.00 
0.50 
0.95 
0.00 
0.96 
7.91 
2.11 
0.46 
1.81 
1.72 
1.21 
1.69 
1.81 
4.57 
16.36 
6.41 
1.64 
10.66 
3.46 
6.29 
6.36 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
27.76 
17.26 
45.41 
26.53 
0.00 
21.19 
0.00 
12.03 
20.58 
I 34 
4 34 
33 20 
9 46 
509 
8 13 
10.39 
7 08 
8.36 
7 04 
2476 
56.57 
26 46 
2898 
4590 
29 31 
37 23 
3060 
000 
18 34 
195.41 
63.89 
000 
0.00 
0.00 
000 
45 20 
5006 
41  91 
73 57 
51  34 
6400 
105 48 
3330 
83 29 
64.45 
6.02 
9.42 
39.51 
14.67 
8.65 
13.69 
15.63 
11 .72 
13.30 
18.79 
39.03 
72.94 
40.42 
38.52 
59.20 
43.41 
49.29 
43.99 
28.03 
45.94 
235.58 
95.10 
22.66 
32.22 
30.82 
28.30 
75.56 
88.06 
83.67 
122.30 
93.67 
95.00 
140.51 
70.42 
117.42 
103.41 
6.02 
9.42 
39.51 
14.67 
8.65 
13.69 
15.63 
1 1.72 
13.30 
26.84 
4674 
80.50 
48.20 
45.98 
66.17 
50.10 
56 39 
51  50 
5 1.40 
71.08 
257.75 
11 9.02 
48.83 
57.26 
55.03 
53 64 
99.90 
130.38 
124.56 
163.38 
134.99 
135.28 
180.88 
107.42 
157.30 
144.14 N 
N  w 
Table 40 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sulrtotaf of alf female 
N 
8640 
11380 
5410 
25432 
50 to 59yrs  9617 
60 to 74yrs  9579 
75+yrs  2122 
sub-total of aff mate  2t9t8 
Total Comparator Cohort  47350 
NSAID ONLY 
50 to 59yrs  9324 
60 to 74yrs  13319 
75+yrs  6768 
sulrtotal of all female  294 11 
50 to 59yrs  7185 
60 to 74yrs  9594 
75+yrs  3022 
sub-total of all male  t9801 
Total NSAID Only Sui>-Cohort  49212 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to  74yrs 
75+yrs 
sulrtotal of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sutrtotal of all male 
33 
75 
42 
150 
24 
28 
10 
62 
Total NSAID &  Misoprostol Sub-Cohort  212 
Female 
Male 
NSAID & H210MEPRAZOLE 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sutrtotal of all female 
339 
623 
284 
1246 
50 to 59yrs  255 
60 to 74yrs  492 
75+yrs  120 
sub-total of all male  867 
Total NSAID & H210meprazole SulrCohort  2113 
Costs(£) Incorporated In the Sensitivity Analysis· when multiple episodes of care represents one single admission· Based on Six Months Observations 
Base Cost  Event Costs  Event Costs  Event Costs  Event Costs 
Drug Rx 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7.11 
7.51 
23.37 
25.14 
22.17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41.08 
41.32 
40.26 
40.37 
37.00 
39.66 
40.73 
NSAID Rx  H2/losec Rx  Other Rx 
11.16 
13.92 
16.32 
13.59 
8.57 
11.66 
14.27 
11 .04 
12.57 
12.84 
14.82 
21.17 
16.12 
15.34 
12.14 
16.62 
14.10 
15.53 
20.09 
16.96 
25.49 
20.75 
13.25 
15.25 
16.11 
14.76 
18.30 
6.49 
8.18 
9.27 
7.83 
6.72 
9.54 
8.14 
8.13 
7.97 
6.18 
8.44 
8.47 
7.73 
6.31 
8.20 
7.32 
7.38 
7.59 
27.76 
41.06 
36.73 
36.92 
26.05 
47.76 
34.93 
36.07 
37.26 
90.27 
94.00 
104. II 
95.29 
75.54 
90.20 
87.48 
85.51 
91.28 
7.90 
6.69 
8.77 
7.55 
4.12 
6.67 
6.85 
5.55 
6.62 
16.22 
17.73 
20.59 
17.91 
12.50 
18.28 
20.77 
16.56 
17.36 
43.48 
23.56 
24.30 
26.15 
12.66 
31.44 
13.83 
21.33 
26.15 
26.25 
36.05 
38.46 
34.46 
25.34 
40.65 
39.73 
36.02 
35. II 
AIIRx 
14.39 
14.87 
18.04 
15.38 
10.84 
16 21 
14 79 
1366 
14  59 
33.56 
40 08 
45.37 
39 23 
27.37 
38.35 
42.36 
34 98 
37 52 
83.88 
79 44 
8220 
81 19 
56 04 
91 36 
65 38 
7350 
78.94 
138.6 1 
14901 
16606 
15052 
114.13 
146.10 
143.33 
136 3 1 
144 69 
Costs of  Cost of  Cost of all  Cost of all  Cost of all  Cost of all  Cost of all 
GP Visits (Rx)  Endoscopies  Gl admissions  CV admissions  RH admissions  OS admissions  admissions 
Shadow 
Costs 
4.40 
4 59 
5 49 
4 72 
285 
4 37 
4.42 
3 71 
4 25 
15.52 
20 36 
24.88 
19 87 
12.76 
19.36 
22.8 1 
17 49 
18 91 
26.72 
30.96 
34.49 
31.46 
22.00 
32.16 
23 70 
2686 
30  11 
38 90 
42.63 
52.01 
43.76 
3305 
40.43 
44 .68 
38.85 
41. 74 
I 30 
152 
I  16 
137 
145 
1.81 
I  15 
I 57 
I 46 
2.06 
1.91 
I  79 
I 93 
I 51 
1.74 
165 
I 64 
I 62 
0 00 
5 56 
0.00 
2 78 
0 00 
000 
000 
0.00 
I 97 
7 37 
7.02 
660 
7 02 
7 35 
5 93 
5 21 
6 25 
6.70 
1.77 
8.35 
7.03 
5.83 
2.99 
6.41 
9.25 
5.26 
5.57 
2.66 
11 .86 
29.81 
13.08 
6.42 
9.53 
19.73 
9.96 
11.82 
0.00 
0.00 
136.62 
36.81 
0.00 
0.00 
0.00 
0.00 
27.46 
18.62 
10.77 
32.51 
17.86 
13.36 
81.40 
6.75 
51.06 
31.46 
3.24 
16.72 
91.92 
26.14 
16.06 
17.77 
76.40 
24.55 
26.46 
15.25 
48.61 
141.00 
59.30 
59.36 
113.26 
66.37 
89.90 
71.61 
0.00 
18.34 
944.14 
273.53 
0.00 
0.00 
0.00 
0.00 
193.53 
27.83 
96.64 
130.86 
85.72 
147.99 
201.00 
76.95 
166.24 
119.58 
0.00 
0.45 
7.51 
1.60 
0.00 
0.28 
0.00 
0.12 
1.02 
2.77 
9.06 
5.35 
6.21 
1.65 
0.54 
0.61 
0.95 
4.10 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
12.56 
14.60 
10.91 
0.00 
10.96 
0.00 
6.22 
8.98 
1.65 
3.00 
24.92 
7.27 
2.28 
5.67 
9.03 
4.60 
6.03 
11.27 
25.87 
90.40 
36.09 
13.62 
30.70 
45.83 
26.85 
32.38 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
52.94 
53.66 
169.66 
60.02 
33.60 
49.25 
0.00 
41.29 
62.71 
6.66 
26 52 
131.37 
43.04 
21  33 
30 13 
9669 
34 53 
39  10 
31  97 
95 40 
266 56 
114.68 
81  25 
154  03 
154 34 
127  67 
119 9 1 
26.94 
49.50 
156.06 
64.50 
36.47 
52.51 
I 17.04 
53.49 
59.40 
83.12 
157.77 
338.59 
175.72 
122.89 
213.48 
22 1.17 
18 1.78 
178.16 
000  112.61 
18 34  134.30 
1082.76  1199.45 
312 34  427.77 
0.00 
000 
0.00 
000 
221 .00 
104.01 
173.84 
347.65 
194.50 
194.96 
342.6 1 
63.70 
266.81 
222.75 
78.05 
123.52 
69.08 
100.36 
332.D2 
266.69 
372.50 
574.53 
395.60 
349.50 
535.07 
276.92 
446.22 
415.89 
Total 
Costs 
26.94 
49.50 
156.06 
64.50 
36.47 
5251 
11 7.04 
53.49 
59.40 
9 1. 17 
165.49 
346.14 
183 50 
130.35 
220.45 
227.86 
166 89 
185.67 
135.97 
159.44 
122 162 
45 1.69 
104.22 
148.56 
113.28 
125 70 
356.35 
33121 
41 3.39 
615.60 
437.12 
389.78 
575.44 
313.92 
488.10 
456.62 N 
N 
+::-. 
Table 41 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 lo 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
Total Comparator Cohort 
NSAIDONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
Total NSAID Only Sub-Cohort 
NSAID & MISOPROSTOL 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
7otal NSAID & Misoprostol Sub-Cohort 
NSAID & H210MEPRAZOLE 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of  all male 
. NSAID & H2/0meprazole Sub-Cohort 
N 
8640 
11380 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
7185 
9594 
3022 
19801 
49212 
33 
75 
42 
150 
24 
28 
10 
62 
212 
339 
623 
284 
1246 
255 
492 
120 
867 
2113 
Costs (£)Incorporated In the Sensitivity Analysis ·when multiple episodes of care represent one single admission ·Based on 12 Months 
Base Cost  Event Costs  Event Costs  Event Costs  Event Costs  Costs of  Costs of all  Costs of all  Costs of all  Costs of all  Costs of all  Costs of all  Shadow 
Drug Rx 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7.11 
7.51 
23.37 
25.14 
22.17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41.08 
41.32 
40.28 
40.37 
37.00 
39.88 
40.73 
NSAID Rx  H21Losec Rx  Other Rx 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
21.72 
27.18 
31 .91 
26.54 
16.50 
23.45 
28.02 
21 .63 
24.56 
24.75 
30.80 
31 .20 
29.58 
28.29 
23.34 
31.27 
26.53 
28.69 
39.29 
37.32 
46.42 
39.93 
29.30 
30.00 
31.33 
29.98 
35.85 
13.23 
17.48 
18.99 
16.35 
13.89 
19.89 
16.91 
16.89 
16.60 
14.02 
18.90 
18.76 
17.32 
14.16 
18.23 
15.78 
16.38 
16.94 
52.68 
91 .23 
64.28 
75.21 
57.45 
96.12 
75.05 
77.75 
75.95 
184.48 
194.05 
211 .11 
195.33 
165.42 
192.37 
188.51 
183.91 
190.65 
19.74 
17.36 
22.75 
19.31 
10.39 
17.72 
21 .11 
14.93 
17.28 
39.35 
42.14 
45.63 
42.06 
31 .87 
46.53 
50.53 
41 .82 
41.96 
143.66 
68.93 
49.58 
79.95 
42.38 
107.54 
33.55 
70.38 
77.15 
74.80 
89.85 
84.65 
84.57 
67.39 
100.22 
84.10 
88.33 
86.11 
All Rx 
32.97 
34.83 
41.74 
35.67 
24.29 
37.61 
38.01 
31 .81 
33.88 
75.10 
88.22 
96.29 
85.92 
62.53 
88.20 
94.33 
79.82 
83.47 
221 .10 
190.96 
145.07 
184.74 
128.11 
227.00 
139.87 
174.67 
181.79 
298.57 
321 .22 
342.18 
319.83 
262.11 
322.60 
303.94 
302.22 
312.61 
GP Visits (Rx) Endoscpies  Gl admlsslonsCV admlssionsRH admlsslonsOS admissions  admissions 
8.58 
8.81 
9.95 
8.97 
5.52 
8 29 
8.34 
7 08 
8.10 
28.30 
36.46 
43.33 
35.46 
23.21 
34.9 1 
40.77 
31.56 
33.89 
44.52 
52.54 
52.06 
50.64 
39.49 
52.95 
38.59 
45.42 
49.11 
67.80 
73.38 
86.60 
74.88 
59.36 
70.93 
77.80 
68.48 
72.25 
2.75 
3.33 
2.12 
2.88 
2.82 
3.57 
2.76 
3.14 
3.00 
3.66 
4.19 
3.76 
3.92 
3.65 
3.84 
3.24 
3.68 
3.83 
0.00 
16.67 
0.00 
8.33 
8.68 
0.00 
0.00 
3.36 
6.88 
15.36 
17.05 
9.54 
14.88 
15.52 
16.09 
10.42 
15.14 
14.99 
5.95 
17.20 
25.06 
15.05 
19.49 
16.12 
31.90 
19.56 
17.14 
6.94 
21.40 
81.68 
30.69 
14.15 
16.54 
45.78 
20.13 
26.44 
0.00 
0.00 
224.68 
62.91 
0.00 
0.00 
0.00 
0.00 
44.51 
35.87 
20.63 
43.91 
30.08 
31 .21 
115.46 
16.47 
76.98 
49.33 
8.67 
46.18 
211.47 
68.59 
30.90 
45.57 
225.40 
61.47 
65.29 
40.69 
105.23 
311 .23 
132.17 
118.72 
221.41 
244.10 
187.61 
154.48 
0.00 
55.57 
1601.73 
476.27 
24.94 
149.82 
0.00 
77.31 
359.60 
51.75 
192.46 
761.78 
283.94 
275.11 
416.52 
142.90 
337.06 
305.74 
0.57 
1.11 
7.62 
2.32 
0.00 
0.52 
0.00 
0.23 
1.35 
10.69 
14.67 
17.12 
13.97 
2.71 
1.44 
61 .25 
11 .03 
12.79 
0.00 
13.31 
0.00 
6.66 
0.00 
0.00 
0.00 
0.00 
4.71 
13.90 
23.68 
31.75 
22.86 
0.00 
19.09 
0.00 
10.83 
17.92 
1.95 
8.28 
49.70 
14.94 
7.03 
8.21 
18.14 
8.92 
12.15 
26.30 
67.92 
187.97 
82.35 
24.72 
59.95 
90.59 
51 .84 
70.08 
0.00 
116.33 
346.98 
155.32 
252.42 
0.00 
0.00 
97.71 
138.47 
103.98 
103.75 
275.94 
143.06 
65.00 
117.93 
0.00 
86.04 
119.66 
17.15 
72.77 
293.85 
100.90 
57.41 
70.42 
275.45 
90.18 
95.93 
84.63 
209.23 
597.99 
259.19 
160.30 
299.33 
441.70 
270.61 
263.79 
0.00 
185.22 
2173.40 
701 .16 
277.36 
149.82 
0.00 
175.03 
547.29 
205.51 
340.51 
111 3.38 
479.94 
371 .32 
669.01 
159.37 
510.91 
492.65 
Costs 
61.44 
11 9.74 
347.66 
148.41 
90.04 
119.88 
324.56 
132.21 
140.91 
191 .69 
338.10 
741 .38 
384.49 
249.70 
426.29 
580.05 
385.68 
384.96 
265.62 
445.38 
2370.53 
944.88 
453.65 
429.76 
178.46 
398.48 
785.08 
587.24 
752.17 
1551 .70 
889.53 
708.32 
1078.63 
551.52 
896.76 
892.50 
Total 
Costs 
6 1.44 
119.74 
347.66 
148.41 
90.04 
119.88 
324.56 
132.21 
140.91 
199.74 
345.81 
748.93 
392.27 
257.16 
433.27 
586.74 
392.79 
392.47 
288.99 
470.52 
2392.70 
968.80 
479.82 
454.80 
202.66 
423.82 
809.42 
629.56 
793.06 
1592.78 
930.85 
748.60 
1119.00 
588.52 
936.64 
933.23 Table42 
base  CO·Rx 
N  drugs  nsaid 
non-aspirin takers 
comparator 47350  0.00  0.00 
NSAID  41554  8.48  5.86 
misoprostol  206  24.50  9.07 
h2  1683  41.82  8.38 
aspirin takers 
comparator 
NSAID 
misoprostol 
h2 
no prior gi 
0 
7658 
6 
430 
comparator 45338 
NSAID  47630 
misoprostol  185 
h2  1740 
had prior gi 
comparator  2012 
NSAID  1582 
misoprostol  27 
h2  373 
no prior cv 
comparator 44515 
NSAID  43143 
misoprostol  183 
h2  1665 
had prior cv 
comparator  2835 
NSAID  6069 
misoprostol  29 
h2  448 
no prior endoscopy 
comparator 43892 
NSAID  45340 
misoprostol  170 
h2  1433 
had prior endoscopy 
comparator  3458 
NSAID  3872 
misoprostol  42 
h2  680 
no prior nsaid 
comparator 4 7350 
NSAID  37871 
misoprostol  193 
h2  1452 
had prior nsaid 
comparator  0 
NSAID  11341 
misoprostol  19 
h2  661 
no risk factors 
comparator 40612 
NSAID  27635 
misoprostol  116 
h2  610 
no mortality (survivors) 
comparator 42081 
NSAID 42445 
misoprostol  184 
h2  1767 
mortality 
0.00 
2.25 
18.73 
36.47 
0.00 
7.51 
24.06 
40.18 
0.00 
7.47 
26.23 
43.27 
0.00 
7.81 
23.76 
41.10 
0.00 
5.36 
27.95 
39.34 
0.00 
7.50 
24.25 
38.52 
0.00 
7.59 
24.70 
45.39 
0.00 
7.00 
24.23 
40.11 
0.00 
9.23 
25.40 
42.10 
0.00 
7.77 
23.08 
38.15 
0.00 
7.55 
24.47 
40.81 
comparator  5269  0.00 
NSAID  6767  7.24 
misoprostol  24  23.43 
h2  346  40.33 
survivors with no risk factors 
comparator 36721  0.00 
NSAID  25332  7.74 
misoprostol  105  23.36 
h2  548  37.91 
0.00 
2.21 
3.15 
2.68 
0.00 
5.27 
7.91 
7.11 
0.00 
5.90 
15.68 
7.76 
0.00 
5.42 
8.44 
7.77 
0.00 
4.37 
11.78 
5.19 
0.00 
5.33 
8.81 
7.29 
0.00 
4.88 
9.25 
7.09 
0.00 
4.19 
8.35 
4.85 
0.00 
8.99 
14.48 
12.44 
0.00 
2.29 
3.28 
3.03 
0.00 
5.08 
8.61 
6.99 
0.00 
6.65 
10.84 
8.41 
0.00 
2.22 
3.15 
3.12 
Sensitivity Analysis of Risk Factors • 45 Days Follow-up Period 
CO•Rx  co·Rx  gp visit 
ulcer  other 
3.70  2.16 
3.27  4.57 
18.86  7.24 
29.23  9.33 
0.00 
3.42 
35.53 
34.40 
2.68 
2.75 
18.04 
29.74 
26.69 
19.77 
28.20 
32.81 
3.32 
2.95 
17.23 
28.74 
9.74 
5.74 
32.61 
36.03 
2.08 
2.15 
17.71 
28.01 
24.34 
16.76 
25.91 
35.07 
3.70 
3.52 
18.95 
28.90 
0.00 
2.55 
23.26 
33.32 
0.76 
0.91 
6.40 
11.68 
3.50 
3.23 
18.05 
29.68 
5.32 
3.70 
27.77 
33.38 
0.73 
0.87 
5.72 
11.41 
0.00 
8.53 
12.45 
15.33 
1.95 
5.06 
6.88 
10.04 
6.87 
9.09 
10.84 
12.94 
1.91 
4.49 
5.71 
9.03 
6.06 
10.16 
17.94 
16.23 
1.74 
4.81 
7.20 
8.98 
7.58 
9.64 
8.16 
13.87 
2.16 
4.91 
7.40 
10.53 
0.00 
6.13 
7.24 
10.62 
0.88 
2.02 
3.12 
3.71 
2.11 
4.84 
7.51 
10.12 
2.58 
7.35 
6.60 
12.74 
0.84 
1.95 
3.09 
3.72 
cost  endoscop' 
1.36  0.40 
5.07  0.31 
11.44  0.00 
11.63  1.49 
0.00 
7.87 
18.05 
14.75 
1.14 
5.36 
10.76 
11.96 
6.21 
9.84 
17.55 
13.72 
1.23 
5.05 
10.14 
11.25 
3.34 
8.77 
21.01 
16.03 
1.00 
5.21 
11.59 
11.71 
5.96 
8.94 
11.77 
13.44 
1.36 
4.74 
11.12 
10.69 
0.00 
8.06 
16.75 
15.74 
0.84 
3.80 
8.29 
8.45 
1.31 
5.15 
10.67 
11.77 
1.77 
7.74 
17.89 
14.81 
0.82 
3.65 
7.35 
8.28 
0.00 
0.52 
0.00 
2.91 
0.28 
0.31 
0.00 
1.80 
3.11 
1.19 
0.00 
1.68 
0.39 
0.26 
0.00 
1.50 
0.66 
0.93 
0.00 
2.79 
0.20 
0.25 
0.00 
0.73 
2.95 
1.40 
0.00 
3.98 
0.40 
0.34 
0.00 
1.87 
0.00 
0.35 
0.00 
1.58 
0.19 
0.17 
0.00 
0.68 
0.38 
0.35 
0.00 
2.12 
0.59 
0.31 
0.00 
0.00 
0.19 
0.16 
0.00 
0.76 
hospital  hospital  hospital  hospital  shadow  total 
gi 
1.32 
4.27 
19.92 
7.81 
0.00 
5.09 
0.00 
5.09 
0.89 
4.06 
22.18 
2.40 
11.09 
14.61 
0.00 
29.91 
1.32 
3.70 
0.00 
7.89 
1.34 
9.32 
141.51 
4.89 
0.98 
3.76 
24.14 
7.84 
5.63 
11.80 
0.00 
6.04 
1.32 
5.14 
21.26 
3.22 
0.00 
1.90 
0.00 
16.11 
0.83 
4.29 
0.00 
0.00 
1.11 
3.35 
22.30 
2.78 
2.98 
10.92 
0.00 
30.09 
0.66 
3.11 
0.00 
0.00 
cv 
5.28 
13.05 
26.60 
22.09 
0.00 
53.85 
0.00 
92.02 
4.86 
18.95 
29.62 
34.48 
14.77 
33.02 
0.00 
44.91 
3.21 
12.48 
7.52 
15.11 
37.89 
68.62 
141.51 
115.16 
4.62 
19.03 
32.23 
41.63 
13.66 
23.69 
0.00 
25.14 
5.28 
20.58 
28.39 
37.22 
0.00 
15.45 
0.00 
34.35 
2.77 
10.22 
11.86 
17.62 
2.31 
14.00 
29.78 
32.14 
28.98 
53.26 
0.00 
57.66 
1.57 
8.76 
13.10 
16.67 
ra 
0.11 
0.87 
0.00 
0.93 
0.00 
0.70 
0.00 
1.01 
0.06 
0.75 
0.00 
1.15 
1.25 
3.77 
0.00 
0.00 
0.06 
0.93 
0.00 
0.94 
0.88 
0.20 
0.00 
0.97 
0.12 
0.63 
0.00 
0.00 
0.00 
3.28 
0.00 
2.94 
0.11 
0.45 
0.00 
0.30 
0.00 
2.14 
0.00 
2.37 
0.07 
0.24 
0.00 
0.00 
0.06 
0.66 
0.00 
0.89 
0.51 
1.99 
0.00 
1.25 
0.00 
0.26 
0.00 
0.00 
oa 
1.70 
7.19 
0.00 
19.84 
0.00 
1.88 
0.00 
24.25 
cost 
16.03 
44.47 
93.12 
110.54 
0.00 
84.07 
69.18 
192.44 
cost 
16.03 
52.95 
117.62 
152.35 
0.00 
86.32 
87.91 
228.90 
1.60  13.46  13.46 
6.48  48.99  56.50 
0.00  95.39  119.45 
13.94  112.61  152.80 
3.96 
2.96 
0.00 
51.55 
1.56 
6.49 
0.00 
20.01 
3.87 
5.47 
0.00 
22.69 
1.65 
6.40 
0.00 
18.26 
2.30 
5.98 
0.00 
25.47 
1.70 
4.27 
0.00 
17.03 
0.00 
13.35 
0.00 
28.38 
1.51 
5.11 
0.00 
0.00 
1.63 
5.56 
0.00 
24.61 
2.26 
11.42 
0.00 
0.00 
1.53 
4.62 
0.00 
0.00 
73.94  73.94 
100.15  107.63 
72.27  98.50 
195.27  238.54 
12.99 
41.78 
49.04 
102.24 
63.79 
113.56 
366.35 
219.98 
12.38 
47.58 
101.68 
124.44 
62.42 
86.38 
55.09 
133.03 
16.03 
48.15 
95.47 
114.60 
0.00 
58.92 
61.72 
154.90 
7.84 
29.05 
32.94 
45.17 
12.41 
42.23 
96.91 
121.11 
45.00 
103.33 
63.10 
158.35 
6.33 
25.61 
32.41 
43.95 
12.99 
49.59 
72.80 
143.34 
63.79 
118.92 
394.30 
259.32 
12.38 
55.08 
125.92 
162.95 
62.42 
93.97 
79.78 
178.42 
16.03 
55.14 
119.70 
154.70 
0.00 
68.15 
87.12 
196.99 
7.84 
36.82 
56.02 
83.32 
12.41 
49.78 
121.38 
161.91 
45.00 
110.57 
86.53 
198.68 
6.33 
33.35 
55.77 
81.86 
225 Table43 
N 
non-aspirin takers 
comparator 4 7350 
NSAID  41554 
misoprostol  206 
h2  1683 
aspirin takers 
comparator  0 
NSAID  7658 
misoprostol  6 
h2  430 
no priorgi 
comparator 45338 
NSAID  47630 
misoprostol  185 
h2  1740 
had prior gi 
comparator  2012 
NSAID  1582 
misoprostol  27 
h2  373 
no prior cv 
comparator 44515 
NSAID  43143 
misoprostol  183 
h2  1665 
had priorcv 
comparator  2835 
NSAID  6069 
misoprostol  29 
h2  448 
no prior endoscopy 
comparator 43892 
NSAID  45340 
misoprostol  170 
h2  1433 
had prior endoscopy 
comparator  3458 
NSAID  3872 
misoprostol  42 
h2  680 
no prior nsaid 
comparator 47350 
NSAID 37871 
misoprostol  193 
h2  1452 
had prior nsaid 
comparator  0 
NSAID  11341 
misoprostol  19 
h2  661 
no risk factors 
comparator 40612 
NSAID  27635 
misoprostol  116 
h2  610 
no mortality (survivors) 
comparator 42081 
NSAID  42445 
misoprostol  184 
h2  1767 
mortality 
comparator  5269 
NSAID  6767 
misoprostol  24 
h2  346 
base 
drugs 
0.00 
8.48 
24.50 
41.82 
0.00 
2.25 
18.73 
36.47 
0.00 
7.51 
24.06 
40.18 
0.00 
7.47 
26.23 
43.27 
0.00 
7.81 
23.76 
41.10 
0.00 
5.36 
27.95 
39.34 
0.00 
7.50 
24.25 
38.52 
0.00 
7.59 
24.70 
45.39 
0.00 
7.00 
24.23 
40.11 
0.00 
9.23 
25.40 
42.09 
0.00 
7.77 
23.08 
38.15 
0.00 
7.55 
24.47 
40.81 
0.00 
7.24 
23.43 
40.33 
survivors with no risk factors 
comparator 36721  0.00 
NSAID  25332  7.74 
misoprostol  105  23.36 
h2  548  37.91 
co-Rx 
nsaid 
0.00 
13.50 
15.24 
21.02 
0.00 
7.51 
25.51 
7.69 
0.00 
12.55 
14.68 
18.18 
0.00 
13.00 
21.33 
18.89 
0.00 
12.74 
14.69 
19.48 
0.00 
11.30 
20.84 
13.94 
0.00 
12.64 
16.25 
18.24 
0.00 
11.69 
12.61 
18.44 
0.00 
7.83 
13.52 
9.43 
0.00 
28.37 
35.94 
37.79 
0.00 
8.15 
12.91 
10.28 
0.00 
11.88 
13.92 
17.56 
0.00 
16.86 
26.07 
22.10 
0.00 
7.85 
11.96 
10.50 
Sensitivity Analysisof Risk Factors - Six Months Follow-up Period 
co-Rx 
ulcer 
7.97 
7.40 
36.23 
86.65 
0.00 
8.59 
72.45 
109.40 
5.89 
6.40 
34.68 
87.67 
54.84 
43.42 
54.95 
108.11 
7.18 
6.80 
30.68 
86.21 
20.37 
13.22 
78.76 
110.11 
4.53 
5.10 
35.16 
80.02 
51.64 
36.69 
43.92 
115.00 
7.97 
7.78 
36.63 
83.28 
0.00 
6.94 
43.66 
108.84 
3.38 
4.11 
22.54 
56.80 
7.59 
7.33 
34.95 
89.35 
11.02 
9.23 
52.40 
101.14 
3.25 
3.90 
19.72 
55.87 
co-Rx  gp visit 
other 
6.62 
14.43 
26.13 
29.77 
0.00 
33.29 
26.84 
56.03 
6.09 
16.97 
23.43 
33.48 
18.52 
29.34 
44.81 
42.70 
5.77 
14.61 
21.61 
27.86 
19.96 
36.95 
54.86 
62.06 
5.46 
16.26 
22.88 
30.38 
21.31 
30.34 
39.40 
45.09 
6.62 
15.81 
26.54 
33.57 
0.00 
22.56 
22.27 
38.46 
4.67 
10.83 
18.79 
18.59 
6.41 
15.95 
23.84 
31.12 
8.30 
26.23 
41.34 
55.47 
4.44 
10.48 
12.11 
18.88 
cost  EndOSCOpJ 
4.25 
16.85 
29.45 
39.57 
0.00 
30.10 
53.03 
50.22 
3.65 
18.54 
28.03 
40.74 
17.83 
30.13 
44.38 
46.43 
3.93 
17.40 
26.75 
39.06 
9.33 
29.69 
51.36 
51.70 
3.24 
18.17 
30.03 
39.69 
17.05 
27.64 
30.47 
46.06 
4.25 
15.20 
28.38 
35.97 
0.00 
31.31 
47.75 
54.53 
2.82 
11.87 
21.77 
27.41 
4.15 
17.74 
27.93 
40.36 
5.02 
26.31 
44.49 
48.78 
2.78 
11.48 
19.47 
26.94 
1.46 
1.64 
2.02 
5.94 
0.00 
2.75 
0.00 
9.69 
1.12 
1.64 
0.00 
6.23 
9.22 
7.24 
15.43 
8.94 
1.36 
1.68 
2.28 
6.01 
3.09 
2.82 
0.00 
9.30 
0.72 
1.27 
2.45 
2.62 
10.84 
8.18 
0.00 
15.32 
1.46 
1.77 
2.16 
6.31 
0.00 
1.97 
0.00 
7.56 
0.65 
1.03 
0.00 
2.39 
1.36 
1.76 
2.26 
7.43 
2.29 
2.19 
0.00 
3.01 
0.62 
0.99 
0.00 
2.28 
hospital  hospital  hospital  hospital  shadow  total 
gi 
5.63 
10.71 
28.34 
23.87 
0.00 
18.45 
0.00 
62.34 
3.59 
9.55 
31.55 
12.53 
51.73 
83.22 
0.00 
122.90 
5.18 
9.96 
0.00 
24.55 
12.72 
25.83 
201.29 
58.30 
3.63 
9.98 
34.34 
29.73 
31.07 
34.62 
0.00 
35.86 
5.63 
12.27 
30.25 
27.64 
0.00 
10.73 
0.00 
40.62 
2.79 
8.41 
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